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Abstract  
The X-chromosome linked transcription factor, FOXP3, is expressed by epithelial 
cells from several organs. In these cells it is considered a potent tumour suppressor 
directly regulating the expression of many important oncogenes. The chemokine 
receptor, CXCR4, can also direct a number of processes relevant to the development 
of breast cancer. These include chemotaxis towards the sole ligand for CXCR4, 
CXCL12, which is expressed at the most common sites of metastatic spread. This 
study was designed to define further the role FOXP3 plays in metastatic breast 
cancer, with a particular focus on its potential to regulate CXCR4. 
In comparison with normal primary breast epithelial cells, FOXP3 was 
downregulated at both transcript and protein levels in the breast cancer cell lines, 
MCF-7 and MDA-MB-231. In the more invasive MDA-MB-231, the remaining 
FOXP3 was located predominately within the cytoplasm and lacked the natural Δ3 
isoform. Following stable FOXP3 overexpression in MDA-MB-231, significant 
decreases were observed in the expression of ErbB2, SKP2, c-MYC and CXCR4. In 
contrast, an increase in p21 expression led to inhibition of cell proliferation, with a 
greater proportion in the G1 phase of the cell cycle suggesting the induction of 
senescence. Specific knockdown of FOXP3 in normal breast epithelial cells with 
siRNA significantly increased ErbB2, SKP2, c-MYC and CXCR4, and decreased p21 
expression. These cells also showed a significantly increased chemotactic response 
towards CXCL12, suggesting a role for FOXP3 influencing cell migration. The 
expression of FOXP3 and CXCR4 in normal breast tissue (n=2), and both lymph 
node negative (n=7) and lymph node positive (n=9) breast cancer samples was 
investigated by immunohistochemistry. Both epithelial and cancer cells in all the 
breast cancer samples showed increased CXCR4 expression in comparison to normal 
tissue. However, the expression of FOXP3 by epithelial or cancer cells did not 
appear different between all the samples examined. 
Results from this study are consistent with FOXP3 functioning as an important 
tumour suppressor in breast cancer. Indeed, the functions of FOXP3 in breast 
epithelium can now potentially be extended to include influencing the expression of 
CXCR4 and response to the pro-metastatic chemokine, CXCL12. Further studies 
should be directed to investigation of the molecular mechanisms involved in this 
influence of chemokine responsiveness by FOXP3.      
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1 General introduction 
 
1.1 Anatomy of the human breast  
The adult breast is a special type of apocrine gland and is often described as a 
modified sweat gland which produces milk. It is made up of predominantly lobules, 
ducts and stroma (Elston and Ellis 1998). The lobules are the regions which contain 
the glands and are responsible for producing milk, whereas, the ducts are tubes which 
branch from the lobules towards the nipple and are responsible for carrying the milk. 
The rest of the breast is stroma, consisting mainly of adipose tissue and connective 
tissue which surrounds the ducts, lobules, blood vessels, lymphatic vessels and 
muscle. Each developed adult breast contains 15-20 lobes, and each lobe contains 
20-40 lobules which branch into a network of ducts that terminate at the nipple 
(Elston and Ellis 1998). The terminal duct lobular units (TDLU) are the sites where 
milk is produced. These are found nearest to the pectoralis major muscle. From these 
lobular units, ducts branch out to form subsegmental ducts. As these ducts branch 
further out, they converge into slightly larger segmental ducts until they reach the 
areola region where they slightly dilate to form lactiferous sinuses. These are 
surrounded by muscle and control the opening and closing of the nipple during 
suckling (figure 1.1 panel A) (Elston and Ellis 1998).  
 
1.2 Mammogenesis  
The development of the mammary glands occurs during different growth cycles. In 
the embryonic stage, both sexes begin mammogenesis by forming rudimentary duct 
trees at birth. From this stage the development of the glands depends on systemic and 
maternal hormones but also the local regulation of paracrine communication between 
epithelial and mesenchymal cells by parathyroid-related hormone protein (PTHrP) 
(Sternlicht 2006). The development of lactiferous ducts is controlled by hormones 
and occurs during pre- and post-natal stages and again later during puberty 
(Sternlicht 2006). At the onset of puberty there is a change in the hormonal 
environment which is key in controlling further development of the mammary 
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glands. The anterior pituitary gland releases follicle stimulating hormone (FSH) and 
lutenzing hormone (LH) in a cyclic manner which stimulates the ovaries to 
synthesise oestrogens and progesterones. Oestrogen acts to further stimulate 
mesenchymal cells which results in an increase in the gland size as the ducts branch 
into the surrounding stroma (Sternlicht 2006). In males, testosterone acts on 
mesenchymal cells to inhibit mammogenesis. At this stage in females the gland is 
considered as matured, but remains inactive until pregnancy where a further onset of 
hormonal changes takes place (Sternlicht 2006).  
During the first trimester, the ductal terminal branches elongate and the epithelial 
cells proliferate from stem cells distributed throughout the gland. During the second 
trimester, the glandular components of the breast enlarge as the adipose tissue and 
stroma progressively get thinner, and the lobules differentiate from terminal end buds 
(TEB). During the third trimester, the lobules mature as the epithelial cells become 
cuboidal and the rate of secretion increases (Sternlicht 2006). After menopause the 
mammary glands undergo involution as the amount of elastic tissue increases, 
adipose tissue decreases and the stroma becomes more fibrous and less cellular. As 
well as this, the levels of circulating ovarian hormones decrease and ductal elements 
begin to degenerate (Sternlicht 2006). 
 
1.3 The lymphatic system  
Lymph nodes are small bean shaped regions which are connected by lymphatic 
vessels. These vessels carry fluid (called lymph) away from the breast. Lymph is 
made up primarily of lymphocytes but also tissue fluid and waste products. The 
tissue in and around the breast is rich in lymph nodes and vessels, therefore, when 
breast cancer cells acquire the ability to invade the most common preliminary site 
they invade to is the lymph nodes. Once the cancer cells have reached the lymph 
nodes there is a high chance they will enter the bloodstream where they can then 
spread to other sites around the body. Most lymphatic vessels in the breast connect to 
the axillary lymph nodes which are situated mainly around the arm pit. The axillary 
lymph nodes consist of the pectoral lymph nodes, low axillary lymph nodes, mid 
axillary lymph nodes and brachial lymph nodes. Other lymph nodes are situated 
around either the clavical (infraclavicular lymph nodes, also known as higher 
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axillary) or near the sternum (supraclaviular lymph nodes and internal mammary 
lymph nodes) (Elston and Ellis 1998) (figure 1.1 panel B). 
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Figure 1-1 - Anatomy of the human breast and lymphatic system 
Cross section of the human breast demonstrates the location of ducts (A,A) which stem from 
milk producing glands called lobes (A,B). The ducts branch and construct into subsegmental 
ducts (A,C) which are surrounded by muscle and terminate at the nipple (A,D). These 
glandular regions are surrounded by stroma which is predominantly made of adipose tissue 
(A,E). The breast tissue typically lies above the pectoralis major muscle (A,F) and extends 
from the level of third rib (A,G). 
The lymphatic system surrounding the breast tissue is made up of a network of lymph nodes 
(B) which are responsible for draining lymph away from the breast. Panel A taken from 
(Breastcancer.org 2013), panel B taken from (Breastcancerbgone.com 2012). 
 
 
 
 
 
 
 
A
B
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1.4 Breast cancer  
In ancient times autopsies were rare so cancers of internal organs were not reported. 
However, cancers of the breast were different as the tumour could be felt through the 
skin, and in later stages, can often ulcerate becoming more visible than other forms 
of cancer. On this basis, breast cancer is considered as one of the oldest diseases on 
record. One of the first descriptions of breast cancer was reported at around 1600BC 
in Egypt on the Edwin Smith papyrus (Aronowitz 2007).  
Observations made by early physicians such as Bernardino Ramazzini in 1713 stated 
that Nuns had a higher risk of developing breast cancer. Ramazzini suggested the 
lack of sexual activity caused instability in the breast. Ramazzini stated that women 
who have never had child (nulliparity), or those who have children later in life have a 
higher relative risk of developing breast cancer.  
In 1926, Janet Lane-Claypon conducted the first case-controlled study on breast 
cancer epidemiology. She published for the British Ministry of Health comparing 
500 breast cancer patients with 500 control patients who had similar lifestyles and 
backgrounds asking many questions of the female lifestyles. Her conclusions still 
agree with many modern reviews on breast cancer susceptibility claiming age at 
menopause, age at first pregnancy (age at marriage used as a proxy), number of 
children, and lactation all impacted significantly on the risk of developing breast 
cancer (Winkelstein 2006).  
 
1.4.1 Epidemiology  
Breast cancer comprises 16% of all female cancers which makes it the most common 
malignancy in women worldwide (cancerresearchuk.org 2012). In 2010, more than 
49,000 UK women were diagnosed with breast cancer. This is equal to roughly 136 
women per day (cancerresearchuk.org 2012). Although breast cancer is much more 
common in woman, it can also occur in males and in 2010 approximately 400 men 
were diagnosed with breast cancer (cancerresearchuk.org 2012). From the mid-
1970s, breast cancer rates in Britain have increased by almost 70% 
(cancerresearchuk.org 2012). This increase can be explained by the raise in 
awareness and screening programs which encourages the public to check for 
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symptoms more frequently and allows tumours to be diagnosed at an earlier stage 
making them potentially more treatable. These programs have been a huge success. 
In 2009/2010, the NHS screening programs detected nearly 16,500 cases of breast 
cancer in the UK. As well as highly successful screening and awareness programs, a 
clearer understanding of the disease has allowed the development of more innovative 
modern medicine which has also played a key part in improving survival rates. 
During the 1970s it was estimated that only 5 out of 10 women survived beyond 5 
years after the original diagnosis, however, more than 8 out of 10 women diagnosed 
now exceed 5 years (cancerresearchuk.org 2012). Although these figures are 
encouraging, breast cancer is still a major burden. In the UK breast cancer is now the 
second most fatal malignancy after lung cancer. The current lifetime risk of women 
developing breast cancer is 1 in 8 (cancerresearchuk.org 2012). Unfortunately, many 
developing countries do not have the same level of treatment, screening programs or 
awareness as more developed countries and possibly as a result of this, almost 69% 
of breast cancer deaths in 2004 occurred in developing countries (WHO.int 2013). 
There are a number of risk factors which can influence the chances of breast cancer 
including child bearing, breast feeding, weight, diet, alcohol and smoking (discussed 
in further detail on cancer.org). However, the most prominent risk factor remains age 
and menopause stage. Unsurprisingly, as females get older their risk of acquiring 
breast cancer markedly increases (figure 1.2). Statistics suggest that the risk of 
women developing breast cancer before the age of 30 is approximately 1 in 2000, 
however, as age increases so does the risk (Breastcancer.org 2013).  
Genetic inheritance of certain mutated genes also carries a significant risk of an 
individual’s susceptibility to breast cancer. Therefore, inherited mutations also 
account for a large proportion of breast cancer cases. This is discussed further in 
section 1.4.5. 
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Figure 1-2 - Risk of breast cancer development by age of women in the UK 
Data suggests a relatively low chance of breast cancer development in women aged below 
29, however, as age increases the risk of developing breast cancer increases 
(Breastcancer.org 2013). 
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1.4.2 Signs and symptoms 
In clinical practise in the UK, breast cancer presents through two main routes; one 
being symptomatic, and the other being asymptomatic. The majority of 
asymptomatic breast cancer cases are caught through the NHS breast screening 
programme. The most common symptomatic sign for the onset of breast cancer is a 
thickening of the skin or the formation of a lump in the breast. Other symptomatic 
changes of the breast which can act as an indicator include dimpling of the skin or 
the nipple, a change in size and shape of the breast, a rash on the breast or blood 
stained discharge from the nipple. Less common is where the cancer erodes or 
fungates through the skin in locally advanced cancer. Inflammatory breast cancer is a 
rare but aggressive form of breast cancer which often presents by the breast looking 
red, inflamed, sore and tougher to touch. Another rarer form of breast cancer is 
Paget’s disease. Symptoms of Paget’s disease can often be firstly misdiagnosed as 
eczema as a red and often scaly rash is found around the areola region.   
In the UK, women aged between 43 and 72 are invited tri-annually for X-ray based 
mammographic screening. These patients are usually completely asymptomatic with 
no palpable abnormalilty within the breast. Some Hospitals involved in screening 
programmes have reported that the majority of breast cancers diagnosed are from 
asympmtomatic patients. This emphasises the benefits of breast sceening units in the 
UK. 
 
1.4.3 Pathology and pathogenesis of breast cancer 
Many lumps discovered in the breast are non-cancerous and are classed as benign as 
they are incapable of invasion and cannot spread outside the site of origin. Benign 
lumps can be formed at any stage of life in many women and are generally caused by 
fibrosis, which is the formation of scar tissue, or a cyst, which is a fluid-filled sac. 
However, when a lump is detected which is considered cancerous, it is classed as a 
carcinoma. An adenocarinoma is a carcinoma subset which originates from glandular 
tissue such as the ducts or lobules of the breast. Rarer cases of cancer exist which 
originate from the connective tissue, such as the muscle or adipose tissue. These 
tumours are classed as sarcomas.   
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Most breast cancers develop due to instability withn the breat tissue. The initial stage 
of carcinogenesis is the formation of atypical ductal hyperplasia (ADH). If 
hyperplasia progresses into a breast carcinoma, the type of breast cancer is then 
divided into either in situ (non-invasive) or invasive breast cancer. Ductal carcinoma 
in situ (DCIS) is thought to be a true pre-inavsive cancer and a precursor of true 
invasive ductal breast cancer, whereas, lobular carcinoma in situ (LCIS) is not 
considered to be a precursor of a true invasive cancer. However, LCIS is considered 
a marker of the potential for the development of both invasive lobular and ductal 
cancers. Because of its true malignant potential, DCIS is subdivided as either high or 
low grade based on the morphological appearance of the tumour cells. Tumours of a 
higher grade have a greater malignant potential and also have a greater tendancy to 
reoccur after treatment.  
There are basic histological types of invasive breast cancer. Those derived from the 
epithelial lining of the breast ducts, the ductal cancers of no special type (NST), and 
those not of a ductal orgin or special type. The most common from of breast cancer is 
invasive ductal carcinoma (IDC). This accounts for approximately 80% of cases. The 
most common special type of breast cancer is derived from the lobular epithelial cells 
(lobular cancer). These account for approximately 10% of cases. Other less common 
forms of special type breast cancer can be mucinous (3%), tubular (3%) or medullary 
(2%) (Breastcancer.org 2013). Breast cancer classification is discussed further in 
section 5.1.2. 
The development of a cancerous tumour is a multi-stage process. For a normal 
healthy cell to transform into a malignant cancer, it must acquire a number of traits 
that are dependent on a series of genetic changes that contribute to growth 
advantages. This notion was extensively reviewed by Hanahan and Weinberg 
(Hanahan and Weinberg 2000) who stated that a minimum of six alterations in the 
physiology of the cells are required before they transform into malignant cells. The 
six alterations stated were: 
 Self sufficiency of growth signals 
 Insensitive to anti-growth signals 
 Evading apoptosis 
 Limitless replication 
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 Promotion of angiogenesis 
 Acquired potential to invade and metastasise 
Normal cells require mitogenic growth signals delivered via transmembrane 
receptors which bind a distinct set of molecules. No normal healthy cell is able to 
proliferate in the absence of these signals, however, many oncogenes will allow the 
tumour to either mimic normal growth signals, or generate their own growth signals, 
thus reducing their dependence of stimulation from the tissue environment (Hanahan 
and Weinberg 2000). As well as receiving signals which encourage proliferation, the 
ability to ignore anti-growth signals is another key trait cancer cells require to 
prosper.  
Performing cell cycle arrest and repairing damaged DNA, or undergoing apoptosis is 
a critical feature cells perform after detecting harmful mutations. As well as being 
able to expand in the number of cells within the tumour mass, the tumour cells also 
have an incessant ability to survive longer by evading apoptosis.  
Research has shown in vivo that most, if not all, tumour cells have a limitless 
replicative potential where they can double many times beyond the specific number 
they should be able to (Hanahan and Weinberg 2000).  
Vasculature is crucial for cell survival and function. Most cells are required to reside 
within approximately 100µm of a capillary blood vessel (Hanahan and Weinberg 
2000). However, because of the increase in tumour mass, space becomes limited and 
cells are overcrowded leading to a lack of nutrients and oxygen levels supplied by 
the vascular system. During transformation, the malignant cells develop specific 
growth advantages, allowing them to survive better in hypoxic conditions. Cancer 
cells are able to promote angiogenesis and form new capillaries around the tumour 
mass providing the malignant cells with a fresh supply of nutrients and oxygen. One 
of the key mediators in this process is vascular endothelial growth factor (VEGF). 
VEGF is able to bind to transmembrane tyrosine kinase receptors on endothelial cells 
causing the receptors to dimerise and become activated (Veikkola and Alitalo 1999). 
The importance of VEGF in cancer is increasing and more frequently a subject of 
research as it has been extensively shown that many tumours have increased levels of 
VEGF compared to their normal tissue counterparts (Rak, Filmus et al. 1995; Rak, 
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Mitsuhashi et al. 1995; Ding, Chen et al. 2006; Luo, Jiang et al. 2008; Ding, Feng et 
al. 2012). 
The most fatal characteristic of cancer is the ability to invade surrounding tissues 
leading to metastasis of the primary tumour. This stage forms in almost all types of 
cancer and generally occurs after the tumour has outgrown the primary site, and 
colonise in new areas of the body where space and nutrients are not limited (Hanahan 
and Weinberg 2000). When cells metastasise they are required to overcome a number 
of physical barriers, including penetration of the basement membrane, chemical 
barriers, such as hypoxia and pH changes, and also biological barriers, such as 
evasion of the immune system and various cytokines. Following transformation of 
the cancer cell, and its initial growth within the breast, these cells continue to grow as 
hyperplasia becomes more atypical. Overtime, atypical hyperplasia often results in 
the formation of a carcinoma in situ. The subsequent continuation of growth may not 
be restricted to the breast as the cells develop the ability to penetrate basement 
epithelia (figure 1.3 panel A). Once the cells have breached the epithelial cells lining 
the ducts or lobules they frequently metastasise to organs which are essential to 
maintaining life, initially migrating to the lymph nodes where they can then access 
the blood stream and metastasise to the lungs, liver, bone marrow and brain (figure 
1.3 panel B). The ability of cells to metastasise, and the choice of site is non-random. 
This process is highly organised as the ‘seed and soil’ hypothesis describes (Fidler 
2001; Fidler 2003; Langley and Fidler 2011). 
The breast itself is not an essential organ. On this basis, metastasis in breast cancer is 
thought to contribute to approximately 90% of mortality (Bendre, Gaddy et al. 2003). 
The ability of cells to proliferate, evade apoptosis, invade and migrate is 
predmoniately mediated by the upregulation of growth factor receptors, hormone 
receptors, and several other types of proteins including cell-cell adhesion molecules 
(CAMs), and integrins (Aplin, Howe et al. 1998). The organ-specific targeting of 
breast cancer is now thought to be regulated by chemotactic cytokines produced in 
the target organ region. The expression of these factors and their constitutive 
receptors expressed on the malignant cells are key factors in the site-specificity of 
metastasis (Muller, Homey et al. 2001). The role of chemokines and chemokine 
receptors in breast cancer metastasis is discussed in sections 1.5 and 1.6. 
Chapter 1 - General introduction 
12 
 
 
Figure 1-3 - Disease progression witnessed in breast cancer and metastasis  
(A) Normal breast epithelia form a basement layer which surrounds the ducts and lobules of 
the breast. Mutations in genes which result in uncontrolled proliferation of cells may result in 
cellular hyperplasia, which may then lead onto more atypical hyperplasia. This can then form 
a carcinoma which may remain in situ or develop the ability to invade beyond the basement 
epithelia. (B) The cells often then metastasise to the lungs, liver, bone marrow and brain.   
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1.4.4 The influence of growth factors and hormone receptors 
Malignant cells gain growth advantages over normal cells by upregulating hormone 
and growth factor receptors. There are three important receptors involved in breast 
cancer. Hormone receptors for oestrogen and progesterone and the growth factor 
receptor, HER2. The expression of these receptors is an important criterion when 
diagnosing breast cancer as they are considered as strong prognostic indicators. 
 
1.4.4.1 Oestrogen and progesterone receptors  
The importance of oestrogen receptors (ER) and progesterone receptors (PR) are two 
key prognostic markers used in breast cancer. It is estimated that approximately 80% 
of breast cancers have either individual or combined overexpression of ERs and PRs.  
The main consequence of oestrogen and progesterone signalling is a rapid increase in 
the proliferation of cells. Oestrogen is a steroid hormone existing in three natural 
forms; estrone, estradiol and estriol. These hormones elicit their responses by 
diffusing across the cell membrane and binding to ERs located in the nucleus.  
ERs were first identified by Elwood V. Jensen at the University of Chicago in 1958, 
for which Jensen was awarded the Lasker Award (Jensen and Jordan 2003). Two 
forms of ER exist: ERα and ERβ. These receptors are often co-expressed, and when 
activated, form either homodimers (αα or ββ) or heterodimers (αβ) (Li, Huang et al. 
2004). Reports demonstrate that as cancer progresses the levels of ERβ decrease, 
whereas, ERα levels increase. For this reason most studies focus more specifically on 
the role of ERα (Bardin, Boulle et al. 2004). Tamoxifen and Raloxifene are two anti-
oestrogen therapies which are successfully used to treat ER positive tumours (Platet, 
Cathiard et al. 2004). 
ER signalling is thought to heavily impact a number of important processes involved 
with most stages involved in breast cancer progression. It has been reported that 
dysregulated ER-signalling can lead to aberrant expression of snail. This can lead to 
a loss of E-cadherin which is a key feature involved with epithelial-to-mesenchymal 
transition (EMT). ER-signalling has also been demonstrated to activate mitogen-
activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K) and protein 
kinase C (PKC) signalling pathways (Chakravarty, Nair et al. 2010; Zheng, Huang et 
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al. 2011). ERα is able to promote invasiveness through increased expression of 
matrix metalloproteinase (MMP) 2 and MMP9 (Qin, Liao et al. 2008), and CXCR4 
through control of HER2 (Li, Pan et al. 2004), therefore, increasing CXCL12-
mediated migration. ER-signalling often cooperates through the interaction with 
several other factors. Many ER-coregulatory proteins are also differentially 
expressed in malignant breast tumours with their functions often altered as the 
tumour progresses (O'Malley 2006).  
 
1.4.4.2 Human epidermal growth factor receptor 2 
Human epidermal growth factor receptor 2 (HER2) also commonly known as Neu, 
CD340 or p185, is a member of the epidermal growth factor receptor family. These 
cell surface receptors are composed of four plasma membrane-bound tyrosine 
kinases which contain an extracellular ligand binding domain, a transmembrane 
domain and an intracellular domain which can interact with a number of signalling 
molecules (Roy and Perez 2009). 
The HER2 protein is encoded by the gene ErbB2 which is located on chromosome 
17 (17q21-22). HER2 can activate many signal pathways involved in promoting the 
proliferation, survival, migration and invasion of cells often utilising MAPK, PI3K, 
PKC and signal transducer and activator of transcription (STAT) pathways (Roy and 
Perez 2009). Because these pathways are frequently activated and are responsible for 
a wide range of carcinogenic features in cells, the control of HER2 must be tightly 
regulated. 
The overexpression of HER2 and the subsequent increase in HER2 signalling is very 
important in the pathogenesis of breast cancer which has led to its involvement being 
identified as an important biomarker. If left untreated, HER2 postive breast cancers 
generally have a worse prognosis than HER2 negative tumours as they not only 
proliferate more rapidly, but are also more resistant to hormone therapies and 
respond less to chemotherapies (Giai, Roagna et al. 1994; Stal, Sullivan et al. 1995; 
De Placido, Carlomagno et al. 1998). HER2 is overexpressed in approximately 30% 
of breast cancer cases (Slamon, Clark et al. 1987), however, it is also implicated in 
other aggressive malignancies including stomach (Jorgensen 2010; Jorgensen and 
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Hersom 2012), uterine (Santin, Bellone et al. 2008), and ovarian cancers (Slamon, 
Godolphin et al. 1989; Tuefferd, Couturier et al. 2007).  
The main method of determining HER2 expression is by immunohistochemistry 
(IHC). The samples staining intensity is graded 0-3. Grade 0-1 is considered as 
HER2 negative, whereas grade 3 means the tumour is HER2 positive. If the tumour 
is graded 2 it means moderate levels are present and additional tests are carried out 
such as fluorescence in situ hybridisation (FISH) to detect over-amplification of the 
ErbB2 oncogene. 
Despite the aggressive nature of HER2 positive tumours, treatment with the 
monoclonal antibody Herceptin
®
 is able to directly target HER2 and is very effective, 
thus, allowing HER2
 
positive tumours a better prognosis if they are diagnosed early 
and treated correctly. Use of Herceptin
®
 was originally thought to have its most 
profound effects on the metastatic actions of breast cancer as it increased survival 
from 20.1 to 25.1 months (Hudis 2007). However, it has also been shown to be 
effective in early stages of disease as it can reduce the risk of relapse after surgery by 
an absolute risk of 9.5% and the risk of death by 3% (Moja, Tagliabue et al. 2012).  
 
1.4.5 Oncogenes and tumour suppressor genes 
Cancer is a complex group of diseases affecting a wide range of cells and tissues. 
Mutations that alter the expression of certain genes and their products are key 
features of all cancers. Research has demonstrated that a number of mutations in 
genes that disrupt steps in the cell cycle are prime candidates for studying 
carcinogenic transformation, and initial tumour growth and development. Generally 
speaking, the cell cycle is controlled by genes that function to suppress cell division, 
and genes which promote cell division. The first group of genes are termed as tumour 
suppressor genes (TSGs). These gene products prevent the passage through the cell 
cycle and, therefore, inhibit cell division. Only when these products are inactive will 
cell division occur. The second group of genes are termed oncogenes. These gene 
products function to promote cell division by the providing signals cells require to 
continue through the cell cycle. Therefore, the cell cycle is controlled through 
constant activation and inactivation of TSGs and oncogenes, therefore, these genes 
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must be very tightly regulated. Mutations which permanently inactivate TSGs or 
activate oncogenes will result in the control of the cell cycle being lost and the 
mutant cell begins to proliferate uncontrollably (Beckmann, Niederacher et al. 1997; 
Kenemans, Verstraeten et al. 2004). 
Although cancer is a genetic disease, the majority of cancers are not classed as 
hereditary. Some cancers, such as retinoblastoma (Rb), carry a greater hereditary risk 
than other malignancies. However, breast cancer also carries a considerable 
inheritable factor.   
A genetic link to cancer was first described by Theodor Boveri in 1902 (Ried 2009). 
Boveri stated that chromosomes with mutations could cause cells to divide more 
rapidly. More importantly, Boveri also stated that these chromosomal mutations 
could be inherited (Ried 2009). The risk of acquiring breast cancer significantly 
increases to almost double if a first degree relative has previously suffered breast 
cancer, which demonstrates that there is a clear inherited risk (Pharoah, Day et al. 
1997). It is now estimated that environmental factors carry the greater risk as they 
contribute to over three quarters of breast cancer cases in the developed world (Key, 
Verkasalo et al. 2001). However, despite this increased risk, more than 85% of 
women with a close relative who has breast cancer do not develop the disease, 
whereas, more than 85% of women who do develop breast cancer have had no 
previous family history. Individuals who inherit a mutant TSG, such as TP53, PTEN, 
STK11/LKB1, CDH1, CHEK2, ATM, MLH1, and MSH2 do carry a substantially 
increased risk of developing breast cancer (Walsh, Casadei et al. 2006; Campeau, 
Foulkes et al. 2008). This is a good illustration of how the development of breast 
cancer can be dictated on either genetic or environmental factors. 
 
1.4.5.1 BRCA1/2  
The majority of cases of familial breast cancers are accounted for by two autosomal 
dominant genes, breast cancer susceptibility gene 1 and 2 (BRCA1 and BRCA2) 
(Lynch, Silva et al. 2008). The main functions of BRCA genes are to encode proteins 
which are key in repairing damaged DNA, or if damage is excessive, initiating 
apoptotic cascades resulting in cell death (Friedenson 2007). 
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It is estimated that 0.1% of the female population contain BRCA mutations. 
Moreover, inherited mutated forms of either BRCA1 or BRCA2 accounts for 5-10% 
of female breast cancers and 10-15% of ovarian cancers in the USA (Campeau, 
Foulkes et al. 2008). Mutations in either BRCA1 or BRCA2 are considered as high-
penetrance as individuals who inherit a mutated BRCA gene have an estimated 30-
70% risk of developing cancer (Aydin, Akagun et al. 2011) and a 45-60% risk of 
breast cancer by the age of 70 (Chen and Parmigiani 2007). 
 
1.4.5.2 p53 
TP53 is arguably, the most well known TSG. TP53 is located on the short arm of 
chromosome 17 and encodes the protein p53. p53 is a transcription factor which has 
strong anti-cancer functions and is implicated in genome stability as approximately 
50% of all human tumours have mutated p53 (Hollstein, Rice et al. 1994; Levine 
1997).  
p53 is able to perform cell cycle arrest, induce senescence and initiate apoptosis. For 
these reasons, p53 is often described as “the guardian of the genome”. p53 is one of 
the most studied proteins in research, however, because it is at the centre of an 
intricate protein network which determines a multitude of cellular responses, 
mapping the precise signalling pathways p53 is involved in is overwhelmingly 
complex.  
p53 is tightly regulated and becomes activated in response to various DNA damaging 
agents, including ultraviolet (UV) radiation and oxidative stress (Han, Muller et al. 
2008). The activation of p53 is thought to be triggered via MAPK family of proteins 
by phosphorylating the N-terminal transcriptional activation domain. When p53 is 
activated it accumulates in cells as the half-life drastically increases when DNA 
damage occurs (Maltzman and Czyzyk 1984; Price and Calderwood 1993; Maki and 
Howley 1997). The effects of p53 on cell cycle arrest is mediated primarily through 
p21 which is a molecule able to induce cell cycle arrest at the G1 phase (Elbendary, 
Cirisano et al. 1996). It has been reviewed that p53 contributes to inducing apoptosis 
through a number of mechanisms but the most common includes the activation of 
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pro-apoptotic genes such as members of the Bcl-2 family (Brouet, Rabian et al. 
1984). 
Because of the strong anti-cancer functions of p53, the prospect of restoring 
endogeneous p53 to tumour cells has shown considerable promise as this caused 
regression of tumours in vivo (Ventura, Kirsch et al. 2007). However, subsequent 
studies have demonstrated that increasing p53 levels can cause premature aging 
(Tyner, Venkatachalam et al. 2002; Dumble, Gatza et al. 2004). 
 
1.4.5.3 PI3K and PTEN  
PI3KCA is an oncogene that encodes the catalytic subunit of PI3K which is a 
transducer of growth factor signalling. Constant activation of PI3KCA allows for 
constant signalling of PI3K which allows cancer cells to grow independently of 
external stimuli (Dillon, White et al. 2007). 
Mutations causing somatic activation of PI3KCA are witnessed in approximately 
25% of breast tumours (Bachman, Argani et al. 2004; Lai, Mau et al. 2008). The 
majority of signalling through PI3K is thought to act through Akt kinases which 
allow the cells to stimulate angiogenesis (Jiang and Liu 2009; Karar and Maity 
2011), avoid apoptosis (Franke, Hornik et al. 2003) and increase the invasive and 
migratory potential of cancer cells (Du, Sun et al. 2010; Wander, Zhao et al. 2013). 
An antagonist of PI3K signalling is a tumour suppressor called phosphatase and 
tensin homologue (PTEN). PTEN is able to repress growth factor induced cell 
division, apoptosis induction, and repression of invasion and angiogenesis (Dillon, 
White et al. 2007). The normal functioning of both PI3K and PTEN is essential in 
normal cell homeostasis and a loss of function in either genes results in high risk of 
breast cancer development (Dillon, White et al. 2007). 
 
1.5 Chemokine-driven cancer progression 
As described, metastasis remains the overwhelming cause of mortality in breast 
cancer. The process of metastasis is known to be the result from a number of 
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organised sequential steps. However, despite the clear importance of this process, the 
precise mechanism leading to metastasis remains one of the most poorly understood 
components of breast cancer pathogenesis.  
Leukocyte biology has taught us that a specific set of small (8-10kDa) molecules 
called chemokines have the ability to regulate cell trafficking (Taichman, Cooper et 
al. 2002). It was hypothesised that tumour cells may also utilise the capabilities of 
chemokines and their constitutive chemokine receptors to govern the site-specific 
metastasis witnessed in breast cancer (Muller, Homey et al. 2001; Ali and Lazennec 
2007). 
As chemokines have roles in normal homeostasis, low levels of chemokines are 
present within normal tissues. For example, normal breast milk is known to contain 
CXCL1, 2, 3, 5, 6, 7 and 8 (Maheshwari, Christensen et al. 2003). Certain 
chemokines are also located within the normal breast but lost in carcinogenic tissues. 
These chemokines include CXCL1, 2, 5, 6, 8, 20, and also CCL2 and CCL7 (Porter, 
Krop et al. 2001). 
Strong evidence, from a large degree of literature, has demonstrated that chemokines 
and chemokine receptors play a pivotal role in driving tumour progression by 
directing cell migration. Chemokine-chemokine receptor interactions are involved in 
many steps of tumour development including cell transformation, survival, growth 
and angiogenesis (Tanaka 2002; Luker and Luker 2006). For instance, CXCL8 has 
been frequently found overexpressed at transcript and protein levels within a number 
of malignancies including breast cancer (Chavey, Bibeau et al. 2007). CXCL8 is able 
to bind not only to its natural chemokine receptor CXCR2, but also a G-protein 
coupled receptor (GPCR) encoded by tumourigenic virus’, such as Human Herpes 
virus 8 (HHV-8), which develop lesions similar to Kaposi’s sarcoma in mice (Yang, 
Chen et al. 2000). Reports have demonstrated that several melanoma cell lines 
express CXCR2 (Varney, Li et al. 2003), and also produce CXCL1 (Payne and 
Cornelius 2002) and CXCL8 (Singh, Gutman et al. 1994). However, blocking either 
the ligands or the receptors inhibits the growth of these cells (Singh, Gutman et al. 
1994; Norgauer, Metzner et al. 1996). This demonstrates that the CXCR2-
CXCL1/CXCL8 axis acts in an autocrine/paracrine manner. 
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Tumours are not simply a solid mass of cancer cells. Tumours are made up of a 
number of non-malignant cells, with the non-malignant cells often out numbering the 
malignant cells (Balkwill and Mantovani 2001). Chemokines are able to recruit 
various leukocytes into the tumour environment. The recruitment of these 
inflammatory cells is able to drive cancer progression by releasing various cytokines, 
proteases or release more chemokines. The infiltration of tumour associated 
macrophages (TAMs) is well documented in cancer and is discussed further in 
section 5.1.1 (Leek and Harris 2002; Laoui, Movahedi et al. 2011; Mukhtar, Nseyo et 
al. 2011). Other reports now indicate that CCL5 is abundant in the tumour 
environment of breast cancer which attracts macrophage infiltration (Luboshits, 
Shina et al. 1999), whereas, CCL2 is responsible for macrophage infiltration in 
oesophageal cancers (Ohta, Kitadai et al. 2002). 
Sarcomas, gliomas and a number of malignancies of the breast, pancreas and ovaries 
have high levels of CC chemokines which are produced by both the malignant cells 
and the stromal cells. These chemokines are reported to be important for homing of 
macrophages and lymphocytes to the tumour mass (Bottazzi, Polentarutti et al. 1983; 
Balkwill and Mantovani 2001). 
 
1.5.1 Chemokines  
Chemokines are a family of small chemotactic cytokines which are secreted by cells. 
These small proteins are present in all vertebrates as well some viruses and bacteria, 
however, they have not been reported in invertebrates (DeVries, Kelvin et al. 2006). 
They induce their actions by binding to their constitutive chemokine receptors 
located on cell surfaces. The main function of chemokines is to direct the migration 
of target cells (Tarrant and Patel 2006). Cells are attracted to chemokines which 
follow a signal of increasing chemokine concentration towards the source of the 
chemokine.  
Chemokines which direct cell migration during normal processes, such as 
lymphocyte homing to the lymph nodes to screen for pathogens, are classed as 
homeostatic chemokines (Zlotnik, Burkhardt et al. 2011). These chemokines are 
constitutively expressed within specific tissues. Other chemokines which are 
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involved in processes such as inflammation are referred to as inflammatory 
chemokines. The expression of inflammatory chemokines must be tightly regulated 
as they are only induced at the onset of specific inflammatory stimuli (Zlotnik and 
Yoshie 2000). These chemokines are key in aspects such as in infections, immune 
disorders and diseases associated with acute and chronic inflammation such as cancer 
(Zlotnik and Yoshie 2000). 
 
1.5.1.1 Structure and classification 
Chemokines consist of between 92-130 amino acids and are organised by their 
structural characteristics and not just their ability to attract cells (Garton, Gough et al. 
2001). When chemokines are synthesised they are created as pro-peptides that 
contain a signal peptide of approximately 20 amino acids which is cleaved from the 
active (or mature) region when they are secreted by the cells (Baggiolini 2001).  
Most chemokines contain four conserved cysteine residues which interact with each 
other in pairs via intracellular disulphide bonds. The organisation of these residues 
dictates the 3-dimensional shape of the chemokine. Typically, the first and third 
cysteines (as they appear in the protein sequence) interact, as do the second and 
fourth residues. The first two cysteines are located near the N-terminal of the active 
protein, whereas, the third cysteine is located near the centre of the protein, and the 
fourth cysteine is towards the C-terminal (figure 1.4). 
Chemokines are predominantly made up of loops, and strands (Fernandez and Lolis 
2002). After the first two residues, approximately 10 amino acids form a loop 
referred to as the N-loop. After the N-loop, there is a single turn helix (referred to as 
the 310-helix), followed by three β stands and finally a C-terminal α helix. These 
helices and strands are connected by turns referred to as 30s loops, 40s loops and 50s 
loops. The third cysteine is located within the 30s loop, and the fourth cysteine is 
located in the 50s loop (Fernandez and Lolis 2002). 
Chemokines are categorised into four groups based on their spacing of the first two 
cysteine residues (figure 1.4). Most chemokines fall into the CC or CXC 
subfamilies. CC chemokines have two adjacent cysteines near their amino terminus. 
Most members of this subgroup contain four cysteine residues, however, CCL1, 
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CCL15, CCL21, CCL23 and CCL28 contain six cysteine residues. In CXC 
chemokines, the two N-terminal cysteines are separated by a single amino acid 
(denoted as X in the CXC term). C chemokines are unique as, they only contain two 
cysteine residues; one located at the N-terminal and one downstream. Finally, the 
CX3C chemokines only contains one member and is defined by three amino acids 
separating the first two cysteine residues. Interestingly, because of its cell surface 
location, it is thought that this chemokine acts as both a chemoattractant and an 
adhesion molecule (Fernandez and Lolis 2002). 
Within mammals 17 CXC chemokines have been identified. These chemokines are 
subcategorised as either glutamic acid-leucine-arginine (ELR) positive or negative 
(Strieter, Polverini et al. 1995; Ali and Lazennec 2007). The ELR
 
positive 
chemokines are CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8 
(Moser and Willimann 2004). Based on the NH2-terminal motif being demonstrated 
in angiogenesis, ELR negative
 
chemokines are known to be angiostatic, whereas, 
ELR positive
 
chemokines are angiogenic (Strieter, Polverini et al. 1995). 
 
1.5.2 Chemokine receptors  
Chemokine receptors are GPCRs. There are approximately 19 chemokine receptors 
which are subdivided into four categories depending on the chemokine they can bind 
(figure 1.5).  
These receptors share many structural features. They all contain seven 
transmembrane domains made up from a single polypeptide chain of approximately 
350 amino acids. Each receptor has three extracellular loops and three intracellular 
loops. The C-terminal end of the receptor is coupled with G-proteins which allows 
the initiation of intracellular signalling after the specific chemokine has bound and 
activated the receptor (Murdoch and Finn 2000). 
Each chemokine receptor is highly specific for certain chemokines and can only bind 
and become activated from chemokines with the conserved cysteine residue in the 
correct location. Hence, only CXC chemokines bind CXC receptors (CXCR), CC 
chemokines bind CC receptors (CCR), the two XC chemokines bind to the XC 
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receptor (XCR1) and the sole CX3C chemokine binds to CX3C receptors. The 
majority of chemokines are able to bind to more than one receptor. 
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Figure 1-4 - Classification of chemokines and the location of cysteine residues 
Chemokines are subclassed into four individual categories depending on the location of the 
cysteine residues present. Blue lines represent the peptide chain, whereas, the green lines 
represent disulphide bonds connecting the cysteine residues. Cx3C chemokines also have a 
mucine-like domain illustrated in red. 
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Figure 1-5 - Chemokines and their constitutive receptors 
Chemokine receptors are categorised into four families which are defined by the type of 
chemokine they can bind. The location and number of the highly conserved cysteine residue 
in the chemokine defines the receptor it can interact with. Some chemokines can bind several 
receptors. Image adapted from (Balkwill 2004). 
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1.5.3 Signal transduction  
Chemokine-chemokine receptor interactions are dependent on intracellular 
heterotrimeric G-proteins. These G-proteins consist of Gα, Gβ and Gγ subunits 
which remain associated to guanosine diphosphate (GDP) at the basal state 
(Mukherjee and Zhao 2013). 
When the appropriate chemokine binds to its constitutive receptor, the receptors 
undergo homo- hetero- dimerisation. GDP is released and replaced with guanosine 
triphosphate (GTP) which leads to the receptor undergoing a change in its tertiary 
structure via the separation of the G-protein subunits into a Gα monomer and two 
Gβγ dimers. Gα can exist in four different forms; Gαs, Gαi, Gαq or Gα12 (Mukherjee 
and Zhao 2013). Originally it was though that CXCR4 was primarily a Gαi-
associated G-protein coupled receptor, however, recently it has been demonstrated 
that CXCR4 can associate with any of the Gα subunits (Rubin 2009). 
The chemokine receptor associating with the G-protein then initiates a number of 
downstream signalling cascades such as PI3K, MAPK, phospholipase-Cβ, p21-
activated kinase, NF-κB, calcium mobilisation and the activation of extracellular 
signal regulated kinases 1 and 2 (Rossi and Zlotnik 2000).  
When a biological response such as inflammation is over, it is important to cease the 
reaction and restore normal homeostasis. Chemokine receptors have the ability to 
mediate this. Upon ligand binding, the Gα subunit of the receptor protein tyrosine 
kinase (PTK) becomes activated causing phophorylation of serine and threonine 
residues at the tail of the chemokine receptor where it becomes inactivated. 
Alternatively, it can enter the lysosomal compartment to be degraded, or become 
rapidly internalised and recycled in the perinuclear region of the cell where it can be 
trafficked into the plasma membrane and stored (Neel, Schutyser et al. 2005). 
 
1.6 Chemokine receptors and breast cancer metastasis  
The importance of chemokines and their receptors at various stages of tumour 
progression is well documented (Muller, Homey et al. 2001; Ali and Lazennec 
2007). A comprehensive report by Muller et al (Muller, Homey et al. 2001) 
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quantitatively analysed the mRNA expression of all known chemokine receptors in 
seven breast cancer cell lines. They reported three separate patterns of expression. 
Firstly, CXCR2 was expressed on the normal mammary cells but expressed at much 
lower levels on their malignant counterparts. Secondly, CCR7 was expressed on both 
malignant and normal mammary cells, whereas, the final scenario demonstrated that 
CXCR4 was absent on normal mammary cells, but was markedly upregulated 
amongst malignant cell lines.  
Despite being present on normal breast cells, CCR7 is still frequently increased on 
breast carcinomas. CCR7 has two major ligands, CCL19 and CCL21. These 
chemokines are expressed at high levels within the lymph nodes and is therefore 
thought to act primarily as a lymph node homing chemokine receptor in breast cancer 
metastasis (figure 1.6 panel A) (Cunningham, Shannon et al. 2010). Wiley et al 
(Wiley, Gonzalez et al. 2001) used murine studies to demonstrate that treatment 
using neutralising anti-CCL21 antibodies was able to reduce the metastasis of B16 
melanoma cells to the regional lymph nodes in comparison to control IgG antibodies. 
This demonstrates that CCR7 was functionally active.  
CXCR4 is the chemokine receptor which is most frequently upregulated in both 
human and murine cancers (Balkwill 2004; Balkwill 2004). In fact, it has now been 
reported that over 23 human malignancies frequently overexpress CXCR4 (Balkwill 
2004) including; acute myeloid leukaemia (AML) (Mohle, Schittenhelm et al. 2000), 
Non–Hodgekin Lymphoma (Weng, Shahsafaei et al. 2003), chronic myeloid 
leukaemia (CML), (Peled, Hardan et al. 2002), multiple myeloma (Moller, 
Stromberg et al. 2003), pancreatic cancer (Koshiba, Hosotani et al. 2000), prostate 
cancer (Taichman, Cooper et al. 2002), breast cancer (Muller, Homey et al. 2001), 
ovarian cancer (Scotton, Wilson et al. 2001; Scotton, Wilson et al. 2002), thyroid 
cancer (Hwang, Chung et al. 2003), colorectal cancer (Zeelenberg, Ruuls-Van Stalle 
et al. 2003), kidney cancer (Schrader, Lechner et al. 2002), glioma (Rempel, Dudas 
et al. 2000), small cell lung cancer (Kijima, Maulik et al. 2002), and melanoma 
(Robledo, Bartolome et al. 2001; Murakami, Maki et al. 2002; Payne and Cornelius 
2002; O'Boyle, Swidenbank et al. 2013). 
Further emphasis on the importance of CXCR4 in breast cancer can be drawn on the 
basis that despite the sole CXCR4 ligand, CXCL12, being expressed relatively 
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constitutively in the body, its highest concentrations are found within the primary 
sites of breast cancer metastasis (figure 1.6 Panel B) (Muller, Homey et al. 2001). 
Intriguingly, it has been reported that stromal cells such as myofibroblasts within 
tumours are able to produce increased levels of CXCL12 in these regions (Allinen, 
Beroukhim et al. 2004). The upregulation of CXCR4 has been reported to occur as 
early as ADH and increases as cancers progress from this stage to invasive cancer. 
This suggests CXCR4 upregulation occurs early in carcinogenesis and could 
contribute to the early stages of tumour progression, and more than just cell 
migration (Schmid, Rudas et al. 2004; Luker and Luker 2006).  
As well as in vitro, in vivo studies have highlighted that the expression of CXCR4 in 
breast cancer patients, and other malignancies including melanoma patients, 
correlated with an increased risk of metastasis and a poorer prognosis (Muller, 
Homey et al. 2001; Altundag, Morandi et al. 2005; Xu, Shen et al. 2013). Treatment 
with the CXCR4 inhibitor, AMD3100, decreases the invasiveness of colorectal (Li, 
Yu et al. 2008) and ovarian cancer cells via the downregulation of MMP9 and VEGF 
(Righi, Kashiwagi et al. 2011). The importance of CXCR4 in breast cancer has also 
been demonstrated using in vivo murine models (Muller, Homey et al. 2001; Kang, 
Mansel et al. 2005). Severe combined immunodeficiency (SCID) mice intravenously 
injected with MDA-MD-231 cells developed spontaneous tumours. CXCR4 was 
detected at mRNA and protein levels within the primary tumours and also lung 
metastases’ (Muller, Homey et al. 2001). However, if SCID mice were injected with 
MDA-MB-231 cells and administered anti-human CXCR4 monoclonal antibodies, 
after 28 days, metastasis to the lung was significantly reduced in comparison to mice 
which were treated with an isotype control antibody (Muller, Homey et al. 2001). In 
vitro experiments have also demonstrated that CXCR4 expressing breast cancer cells 
grow significantly faster than CXCR4 negative cells (Lapteva, Yang et al. 2005). 
Kang et al (Kang, Mansel et al. 2005) validated these findings further by injecting 
MDA-MB-231 into mice to produce metastases to the bone. When the metastatic 
cells were recovered microarray identified CXCR4 as one of few genes that was 
enriched in the population. 
As mentioned, the sole ligand for CXCR4 is CXCL12. However, CXCL12 is not a 
ligand specific for just CXCR4. CXCL12 can also able to bind to CXCR7.  
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CXCR7 is considered by many to be an atypical chemokine receptor as it is reported 
to lack many functions commonly associated with other chemokine receptors. Upon 
binding of CXCL12, CXCR7 does not release intracellular calcium stores (Burns, 
Summers et al. 2006; Odemis, Boosmann et al. 2010), and there are conflicting 
reports on its ability to activate PI3K and MAPK pathways, and direct cell migration 
(Balabanian, Lagane et al. 2005; Hartmann, Grabovsky et al. 2008; Zabel, Wang et 
al. 2009; Zheng, Li et al. 2010).  
However, similar to CXCR4, CXCR7 has also been implicated in promoting the 
growth of a number of malignancies including breast, lung, prostate and liver cancers 
(Zheng, Li et al. 2010) (Burns, Summers et al. 2006; Miao, Luker et al. 2007; Wang, 
Shiozawa et al. 2008). Within these malignancies, CXCR7 has been reported to 
enhance the adhesion of cancer cells to fibronectin and endothelial cells (Burns, 
Summers et al. 2006; Wang, Shiozawa et al. 2008; Zheng, Li et al. 2010), and 
increase cell survival by evading apoptosis (Burns, Summers et al. 2006; Wang, 
Shiozawa et al. 2008). One factor CXCR7 has been shown to influence is the release 
of various angiogenic factors such as VEGF (Wang, Shiozawa et al. 2008; Zheng, Li 
et al. 2010). 
Interestingly, despite both receptors being targeted by CXCL12, and both receptors 
being reported in breast cancer, the roles they are reported to influence in breast 
cancer appear to oppose one another. A comprehensive report by Hernandez et al 
(Hernandez, Magalhaes et al. 2011) demonstrated these opposing roles by 
overexpressing either CXCR4 or CXCR7 into the rat adenocarcinoma cell line, 
MTLn3, and investigating the changes in primary tumour growth and also the 
metastatic changes. They suggested that the overexpression of CXCR4 resulted in 
increased chemotaxis towards CXCL12 in vivo and in vitro. CXCR4 overexpression 
also increased extravasation and motility of cancer cells within the primary tumour in 
vivo. However, CXCR4 overexpression appeared to have little impact on the growth 
of the primary tumour, therefore implying CXCR4 plays the most profound effects 
on the metastatic aspects of breast cancer. 
On the other hand, CXCR7 overexpression did increase the primary tumour growth 
and angiogenesis through upregulation of VEGF-A. However, when CXCR7 was 
overexpressed alone, it had little effect on cancer cells chemotaxis or invasion 
Chapter 1 - General introduction 
30 
 
towards CXCL12 in vitro, whereas in vivo, invasion, intravasation and the formation 
of metastases seemed to decrease. This would suggest that CXCL12 is a key 
mediator in breast cancer progression through selective activation of CXCR7 in early 
stages of tumour development, and CXCR4 in latter stages and metastatic formation.  
Interestingly, the same report by Hernandez et al (Hernandez, Magalhaes et al. 2011) 
demonstrated that when CXCR7 was overexpressed into cells with high level 
CXCR4 expression, it resulted in an increase in chemotaxis in vitro. This suggests 
CXCR7 may increase migration by working cooperatively alongside CXCR4. 
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Figure 1-6 - Distribution of CXCL12 and CCL21 in humans 
The CXCR4 ligand CXCL12 is found within the highest quantities in regions most common 
to breast cancer metastasis including the lymph nodes, lungs, liver and bone marrow (A) 
whereas the CCR7 ligand, CCL21, is found within extremely high quantities within the 
lymph nodes (B). Taken from (Muller, Homey et al. 2001). 
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1.6.1 CXCR4 crystal structure  
As mentioned in section 1.5.2, most chemokine receptors share many structure 
characteristics. The CXCR4 crystal structure was comprehensively described by Wu 
et al (Wu, Chien et al. 2010). This made CXCR4 the first chemokine receptor to be 
crystallised.  
Firstly, similar to other chemokine receptors, the main fold of CXCR4 consists of 7 
transmembrane α-helices. These are similar to other 7 transmembrane α-helical 
GPCR which have been crystallised; however, Wu et al (Wu, Chien et al. 2010) 
described 6 main differences in the CXCR4 structure:   
1) The extracellular end of helix I is shifted slightly towards the central axis of 
the receptor. 
2) Helix II makes a tighter helical turn at Pro92 which causes a 120° rotation of 
its extracellular end.  
3) Both the intracellular and extracellular tips of helix IV substantially deviate 
from their consensus positions in other GPCR.   
4) The extracellular end of helix V is about 1 turn longer. 
5) The extracellular end of helix VI is relatively similar shape in all structures as 
it is characterised by a sharp kink at Pro254, however, its extracellular end is 
shifted by approximately 3Ǻ in CXCR4. 
6) The extracellular end of helix VII is 2 helical turns longer than other GPCRs. 
The extracellular region of CXCR4 consists of 34 N-terminal residues, extracellular 
loop 1 (consists of residues 100-104) which links helices II and III, extracellular loop 
2 (residues 174-192) which links helices IV and V and extracellular loop 3 (residues 
267-273) which links helices VI and VII (Wu, Chien et al. 2010).  
Clear density is apparent from Pro27 (whic is adjacent to Cys28). This residue pins 
the base of the N-terminal of Cys274 at the tip of helix VII via a disulphide bond. 
Extracellular loop 2 is the largest loop in CXCR4. This is formed by a second 
disulphide bond between Cys109 and Cys186. Interestingly, the length, sequence and 
secondary structure of extracellular loop 2 is considerably different amongst most 
GPCRs. However, the disulphide bond connecting extracellular loop 2 with the 
extracellular end of helix III is highly conserved in chemokine receptors. These two 
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disulphide bonds are functionally very important in CXCR4 as they form an entrance 
to the ligand binding pocket (Zhou and Tai 2000).  
The intracellular region of CXCR4 contains intracellular loop 1 (residues 65-71) 
which links helices I and II, intracellular loop 2 (residues 140-149) which links 
helices III and IV, and intracellular loop 3 (residues 225-230) which links helices V 
and VI. The intracellular structure of CXCR4 is reported to be more structurally 
conserved with other GPCRs than the extracellular region (Wu, Chien et al. 2010).       
 
1.6.2 CXCR4-CXCL12 signalling 
Unlike most chemokine receptors which are able to bind several ligands, CXCL12 is 
the sole ligand specific for CXCR4 (Ma, Jones et al. 1998). Two different isoforms 
of CXCL12 have been identified in humans (α and β) (Luker and Luker 2006). 
Splice variant isoforms of this chemokine are not widely reported as they are almost 
identical in structure, differing only by the addition of four amino acids on the 
carboxyl terminus of CXCL12-β (Kryczek, Wei et al. 2007). 
Also, structure-function studies have demonstrated that the binding of CXCL12 to 
CXCR4 is dependent on the amino terminal, and both isoforms bind to CXCR4 and 
do not differ in their functions as ligands for the receptor (Crump, Gong et al. 1997). 
It is thought that the interaction between CXCL12 and CXCR4 occurs between 
residues 12-17 of CXCL12 and 2-26 of CXCR4 (Huang, Shen et al. 2003). Many of 
these signals promote proliferation (Murakami, Maki et al. 2002; Orimo, Gupta et al. 
2005), migration and invasion of cancer cells (Allinen, Beroukhim et al. 2004), as 
well as the ability to evade apoptosis (Broxmeyer, Kohli et al. 2003) and survive, 
thus demonstrating their importance in cancer. 
To cease the actions of CXCL12, it has been demonstrated that both isoforms are 
cleaved by a number of enzymes including dipepidyl peptidase/CD26 (Lambeir, 
Proost et al. 2001), MMPs (McQuibban, Butler et al. 2001) and cathepsin G 
(Delgado, Clark-Lewis et al. 2001). These remove 2-5 amino acids from the amino 
terminus of CXCL12 which inactivates the ability of CXCL12 to interact with 
CXCR4. Following CXCL12 binding, and the subsequent release from CXCR4, the 
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receptor is often internalised and sorted into the lysosome for degradation. However, 
some GPCRs can be also be recycled back to the surface of the membrane 
(Marchese, Chen et al. 2003). CXCR4 can be either recycled or degraded. However, 
the extent of receptor recycling to the surface is poor following CXCL12 stimulation 
(Signoret, Oldridge et al. 1997; Tarasova, Stauber et al. 1998). An alternative paper 
has demonstrated that CXCR4 is ubquitinated, sorted to the lysosome and degraded 
(Marchese and Benovic 2001). The E3 ubiquitin ligase AIP4 is thought to mediate 
this degradation (Marchese and Benovic 2001). 
Specific interaction between CXCL12 and CXCR4 has been demonstrated as 
CXCR4 expressing MDA-MB-231 potently migrated and invaded through matrigel 
coated membranes in a CXCL12 dose-dependent manner (Muller, Homey et al. 
2001). Consistent with the actions of MDA-MB-231, primary tumour cells, isolated 
from patients via pleural effusion, also exhibited a strong chemotactic response to 
CXCL12 (Muller, Homey et al. 2001). Further emphasising the importance of this 
interaction, treatment with anti-CXCR4 antibodies is able to neutralise the response 
(Muller, Homey et al. 2001). This demonstrates that directional migration and 
invasion of breast cancer cells is CXCL12-mediated.   
One of the prerequisites for cell motility and migration is actin polymerisation which 
initiates the formation of pseudopodia and directional migration as well as invasion 
through a reconstituted membrane (Burger, Burger et al. 1999). Human breast cancer 
cells exhibited a transient 2.2-fold increase in filamentous actin within 20 seconds 
after being stimulated with 100nM of CXCL12 (Muller, Homey et al. 2001).  
CXCR4 signalling also drives the adhesive capacity of cells by upregulating various 
components of extracellular matrix involved in cellular adhesion including collagen, 
fibronectin and integrins α2, α4, α5 and β1 (Cardones, Murakami et al. 2003; 
Hartmann, Burger et al. 2005). Cardones et al (Cardones, Murakami et al. 2003) 
demonstrated that when B16 cells were exposed to shear stress conditions, the 
overexpression of CXCR4 caused more than a 10-fold increase in adhesion to 
VCAM1-expressing lung endothelial cells which were stimulated with TNF-α. 
CXCR4 also activates members of src family of protein tyrosine kinases. These 
family members activate components of focal adhesion complexes like RAFTK/Pyk2 
Crk and paxillin (Fernandis, Prasad et al. 2004). 
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MMPs are heavily involved in degradation of extracellular matrix, thereby providing 
a mechanism for cancer cells to penetrate basement membranes aiding invasion. It 
has been demonstrated that CXCL12-dependant activation of CXCR4 is able to 
increase the secretion of MMP2 and MMP9 in MDA-MB-231, and increases their 
capacity to invade (Kang, Mansel et al. 2005). 
The ability of cells to survive in suboptimal conditions is also increased following 
CXCL12-CXCR4 interactions. When cells of several cancer types, including ovarian 
(Scotton, Wilson et al. 2002) and basal cell carcinoma, (Chen, Yu et al. 2006) were 
cultured in suboptimal conditions (such as low serum), the cancer cells which had 
been stimulated with CXCL12 survived and proliferated to a greater extent than 
those which weren’t stimulated.  
Signalling through CXCR4 has been reported to activate a number of downstream 
pathways, many of which are thought to be responsible for these processes. A 
number of these pathways are discussed;  
 
1.6.2.1 PI3K/Akt pathway  
PI3K is an important pathway which regulates a multitude of biological processes 
including apoptosis, metabolism, cell proliferation and cell growth (Carnero, Blanco-
Aparicio et al. 2008). The constant activation and signalling of the PI3K is a key trait 
in many primary and metastatic cancers which has made it an important target for 
drug design (Carnero, Blanco-Aparicio et al. 2008).   
Binding of CXCL12 to CXCR4 is able to stimulate PI3K which subsequently 
activates its major downstream effecter Akt. Based on the wide range of diverse 
functions Akt is involved in, it is thought that many of the responses involved in 
CXCR4 signalling in breast cancer are governed by the activation of PI3K and Akt 
(Murakami, Maki et al. 2002). Breast cancer cells treated with CXCL12 in vitro 
caused activation of Akt kinase within 15 minutes and this activation was sustained 
for at least 4 hours (Prasad, Fernandis et al. 2004).  
As demonstrated in several cancer cell lines, once Akt is activated it is able to 
phosphorylate a number genes involved in inhibiting apoptosis and prolonging cell 
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survival (Luo, Manning et al. 2003). One gene controlled by Akt is NF-κB (Sovak, 
Bellas et al. 1997). NF-κB is often activated in a range of malignancies and is 
discussed further in section 1.6.3.3. 
Another report has demonstrated that CXCR4 activation is able to promote the 
expression of VEGF through activation of the Akt pathway (Liang, Brooks et al. 
2007). Western blot analysis demonstrated that following incubation with CXCL12, 
MDA-MB-231 had a time-dependant increase in phosphorylated Akt with a 
maximum phosphorylation witnessed after 30 minutes incubation (Liang, Brooks et 
al. 2007). The presence of CXCL12 also demonstrated an increase in VEGF 
expression. When MDA-MB-231 were incubated with the CXCR4 antagonist, 
TN14003, the CXCL12-induced Akt phosphorylation was reduced. This blocking of 
CXCR4 also resulted in a decreased expression of VEGF. To demonstrate that the 
control of VEGF by CXCR4 was Akt dependant, MDA-MB-231 treated with the Akt 
inhibitor, LY294002 decreased the VEGF secretion (Liang, Brooks et al. 2007).   
 
1.6.2.2 MAPK/Erk pathway  
Following the binding of a mitogen to cell surface receptors, this causes the 
activation of Ras by phosphorylating GDP to GTP. Ras can then activate Raf which 
in turn phosphorylates MAPKK (also known as MEK). Finally, phosphorylated 
MEK activates MAPK leading to the activation of transcription factors such as c-
Myc, which can influence the expression of specific genes. Because of the order 
these proteins are activating in, this pathway is sometimes referred to as Ras-Raf-
MEK-ERK pathway (Fresno Vara, Casado et al. 2004).  
This pathway was originally synonymous with its role in cell proliferation. However, 
dysregulation of this pathway is now linked to many aspects of tumour phenotypes. 
A mutation in any of these proteins will result in an altered phosphorylation state, 
and as a consequence, signalling will be constantly “on” or “off”. It has now been 
predicted that approximately one-third of all human cancers have dysregulated 
MAPK (Dhillon, Hagan et al. 2007). Because of its clear importance in cancer, many 
compounds have now been developed to target and inhibit steps of the MAPK 
pathway as a cancer therapeutic (Downward 2003; Sebolt-Leopold 2008).  
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CXCR4 is able to activate MAPK which is the upstream activator of Erk1/2 
(Kryczek, Wei et al. 2007). Erk1/2 are often termed as the same effectors as they 
both activate the same downstream transduction pathways. Incubation of breast 
cancer cells with CXCL12 caused activation of Erk1/2 within 15 minutes (Zhou, Luo 
et al. 2002; Prasad, Fernandis et al. 2004). Activation of Erk1/2 are able to 
phosphorylate a number of downstream transcription factors and genes involved in 
promoting proliferation and cancer cell survival (Pearson, Robinson et al. 2001). 
 
1.6.2.3 JAK/STAT pathway 
Another pathway involved in CXCR4 signalling is Janus Kinase (JAK)/STAT. Once 
activated by CXCL12, JAK1, 2 and 3 associate with CXCR4. JAK then activates 
STAT members and recruit them to the nucleus where they transcribe genes involved 
in motility within cells which are not usually involved in migration such as epithelial 
cells (Soriano, Serrano et al. 2003). JAK signalling in breast cells is also able to 
promote proliferation in vitro (Li and Shaw 2004) as well as promoting the 
polymerisation of actin to enhance cells motility. 
 
1.6.2.4 HER2 upregulation  
Evidence of CXCL12-CXCR4 signalling activating HER2 has been demonstrated in 
breast (Cabioglu, Summy et al. 2005) and prostate (Chinni, Yamamoto et al. 2008) 
cancers. Using the CXCR4 and HER2 overexpressing breast cancer cells, MDA-MB-
231 and SKBr3, Cabioglu et al (Cabioglu, Summy et al. 2005) reported that 
inhibitors for HER2, CXCR4, and Src kinase all inhibited CXCL12-induced cell 
migration. The same report also demonstrated that blocking the Src kinase using an 
inhibitor was also able to inhibit HER2 signalling, suggesting that the CXCL12-
CXCR4 axis is able to transactivate HER2 through the Src kinase pathway 
(Cabioglu, Summy et al. 2005). A similar method of CXCL12 induced HER2 
expression involving Src kinase was described in prostate cancer (Chinni, Yamamoto 
et al. 2008)   
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A schematic representation of some the responses involved with CXCL12-CXCR4 
interactions is provided in figure 1.7.  
 
To summarise this section, there are a number of specific molecules which regulate 
the metastatic dissemination of tumour cells to specific anatomical sites. These 
molecules must follow a specific criterion (Muller, Homey et al. 2001). Firstly, they 
have to be expressed at the principle sites of metastasis. Next, adhesion target cells to 
the endothelium and transendothelium migration needs to be promoted. The 
molecules must be capable of mediating invasion of cells in to tissues, and finally, 
the process requires the expression of a distinct receptor repertoire by the target cells. 
Based on this evidence, the CXCR4-CXCL12 axis fits the criteria for molecules key 
in mediating breast cancer spread and illustrates its importance in dictating the 
anatomical specificity witnessed in the metastatic dissemination of breast tumour 
cells.    
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Figure 1-7 - Signalling pathways involved with the CXCL12/CXCR4 axis 
Following binding of CXCL12 to CXCR4 a number of actions involved with tumour 
development and metastasis are initiated including chemotaxis, adhesion, invasion, 
proliferation, angiogenesis, cell growth, and increased survival mechanisms. Many of these 
are governed through signalling of PI3K/Akt, MAPK/Erk and JAK/STAT pathways which 
have also been reported to be activated through CXCL12 binding. 
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1.6.3 CXCR4 regulation  
1.6.3.1 Hypoxia  
During cancer metastasis, the invading and migrating cells frequently encounter 
harsh conditions such as low oxygen levels (hypoxia) and diminished nutrients, 
mainly due to overcrowding of cancerous cells within the tumour mass.  
Schioppa et al (Schioppa, Uranchimeg et al. 2003) demonstrated that a number of 
cells including monocytes, macrophages, endothelial cells, epithelial cells and a 
variety of cancer cells including MCF-7 and MDA-MB-231, increase the mRNA 
levels and surface expression of CXCR4 when cultured in hypoxic conditions for 4-6 
hours incomparison to the same cells cultured in normal 20% oxygen levels. These 
cells release hypoxic inducing factor-1α (HIF-1α) when they experience these 
conditions. HIF-1α is a transcription factor which has been well demonstrated on 
several lines of evidence to be frequently expressed in conditions of low oxygen and 
is considered as the most defined molecule involved in the systemic mechanism of 
oxygen homeostasis. HIF-1α promotes the expression of a number of target genes 
including CXCR4 (Staller, Sulitkova et al. 2003). 
Using the ovarian epithelial cancer cell line, CAOV3, Schioppa et al (Schioppa, 
Uranchimeg et al. 2003) performed chromatin immunoprecipitaion (chIP) assay 
demonstrating that HIF-1α directly upregulated CXCR4 by binding to its promoter. 
Not only does HIF-1α directly cause upregulation of CXCR4 at both transcript and 
protein level, this increase in CXCR4 surface expression correlated with an increased 
migratory response towards CXCL12 (Matteucci, Locati et al. 2005). The HIF-1α 
mediated increase in CXCR4 on these cells is reversible as the transcript and protein 
levels of CXCR4 were returned to baseline levels after 24 hours of reoxygenation. 
Interestingly, the hypoxic conditions also increased the expression of VEGF which 
could also increase tumour cells oxygen and nutrient levels (Liu, Cox et al. 1995; 
Forsythe, Jiang et al. 1996). 
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1.6.3.2 HER2 
As well as CXCR4 being expressed on up to 90% of primary breast tumours and 
being heavily implicated in cancer metastasis, HER2 is also overexpressed in 
approximately 30% of breast tumours, and is associated with particularly aggressive 
forms of cancer  carrying a high risk of forming metastasise  (Yu and Hung 2000). 
Within the literature there is clear evidence of interplay between HER2 and CXCR4 
expression. Li et al (Li, Pan et al. 2004) generated two independent HER2 
overexpressing MDA-MB-435 breast cancer cells and used flow cytometry, Western 
blot and fluorescent microscopy to demonstrate that each stable transfectant had 
approximately a 3-fold increase in CXCR4 expression compared to empty vector 
transfected cells. Moreover, when the HER2 overexpressing MDA-MB-435 were 
treated with Herceptin
®
, there was a subsequent decrease in CXCR4 expression in 
comparison to the same cells which were treated with a control IgG (Li, Pan et al. 
2004). To further validate these findings, BT-474 cells (HER2 overexpressing breast 
cancer cells) were also treated with Herceptin
®
 and a comparable decrease in 
CXCR4 surface expression was witnessed. Similar findings were observed when BT-
474 was treated with HER2-specific siRNA (Li, Pan et al. 2004).  
HER2 signalling can activate Akt which, in turn, can activate mammalian target of 
rapamycin (mTOR). This is known as the PI3K/Akt/mTOR pathway (Zhou, Hu et al. 
2000). To test whether mTOR signalling is involved in the HER2-mediated 
enhancement of CXCR4, inhibitors of HER2 tryosine kinase, PI3K and mTOR were 
administered to HER2 overexpressing breast cancer cells. Results demonstrated that 
treatment with each inhibitor reduced the levels of CXCR4, suggesting that the 
PI3K/Akt/mTOR pathway may be activated by HER2-induced CXCR4 expression 
(Li, Pan et al. 2004).  
Signalling of CXCL12 through CXCR4 usually causes ubquitination of the CXCR4 
receptor. This suggests that CXCR4 expressing cancer cells which reach their 
CXCL12 enriched organs would have partial degradation of the CXCR4 receptor 
(Yu and Hung 2000). Following CXCL12 stimulation, CXCR4 expression on MDA-
MB-435 was rapidly degraded with approximately 40% of the receptor being lost 
within 1 hour (Marchese and Benovic 2001; Li, Pan et al. 2004). However, the levels 
of CXCR4 on MDA-MB-435 stably transfected with HER2 remained almost the 
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same after 1 hour of CXCL12 stimulation (Li, Pan et al. 2004). A pulse-chase assay 
further demonstrated that ligand-induced protein degradation of CXCR4 in HER2 
transfected cells was significantly reduced, therefore, allowing cancer cells to 
maintain high level expression of CXCR4 and extended signalling through the 
receptor potentially contributing to other steps involved in metastasis (McQuibban, 
Butler et al. 2001).  
An in vivo link was also demonstrated between CXCR4 and HER2 expression as 
there was a statistically significant positive correlation between the two in human 
breast tumour samples. The majority of HER2 positive samples also expressed 
CXCR4, whereas, most HER2
 
negative tumours lacked detectable expression of 
CXCR4 (Li, Pan et al. 2004).  
Because CXCL12-CXCR4 signalling has been reported to induce HER2 expression 
in cancer cells, and HER2 signalling has been shown to increase CXCR4 expression, 
this provides an intriguing potential feedback loop between CXCR4 and HER2 
signalling to increase each others expression. 
 
1.6.3.3 NF-κB 
NF-κB is a heterodimeric transcription factor which is made up from a complex of 
Rel family proteins that are physically restricted to the cytoplasm of normal cells by 
interaction with a NF-κB inhibitor. 
NF-κB is able to upregulate the expression of pro-cancer genes including IL-6, IL-8, 
urokinase plasminogen activator (uPA), MMP9 and VEGF (Baeuerle and Henkel 
1994; Nakshatri, Bhat-Nakshatri et al. 1997; Karin and Lin 2002). Because of this 
ability to promote metastasis and angiogenesis, NF-κB activation has been 
implicated in a variety of cancers (Bargou, Emmerich et al. 1997; Sovak, Bellas et al. 
1997; Dong, Chen et al. 1999; Cogswell, Guttridge et al. 2000). In addition to this, 
inhibitors of NF-κB are able to reduce the metastasis in xenograft models (Andela, 
Schwarz et al. 2000). 
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NF-κB is expressed within a wide range of cell types and each cell type has its own 
specific heterodimers, however the most predominant subtype is made up of p50 and 
p65 subunits. 
MDA-MB-231 have a constitutively active NF-κB, however, MDA-MB-231 
generated to overexpress the IκB super-repressor have significantly lowered CXCR4 
transcripts. These cells also had a significantly reduced ability to migrate in response 
to CXCL12 (Helbig, Christopherson et al. 2003). Following transient transfection of 
CXCR4 into MDA-MB-231, the migratory potential of the cells was restored 
(Helbig, Christopherson et al. 2003). The direct control of CXCR4 by NF-κB was 
validated by chIP assay which demonstrated that the NF-κB subunits p65 and p50 
bind directly to sequences between -66 and +7 in the CXCR4 promoter region 
(Helbig, Christopherson et al. 2003).   
Another potential feedback loop could exist between NF-κB and CXCR4 as CXCR4 
signalling through the PI3K/Akt pathway is able to directly regulate NF-κB.    
 
1.6.3.4 VEGF 
VEGF is a signal protein important in angiogenesis and vasculogenesis, functioning 
to promote the formation of new blood vessels which provide essential nutrients to 
tumour cells. The overexpression of VEGF has been implicated in several diseases 
including aggressive forms of breast cancer. Interestingly, it has been reported that 
the expression of VEGF is also able to upregulate CXCR4 in cancer cells (Kijowski, 
Baj-Krzyworzeka et al. 2001; Bachelder, Wendt et al. 2002). 
When brain microvascular endothelial cells were exposed to 50ng/ml of VEGF, the 
mRNA expression of CXCR4 increased 3-fold by 8 hours, and continued to increase 
up to approximately 10-fold after 16 and 24 hours. These findings were similarly 
demonstrated at a protein level where the upregulation of CXCR4 was significantly 
increased after 24 hours (Zagzag, Lukyanov et al. 2006). In vivo studies have 
demonstrated that inhibition of the CXCL12-CXCR4 axis is able to decrease tumour 
growth by inhibiting angiogenesis in a VEGF-dependant manner (Guleng, Tateishi et 
al. 2005).  
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1.6.3.5 Influence of cytokines  
A number of cytokines have been shown to cause an increase in CXCR4 expression 
in a variety of cell types. The cytokines IL-2 (Moriuchi, Moriuchi et al. 1997) IL-4, 
IL-7, IL-15 (Jourdan, Vendrell et al. 2000), IL-10 and TGF-β1 (Wang, Murakami et 
al. 2001) have all been shown to increase the expression of CXCR4. Interestingly, a 
number of these cytokines are present in tumour environments, and could therefore 
lead to the increased expression of CXCR4 and contribute to cancer progression. 
Cancers exist in a state of chronic inflammation where high levels of the 
inflammatory cytokines TNF-α and IFN-γ and IL-1β are present. Interestingly, all 
these cytokines have been reported as causing downregulation of CXCR4 (Feil and 
Augustin 1998; Gupta, Lysko et al. 1998; Han, Wang et al. 2001). 
A schematic representation of factors able to influence an increase in CXCR4 
expression is provided in figure 1.8.  
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Figure 1-8 - Factors able to increase CXCR4 expression on epithelial cells  
CXCR4 upregulation on epithelial cells has been reported to be influenced by a number of 
factors including hypoxia via HIF-1α, HER2, NF-κB, VEGF and also a number of cytokines 
such as IL-2, 4, 7, 15, 10 and also TGF-β1. 
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1.7 FOXP3 
FOXP3 is a forkhead box transcription factor. As a transcription factor, FOXP3 is 
able to work in cooperation with other proteins or directly bind to regulate the 
expression of target genes. FOXP3 is highly expressed in regulatory T-cells (Tregs) 
and governs many of its most characteristic features (Hori, Nomura et al. 2003). In 
addition to Tregs, FOXP3 can also be transiently upregulated in naive T-cells 
conveying many phenotypic features of Tregs, but not the immunosuppressive 
function associated with them (Wang, Ioan-Facsinay et al. 2007). Interestingly, 
FOXP3 has recently been identified within epithelial cells of specific organs. This is 
discussed in the following sections. 
 
1.7.1 Forkhead box protein history and nomenclature 
The first forkhead box (FOX) protein was discovered in the fruit fly Drosophila 
melanogaster in 1990 by Weigel and Jackle (Weigel, Jurgens et al. 1989). It was 
initially identified as a factor required for pattern formation in the terminal regions of 
the embryo (Weigel, Jurgens et al. 1989). Since this discovery, more than 100 FOX 
proteins have been identified in organisms ranging from yeast to humans. The 
number of FOX genes has increased at a greater pace in vertebrates than in 
invertebrates. Within the human genome there are 43 identified FOX genes (Katoh 
2004). These proteins have diverse roles in the body ranging from the development 
and regulation of the immune system (Coffer and Burgering 2004), to development 
of hair (Hong, Noveroske et al. 2001), and hearing and speech (Lai, Fisher et al. 
2001). 
The first international meeting on forkhead transcription factors was held in 1998 at 
La Jolla (California, USA) to agree on a common nomenclature. Prior to this meeting 
forkhead genes were originally given different names such as FKH, FREAC and 
HFH (Kaestner, Knochel et al. 2000). However, because of their common DNA 
binding forkhead box domain, the term FOX was used to describe all chordate 
transcription factors which contain this unique region (Kaestner, Knochel et al. 
2000). FOX proteins are divided into 17 subclasses (denoted A-Q) based on their 
amino acid sequence composition within the forkhead domain. Finally a letter 
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denotes each individual member within the subclass (Kaestner, Knochel et al. 2000). 
The final proposal on this nomenclature was endorsed by more than 20 scientists as 
well as the Human and Mouse Gene Nomenclature Committees. The convention for 
naming human FOX proteins is that all letters are capitalised (e.g. FOXP3) whilst in 
mice, only the first letter is capitalised (e.g. Foxp3) and for all other chordates, the 
first letter and the subclass is capitalised (e.g. FoxP3). Italic script is used to describe 
the genes (e.g. FOXP3 [human]) (Kaestner, Knochel et al. 2000). 
 
1.7.2 Structure  
1.7.2.1 Gene 
The FOXP3 gene is relatively well conserved in mammals (Ziegler 2006). It is 
located on the p arm of the X-chromosome at Xp.11.23. It contains 11 coding exons 
(1–11) and three non-coding exons. The two 5’ non-coding exons (−2a and −2b) are 
located significantly upstream of the coding exons and are spliced into a single 
common non-coding exon (−1) (Lal and Bromberg 2009). There remains controversy 
in the literature over the number of FOXP3 exons; those who describe 11 exons do 
not count the initial −1 non-coding exon which lies outside the protein coding region. 
 
1.7.2.2 Protein 
The full length FOXP3 protein is made up of 431 amino acids. FOXP3 has a 
relatively short half-life of approximately 21 minutes as it undergoes rapid 
polyubquitination and proteosomal degradation (Lee, Gao et al. 2008). 
FOXP3 contains four main domains; a repressor domain, a zinc finger, a leucine 
zipper motif, and the DNA-binding forkhead domain which defines the FOX protein 
membership (figure 1.9). All known FOX proteins share a common, highly 
conserved DNA-binding forkhead box domain. This domain is located towards the 
carboxyl terminus of the protein and contains approximately 80-100 amino acids. 
This alignment of amino acids produces three α helixes, two β strands and two loops 
(figure 1.10) (Kaestner, Knochel et al. 2000). The arrangement of these helix-turn-
helix proteins and the crystal structure when bound to DNA is often said to resemble 
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the wings on a butterfly. As a consequence, this region has been referred to as a 
“winged helix” (Clark, Halay et al. 1993). 
This winged helix is typically invariant across the FOX proteins and the organisms 
they are expressed in; however, the location of the forkhead domain within the 
protein is not so consistent. FOXP3 has similar structural characteristics to all other 
FOXP3 members. FOXP1, FOXP2 and FOXP4 all have centrally located zinc 
fingers, leucine zippers and forkhead domains. However, FOXP3 has the forkhead 
domain located towards the C-terminus (Lopes, Torgerson et al. 2006). This region is 
the primary domain responsible for binding to DNA where the transcription of 
specific genes is regulated. As well as having a relatively invariant forkhead domain, 
a considerable degree of homology in the amino acid composition of FOXP3 across 
different organisms is also maintained. Human FOXP3 shares the greatest 
resemblance with FoxP3 of the rhesus monkey (97%). Interestingly, cows, cats, dogs 
and horses have between 89-90% homology, whereas, mouse Foxp3 shares 86% 
homology to humans (Banham, Lyne et al. 2009). 
A zinc finger is a small structural motif often found in proteins. The term zinc finger 
was first used when describing the finger like appearance in the structure of the 
transcription factor IIA found in the African clawed frog Xenopus laevis (Klug and 
Rhodes 1987). Many zinc finger domains utilise zinc ions to stabilise the folding of 
the protein, however, despite the name, zinc fingers will bind other metals such as 
iron or even non-metals (Krishna, Majumdar et al. 2003). Zinc fingers are frequently 
found in transcription factors, where the vast majority demonstrate a strong capacity 
to interact. Studies frequently report zinc fingers interacting with DNA, RNA, 
proteins and other small molecules depending on their amino acid sequence within 
the finger domain (Krishna, Majumdar et al. 2003). The zinc finger present in 
FOXP3 is classed as a C2H2 (Cys2-His2) which is most common form in mammalian 
transcription factors (Krishna, Majumdar et al. 2003). The full function of the zinc 
finger present in FOXP3 has yet to be fully elucidated, with no current reports 
demonstrating a conclusive role.   
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Figure 1-9 - Schematic representation of human FOXP3 
The X-chromosome located FOXP3 gene consists of 11 coding exons and 1 non-coding 
exon, which is located towards the N-terminal. Full length FOXP3 is made up 431 amino 
acids and 4 domains. Image taken from (Douglass, Ali et al. 2012). 
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Figure 1-10 - Loops and helixes of the forkhead domain in FOXP proteins 
(A) The Forkhead domain in FOX proteins consists of two wings (W1 & W2) and three 
helixes (H1-H3) (Coffer and Burgering 2004). (B) When these helixes and wings are 
arranged they are said to resemble the “wings on a butterfly” (image of FOXP2, taken from 
Protein Data Bank (PBD) rendering based on 2a07.  
 
 
 
 
 
 
 
 
 
 
 
 
A B
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It has been reported that FOXP3 regulates approximately 700 genes in humans, 
functioning as either a transactivator or repressor to these genes (Zheng, Josefowicz 
et al. 2007). 
Despite the difference in location of the forkhead domain in FOXP3, FOXP proteins 
have considerable homology between the forkhead domain, leucine zipper and zinc 
finger domains, however, main differences between FOXP proteins are found within 
the N-terminal region (Lopes, Torgerson et al. 2006). FOXP1, FOXP2 and FOXP4 
contain polyglutamine tracts (Wang, Lin et al. 2003), however, FOXP3 contains a 
proline rich region allowing for kinks and turns in the protein (Lopes, Torgerson et 
al. 2006). As with many transcription factors, reports have demonstrated that 
transcriptional repression of specific genes by FOXP3 is dependent on regions 
outside of the DNA-binding forkhead domain (Lopes, Torgerson et al. 2006). Mutant 
FOXP3 proteins lacking the forkhead domain have an ability to repress transcription 
to a similar level as wild type FOXP3. In addition, this ability to repress transcription 
was not significantly affected in mutants lacking the leucine zipper and zinc finger as 
well as the forkhead domain. However, a FOXP3 mutant lacking the N-terminal 198 
amino acids was not able to significantly repress transcription (figure 1.11). 
Therefore, between amino acids 67-132 in FOXP3 have been termed as the repressor 
domain (Lopes, Torgerson et al. 2006). 
Most transcription factors bind to DNA in a homo-multimeric fashion, or as part of a 
complex containing other transcription factors. However, the majority of FOX 
proteins exist as monomers in a solution and when they bind to DNA (Li and Tucker 
1993). The ability to heterodimerise extends the range of biological functions within 
the FOXP subfamily (Shu, Yang et al. 2001). 
It has been demonstrated that FOXP1, FOXP2 and FOXP4 are all capable of 
interacting with each other either as homodimers or heterodimers (Li, Weidenfeld et 
al. 2004). In addition, it has been demonstrated that FOXP1 and FOXP3 are capable 
of interacting in in vitro assays (Wang, Lin et al. 2003). FOXP3 is also capable of 
homodimerisation. The leucine zipper is the domain which is both necessary and 
sufficient for this activity as mutations affecting this region result in loss of 
homodimerisation (Lopes, Torgerson et al. 2006). 
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As mentioned previously, FOXP3 often functions through the interactions of several 
transcription factors such as Runt-related transcription factor 1 (Runx1) and nuclear 
factor of activated T-cells (NFAT), thereby proving its ability to heterodimerise. The 
association of FOXP3 with other transcription factors is discussed in section 1.7.6. 
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Figure 1-11 - Regions responsible for FOXP3-mediated gene repression 
Image demonstrates that wild type FOXP3 (A) and FOXP3 mutants missing the forkhed 
domain (B) and a mutant only containing the first 1-198 amino acids (C) are capable of 
significant gene repression, however, a mutant FOXP3 missing amino acids 1-198 and the 
forkhead domain (D) and also a mutant only containing the forkhead (E) are unable to 
repress the transcription of gene (Lopes, Torgerson et al. 2006). 
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1.7.3 Scurfy and IPEX 
The Foxp3 gene was first discovered in mice as a result of a spontaneous mutation at 
the Oak Ridge National Laboratory in 1949 (Godfrey, Wilkinson et al. 1991; Chatila, 
Blaeser et al. 2000). This condition was later described as scurfy, whereas, the 
human equivalent of scurfy is known as Immune dysregulation, Polyendocrinopathy, 
Enteropathy, X-linked syndrome (IPEX). A mutation in FOXP3 is the only cause of 
IPEX syndrome. Although, a number of IPEX-like syndromes also exist. These 
individuals have many clinical symptoms of IPEX patients, but they do not have 
mutated FOXP3. Many patients with IPEX-like syndrome also have defective Treg 
development, however, despite having functional FOXP3, studies have described 
these patients as having dysfunctional CD25 expression on CD4
+
 T-cells, a lack of 
sensitivity to IL-2 (since CD25 is the α-chain of the IL-2 receptor and encoded by 
IL2RA) and reduced IL-10 expression (Caudy, Reddy et al. 2007). 
The first IPEX syndrome was reported by Powell et al (Powell, Buist et al. 1982) in 
1982 who described a clinical triad of features including watery diarrhoea, 
eczematous dermatitis and endocrinopathy. IPEX unfortunately has high motility 
rates with symptoms typically presenting within the first year and the majority of 
mortality occurring within the first or second year of life.  
As the master regulator of the function and development of Tregs, it is no surprise 
that the major problems encountered by IPEX patients occur as a result of 
overwhelming chronic autoimmunity due to a lack of Tregs.  
IPEX symptoms generally present within the first few months of life.  A number of 
distinctive and defined symptoms are associated with IPEX. These include 
enteropathy as the immune system attacks the intestinal epithelial cells causing 
severe diarrhea. This is usually the first symptom associated with IPEX. This also 
causes a failure to gain weight and grow at the expected rate with observable 
cachexia. Dermatitis and psoriasis, with heavy inflammation of the skin and eczema 
is also commonly witnessed. IPEX individuals often develop multiple disorders 
associated with the endocrine glands, hence the term polyendocrinopathy. Type 1 
diabetes mellitus is the most common endocrinopathy associated with IPEX, 
although the thyroid gland may also be affected. Autoimmune blood disorders such 
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as anaemia, thrombocytopenia and neutropenia have also been reported in patients, 
although these are less frequent.    
IPEX patients are treated using a haematopoietic stem cell transplant (HSCTx). 
Although there are a number of complications associated with HSCTx, this treatment 
has been demonstrated to be highly effective in alleviating the clinical symptoms. In 
attempts to limit the effects of autoimmunity, immunosuppressive drugs are 
administered until a suitably matched donor is found for the HSCTx. The adoptive 
transfer of FOXP3
+
 T-cells is able to prevent the onset of scurfy in mice (Fontenot, 
Gavin et al. 2003; Huter, Punkosdy et al. 2008). 
 
1.7.4 Natural isoforms 
Human CD4
+
CD25
hi
 Tregs express two natural FOXP3 isoforms (Allan, Passerini et 
al. 2005). This notion was also supported in normal breast epithelial cells (Zuo, 
Wang et al. 2007). Both Tregs and epithelial cells of specific organs express a full 
length version (FOXP3FL) and a version with a complete deletion of exon 3 
(FOXP3Δ3) (or 2 depending on the authors preference to numbering exons), which is 
approximately 4kDa smaller in size than its full length counterpart. It is thought that 
these isoforms are expressed in approximately equal ratio. When originally reported, 
exon 3 was thought to lie in a relatively uncharacterised region which did not have 
any known protein domains.  
Full length and Δ3 variants of FOXP3 were transiently transfected into Jurkat cells 
and measured to see if either isoform could repress the expression of IL-2 by 
suppressing the activation of the IL2 promoter (Smith, Finney et al. 2006). Co-
expression of the isoforms resulted in significant repression of IL2 by both isoforms. 
Importantly, the level of suppression on the promoter was almost identical which 
suggested that FOXP3Δ3 also acts as a transcriptional repressor (Smith, Finney et al. 
2006). A contrasting report by Allan et al (Allan, Passerini et al. 2005) demonstrated 
that expression of FOXP3Δ3 is less effective than the full-length version at 
suppressing IL-2 therefore leaving the functional capabilities of FOXP3Δ3 unclear.  
Since the report by Allen et al (Allan, Passerini et al. 2005) was published it has been 
shown that the region where exon 3 lies has been demonstrated as a repressor domain 
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(described previously in section 1.7.2.2). In T-cells, the region where exon 3 lies has 
been shown to interact and inhibit retinoic receptor-related orphan receptor-α (ROR-
α). This leads to the expression of genes responsible for generating Th17 cells, and 
on this basis, it is thought that only full length versions of FOXP3 are capable of 
regulating the differentiation of Th17. It is thought that the FOXP3Δ3 version acts as 
the dominant negative isoform (Ziegler 2006). It is important to note that unlike in 
humans, mice only express the full length Foxp3 variant which represents the 
orthologue for human FOXP3 (Allan, Passerini et al. 2005). 
 
1.7.5 Intracellular trafficking  
As a transcription factor, the ability to transport to the nucleus is a prerequisite for 
effective functioning of FOXP3. However, because the FOXP3 protein is synthesised 
in the cytoplasm, it must then be actively transported to the nucleus of cells. Despite 
this, few reports have studied the mechanisms involved in the transport of FOXP3 to 
the nucleus.  
A consensus arginine-lysine-lysine-arginine (RKKR) sequence has been reported as 
critical in the localisation of proteins to the nucleus (Mikami, Hori et al. 2005; Lopes, 
Torgerson et al. 2006; Song, Waataja et al. 2006). This sequence is found towards 
the C-terminus of the forkhead domain in FOXP3 and is conserved between human 
and mouse FOXP3. 
Hancock and Ozkaynak (Hancock and Ozkaynak 2009) reported that three domains 
were required for nuclear localisation of full length Foxp3 (figure 1.12). These 
regions were subsequently defined as nuclear localisation sequences (NLS). Firstly, 
the authors reported that in murine Foxp3, the RKKR sequence does not act as a 
classic NLS in full length Foxp3, but is required in shortened versions of the protein.   
Several constructs were designed where single or multiple residues of the RKKR 
sequences were replaced with unrelated amino acids in a full length Foxp3 protein. 
Results showed that none of these constructs altered the proteins ability to translocate 
to the nucleus (Hancock and Ozkaynak 2009). Two further constructs were designed 
where the C-terminal 12 amino acids were cleaved from the protein revealing a C-
short protein. One of these constructs had the RKKR sequence maintained, whereas, 
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the other construct had the entire RKKR sequence replaced with unrelated amino 
acids. Results demonstrated that the C-short construct, with the maintained RKKR 
sequence, transported at a similar rate as a full version, whereas, the construct with 
mutated RKKR suffered a significantly slower rate of nuclear localisation with the 
majority remaining in the cytoplasm (Hancock and Ozkaynak 2009). However, 
removal of this domain appeared to slow the rate of transport, as after 5 days the 
mutant protein was found to be exclusively located in the nucleus (Hancock and 
Ozkaynak 2009). 
When the C-terminal 12 amino acids were restored to the construct, which lacked the 
wild type RKKR sequence, the ability to translocate to the nucleus was also restored 
(Hancock and Ozkaynak 2009). Therefore, the C-terminal 12 amino acids were 
subsequently defined as NLS-1. The fact that the removal of this domain did not 
completely abrogate transport suggests other domains are also involved.  
The second region, defined as NLS-2, lies directly N-terminal to the forkhead 
domain and consists of two histidine–asparagine–methionine (HNM) repeats 
separated by five amino acids (Hancock and Ozkaynak 2009). Foxp3 proteins which 
contain mutations in this region have a significantly impaired ability to translocate to 
the nucleus. Within the five amino acids separating the HNM repeats is a lysine 
residue. When this lysine residue is maintained, the nuclear translocation rate was 
only minimally affected, indicating that this residue plays an important role 
(Hancock and Ozkaynak 2009). 
The final region (NLS-3) is located within the first N-terminal 51 amino acids. A 
protein lacking these amino acids also had a significantly reduced rate of nuclear 
translocation (Hancock and Ozkaynak 2009). Mutant Foxp3 proteins which lacked 
all three of these NLS regions were located almost exclusively in the cytoplasm. 
In contrast to these findings, Lopes et al (Lopes, Torgerson et al. 2006) made a GFP-
FOXP3 fusion protein with a series of overlapping mutations or deletions. Their data 
demonstrated that changing two basic amino acids to acidic amino acids within the 
RKKR sequence abrogated the nuclear import of the protein, thus suggesting this 
sequence was important in the nuclear localisation of FOXP3.    
Chapter 1 - General introduction 
58 
 
When IPEX patients were screened for point mutations, no patients were found to 
contain mutations within the RKKR sequence (Lopes, Torgerson et al. 2006). 
However, one patient did contain a mutation which did slightly abrogate nuclear 
localisation (Lopes, Torgerson et al. 2006). This mutation was found at the opposite 
side of the forkhead domain, and even then nuclear localisation was only slightly 
reduced. These regions either side of the forkhead domain have also been 
demonstrated as NLS in hepatocyte NF-3β which is another forkhead family member 
(Qian and Costa 1995). 
There are possible explanations for these conflicting reports on the RKKR domain in 
murine Foxp3 and the GFP-FOXP3 construct. 
 There are 3 proline residues in the 12 amino acid tail of mouse Foxp3 but 4 
proline residues in the 14 amino acid tail in human FOXP3. This may induce 
changes in the secondary structure of FOXP3 which may alter the function of 
the RKKR sequence. 
  
 Because of the size of GFP, the use of a GFP-tagged human FOXP3 may 
affect the overall structure of the protein, altering the function of specific 
regions.  
 
 Despite considerable homology between human and murine, FOXP3 changes 
are apparent which could have profound consequences on nuclear 
translocation 
Finally, particular caution should be taken regarding results based around the murine 
GFP–FOXP3 construct. The addition of the 238 amino acids GFP protein to the N-
terminus of FOXP3 causes steric hindrance, and thus abrogates the function of 
FOXP3 including the ability to physically interact with other transcriptional partners 
(Darce, Rudra et al. 2012). Based on this finding, much of what we have discovered 
about the functions of FOXP3 using the GFP–FOXP3 construct may be an artefact 
because of the hypomorph. It should also be noted that FOXP3 does not necessarily 
always interact with other transcription factors through its N-terminal domain; it is 
known that FOXP3 is capable of interacting with other FOXP family members 
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through the leucine zipper region and interacts with NFAT through the FKH domain 
(Wu, Borde et al. 2006). This is discussed in the next section.  
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Figure 1-12 - Locations of Foxp3 nuclear sequences  
Schematic representation of sequences and regions demonstrated to be responsible for Foxp3 
nuclear localisation. Brown ovals high each individual as highlighted by Hancock & 
Ozkaynak (Hancock and Ozkaynak 2009). The location of the RKKR sequence deemed 
important by Lopes et al (Lopes, Torgerson et al. 2006) is also demonstrated towards the C-
terminus of the protein. Image taken from (Douglass, Ali et al. 2012).   
 
 
 
 
 
 
 
 
 
 
N C
...HNMDYF KFHNM...
...LEF RKKR SQR...
Amino acid no.
NLS-3 NLS-2 NLS-1
Chapter 1 - General introduction 
61 
 
1.7.6 FOXP3 association with other transcription factors 
An increasing amount of data is being produced to demonstrate that many normal 
functions of FOXP3 are reliant on interactions with other proteins.  
FOXP3 contains conservative non-coding sequences. One of these sequences lies 5’ 
to the transcriptional start site and has been reported to act as a proximal promoter 
region (Zhang, Meng et al. 2008). This region contains several important sequences 
including TATA, GC and CAAT boxes which are considered the key sequences for 
binding transcription factors suggesting FOXP3, like many other transcription 
factors, works in cooperation with other proteins. This notion was further enhanced 
as a mutation in this region significantly decreased the activity of FOXP3 (Mantel, 
Ouaked et al. 2006). 
 
1.7.6.1 Homo-dimersation  
As described in section 1.7.2.2, FOXP3 contains a leucine zipper motif which is 
primarily responsible for the interaction with other transcription factors. It has been 
reported that FOXP3 is able to form both homo-tetramers and homo-oligomers (Zuo, 
Liu et al. 2007). Interestingly, it was also demonstrated that FOXP3 with a mutated 
leucine zipper is also unable to bind the NFAT/forkhead site of the IL-2 promoter 
which suggests that the ability of FOXP3 to homo- hetero-dimerise is a prerequisite 
for transcriptional repression (Lopes, Torgerson et al. 2006; Zuo, Liu et al. 2007).  
On the other hand, it would appear that the actions of FOXP3 are not always solely 
dependent on the interactions with other proteins via the leucine zipper, as a FOXP3 
mutant missing amino acid 250 is still able to suppress IFN-γ (Chae, Henegariu et al. 
2006). 
 
1.7.6.2 NFAT 
NFAT is a transcription factor imperative for the transcription of activation-
associated genes in T-cells, hence the name. Cooperation of FOXP3 and NFAT is 
relatively well documented. Unsurprisingly, many genes including IL2, CD25 and 
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CTLA4 which are regulated by FOXP3 are also closely linked to NFAT, suggesting a 
high level of interaction between the two proteins (Rao, Luo et al. 1997; Hori, 
Nomura et al. 2003; Wu, Borde et al. 2006). 
It has since been demonstrated that FOXP3 does control many NFAT-mediated 
genes by forming a cooperative complex. Amongst the genes involved in this 
cooperation are IL2, CD25 and CTLA4 (Rao, Luo et al. 1997; Hori, Nomura et al. 
2003). This suggests the complex of FOXP3 and NFAT are crucial in the 
development and function of Tregs (Bettelli, Dastrange et al. 2005; Wu, Borde et al. 
2006). Further evidence of this hypothesis is provided by data demonstrating that a 
mutant version of FOXP3, which is incapable of interacting with NFAT, is unable to 
suppress IL-2 production and also fails to upregulate CTLA-4 and CD25. Moreover 
this mutant was also unable to suppress autoimmunity in vivo (Wu, Borde et al. 
2006). NFAT and another transcription factor, activator protein 1 (AP-1) also work 
closely together, however, since it has been shown that FOXP3 is able to directly 
interact with NFAT as well as AP-1 DNA target sequences, it is thought that NFAT 
binds to FOXP3 preferentially and replaces AP-1 (Wu, Borde et al. 2006). 
 
1.7.6.3 NF-κB 
The interaction of FOXP3 and NF-κB has been demonstrated in non-immune cells 
by several reports, however, this interaction has not yet been demonstrated within 
immune cells, therefore, suggesting this interaction could be key for epithelial cell 
homeostasis but not for T-cell function.  
Within non-immune cells, FOXP3 is able to inhibit the transcription of NF-κB 
mediated genes (Bettelli, Dastrange et al. 2005; Kwon, So et al. 2008) and also the 
expression of NF-κB itself (Zhang and Sun 2010; Loizou, Andersen et al. 2011). 
NF-κB is usually located within the cytoplasm and inhibited by IκB. However, after 
activation, the IκB is removed and the protein is actively transported to the nucleus. 
Kwon et al (Kwon, So et al. 2008) produced data which demonstrated that the 
expression of FOXP3 enhanced the stability of IκB which prevented the nuclear 
translocation of NF-κB (Kwon, So et al. 2008). A separate report highlighted that 
FOXP3 directly interacts with c-Rel to inhibit NF-κB expression (Loizou, Andersen 
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et al. 2011). Interestingly, c-Rel has also been demonstrated to influence the 
activation of IL-2 (Huang, Chen et al. 2001). 
  
1.7.6.4 Runx1 
Runx1 is a member of the runt-related family of transcription factors which also 
contains Runx2 and Runx3. Runx1 is expressed within Tregs and T-effector cells and 
has been highlighted as a regulator of IL-2 and IFN-γ (Ono, Yaguchi et al. 2007). 
Within amino acids 278-336 of FOXP3, a region between the leucine zipper and the 
forkhead domain, lies a Runx1 binding domain (Ono, Yaguchi et al. 2007).  
Interactions between Runx1 and FOXP3 appear to have important effects on the 
function of Tregs as a mutant version of FOXP3, unable to bind Runx1, was also 
unable to effectively suppress IL-2 production (Ono, Yaguchi et al. 2007). In 
addition to this, Runx1 knockdown in human Tregs abrogated their suppressive 
capacity (Ono, Yaguchi et al. 2007). A mutation within the Runx1 binding region of 
FOXP3 has also been reported in IPEX patients (Bacchetta, Passerini et al. 2006).  
 
1.7.6.5 ROR-α 
The FOXP3-ROR-α interaction has been confirmed using chIP studies (Du, Huang et 
al. 2008). However, FOXP3 repression of ROR-α is relatively unique. Unlike many 
other interactions, which reportedly require the forkhead domain or the leucine 
zipper, FOXP3 repression of ROR-α is dependent on a region within exon 3, 
therefore, only full length FOXP3 variants are able to fulfil this interaction (Du, 
Huang et al. 2008). ROR-α has recently been identified as a key mediator in the 
development of Th17 cells which has since lead to the hypothesis that FOXP3, and 
moreover, specific FOXP3 isoforms are involved in Th17 development.   
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1.7.7 Cellular expression of FOXP3 
1.7.7.1 Tregs 
Through evolution, our bodies have developed an almost perfect mechanism to 
protect ourselves from pathogens. This is referred to as tolerance. Our central 
tolerance is based within the thymus which aims to delete auto-reactive T-cells 
before they are released into the circulation. However, as effective as this is, some 
harmful T-cells may escape the positive/negative selection process as we now have 
evidence from the presence of various autoimmune disorders. Therefore, we have 
developed a secondary mechanism called peripheral tolerance which attempts to 
combat the autoreactive T-cells that have escaped central tolerance. The main 
effectors involved in peripheral tolerance are Tregs; these cells are capable of 
modulating the activation and proliferation of potentially harmful T-cells. Tregs 
make up approximately 1-2% of whole blood and 5-10% of CD4
+
 T-cells in humans 
(Long, Cerosaletti et al. 2010). In comparison to regular T-cells, Tregs have several 
distinguishable characteristics, most of which are directly controlled through FOXP3 
interactions. FOXP3 is therefore commonly used as the most reliable marker for 
Tregs.   
The ability of FOXP3 to act as a transcriptional activator and repressor of specific 
genes is well documented and can be best demonstrated within the roles it plays in 
defining the most characteristic features of Tregs. As well as expressing CD4, Tregs 
have characteristically high level expression of the IL-2 α-chain receptor (CD25), 
therefore, being referred to as CD4
+
CD25
hi
 T-cells. However, unlike other T-cells, 
despite this high level expression of the IL-2 receptor, they fail to synthesise and 
secrete IL-2, but do require the cytokine to survive (Sakaguchi 2005). FOXP3 has 
been demonstrated to bind directly to the 5’ promoter region of the IL2ra gene 
(which results in the activation and expression of CD25) and also the IL2 gene 
(which results in the repression of the gene responsible for producing IL-2) (Chen, 
Rowell et al. 2006). Tregs also have high expression of CTLA-4, a cell surface 
molecule which is able to interact with CD80 and CD86 which delivers inhibitory 
signals and is thought to be responsible for the direct cell-cell suppression by Tregs. 
FOXP3 binds directly to promoter regions in the CTLA4 gene and is therefore also 
responsible for high level CTLA-4 expression on Tregs (Chen, Rowell et al. 2006). 
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Other key features of Tregs governed directly by FOXP3 are the low level expression 
of IL-7R (by repressing IL7ra) and lack of IFN-γ (by binding to IFNG locus) (Chen, 
Rowell et al. 2006). 
 
1.7.7.2 Epithelial cells  
Because of the high expression and influence FOXP3 has in Tregs it was originally 
thought that FOXP3 was restricted to cells of the lymphocyte lineage. However, 
pioneering research from Chen et al (Chen, Chen et al. 2008) demonstrated the 
expression of Foxp3 within the nucleus of epithelial cells in select organs of mice 
(figure 1.13). FOXP3 has now been demonstrated within the epithelial cells of the 
breast (Zuo, Liu et al. 2007; Zuo, Wang et al. 2007; Chen, Chen et al. 2008; Merlo, 
Casalini et al. 2009; Li, Wang et al. 2011), prostate (Wang, Liu et al. 2009; Li, Wang 
et al. 2011), lung (Chen, Chen et al. 2008), ovaries (Zhang and Sun 2010) and brain 
(Frattini, Pisati et al. 2012). Organ specificity was also demonstrated as Foxp3 was 
not located within liver, intestine or kidney epithelia (Chen, Chen et al. 2008). 
Despite a number of reports demonstrating clear presence of FOXP3 in some 
epithelial tissues, it should also be noted that it is expressed at levels significantly 
lower than the levels found in Tregs, where it is expressed at similar level of 
housekeeping genes (Wang, Liu et al. 2009).  
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Figure 1-13 - Organ specific expression of Foxp3 in epithelial cells  
Foxp3 is found in epithelial cells of specific organs such as the prostate. However, Foxp3 is 
not found within the small intestine. Images taken (Wang, Liu et al. 2009) (top image) and 
(Chen, Chen et al. 2008). 
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1.7.8 FOXP3 involvement in cancer 
A number of malignancies have been linked to FOXP3 expression including 
colorectal cancer (Somasundaram, Jacob et al. 2002), head and neck cancer 
(Schaefer, Kim et al. 2005), hepatocellular carcinoma (Unitt, Marshall et al. 2006), 
cancers of the breast (Zuo, Liu et al. 2007; Zuo, Wang et al. 2007; Merlo, Casalini et 
al. 2009; Li, Wang et al. 2011), pancreas (Liyanage, Moore et al. 2002), 
gastrointestinal tract (Sasada, Kimura et al. 2003; Kawaida, Kono et al. 2005), lung 
(Woo, Chu et al. 2001), ovarian cancer (Zhang and Sun 2010), melanoma 
(Baumgartner, Wilson et al. 2007; Ahmadzadeh, Felipe-Silva et al. 2008; Gerber, 
Munst et al. 2013), cervical cancer (Fattorossi, Battaglia et al. 2004), lymphoma 
(Berger, Tigelaar et al. 2005) and leukemia (Ghiringhelli, Larmonier et al. 2004; 
Beyer, Kochanek et al. 2005). However, FOXP3 appears to act as a “double edged 
sword” in many of these malignancies, with its expression often reported as either 
favourable or bad. The opposing scenarios are often dependant on the cells where 
FOXP3 expression is investigated.    
The filtration of various leukocytes into the tumour microenviroment is well 
established. T-cells, in particular are found in high quantities around the tumour 
mass. Many of these T-cells are Tregs, therefore, FOXP3 is often reported to be 
increased in many malignant tissues and represents a worse prognosis (Matsuura, 
Yamaguchi et al. 2009; Rech, Mick et al. 2010; Yuan, Chen et al. 2010; Gupta, Babb 
et al. 2011). This infiltration of Tregs is thought to act as a mechanism of immune 
evasion by the tumour as the presence of Tregs within the tumour microenvironment 
can suppress the anti-cancer properties of other immune cells recruited to the region. 
In addition to this, it has been demonstrated that many tumours produce and secrete 
high levels of TGF-β (Liu, Wong et al. 2007), therefore, this could also enhance the 
induction of FOXP3 in CD4
+
CD25
-
 T-cells and drive the differentiation of naive T-
cells into acquired Tregs, therefore, contributing further to the suppression. 
Infiltration of T-cells and Tregs into the tumour environment is discussed further in 
section 5.1.1.  
Wang et al (Wang, Liu et al. 2009) were the first group to examine the expression of 
FOXP3 within the epithelial cells of both normal and malignant prostate tissue. 
Firstly, they demonstrated that 85/85 normal prostate tissues examined contained 
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nuclear FOXP3, whereas, only 31.5% of malignant tissue contained nuclear FOXP3 
(Wang, Liu et al. 2009). They also observed that FOXP3 was significantly 
downregulated within samples with clearly identifiable prostate epithelial neoplasia 
(PIN) in comparison to healthy tissues, thus suggesting that FOXP3 downregulation 
occurred at an early stage of carcinogenesis (Wang, Liu et al. 2009).  
When the mRNA levels of FOXP3 were investigated in benign and malignant tissue 
from matched patients, it was demonstrated that 14 out of 18 malignant tissues had a 
2-10-fold reduction of FOXP3. In addition to this, 6 out of 18 cases also contained 
PIN. When these lesions were microdissected it was also demonstrated that FOXP3 
was downregulated, once again emphasizing that FOXP3 downregulation within 
prostate cancer occurs in an early stage of carcinogenesis (Wang, Liu et al. 2009).  
Next, fluorescence in situ hybridisation (FISH) was used to determine whether the 
FOXP3 gene was deleted in any prostate cancer samples. Out of 165 prostate cancer 
tissues they found that 23 samples had FOXP3 deletions (Wang, Liu et al. 2009). 
Moreover, 5 of these 23 cases had X-chromosome polysomy. Interestingly, the 
FOXP3 deletion was observed in all X chromosomes thus demonstrating that the X 
polysomy occurs after FOXP3 is deleted (Wang, Liu et al. 2009). Evidence of 
somatic FOXP3 mutations in primary prostate was demonstrated when DNA from 
malignant and normal tissue from 20 matched patients was compared. Results 
demonstrated that five of the cancer samples contained single base-pair changes. 
Four of these mutations were missense mutations. Two of the samples had clear PIN 
and when these lesions were microdissected they found that both patients contained 
the same mutations as the patients with malignancy (Wang, Liu et al. 2009).  
The presence and importance of FOXP3 regulation within ovarian epithelial cells has 
also been demonstrated by Zhang and Sun (Zhang and Sun 2010). IHC demonstrated 
that FOXP3 protein was found within the normal ovarian epithelium samples, 
however, weak or no expression was found in the malignant samples. Similar results 
were observed when FOXP3 transcripts were compared by real-time PCR in the 
malignant and normal samples. In all 26 cancer samples analysed, FOXP3 transcripts 
were significantly lower than those found in normal ovarian specimens (Zhang and 
Sun 2010).   
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A similar report by Frattini et al (Frattini, Pisati et al. 2012) demonstrated that 
despite normal FOXP3 levels within the human brain, FOXP3 was strongly 
downregulated within the majority of 35 human glioblastoma samples. Interestingly, 
using murine glioma cells they found that Foxp3 was detectable within early stages 
of tumour development, but diminished through tumorigenesis (Frattini, Pisati et al. 
2012). Therefore, this data would suggest that Foxp3 expression could be involved in 
tumour progression more so than initial carcinogenic transformation, thus opposing 
the findings from Wang et al (Wang, Liu et al. 2009).  
A similar scenario of FOXP3 expression within malignant and normal breast tissue 
has also been described in several reports and is discussed in 3.1.1.      
Despite these findings, alternative reports have demonstrated a completely different 
scenario where FOXP3 expression is restricted to cancer cells. Hinz et al (Hinz, 
Pagerols-Raluy et al. 2007) used IHC to demonstrate that normal human pancreatic 
duct cells did not express FOXP3, however, in the pancreatic cancer cells FOXP3 
was clearly identifiable. The fact that the majority of the FOXP3 staining in these 
cells was cytoplasmic would question the contribution of FOXP3 in these cells. 
However, the same authors (Hinz, Pagerols-Raluy et al. 2007) also demonstrated that 
FOXP3 expressing pancreatic cell lines were able to inhibit the proliferation of 
activated T-cells, therefore, suggesting a potential mechanism of conveying immune 
evasion by epithelial cells. 
A similar scenario was described in melanoma cells by Ebert et al (Ebert, Tan et al. 
2008) who used real-time PCR to demonstrate the presence of both natural FOXP3 
isoforms in melanoma cells, but not in normal human melanocytes. IHC also 
demonstrated the presence of FOXP3 protein in the melanoma cells which, in these 
cell, was nuclear. 
It should be noted that these alternative findings could be attributed to differing 
epithelial subsets and therefore the behaviour of FOXP3 in certain epithelia could 
also differ.  
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1.7.9 FOXP3, the X-linked tumour suppressor gene 
A female’s genetic makeup consists of two X-chromosomes (XX), whereas a male’s 
consists of one X-chromosome and one Y-chromosome (XY). In both males and 
females, the X-chromosome is gene rich and is estimated to contain more than 1000 
genes. Because of this, if both X-chromosomes were activated in females this 
“double dosage” would be potentially toxic. In order to equalise this, females have a 
unique way to neutralise this effect by inactivating one of their X-chromosomes and 
silencing one set of X-linked genes. The decision of which X-chromosome is de-
activated is random and begins at the early stages of embryonic stem cell 
differentiation. Once deactivated, the X-chromosome is condensed into a compact 
structure called a barr body (Boumil and Lee 2001). Because of this dose 
compensation, X-linked genes are frequently referred to as dose compensated. 
The vast majority of TSGs (discussed in section 1.4.5) are located on non-sex 
chromosomes and are autosomal and are inherited in a recessive manner. Therefore, 
autosomal recessvie genes require two genetic events to inactivate them. This 
process was first described by Knudson in his two hit hypothesis (Knudson 1971). 
It has been generally accepted now that within epithelial cells FOXP3 acts a TSG by 
controlling the expression of a number of genes implicated in cancer. FOXP3 is able 
to directly repress the expression of the oncogenes ErbB2 (Zuo, Wang et al. 2007), 
SKP2 (Zuo, Liu et al. 2007) and c-MYC (Wang, Liu et al. 2009) whereas, it is able to 
upregulate the expression of a number of anti-cancer genes including CDKN1A (Liu, 
Wang et al. 2009). This emphasises the importance of normal FOXP3 expression in 
epithelial cells. The importance of the aforementioned genes in driving 
carcinogenesis and the control FOXP3 has on them is discussed in section 4.1, 
whereas, the role it plays in LATS2 and BRCA1 regulation is discussed in sections 
1.7.9.1 and 1.7.9.2.   
Due to its genetic location on the X-chromosome, FOXP3 is classed as an X-linked 
TSG. This makes FOXP3 the first X-linked TSG to be identified, however, the 
consequence of being an X-linked TSG is that unlike autosomal TSG’s, they are 
hemizygous and will only require a single genetic event to inactivate them, thus 
increasing the risk of carcinogenic transformation. Based on this, it is important to 
acknowledge and carefully monitor females who carry a recessive FOXP3 mutant. 
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Although these females will not display any phenotypic changes, should this wild 
type gene become damaged or inactivated, the recessive mutant gene will be 
expressed which could lead to a change in the womans phenotype and a much 
increased risk of developing breast or ovarian cancer. Women who are gentyped as 
FOXP3 mutant carriers should perhaps undergo screening more frequently.     
 
1.7.9.1 LATS2 
The Hippo-pathway is made up of the key components Yes-associated protein 
(YAP), LATS1/2 and Mst1/2 (Li, Wang et al. 2011). YAP is a transcription factor 
which functions in an unphosphorylated state where it is able to regulate gene 
expression. When YAP is phosphorylated it is rapidly degraded. The enzymes which 
are responsible for this phophorylation are LATS1/2 (Zhao, Li et al. 2010) Therefore 
LATS2 largely regulates cell cycle proliferation and apoptosis by repressing the 
expression of YAP.  
YAP-overexpression has been reported in several cancers including the prostate, 
liver (Zhao, Wei et al. 2007; Xu, Yao et al. 2009), breast, colon, lung (Wang, Dong 
et al. 2010) and ovaries (Steinhardt, Gayyed et al. 2008), whereas, LATS2 is 
significantly downregulated in cancers of the breast (Takahashi, Miyoshi et al. 2005), 
prostate (Powzaniuk, McElwee-Witmer et al. 2004), brain (Jiang, Li et al. 2006) and 
various blood-born cancers (Jimenez-Velasco, Roman-Gomez et al. 2005). 
FOXP3 has been reported to directly bind and upregulate LATS2 in human prostate 
and breast epithelial cells. Li et al (Li, Wang et al. 2011) stained human tumours for 
FOXP3 and LATS2 and demonstrated that 71% of FOXP3
 
positive tumours also 
expressed LATS2, whereas, only 46% of FOXP3
 
negative tumours expressed 
LATS2. The same report (Li, Wang et al. 2011) used FOXP3-inducible MCF-7 cells 
to demonstrate that following FOXP3 induction, LATS2 transcripts were increased 
10-fold after 3 days. Further evidence was provided when a major reduction of 
LATS2 transcripts was witnessed following FOXP3 knockdown in TSA (mouse 
breast cancer cell line) and MCF-10A cells, whereas, an increase in YAP 
phosphorylation was reported when FOXP3 was transfected into 293 cells (Li, Wang 
et al. 2011).   
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This demonstrates that FOXP3 regulates the phosphorylation of YAP by directly 
regulating LATS2 expression.   
 
1.7.9.2 BRCA1  
Li et al (Li, Katoh et al. 2013) demonstrated that FOXP3 directly binds and represses 
the expression of BRCA1 and that silencing of FOXP3 in human sarcoma cells 
increased the rate of DNA repair. This suggests that FOXP3 is able to inhibit DNA 
repair and suggests that in contrast to other reports demonstrating the strong tumour 
suppressor properties of FOXP3, it may also work to promote tumorigenesis.  
The influence of FOXP3 on BRCA1 expression was further validated using several 
lines of evidence by Li et al (Li, Katoh et al. 2013). Firstly, silencing of FOXP3 in 
MCF-10A cells resulted in an increase in BRCA1 transcripts and protein, whereas 
induction of FOXP3 in MCF-7 cells also resulted in a decreased expression of 
BRCA1 transcripts and protein (Li, Katoh et al. 2013). Similar findings were 
witnessed in mammary cells isolated from scurfy mice which also had increased 
levels of BRCA1 (Li, Katoh et al. 2013). The ability of FOXP3 to repress BRCA1 
activity was tested in 10 breast and prostate cancer samples which had FOXP3 
missense mutations. Results demonstrated that all samples had significantly reduced 
ability to repress the BRCA1 promoter (Li, Katoh et al. 2013).  
Radiation is used in therapies for approximately 50% of cancer patients (Delaney 
2005; Begg, Stewart et al. 2011). Despite this, many malignancies acquire resistance 
to irradiation (Delaney, Jacob et al. 2005; Bhide and Nutting 2010). Irradiation works 
by inducing DNA damage and initiating apoptosis to cancer cells. However, because 
the main role of BRCA1 is involved with DNA repair, Li et al (Li, Katoh et al. 2013) 
investigated whether the ability of FOXP3 to control BRCA1 has any correlation with 
radiotherapy-resistance in cancer patients. TSA cells were transfected with; FOXP3 
shRNA, BRCA1 shRNA, FOXP3/BRCA1 shRNA or scrambled shRNA. Each cell 
was then exposed to irradiation or not. They then measured tumour cell survival 
using a colony forming assay to investigate the colony growth after these effects.  
FOXP3 silencing in cells which were not exposed to irradiation had no effect 
however, if these cells were subjected to irradiation, at all doses, there was a 
Chapter 1 - General introduction 
73 
 
significant increase in the number of colonies (Li, Katoh et al. 2013). This therefore 
demonstrates that the presence of FOXP3 is required for the effects of irradiation 
through the direct repression of BRCA1 and that a lack of FOXP3 in cancer cells can 
increase the chances of radio-resistance in cancer therapy.  
 
1.7.10 Regulation of FOXP3 
Despite an increasing interest in FOXP3 in both cancer and immunological research, 
much work has focused on various downstream targets of the transcription factor, 
whereas, the underlying mechanisms which regulate FOXP3, particularly in 
epithelial cells, remain undefined. T-cell biology has produced a number of reports 
which have highlighted several mechanisms involved in the transcription of FOXP3.  
The FOXP3 promoter region is located approximately -6200bp upstream of the 
transcriptional start site. This region contains sequences specific for six NFAT and 
AP-1 binding sites, TATA sequences and CAAT boxes (Mantel, Ouaked et al. 2006). 
This promoter is highly conserved between mice and humans. 
At an epigenetic level it has been relatively well reported that methylation of CpG 
sequences within the promoter region of genes inhibits acetylation of histones and 
binding of transcription factors to DNA, whereas, demethylation of CpG sequences 
and the acetylation of histones are features of activated genes. Reports suggest that 
control of FOXP3 occurs by a similar mechanism involving the methylation status of 
CpG sequences in the promoter of FOXP3 (Janson, Winerdal et al. 2008).  
The epigenetic regulation of CpG methylation at specific sites in T-cells is a key 
factor involved in differentiation of T-cells (Lee, Fitzpatrick et al. 2001; Lee, Kim et 
al. 2006; Wilson, Rowell et al. 2009). 
It has been reported that in naïve CD4
+
CD25
-
 T-cells, approximately 10-45% of CpG 
motifs in the proximal Foxp3 promoter are methylated, whereas all were 
demethylated in natural Tregs (Kim and Leonard 2007). Further importance of 
methylation at the proximal promoter is suggested as Kim et al (Kim and Leonard 
2007) demonstrated that in CD4
+
CD25
lo
 cells this site was approximately 70% 
methylated, whereas, in the CD4
+
CD25
hi 
cells only approx 5% were methylated. 
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Methylation of these sites within the FOXP3 promoter can block the binding of 
transcription factors which have been reported to be involved in the activation of 
FOXP3 such as CREB and ATF (Kim and Leonard 2007).   
Several reports have now demonstrated that conventional CD4
+ 
T-cells are able to 
transiently upregulate FOXP3 following activation through the T-cell receptor (TCR) 
(Morgan, van Bilsen et al. 2005; Gavin, Torgerson et al. 2006; Tran, Ramsey et al. 
2007). The level of FOXP3 expression after activation is thought to be comparable to 
that of resting Tregs but is significantly lower than that of a similarly activated Tregs 
(Allan, Crome et al. 2007). Moreover, the expression of FOXP3 in these cells is only 
transient and is unable to convey a suppressive phenotype as these cells fail to 
suppress T-cell division and cytokine production (Morgan, van Bilsen et al. 2005; 
Gavin, Torgerson et al. 2006). 
These findings demonstrate that conversion of CD4
+
 T-cells to acquired Tregs 
requires more than just FOXP3 expression and is perhaps more dependent on the 
magnitude and the stability of FOXP3 expression. 
As well as the epigenetic control of FOXP3, various reports have also investigated 
the extrinsic regulation of FOXP3 by various cytokines, such as IL-2 and TGF-β 
(discussed in section 3.1.2) and antibiotics demonstrating that it can be regulated at 
both an epigenetic level and a genetic level. A good example of this is NK-cells 
which do not express FOXP3, are able to upregulate and express FOXP3 when they 
are treated with a DNA methylation inhibitor 5-aza-2’deoxycytidine (Zorn, Nelson et 
al. 2006). 
The notch pathway has been reported in various stages of T-cell maturation and also 
FOXP3 transcription (Anastasi, Campese et al. 2003; Vigouroux, Yvon et al. 2003). 
Blockage of the Notch pathway using anti-Notch1 antibodies is capable of inhibiting 
the suppressor function of Tregs in vitro (Asano, Watanabe et al. 2008). 
Interestingly, Notch1 signalling is thought to control FOXP3 expression in a bi-
phasic manner as low magnitude notch signalling resulted in activation of the 
FOXP3 promoter via a notch intracellular domain (NICD)-RBP-J complex, however 
high magnitude signalling repressed the promoter via HES1 (hairy-enhance of split 
1) (Ou-Yang, Zhang et al. 2009). 
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IL-6, which acts as an inflammatory cytokine, also is thought to influence FOXP3 
expression indirectly as it is able to suppress the development and function of Tregs 
(Lal, Zhang et al. 2009). A report by Lal et al (Lal, Zhang et al. 2009) demonstrated 
that IL-6 is able to induce DNMT1 expression. This is then able to induce STAT3-
dependant methylation of the FOXP3 enhancer by DNMT1 in Tregs which results in 
the repression of Foxp3 in these cells (Lal, Zhang et al. 2009). 
A report by Tone et al (Tone, Furuuchi et al. 2008) published data which 
demonstrated that Smad3 and NFAT work in cooperation to activate FOXP3 
expression. They showed that NFAT bound to the FOXP3 enhancer, whereas, Smad3 
was responsible for the regulation of the enhancer activity and that subsequent 
FOXP3 induction is dependent on the binding of Smad3 and NFAT to the 5’ 
enhancer of FOXP3. 
As discussed in section 1.4.5.2, p53 is one of the most well known TSG involved 
with cancer. Interestingly, FOXP3 has been suggested as a potential direct target of 
p53 in breast cells. Jung et al (Jung, Jin et al. 2010) used chIP which suggested that 
one motif approximately -1408bp to -1399bp from the transcriptional start site of 
FOXP3 shared strong homology with the binding consensus sequence of p53 (Jung, 
Jin et al. 2010). This indicates that the regulation of FOXP3 by p53 could be direct 
and the tumour suppressor function and induction of FOXP3 in breast epithelial cells 
is largely regulated and dependant on functional p53.  
Lymphocyte-specific protein tyrosine kinase (LCK) is a member of Src family of 
non-receptor protein tyrosine kinases which is predominately expressed in T-cells, 
however, it is also present in normal breast tissue and breast cancer cell lines (Koster, 
Landgraf et al. 1991). A recent report by Nakahira et al (Nakahira, Morita et al. 
2013) identified LCK as a binding partner of FOXP3. LCK is able to upregulate 
FOXP3 in breast cancer cell lines by phosphorylating the protein at tyrosine-342 
(Tyr-342) (Nakahira, Morita et al. 2013).  
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1.8 Hypothesis of the study 
The majority of breast cancer mortality is due to the metastatic dissemination of the 
primary tumour to organs more imperative to maintaining life such as the lungs, bone 
marrow, and brain. 
FOXP3 is a transcription factor recently demonstrated to be expressed within the 
nucleus of epithelial cells of specific organs. Within these cells it has been 
demonstrated to act as a potent TSG repressing the expression of several oncogenes 
including HER2, SKP2, and MYC. In correlation it has also been widely reported that 
within most aggressive forms of breast cancer, FOXP3 is found to be downregulated, 
often mutated, or restricted to the cytoplasm. Chemokines such as CXCL12 and 
chemokine receptors such as the CXCL12 ligand CXCR4 has been heavily 
implicated in breast cancer metastasis due to their roles in cell migration and 
invasion. Normal breast epithelia fail to express chemokine receptors, whereas, 
approximately 80% of primary breast tumours upregulate CXCR4. Moreover, the 
CXCR4 positive breast cancer cells frequently metastasise to sites in the body most 
enriched with CXCL12 which are the lymph nodes, lungs and bone marrow. These 
sites are also the most common sites of metastasis.  
This study was designed to test the hypothesis that the presence of constitutive 
nuclear FOXP3 in mammary epithelial cells is important in preventing tumour 
metastasis by regulating the expression of key oncogenes and specific chemokine 
receptors which enhances the cells ability to migrate and invade in response to 
ligand. This may provide a potential mechanism for chemokine-mediated breast 
cancer metastasis.  
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1.9 Aims of the study 
 Investigate the expression, distribution and potential mutations in FOXP3 
within breast cancer cell lines and normal mammary epithelial cells.   
 
 Investigate the transcriptional, proteomic and functional consequences of 
restoring FOXP3 into an invasive breast cancer cell line and also effects 
following knockdown of wild type FOXP3 in HMEpC. 
 
 Investigate potential correlations between FOXP3 and CXCR4 expression in 
breast cancer samples in patients with aggressive and progressive cancer and 
patients in early disease development.  
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2 General materials and methods 
 
2.1 Cell lines  
2.1.1 Human mammary epithelial cells 
Human mammary epithelial cells (HMEpC) were purchased from Invitrogen 
(Paisley, UK). HMEpC are a primary cell line isolated from reduction mammoplasty 
tissue. Before delivery the cells are tested for the expression of normal mammary cell 
markers including cytokeratins 5, 6, 8, 18 and E-cadherin. An independent laboratory 
confirmed the complete absence of Hepatitis B, C and HIV-1 viruses. 
 
2.1.2 MCF-7 
MCF-7 was provided by the University of Texas, MD Anderson Cancer Center 
(Houston, TX, USA). MCF-7 is an immortalised human breast adenocarcinoma cell 
line derived from the pleural effusion of a 69-year-old Caucasian female in 1970. 
The woman previously underwent two mastectomies in a five-year span. The tissue 
removed at the first mastectomy was benign, but the second mastectomy revealed a 
malignant adenocarcinoma. Over three years she was treated with radiotherapy and 
hormone therapy for local recurrences. In vivo these cells are capable of forming 
primary tumours in nude mice but they are incapable of penetrating a collagen 
fibroblast matrix and have a low activity in a boyden chemo-invasion assay (Soule, 
Vazguez et al. 1973). MCF-7 are therefore considered as low-to-non invasive in 
vitro. 
 
2.1.3 MDA-MB-231 
MDA-MB-231 was provided by the University of Texas, MD Anderson Cancer 
Center. MDA-MB-231 is an immortalised human breast adenocarcinoma cell line 
derived from the pleural effusion of a 51-year-old Caucasian female in 1973. The 
patient underwent a mastectomy and radiotherapy before removal of the specimen. 
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MDA-MB-231 has a 23-hour doubling time and therefore grow rapidly. MDA-MB-
231 will form mammary and metastatic tumours in nude mice, are extremely active 
in both chemotaxis and chemo-invasion assays, and are considered highly invasive in 
vitro and in vivo (Cailleau, Young et al. 1974).  
 
2.1.4 Validation of immortalised cancer cell lines 
Immortalised cancer cell lines were validated by STR (short tandem repeats) DNA 
fingerprinting using the AmpF STR Identifier kit (Applied Biosystems, Paisley, UK) 
according to manufacturers instructions. STR fingerprinting is a popular method 
required by many journals to validate cell lines. STR are regions of microsatellite 
instability with defined tri- or tetrad-nucleotide repeats located throughout the 
chromosome. PCR reactions using primers on non-reactive flanking regions generate 
products of varying sizes depending on the number of repeats they contain in the 
region. When between 8 and 16 of these STR loci are combined it is possible to 
identify the sample. 
The STR profiles were compared to known ATCC fingerprints (ATCC.org), and to 
the Cell Line Integrated Molecular Authentication database (CLIMA) version 
0.1.200808 (http://bioinformatics.istge.it/clima/) (Nucleic Acids Research 37:D925-
D932 PMCID: PMC2686526). The STR profiles matched known DNA fingerprints 
or were unique. 
 
2.1.5 Flp-InTM T-RexTM Human embryonic kidney-293 cells 
The transfected human embryonic kidney-293 cell line (referred to as HEK) was a 
gift from Dr Marcin Pekalski (Cambridge University, UK). This system was 
generated from the Flp-In
TM 
T-Rex
TM
 293 cell line purchased from Invitrogen. This 
system allows the generation of stably transfected cell lines that have homogeneous 
expression of a protein of interest within the Flp-In
TM
 expression vector. These 
tetracycline repressor expressing cells contain an integrated Flp recombination target 
(FRT) site which allows stable genomic incorporation of a specific gene. The control 
of this gene is then governed by tetracycline presence. Transfected HEK cells were 
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grown in complete Royal Park Memorial Institute (RPMI) medium (Sigma-Aldrich, 
Dorset, UK) containing 10% Foetal Bovine Serum (FBS) (Lonza, Slough, UK) 
which was sterile filtered through a 0.22µm pore sterile syringe filter, (VWR 
international, Leicestershire, UK), 100U/ml penicillin, 100µg/ml streptomycin, and 
L-glutamine (200mM) (Sigma-Aldrich) in culture flasks. Hygromycin B (100µg/ml) 
(Sigma-Aldrich) was used a selection antibiotic to select transfected cells. The 
expression of FOXP3 was induced by tetracycline (Tet) (100µg/ml) (Sigma-Aldrich). 
A schematic overview of the Tet-on mechanism is provided in figure 2.1. Briefly, 
the Flp-In
TM 
T-Rex
TM 
operator system works utilising a plasmid which contains Tet 
operator sequences (TetO2). The construct also transcribes for the production of Tet 
repressor Proteins (TetR) which are capable of homo-dimersing and binding to the 
TetO2 sequences which are directly upstream of the gene of interest, in this case 
FOXP3. Once the TetR proteins are bound to the TetO2 sequences these blocks and 
prevents the transcription of the gene. The presence of tetracycline in the growth 
culture is able to bind to the TetR which causes a conformational change and 
prevents the TetR from being able to bind to the TetO2 sequences and thus allows 
transcription of FOXP3.  
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Figure 2-1 - Schematic representation of Flp-In
TM 
T-Rex
TM
 system 
In the absence of tetracycline (A), Tet repressor gene encodes for the tetracycline repressor 
proteins. These proteins homodimerise and bind to TetO2 sequences which prevent the 
transcription of the FOXP3 gene. When tetracycline is present (B), it binds to the 
homodimerised Tet repressor proteins which causes a conformational change in the shape. 
This prevents the Tet repressor proteins from binding to the tetO2 sequences and allows the 
transcription of FOXP3 to occur.  
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2.2 Cell culture methods 
All cell culture methods were performed within class II laminar flow hoods in sterile 
conditions with equipment which was autoclaved prior to use. All cell lines and 
chemicals had the relevant COSHH and bioCOSHH forms signed prior to use.  
 
2.2.1 Cryopreservation of cells 
Cells were routinely cryopreserved in liquid nitrogen for long term storage. Cells 
were centrifuged to pellet and then resuspended in 90% FBS (sterile filtered through 
0.22µm filter) and 10% dimethyl sulphoxide (DMSO) (Sigma-Aldrich) in a final 
volume of 1ml. The suspension was then transferred to a cryogenic vial which is 
placed in an isopropyl alcohol freezing medium and transferred to a -80°C freezer to 
cool the vials at 1°C/minute. The gradual freezing process prevents the cells from 
being “shocked” after taken from room temperature to a freezing temperature and 
therefore improves cell viability when the cells are re-cultured. When cells had been 
stored at -80°C for approximately 6 hours they can be transferred to liquid nitrogen 
for long-term storage. Cells were recovered by rapid thawing of the vial at 37°C and 
centrifuged to pellet in 10ml of their appropriate growth medium. Cells were then 
resuspended in growth medium and cultured appropriately.      
 
2.2.2 Cell counting  
Some experiments require a specific number of cells to be used. Prior to these 
experiments, cells were mixed at an equal ratio with trypan blue (Sigma-Aldrich) to 
determine cell viability and counted using an improved Neubauer haemocytometer 
(VWR, international). Only viable cells were considered in cell counts. Cells located 
within each 4 corner grids and centre grid of the 25 square grid were counted. The 
cell number was divided by 0.02 and multiplied by 1000 to obtain the number of 
cells/ml. To find the total number of cells, this number was multiplied by the total 
volume the cells were resuspended in. These fields were counted twice and the 
average was taken to avoid error. 
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2.2.3 Growth media for immortalised cell lines 
MCF-7 and MDA-MB-231 were cultured in Dulbeccos Modified Eagle Media 
(DMEM) without phenol red (Sigma-Aldrich,) supplemented with 10% FBS which 
was sterile filtered through a 0.22µm pore sterile syringe filter, 100U/ml penicillin, 
100µg/ml streptomycin, and L-glutamine (200mM) in culture flasks. 
 
2.2.4 General maintenance of immortalised cell lines 
Adherent cells were seeded into either 25cm
2
 (T25) or 75cm
2
 (T75) vented flasks 
(Greiner Bio-One, Gloucestershire, UK)  and cultured in normal growth conditions 
within a 37°C humidified incubator with 5% CO2 in a horizontal position. The cells 
were split at a ratio of 1:3 when they were approximately 80-90% confluent. Medium 
was changed as required. Adherent cells were detached from the surface of the flask 
by washing the cells in phosphate buffer saline (PBS) (Sigma-Aldrich) followed by 
incubation at 37°C for 3-5 minutes with 1mM Trypsin-EDTA solution (Sigma-
Aldrich). Complete growth media containing 10% FBS was added to inactivate the 
trypsin before centrifugation to remove cells from suspension. Cell pellets were re-
suspended in an appropriate volume of fresh medium before passage into new flasks. 
 
2.2.5 General maintenance of primary cells 
HMEpC were cultured in T25 flasks in normal growth conditions within a 37°C 
humidified incubator with 5% CO2. Cells were seeded into T25 flasks at a density 
receommended by the manufacturers (2.5x10
3
/cm
2
). When the cells were at least 
50% confluent, growth medium was replaced until the cells reached 90% confluency, 
which were then passaged into new flasks. Because HMEpC are a primary cell line, 
they can only undergo a limited number of doublings and must be used at early 
passage. In this study, HMEpC were not used beyond three passages as cells beyond 
this stage begun to de-differentiate.  
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2.2.6 Mycoplasma testing 
Mycoplasma is a specific genus of bacteria which lacks a cell wall allowing 
resistance to antibiotics like penicillin and streptomycin. Mycoplasma cannot be seen 
by microscopy as they are one of the smallest known cells and have a diameter of 
approximately 0.15-0.3µm. Mycoplasma is often found in laboratories as a result of 
contamination from the individual or from cell media. They can induce cellular 
changes, chromosome alterations and changes in metabolism and growth.  
Mycoplasma testing was carried out within the laboratory using mycoAlert
TM
 
mycoplasma testing kit (Lonza). This kit is a biochemical test which utilises the 
activity of mycoplasma enzymes found in the vast majority of the 180 mycoplasma 
species. Mycoplasma testing was carried out routinely according to the 
manufacturers protocol. Briefly, 100µl of culture media was incubated with 50µl of 
mycoAlert
TM
 reagent for 5 minutes. After 5 minutes the luminescence was measured 
(TD-20/20 turner design luminometer, Promega, Southampton, UK). Next, 50µl of 
mycoAlert
TM
 substrate was added and left to incubate for a further 10 minutes, 
followed by a second luminescence reading. A ratio between the first reading and the 
second reading of more than 1.5 demonstrates mycoplasma presence.  
The addition of the mycoAlert
TM
 reagent lyses mycoplasma releasing mycoplasma 
enzymes. The addition of mycoAlert
TM 
substrate catalyzes the conversion of 
adenosine diphosphate (ADP) to adenosine triphosphate (ATP) which is detected by 
luminescence. If these enzymes are not present there will be no increase in the two 
readings, however, if enzymes are present they will be converted by the mycoAlert
TM
 
substrate into ATP, causing a detectable increase in luminescence.  
Cells positive for mycoplasma were quarantined in a separate incubator and treated 
with 0.5µg/ml of mycoplasma removal agent (Abd Serotec, Kidlington, UK). Since 
this antibiotic does not affect eukaryotic cell growth, mammalian cells can still be 
grown in the presence of this antibiotic. Contaminated cells were treated in 
quarantine for one week and re-tested. 
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2.3 DNA methods 
2.3.1 Agarose gel electrophoresis 
Agarose gels (1.2%) were prepared by heating and dissolving agarose powder 
(Bioline, London, UK)  in TAE buffer (1L stock consists of 48g Tris base, 11ml 
acetic acid and 20ml 0.5M EDTA at pH8.0, all purchased from Sigma-Aldrich). 
After allowing the agarose liquid to cool, ethidium bromide (0.5µg/ml) (Promega) 
was added to the gel and allowed to set in a plastic casting stand. Ethidium bromide 
is a DNA intercalating agent which causes DNA to fluoresce under UV light. After 
setting, the gel was transferred to an electrophoresis tank filled with TAE buffer. 
DNA Ladders (Fermentas, Sunderland, UK) were used to establish the size of the 
bands. The nucleic acid was mixed with orange G (10% of final volume) and run at 
120V for approximately 1 hour. Following electrophoresis, bands were visualised 
using an Alpha Imager® Instrument (Alpha Innotech Corporation, San Leandro, CA, 
USA).  
 
2.3.2 DNA extraction and purification from agarose gel 
Extraction of DNA from agarose gels was performed using a QIAquick Gel 
Extraction Kit (QIAgen, Manchester, UK). This kit uses silica-binding technology 
and spin columns and ensures greater than 80% recovery of DNA which is free from 
primers, nucleotides, enzymes, salts, agarose and ethidium bromide. DNA was 
extracted according to the manufacturers protocol. Briefly, bands were visualised 
under UV light and cut out of the gel using a sterile scalpel. The gel was dissolved in 
an agarase containing buffer (3x the weight of the extracted gel) for 10 minutes in a 
water bath at 45°C. When the gel had completely dissolved, iso-propanol was added 
(1x the weight of the extracted gel) to precipitate the DNA, the contents was added to 
the spin column and centrifuged for 1 minute at 13000xg. This was followed by two 
wash steps using an ethanol containing buffer, before being eluted from the column 
into a fresh collection tube using 20µl of an elution buffer.  
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2.3.3 DNA sequencing  
DNA Sanger sequencing was performed at Source Bioscience (Nottingham, UK). 
Sequencing data was analysed using A Plasmid Editor (ApE) software to align 
sample sequences against wild type sequences acquired from National Centre for 
Bioscience Institute (NCBI.gov).   
 
2.4 Polymerase chain reaction  
The polymerase chain reaction (PCR) was developed in 1986, with the significance 
of this technique being fully acknowledged later when Kary Mullis was awarded the 
Nobel Prize for Chemistry in 1993 (Mullis 2013). PCR is a technique which allows 
scientists to generate many copies of a specific DNA sequence using in vitro 
reactions. For instance, 25 cycles of PCR increase DNA copies by more than 10
6
.  
PCR is based on the fact that DNA polymerases are primer dependant. A pair of 
primers is designed and synthesised complementary to a sequence of interest on both 
the coding and complementary DNA strands. The polymerase will then extend these 
primers past the sequence of interest by incorporating new complementary bases.  
A PCR cycle consists of three phases; heating to denature DNA double helices, 
followed by a cooler temperature which allows the primers to anneal to the DNA 
along with complementary oligonucleotides. The final phase is another heated step 
which allows the DNA polymerase enzyme to extend the primers and copy the 
sequence of interest.  
Because the temperatures used are so high it is important that the DNA polymerase 
enzymes used are thermostable and can withstand high temperatures without 
denaturing. Taq polymerase was used in conventional PCR experiments. Taq was 
originally isolated from hyperthermophilic archea (Thermus aquaticus). It is stable at 
high temperatures and has an error rate of approximately 1.3x10
-5
. The Taq enzyme 
used in the reaction is a hot-start enzyme. This means it contains a mixture of Taq 
polymerase enzyme and a monoclonal antibody which binds to the enzyme until a 
reaction temperature is raised to denature the antibody and release it from the 
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enzyme. Therefore, an initial 95°C step is required to activate the enzyme before the 
cycles start.  
 
2.4.1 RNA isolation 
Total RNA was isolated from cells using TRI reagent (Sigma-Aldrich) unless 
specified. All RNA work was carried out with ribonuclease-free and contaminant-
free apparatus. All water used in RNA work and analysis was diethyl pyrocarbonate 
(DEPC) treated. Cells were released from the flask using 1mM trypsin-EDTA as 
described in 2.2.4. The pellet was resuspended and lysed in 1ml TRI reagent and left 
for 5 minutes at room temperature. 200µl of chloroform (Sigma-Aldrich) was added 
and the homogenate was shaken vigorously for 15 seconds, incubated on ice for 2-3 
minutes then centrifuged at 12000xg for 15 minutes at 4°C. The aqueous phase was 
removed and RNA was precipitated by adding an equal volume of iso-propanol 
(Sigma-Aldrich). This was left to incubate for 15 minutes followed by centrifugation 
at 12000xg for 10 minutes at 4°C. The supernatant was removed and the RNA pellet 
was washed and precipitated with 75% ethanol before being centrifuged at 12000xg 
for 10 minutes at 4°C. The RNA was resuspended in an appropriate amount of DEPC 
water, and the concentration and quality of RNA was assessed using a nanodrop 
spectrophotometer (nanodrop ND-1000 spectrophotometer, Thermo Scientific, 
Waltham, MA, USA).   
 
2.4.2 Nucleic acid quantification  
The concentration and quality of the isolated nucleic acid was assessed using the 
nanodrop spectrophotometer (figure 2.1). The spectrophotometer measures three 
absorbances; the 230nm readout measures organic solvents, the 260nm readout 
measures nucleic acids and the 280nm readout measure the protein content. The 
260/280 ratio provides an estimate of nucleic acid purity. Pure preparations of DNA 
and RNA have OD260/280 values of between 1.8 and 2.0 respectively. Isolated 
nucleic acid which fell below a 260/280 ratio of 1.8 was not used. 
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2.4.3 cDNA synthesis  
cDNA synthesis was performed using a tetro cDNA synthesis kit purchased from 
Bioline. cDNA was synthesised according to the manufacturers protocol. Briefly, up 
to 5µg of total RNA was mixed with 1µl of Oligo dT, 10mM dNTP mix, 5x reverse 
transcriptase buffer, 1µl ribosafe RNase inhibitor and 200u/µl of MMLV tetro 
reverse transcriptase. DEPC was used to make a final reaction volume of 20µl. The 
reaction was incubated at 45°C for 30 minutes followed by 5 minutes of incubation 
at 85°C to terminate the reaction. cDNA synthesis was carried out using a T100 
thermal cycler (BIO-RAD, Hercules, CA, USA). 
Prepared cDNA was immediately stored at -20°C. cDNA was not frozen and thawed 
more than twice to ensure quality was maintained.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 - General materials and methods 
89 
 
 
Figure 2-2 - Representative images of highly pure plasmid DNA isolated from 
bacteria and RNA from cell lines. 
The nanodrop spectrometer is able to determine the RNA (A) and DNA (B) purity from cell 
lines and bacteria can measure the absorbance levels of protein (280nm), nucleic acid 
(260nm) and the presence of organic solvents (230nm).    
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2.4.4 Conventional PCR 
Conventional PCR was performed using synthesized cDNA in a reaction typically 
consisting of 5µl of cDNA template, 0.5µg/µl of forward/reverse primers (manually 
designed and purchased from IDT, [Leuven, Belgium], and listed in section 3.3.3) 
and 25µl master mix (2x) (Bioline) (consisting of: dNTPs, which provide the 
nucleotides required to construct each daughter strand after each cycle, divalent 
cations such as magnesium and monovalent cations such as potassium ions, and a 
buffer solution to provide the correct chemical environment). The reaction was made 
up to a final volume of 50µl using DEPC-treated water.  
PCR was carried out using a T100 thermal cycler. A typical PCR cycle comprised of; 
30 seconds at 95°C to denature, 30 seconds at the optimum temperature for the 
primers to anneal, followed by 1 minute at 70°C for the elongation of the primers by 
the polymerase enzyme. The cycles were repeated 40 times and PCR products were 
ran on 1.2% agarose gels as described in section 2.3.1.  
 
2.4.5 Real-time PCR  
In real-time PCR, after the completion of each cycle fluorescence is emitted and 
measured by a detector which allows determination of the amount of template DNA 
being amplified as the reaction progresses. This is a key feature in real-time PCR and 
is the major difference compared to conventional PCR, which is only capable of 
detecting amplified DNA at the end-point. Real-time PCR allows for both the 
detection and quantification of DNA, where the quantity can be expressed as 
absolute number of copies, or relative gene expression when compared to the 
expression of an endogenous control. Real-time PCR also uses primers and follows 
the same 3 steps of denaturation, primer annealing and elongation as described in 
section 2.4.  
All real-time PCR was conducted using a StepOnePlus
TM
 PCR machine (Applied 
Biosystems) using TaqMan® probes (Applied Biosystems). A list of TaqMan® 
primers used is provided in table 2.1.  
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2.4.5.1 TaqMan® chemistry 
TaqMan® chemistry is based around an oligonucleotide probe which has a 
fluorophore covalently attached to the 5’ end and a quencher at the 5’ end. The 
fluorophore used was 6-carboxyfluorescein (FAM) and the quencher was 
tetramethylrhodamine (TAMRA). The purpose of a quencher is to inhibit 
fluorescence emitted by the fluorophore which is excited by the cycler’s light source. 
As long as the quencher is in close proximity to the fluorophore, the degree of auto-
fluorescence will be inhibited. The TaqMan® probes are designed so that they will 
bind to a target sequence of the single stranded DNA which will be amplified by a 
specific set of primers.  
A schematic representation of the principle behind TaqMan® chemistry is provided 
in figure 2.2. Briefly, during the PCR reaction, as the Taq polymerase enzyme 
extends the primers and synthesises a new strand adjacent to the template DNA, the 
polymerase enzyme will degrade the TaqMan® probe which subsequently breaks the 
close proximity set between the quencher and the fluorophore and allows the 
fluorophore to fluoresce which is detected by a source. The specificity of the 
hybridization between the target sequence and probe is essential to cause 
fluorescence signals. This therefore reduces both the chance of false positives and 
background fluorescence. 
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Figure 2-3 - Schematic representation of TaqMan® real-time PCR reaction 
TaqMan® probes with FAM fluorochrome (labelled R) and a TAMRA quencher (labelled 
Q) anneal to specific sequences within the target DNA which are up-stream of the primers 
(A). As the primers extend along the template the polymerase degrades the probes (B) and 
releases the fluorochrome from the proximity of the quencher causing fluorescence (C).   
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Target gene Assay ID 
(Applied Biosystems)  
GAPDH H202758991_g1 
β-ACTIN Hs01060665_g1 
β-TUBULIN Hs00258236_m1 
FOXP3 Hs01085834_m1 
CXCR4 Hs00607978_s1 
HER2 Hs01001580_m1 
SKP2 Hs01021864_m1 
CDKN1A Hs00355782_m1 
MYC Hs00153408_m1 
Table 2-1 - List of TaqMan® primers used in real-time PCR 
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2.4.5.2 Relative quantification of gene expression 
In order to measure changes in the expression of a gene, two methods can be used. A 
standard curve, or the comparative crossing threshold (Ct). Comparative ΔΔCt 
method was used in all experiments and relies on determining the expression levels 
of the gene of interest relative to a normal housekeeping gene.  
Before carrying out the experiment, the efficiency of primers was assessed using 
serial dilutions of template cDNA from 1µl (neat) to 0.0625µl (1:16) and examining 
how the Ct varies with the template dilution. The slope of the linear regression 
witnessed is then used to determine the efficiency of amplification. A number of 
variables can affect the efficiency of a PCR reaction including length of the 
amplicon, the quality of the primers and the quality of the cDNA template. Examples 
of primer validation are included in section 3.4.3 (figure 3.8) and section 4.4.6.1 
(figure 4.9). 
When calculating the relative expression of a gene of interest in two or more 
different samples, one of the samples should act as a reference to normalise against. 
The comparative ΔΔCt method starts by initially determining the ΔCt of each 
sample:  
ΔCt = Ct of the gene of interest in each sample – Ct of the housekeeping gene in 
each sample. 
Following this, the ΔΔCt of each sample can be calculated. This involves finding the 
difference between the ΔCt of the test sample and the ΔCt of the normalised sample 
(or sample to which it is to be compared against):  
ΔΔCt = ΔCt of gene of interest in sample of interest – ΔCt of the gene of interest 
in the normalised sample. 
The final calculation is to determine the comparative expression level of the gene in 
the sample compared to normalised sample and is done so using the following 
equation:  
Comparative expression level = 2
-ΔΔCt
. 
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2.5 Protein methods 
2.5.1 Protein extraction 
Total protein was isolated from cell lines after being released from culture flasks as 
described in section 2.2.4. The cell pellet was resuspended in a cell lysis buffer 
(Ambion, Paisley, UK) which contained protease and phosphatase inhibitors. Cells 
were mixed every 5 minutes whilst on ice for 20 minutes. The suspension was then 
sonicated (Soniprep 150 sonicator, MSE, London, UK) on ice, and centrifuged at 
15000xg for 20 minutes at 4°C. The supernatant was removed and dispensed into a 
fresh Eppindorf to be used for future experiments or stored at -20°C for long term 
storage.   
 
2.5.2 Fractionation of nuclear and cytoplasmic protein 
To define the subcellular distribution of FOXP3, the nuclear and cytoplasmic protein 
contents were separated using a NE-PER® nuclear and cytoplasmic extraction kit 
(Thermo scientific). Cells in culture were released from the flask as described in 
section 2.2.4. The pellet was resuspended in a solution, supplemented with protease 
inhibitors, to cause lysis of the cell membrane, vortexed and incubated on ice for 10 
minutes. A second cytoplasmic lysis reagent was added to the reaction and was 
centrifuged at 16000xg for 5 minutes. The cytoplasmic content within the 
supernatant was collected into a fresh tube. The nuclear extract within the pellet was 
resuspended in a third lysis buffer causing nuclear membrane disruption. The 
reaction was vortexed and centrifuged for 10 minutes at 16000xg. Nuclear contents 
within the supernatant were placed into a fresh tube.  
 
2.5.3 Protein quantification 
Protein in prepared cell lysates was quantified using a Pierce® BCA protein assay kit 
(Thermo scientific). The assay is based around two chemical reactions. Firstly, 
peptide bonds in the protein reduce Cu
+2
 from cupric sulphate to Cu
+1
. This reduction 
of Cu
+2
 to Cu
+1
 is directly proportional to the amount of protein present in the 
solution. Following this initial reduction reaction, two molecules of bicinchoninic 
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acid (BCA) (present in the highly alkaline reagent) chelate with each Cu
+1
 ion to 
form a purple coloured product which can be measured at 562nm using a microplate 
reader (DYNEX, OPSYS MR). 
A standard curve was prepared in 96-well plates using albumin supplied by the 
company and was diluted between 0µg/ml to 2000µg/ml. The protein concentration 
in prepared samples was determined by pipetting 25µl of sample into appropriate 
wells along with 200µl of working reagent (50 parts of reagent A containing; sodium 
carbonate, sodium bicarbonate, bicinchoninic acids and sodium tartrate in 0.1M 
sodium hydroxide, with 1 part of reagent B containing 4% cupric sulphate). The plate 
was then mixed thoroughly and incubated for 30 minutes at 37°C. Following 
incubation, the absorbance of each well was measured at 562nm and the sample 
concentration was determined by reading off the standard curve (figure 2.4).      
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Figure 2-4 - Representative standard curve to determine protein concentration 
A standard curve was prepared using Pierce® BCA protein assay kit ranging from 0µg/ml to 
2000µg/ml. Protein in samples were quantified by reading off the standard curve. Error bars 
are representative of mean ± standard deviation (n=2).   
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2.5.4 Flow cytometry  
Flow cytometry is a technique used to measure the physical characteristics of cells. 
Cells are suspended in a fluid and passed through the cytometer in a stream of single 
cells. As the cells pass through the machine they are subjected to a stationary laser 
light. When the light hits the cells it causes scattering and is deflected off the cells 
and is detected in two directions. Light which is scattered in the plane of the 
excitation laser is proportional to the size of the cell and is called forward scatter. 
Light which is scattered at right angles to the path of the excitation laser is side 
scatter. Side scatter is proportional to cell granularity.  
Flow cytometry utilises antibodies which are conjugated to fluorochromes to detect 
specific antigens on or in the cells. The detection of these molecules is based on 
fluorescence which occurs when the fluorochrome is stimulated by light of a 
particular wavelength. However, the wavelength of the light used for excitation 
needs to be removed from that of the fluorescence to allow separation of both 
wavelengths. Dichronic mirrors and optical filters are used to reflect and absorb the 
light which is deflected into photomultiplier tubes and converted into an electric 
current. This current is then fed into an amplifier creating a signal which is 
proportional to the number of photons that reach the photodetector.   
All flow cytometry was carried out using a Becton Dickinson FACS canto II flow 
cytometer (Becton Dickinson, Franklin Lakes NJ, USA). Data was analysed using 
FlowJo software (Becton Dickinson).   
 
2.5.4.1 Cell surface staining  
Cells to be stained were released from culture using trypsin-EDTA, counted and 
1x10
6
 cells were pelleted by centrifugation at 500xg for 5 minutes in complete 
growth media. All staining was performed in FACS tubes. Cells were resuspended in 
50µl of PBS+2% FBS (referred to as FACS buffer) and primary antibody (according 
to the manufacturers datasheet). Cells were incubated at 4°C for 1 hour with the 
primary antibody. At the end of the incubation, cells were washed twice in 1ml of 
FACS buffer and resuspended in 300µl of FACS buffer before run on the canto II 
flow cytometer.  
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2.5.4.2 Intracellular staining  
As a transcription factor, the nuclear localisation of FOXP3 is imperative to its 
function. Therefore, in order to detect FOXP3, cells must firstly be permeabilised to 
allow antibodies to pass through the plasma membrane to reach its target. FOXP3 
was stained using a FOXP3 staining buffer set (eBioscience, Hatfield, UK). This kit 
has been formulated and optimised for a number of monoclonal FOXP3 antibodies 
including PCH101 and 236A/E7.  
Intracellular staining was performed following cell surface staining. Cells in FACS 
tubes were centrifuged at 12000xg to pellet cells. Cells were then fixed and 
permeabilised using a fix/Perm buffer which contains formaldehyde and a detergent. 
This buffer was prepared at a 1:3 ratio of fix/perm concentrate to fix/perm diluent. 
Cells were incubated at 4°C in fix/perm buffer for 30 minutes. Cells were washed in 
perm buffer followed by 1 hour incubation with the FOXP3 antibody for 1 hour. 
Cells were washed twice in perm buffer before being resuspended in FACS buffer 
and ran on the canto II flow cytometer. 
The expression of FOXP3 and CXCR4 was assessed by performing cell surface 
staining followed by intracellular staining. Matched isotype controls which have no 
relevant specificity were used to separate non-specific staining from the specific 
antibody staining. The antibodies used are included in table 2.2. 
 
2.5.5 Western blot 
Western blot is a technique which is used to detect proteins in a sample. It used 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) to 
separate denatured proteins by size. Proteins are then transferred onto a membrane 
which is then probed with antibodies in attempt to detect specific proteins in the 
sample. Depending on the experiment, protein was isolated from cells as described in 
section 2.5.1 or 2.5.2. 
Protein samples were prepared in Laemmli loading buffer (12% SDS, 60% [v/v] of 
20% glycerol, 30% [v/v] 0.0012% bromophenol blue [all prichased from Sigma-
Aldrich], 0.37M Tris-base at pH6.8), β-mercapnoethanol (Sigma-Aldrich) and the 
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final sample volume was made up to 20µl with distilled water. Each sample was 
boiled at 100°C for 5 minutes before loading into a 10% acylamide gel with a pre-
stained protein ladder (Fermentas).  
The gel was then transferred onto a polyvinylidene fluoride (PVDF) membrane (GE 
healthcare) at 30V overnight in transfer buffer (25 mM Tris, 192 mM glycine, 10% 
methanol, 0.1% SDS [all purchased from Sigma-Alrdich]). The membrane was then 
blocked in 5% milk powder in PBS for 3 hours before being incubated at 4°C 
overnight with the primary antibody (all antibodies used included in table 2.2) with 
5% milk powder in PBS. The membrane was washed 3 times for 10 minutes in 0.1% 
PBS/tween (Sigma-Aldrich) followed by incubating at room temperature with a 
horseradish peroxidase (HRP)-conjugated secondary antibody (included in table 2.2) 
for 1 hour.  
The membrane peroxidase activity was detected using ECL (Thermo scientific) and 
then exposed to photographic film (Koodak). Membranes were stripped using harsh 
stripping buffer (10% SDS, 0.5M Tris-Hcl [pH 6.8] and 0.8ml β-mercapnoethanol) 
for 30 minutes at 50°C and then re-probed with the appropriate primary antibody.  
 
2.5.6 Immunofluorescence 
Immunofluorescence (IF) was performed on cells grown in chamber slides (5x10
4
 
cells/chamber) overnight in normal growth conditions. The next day, growth media 
was removed and cells were fixed with 4% paraformaldehyde (PFA) for 30 minutes. 
Following fixation, cells were permeabilised using 0.1% Triton X-100 (Sigma-
Aldrich) for 15 minutes at 4°C. Each chamber was then blocked using PBS+5%FBS 
for 1 hour before being incubated at 4°C overnight with the primary antibody 
(included in table 2.2), which was diluted in PBS+5%FBS. Slides were then 
incubated with a FITC-conjugated secondary antibody (included in table 2.2) for 2 
hours at 4°C, then counter stained with 4',6-diamidino-2-phenylindole (DAPI) and 
mounted using Vectashield (Vector LABORATORIES, Peterborough, UK). Cells 
were viewed using a Leica fluorescent microscope.  
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2.6 List of antibodies 
Experiment Target 
antigen 
Reactive 
species 
Species 
raised in 
Company Isotype Concentration/ 
Working 
concentration 
WB/ IF FOXP3 Human Mouse Abcam 
(Cambridge,
UK) 
(236A/E7)  
IgG1 
1:100 
WB IgG (2°) Mouse Rabbit Sigma-
Aldrich 
IgG 1:5000 
IF IgG (2°) Mouse  
(FITC 
conjugate) 
Goat Abcam IgG 1:1000 
IF CK8 Human Mouse Santa Cruz IgG2a 1:250 
IF CK18 Human Mouse Santa Cruz IgG1 1:250 
WB Anti-
TATA 
Human Mouse Abcam IgG1 1:1000 
WB β-Actin Human Mouse Sigma-
Aldrich 
IgG2a 1:5000 
Flow 
cytometry 
FOXP3 Human 
 (APC 
conjugate) 
Rat eBioscience PCH101 
(IgG2aκ) 
0.5µg (5µl) 
Flow 
cytometry 
-  Human  
(APC 
conjugate) 
Rat eBioscience eBR2a 
(IgG2aκ) 
0.25µg (2.5µl) 
Flow 
cytometry 
CXCR4 Human 
(FITC 
conjugate) 
Mouse Becton 
DIckinson 
IgG2a 10µl 
Flow 
cytometry 
-  Human 
(FITC 
conjugate) 
Mouse Biolegend IgG2aκ 10µl 
Flow 
cytometry 
CD3 Human 
(PE 
conjugate) 
Mouse  Becton 
Dickinson 
IgG2bκ 10µl 
 
Table 2-2 - List of antibodies used in studies 
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2.7 Statistical analysis 
Data was organised and analysed using Microsoft office Excel 2007 and GraphPad 
Prism 5. Quantitative values were plotted as the mean ± standard deviation (SD). 
Unless stated, a direct comparison between two columns was performed using the 
unpaired Students t-test. Multiple column analysis was performed with one-way 
ANOVA. Values <0.05 were considered as statistically significant. Outliers from 
experiments were excluded using the Grubbs’ test on Prism.    
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3 Study of FOXP3 expression in normal and 
malignant breast cell lines 
 
3.1 Introduction  
3.1.1 Dysregulated expression of FOXP3 in malignant breast 
epithelia 
The expression of FOXP3 within normal and malignant breast tissue has been 
investigated by a number of groups. Each group have consistently demonstrated the 
presence of nuclear FOXP3 within normal mammary epithelial cells (Zuo, Liu et al. 
2007; Zuo, Wang et al. 2007; Merlo, Casalini et al. 2009; Wang, Liu et al. 2009; 
Zhang and Sun 2010; Lal, Chan et al. 2013). However, within the malignant breast 
cells several scenarios have been described and are summarised within this section.  
FOXP3 is well known for its role in the immune system as the master regulator of 
the development and function of Tregs. Until several years ago it was thought 
FOXP3 expression was restricted to the lymphocyte lineage. However, it has now 
been well documented that FOXP3 is also expressed in non-immune cells. Chen et al 
(Chen, Chen et al. 2008) used Rag2
-/-
 mice and scurfy mice to demonstrate that 
Foxp3 was expressed at transcript and protein levels in the nucleus of epithelial cells 
within the breast, prostate and lung. Separate reports have also demonstrated the 
expression of FOXP3 within ovarian epithelial cells (Zhang and Sun 2010) and the 
brain (Frattini, Pisati et al. 2012). Within Tregs, FOXP3 is expressed at a similar 
level to housekeeping genes such as GAPDH, however, within epithelial cells the 
expression is significantly lower, approximately 100-fold less than levels found in 
Tregs (Wang, Liu et al. 2009).  
Several studies have investigated the expression and distribution of FOXP3 within 
human breast epithelial cells and have consistently demonstrated that FOXP3 is 
expressed constitutively within the nucleus of normal breast epithelial cells (Zuo, 
Wang et al. 2007; Merlo, Casalini et al. 2009). The expression of FOXP3 within 
breast cancer samples is slightly more ambiguous. Some cases demonstrated levels 
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of FOXP3 which were comparable to normal breast epithelia, whereas, the majority 
of cases had significantly dysregulated expression of FOXP3, being completely 
absent, downregulated, mutated or being predominately restricted to the cytoplasm of 
the cells (Zuo, Liu et al. 2007; Zuo, Wang et al. 2007; Merlo, Casalini et al. 2009; 
Wang, Liu et al. 2009; Zhang and Sun 2010).   
Merlo et al (Merlo, Casalini et al. 2009) published a comprehensive report focusing 
on the subcellular distribution of FOXP3 from two trials (Milan 1 and Milan 3) 
amongst a large cohort of breast cancer patients. The Milan 3 trial, which analysed 
183 patient samples, revealed that 78 samples had no detectable levels of FOXP3, 44 
samples were weakly positive, and 61 samples were strongly positive. However, 
within the samples which stained strongly positive, the majority of samples 
expressed FOXP3 predominately restricted to the cytoplasm with very few samples 
expressing nuclear FOXP3. This demonstrates that FOXP3 is frequently unregulated 
in breast cancer.     
The same authors (Merlo, Casalini et al. 2009) then correlated the localisation of 
FOXP3 to the overall survival of the patients. Patients with no detectable levels of 
FOXP3 generally had a worse prognosis than those with normal FOXP3, situated 
within the nucleus. Interestingly, patients which had detectable FOXP3 restricted to 
the cytoplasm, had a similarly poor, or worse prognosis as the patients with no 
detectable FOXP3 (Merlo, Casalini et al. 2009). This suggests that the failure to 
recruit FOXP3 to the nucleus could be an important prognostic indicator of 
aggressive (or the potential to be aggressive) forms of breast cancer.  
Another study (Zuo, Wang et al. 2007) analysed the expression of FOXP3 by IHC in 
50 normal breast samples and 275 breast cancer samples. It was found that only 21% 
of tumours expressed FOXP3 within the nucleus, whereas, 80% of normal healthy 
tissues expressed nuclear FOXP3. The same report (Zuo, Wang et al. 2007)  then 
analysed the mRNA expression of FOXP3 in ten breast cancer cell lines and two 
non-malignant breast cell lines by real-time PCR. The two non-malignant epithelial 
cell lines expressed relatively normal levels of FOXP3 and also expressed both 
natural isoforms. On the other hand, all ten malignant cell lines had significantly 
fewer FOXP3 transcripts than the normal cell lines. Moreover, all the malignant cell 
lines failed to express a full length FOXP3, each consistently missing certain exons. 
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Some cell lines expressed only the FOXP3Δ3 isoform, whereas others expressed 
versions missing exons 3 and 4 and exons 3 and/or 8.  
The same study (Zuo, Wang et al. 2007) examined 50 normal and cancerous tissues 
from matched patients suffering IDC and showed that when cancerous tissues were 
compared with the normal tissues, 36% showed somatic FOXP3 mutations. Of these 
samples, 38% of cases had lost the wild type allele.  Moreover, when similar FOXP3 
mutations where witnessed in IPEX patients, they were deemed as important for 
normal FOXP3 functioning (Ziegler 2006). This data demonstrates the wide spread 
dysregulated expression of FOXP3 at protein and transcript level within malignant 
breast epithelial cells. 
An alternative report by Lal et al (Lal, Chan et al. 2013) quantitatively assessed the 
levels of Treg and epithelial cell derived-FOXP3 in 32 breast tumours from DCIS 
and IDC with synchronous normal epithelial cells. In line with other reports in the 
literature, Lal et al (Lal, Chan et al. 2013) reported that FOXP3 expressing Tregs 
significantly increased with malignant progression. However, although this study 
reported that FOXP3 was expressed within normal breast epithelial cell, they also 
reported that epithelial cell derived-FOXP3 expression also increased with invasive 
progression. This demonstrates the slight ambiguity within the literature regarding 
epithelial cell FOXP3 expression and breast cancer.    
 
3.1.2 Cytokine-driven FOXP3 expression 
A number of reports have investigated the effects of FOXP3 expression in T-cells 
after treatment with various cytokines. The greatest increase in FOXP3 expression 
was produced by treatment with IL-2 (Zorn, Nelson et al. 2006) and TGF-β 
(Nishihara, Ogura et al. 2007; Xiao, Jin et al. 2008; Yang, Anderson et al. 2008; 
Zhou, Lopes et al. 2008). Although recently, Frattini et al (Frattini, Pisati et al. 2012) 
reported that TGF-β is unable to increase the mRNA or protein levels of FOXP3 in 
glioblastoma cells, the effect of cytokines on FOXP3 expression in breast epithelial 
cells remains largely unreported.   
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3.1.2.1 TGF-β 
TGF-β has been evolutionary conserved between vertebrates and invertebrates 
(Massague, Blain et al. 2000). Although no TGF-β response elements have been 
identified in or around the FOXP3 gene, TGF-β has long been identified as a key 
regulator of FOXP3 expression in Tregs of animals and humans (Yamagiwa, Gray et 
al. 2001; Schramm, Huber et al. 2004). The effects of TGF-β on the differentiation of 
T-cells appears to be dose-dependent as low levels of TGF-β are able to promote the 
development of Th17 cells, whereas, higher concentrations of TGF-β favour the 
differentiation of FOXP3
+
 Tregs (Nishihara, Ogura et al. 2007; Xiao, Jin et al. 2008; 
Yang, Anderson et al. 2008; Zhou, Lopes et al. 2008). 
Many of the actions of TGF-β are governed through the interactions with Smad 
proteins as these are classed as signal transducers of TGF-β (Derynck, Zhang et al. 
1998). A report by Tone et al (Tone, Furuuchi et al. 2008) discovered  a conserved 
enhancer site within FOXP3 which is able to bind Smad3, therefore, suggesting 
TGF-β influences FOXP3 expression through Smad3 dependant signalling 
mechanisms.    
Differentiation of naive CD4
+
 T-cells to acquired (CD4
+
)CD25
hi
FOXP3
+
 Tregs can 
be achieved by TGF-β in both mouse and human. In fact, these naïve peripheral T-
cells which are activated in the presence of TGF-β or IL-2 are also able to gain an 
immunosuppressive characteristic both in vitro (Chen, Jin et al. 2003; Zheng, Wang 
et al. 2006) and in vivo (Andersson, Tran et al. 2008; Huter, Punkosdy et al. 2008). 
However, Floess et al (Floess, Freyer et al. 2007) reported that the removal of TGF-β 
from the environment caused a rapid reduction in FOXP3 expression suggesting that 
TGF-β is a key mediator of FOXP3 development in induced Tregs.  
As previously discussed in section 1.7.10, the methylation status of CpG sites in the 
promoter of FOXP3 is key in regulating expression of the FOXP3 gene in T-cells. 
Interestingly, TGF-β was demonstrated to cause demethylation at these sites in 
CD4
+
CD25
-
 T-cells to induce FOXP3 in naïve T-cells, however, the expression of 
FOXP3 was only transient (Kim and Leonard 2007).  
It has also been reported that TGF-β can influence FOXP3 expression via other 
indirect mechanisms. TGF-β is able to inhibit the phosphorylation of Erk which 
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results in the inhibition of DNA methyltransferases (DNMT) (Luo, Zhang et al. 
2008). The subsequent inhibition of DNMTs in T-cells has been reported to increase 
the expression of FOXP3, therefore providing an alternative indirect mechanism. 
 
3.1.2.2 IL-2  
T-cells express the IL-2 receptor, however, upon antigenic stimulation of the TCR, 
these cells then secrete IL-2 which provides a feedback loop between IL-2/IL-2 
receptor, and promotes cell growth, differentiation and survival (Beadling and Smith 
1993; Beadling and Smith 2002). 
Studies using different patient populations have consistently demonstrated the effects 
of IL-2 on FOXP3 expression in T-cells (Sereti, Imamichi et al. 2005; Ahmadzadeh 
and Rosenberg 2006). Zorn et al (Zorn, Nelson et al. 2006) demonstrated using T-
cells from healthy donors that IL-2 caused rapid upregulation of FOXP3 at transcript 
and protein levels after 2 hours of culture in CD4
+
CD25
+
 T-cells, but not in 
CD4
+
CD25
-
 cells (Zorn, Nelson et al. 2006). In vitro studies often use IL-2 for the 
expansion of FOXP3
+
 Tregs as these cells, despite not secreting IL-2, require the 
cytokine to survive. In vivo studies have also demonstrated that low doses of IL-2 are 
capable of expanding Tregs, however, the effects are only transient as removal of IL-
2 caused a decrease in Treg numbers (Zorn, Nelson et al. 2006). These effects of IL-
2 on FOXP3 expression are governed by IL-2 receptor-mediated signalling cascades 
which act through JAK (Frank, Robertson et al. 1995). JAKs are able to activate 
STATs by tyrosine phosphorylation which causes them to dimerise and translocate to 
the nucleus where they can regulate gene transcription. In particular STAT5 is a key 
member of the IL-2 signalling pathway. Evidence suggests the effects of IL-2 on 
FOXP3 could be governed through STAT5 as it has been reported that a deficiency 
in STAT5 leads to autoimmunity because of a lack of natural Tregs (Tsuji-
Takayama, Suzuki et al. 2008; Tsuji-Takayama, Suzuki et al. 2008). In vitro studies 
have demonstrated that STAT5a/b directly bind to the Foxp3 gene and were required 
for the induction of gene expression (Snow, Abraham et al. 2003; Yao, Kanno et al. 
2007; Passerini, Allan et al. 2008). Further evidence of IL-2 signalling-mediated 
induction of FOXP3 involving both JAK and STAT pathways, is provided as mice 
with JAK3 knockout have a complete lack of FOXP3
+
 cells (Mayack and Berg 
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2006), whereas, STAT5 knockout mice have strongly reduced FOXP3 expression 
(Yao, Kanno et al. 2007). Interestingly, IL-2 is not the only cytokine to induce 
STAT5 signalling. Studies have since demonstrated that IL-7 and also IL-15 can 
phosphorylate STAT5 which subsequently results in increased transcription of 
FOXP3 in Tregs (Bayer, Lee et al. 2008; Mazzucchelli, Hixon et al. 2008). 
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3.2 Aims and objectives  
 To confirm the tetracycline-inducible expression of FOXP3 in transfected 
HEK cells and validate these cell lines as good positive and negative controls 
for FOXP3. 
 
 To quantitatively determine the epression levels of FOXP3 protein and 
transcripts in breast cancer cell lines and HMEpC. 
 
 To investigate the subcellular distribution of FOXP3 protein in breast cancer 
cell lines and HMEpC.  
 
 To investigate potential mutations and/or alternative splice varient isoforms 
of FOXP3 within breast cancer cell lines. 
 
 To investigate the effects of IL-2 and TGF-β on FOXP3 expression in breast 
cancer cell lines. 
 
 
 
 
 
 
 
Chapter 3 - Study of FOXP3 expression in normal and malignant breast cell lines 
110 
 
3.3 Specific materials and methods 
3.3.1 Protein dialysis 
Before use, protein lysates from cell lines underwent dialysis to remove low 
molecular weight contaminants such as detergents which could interact and affect 
results. The membranes in the dialysis cassettes (Slide-A-Lyzer
®
Dialysis cassettes, 
Thermo Scientific) are composed of low-binding regenerated cellulose and have a 
sealed sample chamber which maintains high sample retention. The cassettes were 
hydrated for 2 minutes, and then the excess liquid was removed gently by tapping the 
edge of the cassette. Each sample was added slowly to separate cassettes using a 
syringe. The samples were then dialysed overnight at room temperature in dialysis 
buffer containing 25% acetic acid. The sample was removed from the cassette by 
initially injecting a small pocket of air to separate the membranes, then gently 
collecting the sample by injecting air into the cassette to make a pocket and extract 
the liquid via a needle.     
 
3.3.2 ELISA 
A pre-coated human FOXP3 ELISA kit (Biorbyt, Cambridge, UK) was used to 
quantify FOXP3 protein expression in cell lines. Samples and controls were prepared 
to contain 20µg of protein in 100µl. FOXP3 quantification was performed according 
to the manufacturers protocol. Briefly, samples and standards were added to 
individual wells and incubated at 37°C for 2 hours. Liquid was then removed from 
the wells and a reagent containing a biotin-conjugated polyclonal antibody was added 
and left to incubate for 1 hour at 37°C. Excess reagent was removed from each well 
before being washed three times in ELISA wash solution. Next a reagent containing 
avidin conjugated to HRP was added to each well and incubated for 30 minutes at 
37°C. Excess reagent was removed from wells before washing with an ELISA wash 
buffer a further three times before finally adding 3,3',5,5'-Tetramethylbenzidine 
(TMB) and incubating for 25 minutes at 37°C. The reaction between TMB and HRP 
is based on TMB acting as a hydrogen donor in reducing hydrogen peroxide to water 
by the presence of peroxidase in HRP. This results in a blue coloured solution which 
can be measured at wavelengths of 650nm. The addition of sulphuric acid stopped the 
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reaction and turned the TMB solution a stable yellow colour which can be measured 
at 450nm. The intensity of the yellow product is proportional to the FOXP3 
concentration in the sample. The absorbance was measured using a microplate reader 
at 450nm. A schematic representation of the test principle is provided in figure 3.1. 
FOXP3 concentration was determined by plotting absorbance against the prepared 
standard curve (figure 3.2). 
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Figure 3-1 - Test principle of FOXP3 ELISA 
Each well is coated with a monoclonal antibody specific for human FOXP3 (A) which will 
detect and bind any FOXP3 present in the sample lysates (B). A reagent which contains a 
secondary antibody directly conjugated to biotin is then added to each well (C) followed by a 
reagent containing avidin-HRP (D). When TMB is added to the well, it oxidises to TMB 
diimine resulting a blue colour change (E). Sulphuric acid is added to cease the reaction and 
cause a stable yellow colour change (F) which is measured using a microplate reader at 
540nm.  
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Figure 3-2 - Standard curves for FOXP3 ELISA 
A FOXP3 standard curve was constructed using seven points of concentration. Standard 
concentration points were prepared by reconstituting standard concentrate with the provided 
diluent producing a double dilution series ranging from 20ng/ml to 0.312ng/ml and a blank 
sample (0ng/ml) (A). A separate curve was produced which further diluted the 0.312ng/ml 
sample producing four further points to determine test sensitivity at concentrations below 
0.312ng/ml (B).     
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3.3.3 Primer design 
All primers were manually designed and purchased from IDT. Information for each 
primer is listed in figure 3.3. Primers are generally 15 to 30 base pairs in length and 
have a large degree of homology with the target sequence. The melting temperature 
of a primer is one parameter which dictates the primer to template DNA stability. 
This melting temperature is the temperature when one half of a DNA duplex will 
dissociate and becomes single stranded. Primers with melting temperatures between 
52-58°C generally produce best results; temperatures over 65°C increase the risk of 
secondary annealing. The actual melting temperature is heavily influenced by several 
parameters including concentrations of magnesium, potassium and co-solvents, 
however, a simple formula for calculating the melting temperature is;  
Tm = 4(G+C) + 2(A+T) °C. 
The primers should have a G/C content of approximately 50% of the primer 
sequence. Because the annealing temperature for the reaction can only be held at one 
temperature, the G/C content determines annealing temperature for the reaction. 
Therefore, the forward and reverse primers should have approximately the same G/C 
percentage content to produce a compatible annealing temperature. Typically, this is 
no more than 5°C difference. To ensure that designed primers are specific only for 
the sequence of interest, a BLAST search was carried out on each primer used 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
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Primer name Sense/ 
anti-sense 
Nucleotide sequence 
5’---------3’ 
% 
GC 
Tm 
(°C) 
FOXP3 primer 1 F Sense TTG GAC AAG GAC CCG ATG 55.6 54.6 
FOXP3 primer 1 R Anti-sense CAA ATG GTG TCT GCA AGT GG 50.0 54.5 
FOXP3 primer 2 F Sense TTC CCA AAT CCC AGT GCA CC 55.0 58.0 
FOXP3 primer 2 R Anti-sense AGA AGC AGC GGA CAC TCA AT 50.0 56.8 
FOXP3 primer 3 F Sense CAG AGT TCC TCC ACA ACA TGG 52.4 55.6 
FOXP3 primer 3 R Anti-sense CAA GAA GTG AGG TTT CCA CTG 47.6 53.5 
GAPDH primer F Sense ACC CAG AAG ACT GTG GAT GG 55.0 56.6 
GAPDH primer R Anti-sense CAG TGG AAC CTC ACT TCT TG 50.0 53.1 
 
Figure 3-3 - Manually designed primers for FOXP3 sequencing 
Three sets of FOXP3 primers were designed to span the entire FOXP3 protein coding domain.  
Sequences in red regions highlighted represent the 3 NLS regions identified by Hancock and Ozkaynak 
(Hancock and Ozkaynak 2009). Panel A: Schematic diagram of the forward and reverse primer 
locations on FOXP3. Panel B; sequences covered by 1
st
 primer set, panel C; sequences covered by the 
2
nd
 primer set and panel D; sequences covered by the 3
rd
 primer set. Black boxes represent the RKKR 
sequence identified by Lopes et al (Lopes, Torgerson et al. 2006) as responsible for nuclear localisation. 
The Table (panel E) represents the information for each primer set.  
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3.4 Results 
3.4.1 Characterisation of inducible FOXP3 in transfected 
HEK cells 
The transfected HEK system utilises the presence of tetracycline to induce the 
expression of FOXP3 (as described in section 2.1.5). Cells cultured with tetracycline 
to induce FOXP3 expression are referred to as HEK+’ve Tet, whereas, HEK cells 
cultured without tetracycline are referred to as HEK-‘ve Tet. The construct also 
confers the ability to resist the antibiotic Hygromycin B, therefore, cells which are 
stably transfected have correctly integrated the plasmid into their genome and can be 
successfully grown in the presence of 100µg/ml Hygromycin B. 
The ability of transfected cells to induce FOXP3 was determined using IF and 
Western blot (figure 3.4 panel A and B). Wild type HEK cells do not naturally 
express FOXP3. Cells successfully cultured in Hygromycin B similarly expressed no 
detectable expression of FOXP3, however, following the addition of tetracycline to 
the growth culture, there was a rapid increase in FOXP3 expression in these cells. 
When the nuclear and cytoplasmic fractions from these cells were isolated, results 
demonstrated that FOXP3 was exclusively expressed within the nucleus (figure 3.4 
panel C).  
The specificity of tetracycline-mediated FOXP3 induction in these cells was 
demonstrated when tetracycline was removed from the media, the FOXP3 expression 
declined in a time-dependant manner (figure 3.5). Despite a marked decrease, 
FOXP3 was still detectable 72 hours after tetracycline removal, however, expression 
levels returned to a non-detectable baseline level by 96 hours. Transfected HEK cells 
were used as positive and negative controls for subsequent experiments.  
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Figure 3-4 – Tetracycline-inducible expression of FOXP3 in transfected HEK 
cells 
(A) Representative IF images of tetracycline induced FOXP3 expression. HEK wild type and 
transfected HEK cells were seeded into chamber slides and left to grow overnight. The 
following day, cells were fixed, permeabilised and stained using a human anti-FOXP3 
primary antibody and a FITC-conjugated secondary antibody. (B) Western blot was also 
used to demonstrate FOXP3 expression in transfected HEK cells cultured with and without 
tetracycline. (C) Subcellular distribution of FOXP3 in transfected HEK cells was determined 
by Western blot following isolation of nuclear (Nuc) and cytoplasmic (Cyto) domains. The 
coomassie blue stained gel was used to demonstrate equal loading between samples  
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Figure 3-5 - Decline of FOXP3 expression following the removal of tetracycline 
from growth media 
Culture flasks of HEK+’ve Tet were seeded with 100ng/ml tetracycline. Each day (24 hours) 
one flask had growth culture removed, was washed in PBS and replaced with fresh media 
without tetracycline. Total protein from all samples was isolated after 96 hours and Western 
blot was performed (upper panel). Densitometry of bands demonstrates decline in FOXP3 
expression (lower panel). HEK-’ve Tet (-’ve Tet) was used as a negative control and 
HEK+’ve Tet (+’ve Tet) was used as a positive control.  
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3.4.2 Validation of HMEpC 
Primary HMEpC were purchased from Invitrogen. Each vial of cells was routinely 
tested for several markers of normal mammary epithelial cells including cytokeratins 
5, 6, 8, 18 and E-Cadherin before delivery. They were also tested for the absence of 
viruses including HIV-1, Hepatitis B & C, bacteria, yeast and fungi to ensure the 
cells are to highest standard for usage. Upon arrival of HMEpC, the cells were 
stained for cytokeratin 8 and 18 to validate the quality of these cells. IF demonstrated 
high level expression of both cytokeratin 8 and 18 (figure 3.6). 
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Figure 3-6 - Validation of HMEpC by staining for cytokeratins 
HMEpC were stained with primary monoclonal human anti-cytokeratin 8 and anti-
cytokeratin 18 antibodies and FITC conjugated secondary antibodies. No primary antibody 
(NPA) and brightfield images included as controls.  
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3.4.3 Determination of FOXP3 expression in cell lines  
The expression of FOXP3 at transcript and protein levels was determined in 
HMEpC, MCF-7 and MDA-MB-231. Prior to PCR, the integrity of RNA was 
determined by running a sample of the isolated RNA in a 1.2% agarose gel. The 
presence of the ribosomal subunits, 18S and 28S, confirmed good quality RNA from 
cell lines (figure 3.7). RNA was reverse transcribed and FOXP3 transcripts were 
determined using real-time PCR with TaqMan® probes specific for FOXP3. The 
reaction efficiency of FOXP3 and GAPDH (which was used as a housekeeping gene) 
real-time PCR primers was assessed by preparing serial dilutions of a template 
cDNA (figure 3.8). A linear drop in Ct value with declining levels of template 
cDNA demonstrates primer specificity and high reaction efficiency. Both FOXP3 
and GAPDH primers had efficiencies greater than 98% for both primers.  
Real-time PCR results demonstrated that FOXP3 was expressed constitutively in 
HMEpC, however, in both MCF-7 and MDA-MB-231 FOXP3 was significantly 
downregulated in comparison to HMEpC (figure 3.9).  
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Figure 3-7 - Confirmation of RNA integrity in cell lines 
Total RNA was extracted from cell lines using TRI reagent. Following quantification of 
RNA by the nanodrop spectrophotometer, the quality of isolated RNA was confirmed by 
agarose gel (1.2%) electrophoresis by demonstrating ribosomal RNA subunits (28S & 18S).  
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Figure 3-8 - Reaction efficiency of FOXP3 and GAPDH Taqman® real-time 
PCR primers 
HEK+’ve Tet cDNA was used to measure reaction efficiency of GAPDH and FOXP3 
TaqMan® primers. cDNA was serially diluted and ran for 35 cycles (representative image 
from FOXP3 amplification plot) (A). Ct values obtained were plotted against cDNA input in 
log2 format and represented as linear regression line plot of Ct value versus cDNA input (B). 
Reaction efficiency from each primer was calculated incorporating the slope of the linear 
regression into the equation:  
Reaction efficiency = 10
(-1/slope)
-1x100 (C). 
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Figure 3-9 - Determination of FOXP3 transcripts in HMEpC and breast 
cancer cell lines  
Data represents relative levels of FOXP3 transcripts. After normalising against 
endogenous GAPDH, the amounts of transcripts were compared to those from HMEpC, 
which was arbitrarily defined as 1.0. Data shown are means and SD of duplicate (n=3). 
Statisitcal analysis was performed using an unpaired t-test.  
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Initially Western blot was used to determine protein levels of FOXP3. However, 
because the expression of FOXP3 in breast epithelial is low, limited success was 
achieved using this technique. High level protein loading and extended exposures 
were required to achieve any form of signal in lysates from HMEpC, MCF-7 and 
MDA-MB-231 (figure 3.10 panel A). Results determined from Western blots 
suggested the presence of two bands within the HMEpC. The upper band at 47kDa 
represented the full length variant of FOXP3, and a band of lower molecular weight 
at 44kDa represented the other FOXP3 isoform (FOXP3Δ3). Although the bands 
were not as strong as those in HMEpC, two distinct bands were also produced at the 
same molecular weights in MCF-7. FOXP3 expression was barely detectable in 
MDA-MB-231. Because of the difficulty in detecting FOXP3 using Western blot a 
more sensitive and quantitative technique was required.  
A FOXP3 ELISA was purchased which has a reported minimum sensitivity level of 
less than 0.085ng/ml. ELISA results quantitatively demonstrated FOXP3 was 
expressed by HMEpC, whereas, FOXP3 was significantly lower in both MCF-7 and 
MDA-MB-231 (figure 3.10 panel B). This correlates with findings produced in 
Western blots. These findings were further validated by IF (figure 3.11). 
Furthermore, the IF images highlight that FOXP3 expression was predominately 
located within the nucleus in HMEpC.   
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Figure 3-10 - Quantitative expression of FOXP3 protein levels in breast cell 
lines 
Total protein was extracted from cell lines using a cell lysis buffer supplemented with 
protease and phosphatase inhibitors. Following quantification of protein concentrations, 
Western blot was performed using 100µg of total protein separated by SDS-PAGE and 
probed for FOXP3 using a human anti-FOXP3 primary antibody and a HRP-conjugated 
secondary antibody. β-actin was used as a loading control (A). ELISA was used to quantify 
FOXP3 protein present in 20µg of total protein from each cell line lysate (B). Absorbance's 
of each sample was measured by spectorphotometery using a microplate reader at 450nm. 
Concentrations of FOXP3 protein was determined by comparing absorbance values of 
samples against a standard curve after subtracting background readout. Error bars show SD 
of means from experiments performed in duplicate (n=5).  Statistical analysis was performed 
using an unpaired t-test.  
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Figure 3-11 - IF images of FOXP3 in cell lines 
Cells were seeded into chamber slides and grown in normal growth conditions overnight. 
The following day cells were fixed, permeabilised and stained using a human anti-FOXP3 
primary antibody and a FITC-conjugated secondary antibody. Cells were also counter 
stained with DAPI to demonstrate nuclear localisation. (A) HMEpC, (B) MCF-7, (C) MDA-
MB-231 and (D) HEK-’ve Tet. 
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3.4.4 Quantification of subcellular distribution of FOXP3 in 
cell lines  
After confirming the presence, albeit at low levels, of FOXP3 within each cancer cell 
line, the subcellular distribution of FOXP3 in each of these cell lines was 
investigated. Results in section 3.4.3 (figure 3.11) demonstrated that FOXP3 was 
predominantly nuclear in the HMEpC. However, because the expression of FOXP3 
in each cancer cell line was significantly reduced, the IF images could not be used to 
determine the distribution of the protein in the cancer cells.   
Using the subcellular NE-PER® fractionation kit, the nuclear and cytoplasmic 
proteins from each cell line was isolated and FOXP3 protein from each domain was 
quantified using the FOXP3 ELISA kit (figure 3.12 panel A). Before quantifying 
protein levels in each domain, Western blots were produced to determine the levels 
of cross contamination between domains. The NE-PER® fractionation kit has a 
reported less than 10% cross contamination level which was demonstrated by 
Western blots using antibodies specific for each domain (figure 3.12 panel B). 
Results once again showed that FOXP3 was lower within MCF-7 and MDA-MB-231 
when compared to the HMEpC. FOXP3 protein levels were higher within nuclear 
fractions of the HMEpC, however, a proportion of FOXP3 protein was also detected 
within the cytoplasm. This level of cytoplasmic FOXP3 in HMEpC could be 
explained as the synthesis of FOXP3 occurs in the cytoplasm, and is then actively 
transported to the nucleus. FOXP3 was found at relatively equal proportions in the 
nuclear and cytoplasmic fractions in MCF-7 with slightly higher levels in the nuclear 
fraction. On the other hand, MDA-MB-231 had a significantly greater proportion 
within the cytoplasmic domain.  
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Figure 3-12 - Quantitative distribution of FOXP3 in subcellular fractions 
Nuclear and cytoplasmic proteins were isolated from cell lines using a NE-PER® 
fractionation kit. Following quantification of protein levels in each sample, 35µg of protein 
was used from each sample to maintain equal loading, except for HEK+’ve Tet which had 
10µg loaded in order to make sure values did not exceed the kit sensitivity. The absorbance 
of each samples were determined by spectrophotometry using a microplate reader at 450nm 
using a microplate reader and protein levels were quantified by measuring the samples 
absorbance against a standard curve after subtracting background readout (A). Error bars 
show SD of means from experiments performed in duplicates (n=4). To demonstrate the low 
cross contamination levels between fractions, a Western blot was performed on protein 
samples using antibodies specific for nuclear (human anti-TATA binding protein) and 
cytoplasmic (human anti-tubulin) fractions (B). Statistical analysis was performed using an 
unpaired t-test.  
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3.4.5 Sequencing of FOXP3 in cell lines for mutations and 
splice variant isoforms 
Dysregulation of FOXP3 within breast cancer is widely reported and discussed in 
section 3.1.1. Having demonstrated that FOXP3 is downregulated within both MCF-
7 and MDA-MB-231, and is also found predominately within the cytoplasm of 
MDA-MB-231, possible mutations or splice variant isoforms which could be 
responsible for this was investigated by sequencing the FOXP3 protein coding region 
in all cell lines. Particular interest was focused around the three NLSs identified by 
Hancock & Ozkaynak (Hancock and Ozkaynak 2009) and the RKKR sequence 
identified by Lopes et al (Lopes, Torgerson et al. 2006) as these have been 
demonstrated to be relavent in protein nuclear localisation of FOXP3.  
 
3.4.5.1 Annealing temperature gradient for FOXP3 
primer sets 
FOXP3 primers were manually designed, ensuring that the entire protein coding 
region of each exon was completely spanned by the primers. This ensures that any 
splice variant isoforms of FOXP3 which may lack specific exons will be detected. 
Despite maintaining a relatively similar melting temperature between the forward 
and reverse primer pairs in each set, annealing temperature gradients were carried out 
to determine an optimum temperature to produce the greatest amount of product. 
FOXP3 primer sets were optimised using varying annealing temperatures ranging 
from between 40°C to 65°C. Results for each primer produced a single band at the 
correct number of base pairs, therefore, highlighting their specificity and 
thermostability. Temperatures between 51°C and 58°C seemed to produce the most 
product for each primer set (figure 3.13). The annealing temperature for each primer 
was set to 55°C.    
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Figure 3-13 - Annealing temperature gradient for FOXP3 primers 
Primers for conventional PCR were designed manually. Each set of primers: FOXP3 primer 
set 1 (A), FOXP3 primer set 2 (B), and FOXP3 primer set 3 (C) were designed so melting 
temperatures were no more than 5°C apart. Conventional PCR with a temperature gradient 
ranging from 48.9°C to 59.7°C was used to determine the optimal temperature each primer 
set annealed. 30 cycles of PCR using HEK+’ve Tet cDNA as a template for FOXP3 primer 
set 1 and set 2, whereas, MCF-7 cDNA was used as a template for FOXP3 primer set 3 as 
the reverse primer falls outside of the FOXP3 region cloned into transfected HEK cells. 
Samples were ran on 1.2% agarose gel supplemented with 0.5µg/ml ethidium bromide.  
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3.4.5.2 Sequencing of FOXP3 primer set 1 
High quality RNA was isolated from cell lines and reverse transcribed into cDNA. 
Using FOXP3 primer set 1, cDNA was amplified for 35 cycles followed by the 
amplified product being run on a 1.2% agarose gel supplemented with 0.5µg/ml 
ethidium bromide. The PCR product was visualised under UV light and single bands 
were excised from the gel. DNA was eluted from the gel and sent for sequencing.  
FOXP3 primer set 1 used primers which completely span exons 2 (starting from the 
protein coding region in exon 2) to exon 5. Agarose gel PCR demonstrated that both 
HMEpC and MCF-7 produced two single bands after amplification using FOXP3 
primer set 1. When these were sequenced the upper band of 620bp contained no 
missing exons or mutations. However, in HMEpC and MCF-7 the lower band of 
510bp was completely missing exon 3 (Figure 3.14). Representative 
electropherograms from MCF-7 sequencing illustrating the deletion of exon 3 in the 
lower band is provided in figure 3.15. MDA-MB-231 only produced a single band at 
620bp which also contained no mutations.  
The findings from FOXP3 primer set 1 show that HMEpC, MCF-7 and MDA-MB-
231 all contain a FOXP3 isoform containing exons 2-5 with no mutations, whereas, 
HMEpC and MCF-7 also contain a separate isoform which completely lacks exon 3. 
These results also demonstrate that all cell lines and FOXP3 isoforms contained no 
mutations within the NLS-1.     
Sequencing results for HMEpC using FOXP3 primer set 1 are provided in appendix 
1. 
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Figure 3-14 - Sequencing of FOXP3 in breast cancer cell lines using FOXP3 
primer set 1 
Following 35 cycles of PCR with a previously determined annealing temperature for FOXP3 
primer set 1, the final product was ran on a 1.2% agarose gel (A). GAPDH primers were 
used as a loading control between samples and to ensure cDNA quality. cDNA from 
HEK+’ve Tet was used as a positive control, whereas HEK-‘ve Tet was used as a negative 
control. Sequencing data from the upper band of MCF-7 (B), the lower band in MCF-7 (C) 
and MDA-MB-231 (D) was analysed and aligned alongside wild type FOXP3 (accession 
number NM_014009.3) using ApE software. Upper rows represent sample sequences and 
lower rows represent wild type. Blue boxes represent NLS-1 identified by Hancock and 
Ozkaynak (Hancock and Ozkaynak 2009). Data is representative of two experiments which 
produced similar results. 
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Figure 3-15 - Electropherogram demonstrating FOXP3Δ3 isoform in MCF-7 cells 
(A) Sequencing data from upper band in MCF-7 demonstrates the presence of exons 2, 3 and 4. (B) Data from lower band in MCF-7 cells demonstrates 
complete deletion of exon 3. Data was analysed using ApE software.  
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3.4.5.3 Sequencing of FOXP3 primer set 2 
FOXP3 primer set 2 completely spans exons 6-10. Results highlighted that HMEpC, 
MCF-7 and MDA-MB-231 produced a single band at approximately 560bp which 
demonstrates a single isoform. Moreover, all cell lines contained no missing exons 
between exon 6 and 10. Sequencing these products also illustrated that no mutations 
were detected in any cell lines (figure 3.16). FOXP3 primer set 2 also covers NLS-2 
which also contained no mutations.   
 
3.4.5.4 Sequencing of FOXP3 primer set 3 
FOXP3 primer set 3 completely spans exon 11 and slightly downstream of the 
protein coding domain in exon 12. Once again, single bands were produced in each 
cell line with no mutations detected (figure 3.17). Both NLS-3 and the RKKR 
sequences were covered by FOXP3 primer set 3. No mutations were detected in 
either cell line.   
No positive control was used for this primer set. In previous studies we have used 
HEK+’ve Tet as a positive control however this primer set uses a reverse primer 
which lies outside of the FOXP3 gene which was cloned into the vector therefore 
meaning it is not detectable with these primers.  
Sequencing results using FOXP3 primer sets 2 and 3 for HMEpC are provided in 
appendix 2. 
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Figure 3-16 - Sequencing of FOXP3 in breast cancer cell lines using FOXP3 
primer set 2 
Following 35 cycles of PCR with a previously determined annealing temperature for FOXP3 
primer set 2, the final product was ran on a 1.2% agarose gel (A). GAPDH primers were 
used as a loading control between samples and to ensure cDNA quality. cDNA from 
transfected HEK+‘ve Tet was used as a positive control whereas HEK-ve Tet was used as a 
negative control. Sequencing data from MCF-7 (B) and MDA-MB-231 (C) was analysed 
and aligned alongside wild type FOXP3 (accession number NM_014009.3) using ApE 
software. Upper rows represent sample sequences and lower rows represent wild type 
FOXP3. Blue boxes represent NLS-2 identified by Hancock and Ozkaynak (Hancock and 
Ozkaynak 2009). Data is representative of two experiments which produced similar findings. 
FOXP3
GAPDH
560bp
A
B
C
590bp
Chapter 3 - Study of FOXP3 expression in normal and malignant breast cell lines 
137 
 
 
Figure 3-17 - Sequencing of FOXP3 in breast cancer cell lines using FOXP3 
primer set 3 
Following 35 cycles of PCR with a previously determined annealing temperature for FOXP3 
primer set 3, the final product was ran on a 1.2% agarose gel (A). GAPDH primers were 
used as a loading control between samples and to ensure cDNA quality. cDNA from 
transfected HEK-‘ve Tet was used as a negative control. Sequencing data from MCF-7 (B) 
and MDA-MB-231 (C) was analysed and aligned alongside wild type FOXP3 (accession 
number NM_014009.3) using ApE software. Upper rows represent sample sequences and 
lower rows represent wild type FOXP3. Blue boxes represent NLS-3 identified by Hancock 
and Ozkaynak (Hancock and Ozkaynak 2009) whereas orange boxes represent RKKR 
sequences identified by Lopes et al (Lopes, Torgerson et al. 2006). Data is representative of 
two experiments which produced similar findings. 
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3.4.6 Effects of IL-2 and TGF-β on FOXP3 expression in 
breast cancer cell lines  
Several reports have demonstrated that cytokines including TGF-β and IL-2 can 
increase the expression of FOXP3 in T-cells (Zorn, Nelson et al. 2006; Nishihara, 
Ogura et al. 2007; Xiao, Jin et al. 2008; Yang, Anderson et al. 2008). However, no 
reports have investigated whether these cytokines can also influence FOXP3 
expression in breast cancer cells.  
MDA-MB-231 and MCF-7 were treated with either 10ng/ml or 20ng/ml of either 
TGF-β or IL-2 for up to 24 hours and the transcript expression of FOXP3 was 
analysed by real-time PCR (figure 3.18). Results demonstrate that treatment with 
TGF-β and IL-2 did not significantly increase the expression of FOXP3 in either 
MDA-MB-231 or MCF-7 even after increasing both concentrations and incubation 
periods. CD4
+ 
T-cells were also treated with 20ng/ml TGF-β and IL-2 for 24 hours 
and despite a marked increase in FOXP3 after TGF-β treatment, there was no 
increase after IL-2 treatment.  
This demonstrates that neither TGF-β nor IL-2 can increase FOXP3 expression in 
breast cancer cell lines.  
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Figure 3-18 - Effects of IL-2 and TGF-β treatment on FOXP3 expression in 
breast cancer cell lines 
MDA-MB-231 and MCF-7 were seeded into 6-well plates and cultured with either 10ng/ml 
or 20ng/ml of TGF-β or IL-2. After 6, 16 and 24 hours RNA was isolated. Freshly isolated 
CD4
+
 T-cells were treated with 20ng/ml of TGF-β and IL-2 for 24 hours as a positive 
control. cDNA was synthesised and real-time PCR was performed for FOXP3 transcripts 
after normalising against endogenous GAPDH (n=2). Statisitical analysis was performed 
using a paired t-test. 
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3.5 Summary of chapter 3 results 
 Following the introduction of tetracycline to the growth media, FOXP3 was 
rapidly induced in transfected HEK cells. When tetracycline was removed the 
FOXP3 protein was degraded and undetectable after approximately 96 hours.  
 
 FOXP3 is significantly downregulated at both a protein and transcript level in 
MCF-7 and MDA-MB-231 cell lines in comparison to HMEpC. 
 
 FOXP3 is located predominantly within the cytoplasm of the typically more 
invasive MDA-MB-231 cell line, whereas it remains predominantly nuclear 
in less invasive MCF-7 cells. 
 
 HMEpC and MCF-7 cells contained both natural FOXP3 isoforms 
(FOXP3FL and FOXP3Δ3) at approximately equal levels, whereas, MDA-
MB-231 only expressed a full length variant.  
 
 Neither IL-2 nor TGF-β was able to upregulate FOXP3 in either MDA-MB-
231 or MCF-7 breast cancer cells. 
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3.6 Discussion  
Following the discovery of FOXP3 in epithelial cells, research has now demonstrated 
that FOXP3 is frequently dysregulated in a number of malignancies at protein and 
transcript levels. This has demonstrated that FOXP3 is more than just a marker for 
Treg function and development, it is also a potent tumour suppressor required for 
maintaining epithelial cell homeostasis. Studies have reported a number of scenarios 
including downregulation, mutations, splice variants, skewed cellular distribution 
and even normal nuclear expression of FOXP3 in several forms of malignancy (Zuo, 
Liu et al. 2007; Zuo, Wang et al. 2007; Merlo, Casalini et al. 2009; Wang, Liu et al. 
2009; Zhang and Sun 2010; Frattini, Pisati et al. 2012).  
However, a recent report by Lal et al (Lal, Chan et al. 2013) reported that both Treg 
and epithelial cell derived FOXP3 expression increased with malignancy. On this 
basis, the aim of this chapter was to further investigate the expression of FOXP3 
within primary normal mammary epithelial cells and two breast cancer cell lines, 
with different invasive capacities.  
 
3.6.1 Validation of FOXP3 induction in transfected HEK cells 
The first aim of this chapter was to validate the tetracycline-inducible FOXP3 system 
in transfected HEK cells generated by Dr Marcin Pekalski. Following the addition of 
tetracycline, the expression of FOXP3 was rapidly increased within transfected HEK 
cells. As a transcription factor, it is important that FOXP3 is located within the 
nucleus. When FOXP3 was induced in these cells the expression was found to be 
exclusively within the nucleus. This demonstrates that the inducible system described 
acts as a good positive and negative control for FOXP3 expression for subsequent 
experiments. The inducible induction of FOXP3 in the transfected HEK cells is 
reversible as the removal of tetracycline from the growth media resulted in a time-
dependant decrease in FOXP3 expression. This emphasises that the induction of 
FOXP3 in the HEK cells was tetracycline-dependant.  
It has been reported in T-cells that the FOXP3 protein is relatively unstable and has a 
half-life of approximately 21 minutes before it undergoes rapid polyubiquitination 
and the protein is degraded (Lee, Gao et al. 2008). However, when tetracycline was 
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removed from the growth media FOXP3 was still detectable for up to 72 hours and 
completely absent after 96 hours. This extended presence of FOXP3 could be 
explained on the basis that FOXP3 is not a native protein to these cells, and they may 
lack the required mechanisms to effectively degrade the protein. This demonstrates 
that the presence of FOXP3 in these cells acts as a good control for expression but 
not as a functioning protein. Another aspect to be considered is the promoter stability 
in the transfected HEK cells. The tetracycline-inducible FOXP3 expression in the 
transfected HEK cells is under the control of a CMV promoter which could be more 
stable for longer periods than the natural FOXP3 promoter found in T-cells.   
 
3.6.2 FOXP3 expression in normal and malignant cell lines   
In Tregs, FOXP3 is expressed at high levels and is therefore considered a good 
marker for these cells. However, the expression in epithelial cells is considerably 
lower (Wang, Liu et al. 2009). Three methods of detecting FOXP3 were attempted in 
this aspect of the study. Each technique used antibodies which detect FOXP3 
epitopes outside of exon 3, therefore, both FOXP3FL and FOXP3Δ3 isoforms will 
be detected. Initially, Western blot was used to detect the expression of FOXP3 in 
cell lines. However, even after excessive protein loading, extended incubation 
periods and exposure times, the FOXP3 signal produced in all breast epithelial cells 
(including HMEpC) was weak. This finding demonstrates the presence of FOXP3 in 
these cells, albeit at a low level. This finding was further validated by IF. In order to 
amplify the signal, a more sensitive technique was used in the form of a FOXP3 
ELISA which has a reported minimum sensitivity of less than 0.085ng/ml. In order to 
quantify FOXP3 levels, a standard curve was produced using concentrations ranging 
from 20ng/ml down to 0.312ng/ml. The accuracy and sensitivity was demonstrated 
by further serial diluting the 0.312ng/ml sample four more times to reach to 
concentration of 0.039ng/ml which still produced a measurable signal with relatively 
low error bars.  
ELISA results enabled, for the first time, the quantification of FOXP3 expression in 
normal mammary cells. The level of FOXP3 within these cells was low. This finding 
is consistent with the literature. FOXP3 protein and transcripts within MCF-7 and 
MDA-MB-231, were significantly less in comparison to HMEpC. The levels of 
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FOXP3 protein and transcripts were approximately the same in MCF-7 and MDA-
MB-231 which could indicate that FOXP3 downregulation may have occurred at 
earlier stages of carcinogenesis rather than latter stages.  On the contrary, Frattini et 
al (Frattini, Pisati et al. 2012) reported that Foxp3 was still present within early 
stages of tumours in glioblastoma, however, the expression diminished as the tumour 
progressed, possibly suggesting that FOXP3 plays a greater role in later stages of 
tumorigenesis.    
After confirming the presence of FOXP3 within both breast cancer cell lines, the 
cytoplasmic and nuclear distribution of FOXP3 was investigated. Since FOXP3 is 
synthesised within the cytoplasm and actively transported into the nucleus, it is often 
referred to as a shuttling protein. On this basis, it is expected that some FOXP3 
would be present within the cytoplasm. Findings demonstrated that a proportion of 
FOXP3 was located within the cytoplasm in HMEpC although the nuclear content 
was clearly greater. Combined levels of nuclear and cytoplasmic FOXP3 contents 
from MCF-7 were less than that found in HMEpC. MCF-7 appeared to contain both 
nuclear and cytoplasmic FOXP3. However, when the distribution within MDA-MB-
231 was investigated, the proportion of FOXP3 within the cytoplasm was 
significantly greater than the nuclear content. One question which can be posed from 
this finding is: Does the skewed distribution of FOXP3 have further detrimental 
effects to epithelial cells when it is present in the cytoplasm? As a transcription 
factor, the primary role of FOXP3 is to bind to DNA and influence gene expression. 
To carry out this function, FOXP3 needs to be present within the nucleus. Although 
the presence of FOXP3 has been observed in the cytoplasm in several reports (Hinz, 
Pagerols-Raluy et al. 2007; Merlo, Casalini et al. 2009; Wang, Liu et al. 2009), the 
exact consequences of this dysregulated distribution have never been investigated. 
This suggests that FOXP3 acting detrimentally in the cytoplasm is less likely, with 
the mere absence of FOXP3 from the nucleus being more important. However, in 
contrast to this, when Merlo et al (Merlo, Casalini et al. 2009) looked at the 
distribution of FOXP3 in a large cohort of breast cancer patients they reported that 
patients with FOXP3 restricted to the cytoplasm had an equal, or worse, prognosis to 
those who had no detectable FOXP3. This suggests that the cytoplasmic location 
could be more detrimental than a complete absence of the protein.  
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The levels of FOXP3 within the nuclear compartment of MCF-7 and MDA-MB-231 
were relatively equal. This suggests that if the level of nuclear FOXP3 within MCF-7 
was at a functioning level, then it should be equally functional within MDA-MB-
231, proposing that a cytoplasmic distribution could be consistent with a worse 
prognosis.  
Aceylation is the process of adding an acetyl group into a chemical compound, 
generally by replacement of an active hydrogen atom. This is catalyzed by enzymes 
which contain histone/protein acetyltransferases (HATs). Acetylation is an important 
part of biology as it can regulate the expression and stability of proteins. 
Interestingly, Foxp3 is a protein demonstrated to be influenced heavily by 
acetylation. Deacetylase inhibitors can increase acetylation of Foxp3 which results in 
an increased suppressive function in Tregs in vitro and in vivo (Hansen, Baeuerle et 
al. 1994). Indeed, HAT p300 in particular can cause acetylation of Foxp3 which 
subsequently increases the protein stability in transfected cells, whereas, inhibition of 
HAT p300 is able to inhibit the function of Tregs through impaired Foxp3 function 
(Liu, Wang et al. 2013). Interestingly, the effects of Foxp3 acetylation in normal or 
malignant epithelial cells have not been reported and, therefore, require further 
investigation. Acetylation has been reported to be important in nuclear translocation 
of proteins, whereas, lysine residues are often targeted in the acetylation of proteins. 
These residues are also involved in nuclear translocation of proteins, including the 
RKKR sequence in FOXP3 reported by Lopes et al (Lopes, Torgerson et al. 2006). 
However, despite the importance of HAT p300 in controlling Foxp3, a report by Van 
Loosdregt et al (van Loosdregt, Vercoulen et al. 2010) has demonstrated that the 
acetylation of Foxp3 by HAT p300 does not influence the subcellular distribution of 
Foxp3.  
 
3.6.3 FOXP3 mutations and isoforms in breast cancer cells 
It is well established that mutations can cause significant downregulation of gene 
expression which subsequently affects the protein expression. In addition to being 
downregulated, the distribution of FOXP3 in many cancers is found to be restricted 
to the cytoplasm (Merlo, Casalini et al. 2009; Wang, Liu et al. 2009). Hancock and 
Ozkaynak (Hancock and Ozkaynak 2009) used murine Foxp3 to demonstrate three 
Chapter 3 - Study of FOXP3 expression in normal and malignant breast cell lines 
145 
 
regions which are imperative to nuclear transport and have highly conserved 
homology within human FOXP3. A separate report from Lopes et al (Lopes, 
Torgerson et al. 2006) demonstrated the importance of an RKKR sequence in human 
FOXP3. This sequence is important for nuclear translocation of other proteins 
(Mikami, Hori et al. 2005; Song, Waataja et al. 2006) including FOXP3 in prostate 
cells (Wang, Liu et al. 2009). Therefore these regions were of particular interest.  
HMEpC contained both natural FOXP3 isoforms and no mutations. MCF-7 also 
contained both natural isoforms with no mutations. However, MDA-MB-231 only 
contained the full length variant and is therefore missing the natural FOXP3Δ3 
isoform. Interestingly, these findings also match the results from Western blots, 
which showed the presence of two faint bands, one at approximately 47kDa, and one 
approximately 4kDa smaller in HMEpC and MCF-7. This finding was validated 
from the sequencing results which demonstrated the presence of FOXP3FL and 
FOXP3Δ3 in HMEpC and MCF-7.    
These findings show that FOXP3 is downregulated within both non-invasive and 
invasive breast cancer cell lines. However, FOXP3 in the invasive cell line is not 
only predominately restricted to the cytoplasm, but also missing a natural isoform 
therefore posing another question: Because MDA-MB-231 still contains a full length 
isoform, does the specific absence of the Δ3 isoform contribute to cancer invasion? 
To address this question, understanding the role of the Δ3 isoform, and perhaps exon 
3, is of particular importance. Unfortunately, the functional differences between the 
two isoforms are still largely unclear (Allan, Passerini et al. 2005; Ziegler 2006). 
A report by Zuo et al (Zuo, Wang et al. 2007) investigated the expression of FOXP3 
in ten malignant breast cancer cell lines. They reported that FOXP3 was 
downregulated between 1.5- and 20-fold in all malignant cell lines including MCF-7 
and MDA-MB-231, a similar finding to results in this study. The same report also 
determined the presence of splice variant isoforms in each cell line. Firstly, 70% of 
the malignant lines still expressed the FOXP3Δ3 variants demonstrating that the 
absence of exon 3 was most consistent between the cell lines. However, even the 
immortalised non-malignant MCF-10A cell line expressed only the Δ3 isoform. 
Secondly, they reported that MCF-7, as well as missing a full length variant, also 
lacked exon 3 and 4, whereas, MDA-MB-231 was missing the full length and exons 
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3 and 8. Although these findings are inconsistent with results in this study, they do 
suggest widespread lack of exon 3 amongst breast cancer cell lines and suggest an 
important role of exon 3 in normal homeostasis.    
Both full length and Δ3 FOXP3 versions have been demonstrated in Tregs and 
epithelial cells (Allan, Passerini et al. 2005; Zuo, Wang et al. 2007). However, very 
little has been reported regarding the role of the Δ3 isoform. FOXP3Δ3 has been 
described as the dominant negative isoform (Ziegler 2006). Exon 3 is located within 
amino acids 72-106 of FOXP3 and is located within the repressor domain which is 
known to specifically interact and inhibit ROR-α which leads to the expression of 
genes responsible for Th17 generation (Du, Huang et al. 2008). Therefore, it is 
thought that only full length FOXP3 in T-cells can generate Th17 lineage. 
Although many reports have demonstrated downregulation of FOXP3, along with 
mutations and missing isoforms, few reports have investigated the role of FOXP3Δ3 
in epithelial cells. A recent report by Frattini et al (Frattini, Pisati et al. 2012) is the 
only paper to date which has investigated the functional aspects of each FOXP3 
isoform within non-immune cells. Interestingly, they reported that overexpression of 
either FOXP3FL or FOXP3Δ3 resulted in a reduced proliferation rate (Frattini, Pisati 
et al. 2012). However, only the FOXP3Δ3 isoform was able to reduce the migratory 
potential of these cells (Frattini, Pisati et al. 2012). Transfection of the full length 
isoform failed to significantly inhibit migration. This would suggest that the 
FOXP3Δ3 isoform has a greater importance in controlling the migration of cells than 
the full length isoform, and the lack of FOXP3Δ3 in MDA-MB-231 could be 
responsible for promoting the invasive phenotype.  
Because exon 3 interacts with ROR-α, only full length FOXP3 can inhibit ROR-α. 
ROR-α has been implicated in several forms of malignancy including cancers of the 
prostate (Moretti, Montagnani Marelli et al. 2002), colon (Lee, Kim et al. 2010) and 
breast (Xiong, Wang et al. 2012). Within these malignancies, ROR-α is often 
downregulated, indicating strong anti-cancer properties. Moreover, the presence of 
ROR-α is reported to inhibit tumour invasiveness (Xiong, Wang et al. 2012). 
Because both HMEpC and MCF-7 express both FOXP3 isoforms, and T-cell biology 
has demonstrated that only full length FOXP3 is capable of inhibiting ROR-α, we 
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could speculate that FOXP3FL and FOXP3Δ3 work in an antagonistic fashion to 
control the expression of ROR-α.  
As MDA-MB-231 lack the FOXP3Δ3 isoform, and only expresses a full length 
isoform which represses ROR-α, MDA-MB-231 maybe inhibiting and repressing the 
expression of ROR-α. Therefore, could this be a key factor in contributing to the 
invasive capacity of MDA-MB-231?   
Although we did not find any mutations within our cell lines, the presence of 
mutations in FOXP3 is widespread and well documented in both breast and prostate 
cancers (Zuo, Wang et al. 2007; Wang, Liu et al. 2009). Zuo et al (Zuo, Wang et al. 
2007) sequenced 65 breast cancer patient samples with matched normal tissue and 
found that 23 out of 65 samples (35%) contained somatic mutations in FOXP3. 
When these mutations were mapped, only 2 of the samples had mutations in exon 3, 
with the majority lying towards the C-terminal in regions around the forkhead 
domain or the zinc finger. Similar findings were demonstrated in a study which 
investigated FOXP3 mutations in prostate cancer samples (Wang, Liu et al. 2009) 
and IPEX patients (Lopes, Torgerson et al. 2006). This would suggest that regions 
towards the C-terminus are more frequently affected in diseases and may be more 
important for FOXP3 functioning.  
It could be asked why the FOXP3 sequencing results for MCF-7 and MDA-MD-231 
differ from findings of the Zuo group (Zuo, Wang et al. 2007). One possibility is that 
the cell lines used were in fact not the ones thought to be used. It has been reported 
that specific cell lines within laboratories can have similar appearances and also 
grow consistently with other cell lines. For instance it is estimated that between 10-
20% of in vitro cell lines may have HeLa cell contamination, an issue risen by 
Stanley Gartler in 1967 (Gartler 1967) and Walter Nelson-Rees in 1975 (Nelson-
Rees, Flandermeyer et al. 1974). The cells used in this study were provided by the 
MD Anderson centre (Houston, TX, USA) and are thoroughly validated as described 
in section 2.1.4. The most plausible conclusion is that within each cell line there is 
considerable heterogeneity and not all cell lines are exactly the same. This concept 
has been reviewed by Baguley and Leung (Baguley and Leung 2011) who have 
demonstrated a large degree of heterogeneity in growth factor receptors and 
signalling pathways in breast cancer cell lines. The way cells are currently and 
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previously looked after (i.e. previous experiments performing knockdown etc), the 
culture methods and even passage number can alter the expression and profile of 
each cell line. 
 
3.6.4 p53 status in cancer cell lines and FOXP3 regulation 
As reported, the level of FOXP3 is correlated with tumour development which 
suggests FOXP3, as a TSG, moderates cellular responses to genotoxic stress (Jung, 
Jin et al. 2010). We have demonstrated that FOXP3 was further dysregulated in the 
invasive MDA-MB-231 in comparison to the less invasive MCF-7. This suggests 
that as breast cancer progresses, FOXP3 becomes increasingly dysregulated.  
As mentioned in section 1.7.10, a report by Jung et al (Jung, Jin et al. 2010) 
suggested that FOXP3 was directly regulated by p53. Following treatment with the 
DNA damaging agent, doxorubicin, levels of FOXP3 was significantly increased in 
MCF-7, but not in MDA-MB-231, MDA-MB-453 or MDA-MB-157 (Jung, Jin et al. 
2010). Interestingly, of these cell lines, only MCF-7 expressed wild type p53. 
Furthermore, when p53 specific siRNA was used to knockdown the wild type 
expression of p53 in MCF-7, the induced expression of FOXP3 by doxorubicin 
previously witnessed was significantly hindered (Jung, Jin et al. 2010). This suggests 
that MCF-7 is able to successfully upregulate FOXP3 expression under genotoxic 
stress through the interactions of p53 which restores capacity to function or localise 
to the nucleus and possibly inhibits the potential to invade. However, because MDA-
MB-231 fails to express functional p53 they are unable to upregulate FOXP3 
expression under genotoxic stresses and potentially promotes the more aggressive 
phenotype.  
 
3.6.5 FOXP3 expression by cytokine-treatment in cancer cells 
As discussed in section 3.1.2, certain cytokines, particularly TGF-β and IL-2, 
increase the expression of FOXP3 in T-cell subsets. It has been reported that breast 
epithelial cells respond to TGF-β and, therefore, have TGF-β receptors (Miettinen, 
Ebner et al. 1994; Dore, Edens et al. 1998). IL-2 receptors have also been 
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demonstrated on intestinal and lung epithelial cells (Ciacci, Mahida et al. 1993; 
Lesur, Arsalane et al. 1997), whereas, a study by Garcia-Tunon et al (Garcia-Tunon, 
Ricote et al. 2004) demonstrated IL-2 receptor presence on cells from breast cancer 
patients.  
Treatment of the breast cancer cell lines MDA-MB-231 and MCF-7 with TGF-β or 
IL-2 failed to induce any change in FOXP3 expression after 6, 16 and 24 hours. As a 
positive control, freshly isolated CD4
+ 
T-cells were also treated with IL-2 and TGF-
β. An increase in FOXP3 expression was witnessed after TGF-β treatment but not 
with IL-2. Zorn et al (Zorn, Nelson et al. 2006) reported that treatment of IL-2 
increased FOXP3 in CD4
+
CD25
+
 cells but not in CD4
+
CD25
-
 cells. Because CD25 is 
the α chain of the IL-2 receptor, this could therefore suggest IL-2 may only have its 
effects on expanding pure Tregs which are defined as CD25
hi
 and therefore have 
high levels of IL-2 receptors. Tregs make up approximately 5-10% of human CD4
+
 
T-cells (Long, Cerosaletti et al. 2010) and the content of Tregs in our CD4
+
 isolation 
may have been too low to witness the effects of IL-2 treatment. This data 
demonstrates, for the first time, that FOXP3 within breast epithelial cells does not 
respond to TGF-β and IL-2. Similar findings have been demonstrated by Frattini et al 
(Frattini, Pisati et al. 2012) who reported that treatment of TGF-β1 and TGF-β2 did 
not influence the mRNA or protein levels of FOXP3 in three glioblastoma cell lines. 
As described, FOXP3 downregulation is widespread amongst breast cancer patients, 
whereas, even the level of FOXP3 in healthy epithelial cells is still realtively low. 
TGF-β is a cytokine which is key in homeostasis and tumour suppression. However, 
when cancer cells lose responsiveness of TGF-β, they can use this cytokine to their 
advantage as reviewed by Massague (Massague 2008). Because TGF-β is often 
enriched in tumour environments, if TGF-β was able to cause increased FOXP3 
expression in epithelial cells, it would seem unlikely that the majority of breast 
cancers and breast epithelia would have downregulated or low levels of FOXP3.  
The importance of TGF-β in cancer can be further illustrated by several lines of 
evidence. As mentioned in section 1.7.8, chronic inflammation is associated with 
breast cancer where T-cell infiltration is high. Infiltration of Tregs are also frequently 
witnessed and thought to act as a mechanism of immune evasion. Therefore, the 
presence of TGF-β could increase the levels of Tregs within the tumour environment 
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by converting CD4
+
 T-cells into acquired Tregs and thus leading tumour progression 
via immune evasion. 
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3.7 Conclusion  
This chapter has demonstrated dysregulation of FOXP3 in breast cancer cell lines of 
both low and high level invasive capacity. Data in this chapter for the first time 
quantifies the levels of FOXP3 in breast epithelia as well as quantifying the 
subcellular distribution of the protein in breast cancer cell lines. Although these 
aspects are consistent with data in other reports, the data from sequencing FOXP3 in 
breast cancer does not fit in with the current literature. Despite the discovery of a 
missing natural FOXP3 variant in MDA-MB-231, data from the experiments 
reported here failed to show any mutations in either breast cancer cell lines.  There is 
much debate around the relevance of using cell lines and this data further emphasises 
the high level of heterogeneity in cell lines, and emphasises the importance of cell 
line validation.  
Because data in this chapter has demonstrated the high level dysregulation of FOXP3 
in the invasive breast cancer cell line MDA-MB-231 and regular constitutive 
expression of FOXP3 in the HMEpC, it would be of interest to investigate the effects 
of restoring wild type FOXP3 in MDA-MB-231, and also what the consequences are 
if wild type FOXP3 was knocked down in HMEpC. This is addressed in the next 
chapter.   
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4 In vitro modelling of FOXP3 functions in normal 
and malignant breast epithelia  
 
4.1 Introduction 
As a transcription factor the primary role of FOXP3 is to regulate the expression of 
genes (Zheng, Josefowicz et al. 2007). Many of the genes reported as FOXP3 targets 
are considered as oncogenes as they are frequently overexpressed in cancer cells. The 
influence of FOXP3 on a number of specific oncogenes has been reviewed by 
Douglass et al (Douglass, Ali et al. 2012) and is briefly discussed. 
 
4.1.1 HER2 (ErbB2) 
The importance of HER2 in breast cancer has been discussed in section 1.4.4.2. The 
ErbB2 gene encodes the HER2 protein which is a transmembrane receptor tyrosine 
kinase and member of the epidermal growth factor receptor family. Overexpression 
of HER2 has been linked to more aggressive forms of breast cancer. On this basis, it 
has recently emerged as an important prognostic marker in breast cancer diagnosis 
(Slamon, Clark et al. 1987; Press, Bernstein et al. 1997). 
HER2 activation is dependent on phosphorylation of specific tyrosine residues on the 
intracellular region of HER2 which act as binding sites for molecules linking HER2 
to downstream pathways which include MAPK and PI3K leading to cell growth and 
survival (Roy and Perez 2009). 
The potential of FOXP3 to modify the expression of HER2 in breast epithelial cells 
has been demonstrated on several lines of evidence by Zuo et al (Zuo, Wang et al. 
2007). Following transfection of a FOXP3 expressing vector into a HER2 
overexpressing mouse breast cancer cell line (TSA) there was a significant reduction 
of ErbB2 transcripts. Whereas, when FOXP3 was silenced in normal mammary cells 
there was a subsequent increase in ErbB2 transcripts. Further evidence of this 
repression was provided when the 5′ sequence of the ErbB2 gene was analysed and 
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revealed multiple binding motifs for the forkhead domain of FOXP3 (Zuo, Wang et 
al. 2007). This demonstrates that the effects of FOXP3 on ErbB2 are direct. In vitro 
experiments using human breast cancer cell lines have produced results similar to 
those observed from in vivo (Zuo, Wang et al. 2007). Analysis of ten malignant 
breast cancer cell lines, all with significantly reduced levels of FOXP3, revealed that 
seven cell lines overexpressed ErbB2 transcripts in comparison to normal epithelial 
cells (Zuo, Wang et al. 2007). However, the fact that the other three cell lines did not 
overexpress HER2, demonstrates that FOXP3 is most likely not the sole regulator of 
HER2 expression. Finally, when wild type FOXP3 was silenced using siRNA in 
normal mammary epithelial cells, a 7-fold increase was observed in ErbB2 mRNA 
and cell-surface expression of HER2 (Zuo, Wang et al. 2007). 
 
4.1.2 S-phase kinase-associated protein 2 
S-phase kinase-associated protein 2 (SKP2) has been reported in a wide variety of 
cancers (Nakayama and Nakayama 2006) and is overexpressed in nearly 50% of 
breast cancers (Sonoda, Inoue et al. 2006). SKP2 overexpression in these 
malignancies generally correlates with a poor prognosis (Signoretti, Di Marcotullio 
et al. 2002; Radke, Pirkmaier et al. 2005).  
Cell cycle progression is controlled by a number of short lived enzymes called cyclin 
dependant kinases (CDK) and CDK inhibitors. The expression of these enzymes 
must be tightly regulated and are frequently degraded by the proteolytic ubiquitin–
proteosome pathway. This pathway consists of three enzymes, ubiquitin-activating 
enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin ligase enzymes 
(E3). SKP2 is an essential component of E3 ubiquitin ligase and has specificity for 
degrading the CDK inhibitor p27 (Nakayama, Nagahama et al. 2004). As well as 
regulating cell cycle, overexpression of SKP2 has also been suggested to influence 
the migration and invasiveness of cancer cells (Einama, Kagata et al. 2006).  
The expression of SKP2 and FOXP3 has been investigated in a panel of malignant 
human breast tissues (Zuo, Liu et al. 2007). It was found that 30% of FOXP3 
positive samples overexpressed SKP2. However, only 56% of FOXP3 negative 
samples overexpressed SKP2 (Zuo, Liu et al. 2007). It was also shown that MCF-7 
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with inducible FOXP3 expression had an 8-fold increase in SKP2 transcripts 48 
hours after FOXP3 expression was un-induced (Zuo, Liu et al. 2007). This highlights 
that FOXP3 is able to rapidly reduce the expression of SKP2. Similarly, SKP2 was 
increased when FOXP3 was silenced in an early passage of HMEpC, whereas, when 
wild type FOXP3 was transfected into TSA cell lines, SKP2 expression was reduced 
between 10- and 20-fold (Zuo, Liu et al. 2007). chIP assay demonstrated a number of 
FOXP3-specific binding regions located within the SKP2 gene, and a deletion in 
either binding site results in an increased level of SKP2 expression (Zuo, Liu et al. 
2007). This confirms that FOXP3 directly represses the expression of SKP2 in breast 
epithelial cells.  
 
4.1.3 c-Myc 
c-Myc is overexpressed in more than 30% of human cancer cases. This has led it to 
becoming one of the most researched genes in cancer (Grandori, Cowley et al. 2000). 
The c-Myc gene is located on chromosome 8 and encodes a transcription factor 
which is an integral part of controlling cell cycle progression, as it acts as a CDK 
inhibitor with high affinity for p21 (Jung, Menssen et al. 2008) and p15 (Iavarone 
and Massague 1997).  
Although the effects of FOXP3 controlling c-Myc expression have never been 
reported in breast cancer, a report by Wang et al (Wang, Liu et al. 2009) suggested 
that FOXP3 is able to regulate the expression of c-Myc in prostate epithelia. This is 
based on several strong lines of evidence. Firstly, when wild type FOXP3 was 
knocked down in human prostate cells, an increase in c-Myc transcripts and protein 
was observed resulting in an increased rate of proliferation (Wang, Liu et al. 2009). 
Corresponding to this, when FOXP3 was transfected into two human prostate cancer 
cell lines, the expression of c-Myc was almost completely abrogated (Wang, Liu et 
al. 2009). As demonstrated by chIP assay, using prostate epithelial cells, FOXP3 
directly regulates the expression of c-Myc as an abundance of forkhead binding 
motifs was revealed within the 5’ region of the transcriptional start site in the c-Myc 
gene (Wang, Liu et al. 2009). 
Chapter 4 – in vitro modelling of FOXP3 functions in normal and malignant breast epithelia  
155 
 
4.1.4 p21 (CDKN1A) 
p21 is a protein encoded by the CDKN1A gene. Dysregulated expression of p21 has 
been implicated in many forms of cancer, particularly breast cancers (Pinto, Andre et 
al. 2005). Interestingly, in these cancers, p21 itself is often not mutated (Pinto, Andre 
et al. 2005), suggesting that the association between p21 expression and cancer is due 
to its role as a downstream target of other genes (el-Deiry, Tokino et al. 1993; Dulic, 
Kaufmann et al. 1994; Somasundaram, Zhang et al. 1997).  
p21 is a CDK inhibitor with specificity for CDK1 and CDK2. p21 causes cell cycle 
arrest in the G1 phase and is therefore, important in cell cycle progression and 
senescence (Xiong, Hannon et al. 1993). As well as causing cell cycle arrest, it can 
interact with proliferating cell nuclear antigen (PCNA), which is an accessory factor 
for DNA polymerase and is important in DNA synthesis and repair (Cayrol, 
Knibiehler et al. 1998). 
Although p21 itself is not thought to influence the migration of cells (Goetze, Scholz 
et al. 2010) it has recently been suggested that p21 is able to influence the migration 
and invasion of cancer cells through other mechanisms such as p21-activated kinase 
4 (PAK4) (Li, Katoh et al. 2013). 
In addition to repressing the expression of several oncogenes, FOXP3 can also 
upregulate factors involved in reducing tumour growth. FOXP3 binds to intron 1 in 
CDKN1A and increases histone H3 acetylation by reducing the binding of HDAC2 
and HDAC4, providing a potential mechanism for upregulation of p21 expression 
(Liu, Wang et al. 2009). When FOXP3 was knocked down in MCF-7 and human 
mammary epithelial cells, there was a decrease in the expression of p21 (CDKN1A) 
transcripts and protein (Liu, Wang et al. 2009). This knockdown also correlated with 
an increase in the size and number of the colonies compared to wild type cells (Liu, 
Wang et al. 2009). The link between FOXP3 and p21 regulation in breast cancer was 
further validated when 62 human breast cancer cases were assessed for FOXP3 and 
p21. Results demonstrated that only 30% of FOXP3 negative cases expressed p21 
(Liu, Wang et al. 2009). Despite these important findings, it should be noted that 
other TSGs such as p53 (el-Deiry, Tokino et al. 1993) and BRCA1 (Somasundaram, 
Zhang et al. 1997) are also able to control p21 levels. 
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A recent report has also demonstrated that FOXP3 is able to bind directly to the 
transcriptional start site of both p21 and c-MYC within glioblastoma stem cell-like 
cells and control the expression of these genes in a similar manner as described in 
breast epithelia (Frattini, Pisati et al. 2012). 
 
4.1.5 CXCR4 
Although the potential of FOXP3 to influence CXCR4 expression has never been 
reported in epithelial cells, Zheng et al (Zheng, Josefowicz et al. 2007) performed a 
genome-wide analysis of FOXP3 target genes in Tregs and demonstrated that 
CXCR4 is a gene directly under the influence of FOXP3 in thymic T-cells. 
Interestingly, the gene for another chemokine receptor heavily associated with breast 
cancer metastasis, CCR7, was also reported to be regulated by FOXP3 in Tregs. 
However, the influence of FOXP3 on CXCR4 is yet to be fully defined.    
 
4.1.6 The influence of FOXP3 on cellular function  
As discussed by Douglass et al (Douglass, Ali et al. 2012), many of the genes 
regulated by FOXP3 in epithelial cells encode receptors which control the growth, 
proliferation, migration and invasion of cells Several in vitro and in vivo reports 
using breast, brain, prostate and ovarian epithelial cells have now shown that 
dysregulated FOXP3 expression does not merely affect the expression of the 
aforementioned genes and proteins, but is also able to alter the function of these cells 
(Zuo, Wang et al. 2007; Liu, Wang et al. 2009; Wang, Liu et al. 2009; Zhang and 
Sun 2010; Li, Wang et al. 2011; Frattini, Pisati et al. 2012; Li, Katoh et al. 2013; 
Nakahira, Morita et al. 2013). 
When FOXP3 DNA was transfected into two human breast cancer cell lines, MCF-7 
and SKBr3, and one mouse breast cancer cell line, TSA (all of which lack normal 
FOXP3 expression), the colonies grew at significantly reduced rate, whereas, cells 
transfected with an empty vector grew rapidly (Zuo, Wang et al. 2007). This 
demonstrates that FOXP3 is able to suppress the growth of breast cancer cells. In 
vivo studies have also demonstrated the intrinsic importance of Foxp3 and the effects 
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of Foxp3 deletions. A strain of mice with a floxed Foxp3 locus was generated so 
these mice contain prostate specific deletions of Foxp3 within the epithelia (Wang, 
Liu et al. 2009). By 8-12 weeks there was a 16-fold decrease in Foxp3 expression 
which was validated at protein level by Western blot (Wang, Liu et al. 2009). After 
12-15 weeks there was a 5-fold increase in the percentage of Ki67
+
 proliferating cells 
in comparison to wild type mice. MRI scans also demonstrated a significant 
enlargement of the prostate in live mice (Wang, Liu et al. 2009). After 14-16 weeks, 
5 out of 6 Foxp3 deficient mice showed hyperplasia. After 23-26 weeks, 80% of the 
Foxp3-floxed mice showed extensive hyperplasia, whereas none of the age matched 
mice showed this pathology (Wang, Liu et al. 2009). Finally, by 43-60 weeks, all the 
mice with prostate specific Foxp3 deletions showed extensive hyperplasia (Wang, 
Liu et al. 2009).   
The data by Wang et al (Wang, Liu et al. 2009) demonstrates that a lack of Foxp3 in 
prostate epithelial cells leads to spontantous tumour growth in mice which began the 
process of sexual maturity. This finding could have profound clinical significance on 
male IPEX patients. As described in section 1.7.3, IPEX patients undergo HSCTx 
which has a high success rate in allivating chronic autoimmunity. However, IPEX 
patients will still have mutated versions of FOXP3 within their epithelial cells and, 
similar to the mice reported in the study by Wang et al (Wang, Liu et al. 2009), may 
have an increased risk of developing prostate hyperplasia and tumour formation 
when they begin puberty. This would suggest that from this stage, IPEX patients 
should be monitored carefully for the formation of prostate specific tumours.     
When a FOXP3 vector was re-introduced into an ovarian cancer cell line, the growth 
and proliferation of these cells was significantly reduced (Zhang and Sun 2010). 
There was also significant inhibition of cell cycle associated proteins as a 
predominant accumulation of FOXP3 transfected cells were caught in the G0-G1 
phase of the cell cycle. In addition to this, the metastatic potential of these cells was 
reduced as the migration and invasive potential of these cells was inhibited following 
FOXP3 transfection. It is thought that the majority of these effects can be attributed 
to inhibiting the signalling of NF-κB and mTOR and the expression of uPA and 
MMP2 and MMP9 (Zhang and Sun 2010). The ability FOXP3 to influence the 
expression of MMP9 was also suggested in MCF-7 (Nakahira, Morita et al. 2013). 
Nishihira et al (Nakahira, Morita et al. 2013) reported that following the activation of 
Chapter 4 – in vitro modelling of FOXP3 functions in normal and malignant breast epithelia  
158 
 
FOXP3 through LCK, the invasiveness of MCF-7 cells was significantly decreased. 
Interestingly the same report also demonstrated that FOXP3 expression resulted in a 
decrease in VEGFA expression (Nakahira, Morita et al. 2013).   
As described in section 1.7.8, FOXP3 has also been reported to be downregulated 
within the majority of glioblastoma cases (Frattini, Pisati et al. 2012). The same 
report investigated the functional effects of FOXP3 overexpression in a FOXP3 
deficient glioblastoma cell line, and also the effects of FOXP3 knockdown in a 
glioblastoma cell line within constitutive FOXP3 expression and an adequate 
proliferation rate. Results demonstrated that overexpression of either of the natural 
FOXP3 isoforms were able to reduce proliferation, however, only isoform b (also 
referred to as FOXP3Δ3) was able to reduce the migration of these cells (Frattini, 
Pisati et al. 2012). On the other hand, FOXP3-silencing resulted in an increase in the 
proliferation and migration of these cells in comparison to scrambled shRNA 
transfected cells (Frattini, Pisati et al. 2012).  
Similar findings were reported in vivo as mice injected with FOXP3 silenced 
glioblastoma cells developed tumours which were FOXP3 negative. As measured by 
Ki67
+
 cells, these mice also had a significantly higher proliferation and reduced 
survival in comparison to mice with scrambled shRNA transfected cells (Frattini, 
Pisati et al. 2012). 
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4.2 Aims and objectives 
 Construct a FOXP3-expressing plasmid. 
 
 Generate stably transfected FOXP3-overexpressing MDA-MB-231. 
 
 Knockdown wild type FOXP3 expression in HMEpC using commercial 
siRNA. 
 
 Following FOXP3 transfection into MDA-MB-231 and FOXP3 knockdown 
in HMEpC: 
 
 Use real-time PCR to determine transcriptional changes in ErbB2, 
SKP2, MYC, CXCR4 and CDKN1A. 
 
 Use flow cytometry to determine the changes in cell surface 
expression of CXCR4.  
 
 Assess functional changes affecting cell cycle, cell proliferation, 
invasion and migration in response to CXCL12. 
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4.3 Specific materials and methods 
4.3.1 Bacterial cell culture methods  
A culture of chemically competent EB5α E.coli (BioEdge, Gaithersburg, MD, USA) 
(Referred to as E.coli from here on) was used in cloning and the generation of a 
FOXP3-expression plasmid. FOXP3 DNA was transformed into E.coli and used to 
generate large quantities of plasmid DNA for transfections.  
 
4.3.1.1 Lysogeny broth  
The original formula of lysongy broth (LB) was published in 1951 in the first paper 
of Bertani on bacterial lysogeny (Bertani 2004). The recipes have not changed 
greatly since. LB is a nutritionally rich medium that is primarily used for 
the growth of bacteria. LB (Sigma-Aldrich) consists of 10g/L bacto-tryptone, 5g/L 
bacto-yeast extract, and 10g/L NaCl (at pH7). To make LB agar, 10g/L agar was 
added and heated to dissolve.  
Everything needed for optimum growth of a bacterial suspension is provided in the 
recipe. Peptides and peptones are provided by tryptone and vitamins, and certain 
trace elements are provided by yeast extract, sodium ions for transport and osmotic 
balance is provided by sodium chloride. All media was sterilised by autoclaving at 
121°C for 15 minutes.  
Bacteria were grown on LB media agar plates at 37°C, or in liquid LB at 37°C 
overnight on a shaker. Bacterial stocks were made for long term storage by freezing 
cells in LB with 50% glycerol (Sigma-Aldrich) at -80°C.  
 
4.3.1.2 Transformation of chemically competent E.coli 
Chemical competence refers to the ability of cells to take up extracellular DNA from 
its environment. Competent E.coli were transformed by defrosting 25µl of cells on 
ice, followed by incubating with 2µg of DNA on ice for 30 minutes. This allows the 
DNA to adsorb onto the surface of cells. The cells were then heat shocked for 90 
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seconds at 45°C and returned to ice for 2 minutes. This process causes the cells to 
open pores in their membranes allowing the DNA to enter, whilst incubation on ice 
causes the pores on the membrane to close, thereby trapping DNA in the cells. The 
cells were then grew in 1ml of LB for 2 hours at 37°C before being spread onto LB 
agar plates containing an appropriate concentration of the selection antibiotic for the 
plasmid type (Ampicillin for FOXP3-vector and Kanamycin for pmaxGFP-vector). 
The LB agar plates were incubated at 37°C overnight and the following day 
individual colonies were picked for further analysis. Negative controls were used 
which consisted of LB agar plates with antibiotic but no cells.  
 
4.3.1.3 Recovery of plasmid DNA from bacterial cell 
culture 
Plasmid DNA was isolated from E.coli cultures using a QIAgen mini-prep kit 
(QIAgen). This technique utilises silica-binding technology and spin columns. 
Universal tubes containing 10ml of LB, antibiotic and previously transformed E.coli 
were grown overnight on a shaker at 37°C. The following day the cells were pelleted 
by centrifugation at 500xg for 5 minutes. Bacteria were then resuspended in 250µl of 
buffer containing RNase followed by lysis of cells using 250µl of an alkaline SDS 
solution. 350µl of a neutralising buffer was added to stop the reaction. The lysate 
was centrifuged at 13000xg for 10 minutes to pellet cell debris, protein, 
chromosomal DNA and lipids. The clear lysate produced was then added to a silica 
spin column and centrifuged for 1 minute at 13000xg. The eluate was disposed of 
and the plasmid DNA was washed twice in an ethanol containing buffer before being 
eluted from the column in to a fresh sterile collection tube with 50µl of elution 
solution.  
 
4.3.1.4 Restriction enzyme digestion of DNA 
Restriction enzymes recognise short, symmetrical base pairs and cut DNA into small 
specific segments. Depending on the endonuclease selected, enzymatic digestion can 
produce either blunt or sticky ends. A blunt ended digestion can ligate to any other 
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blunt end digested DNA, however, a sticky end can only bind to other sequences 
with the same overhanging sequence. This produces specific annealing of 
complementary ends and restoration of the original restriction site. It is generally 
accepted that 1 unit of enzyme (Promgea) is used to digest 1µg of DNA in 1 hour at 
37°C. Digestions were left for between 3-6 hours at 37°C, however, for complete 
digestion of larger DNA quantities additional time may be required and was often 
left overnight. The restriction enzymes used are listed in table 4.1 along with their 
target sequences. 
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Restriction enzyme  Target sequence Experiment used in 
BamHI 
 
Digest pcDNA3.1/Zeo(+) plasmid 
to allow FOXP3 insert to ligate 
XhoI 
 
Digest pcDNA3.1/Zeo(+) plasmid 
to allow FOXP3 insert to ligate 
ScaI 
 
Used to linearise the 
pcDNA3.1/Zeo-FOXP3 plasmid 
for stable transfections 
Table 4-1 - Restriction enzymes used in plasmid cloning and linearization 
When cloning the FOXP3 gene into the pcDNA3.1/Zeo(+) backbone BamHI and XhoI were 
used. To linearise the plasmid for transfection, ScaI was used which cuts specifically at a site 
within the ampicillin resistance gene region.  
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4.3.2 Transfection methods 
Transfection is a common technique used in biological research where the aim is to 
genetically manipulate a cell by deliberately introducing new nucleic acid. The aim 
of transfection can be either to upregulate expression of a specific gene of interest, 
often delivered in the form of a plasmid, or to knockdown the expression of a wild 
type gene which is expressed within the target cell.  
Many methods of transfection have been developed. These methods are best 
categorised as chemical, electrical or viral based methods. Chemical and electrical 
methods were used in this study.  
Electrical-based transfection is electroporation (also known as nucleofection). This 
technique is based on physical parameters instead of chemical. It uses electrical 
pulses to significantly increase the electrical conductivity and permeability of the 
cells plasma membrane. The mechanism of electroporation occurs through a number 
of phases: The initial phase is the application of a current (generally between 300-
400mV) for less than 1ms across the plasma membrane. This current results in a 
migration of ions into the surrounding solution which charges the membrane and 
results in a rearrangement in the morphology of the lipids making pores 
approximately 0.3nm in size allowing linearised DNA to enter the cells. Finally, the 
pores will heal and reseal, or, if the critical size was exceeded, the pore will expand 
causing the cell to rupture resulting in cell death.  
The most commonly performed chemical-based transfection is referred to as 
lipofection (also known as lipid-based transfection). This technique is highly 
effective as it uses transfection reagents which contain cationic lipid subunits which 
form liposomes in aqueous environments. The positively charged lipids can then 
encapsulate negatively charged plasmid DNA when the two are mixed. The 
liposomes containing the DNA are then able to fuse directly with the cells negatively 
charged plasma membrane and enter the cell. Once inside the cell, the liposome 
avoids the endosomal pathway and enters the nucleus.      
Transfections can be either transient or stable. When the genetic material is only 
transiently transfected, the foreign DNA will not be incorporated into the host cells 
genome therefore the expression of the exogenous DNA will only be present in the 
Chapter 4 – in vitro modelling of FOXP3 functions in normal and malignant breast epithelia  
165 
 
cell for a limited time whilst the cell undergoes mitosis and eventually dilutes the 
DNA out. However, if the DNA is incorporated into the genome, when the cell 
undergoes mitotic division, each new daughter cell will also express the transfected 
DNA. Stably transfected cells are often selected from non-transfected cells via the 
use of a selection antibiotic. The plasmid contains a gene to encode the resistance to 
the antibiotic, therefore, cells which survive in the presence of the antibiotic are 
considered to have incorporated the plasmid DNA into their genome.  
  
4.3.2.1 Stable transfection of MDA-MB-231 using 
Amaxa
TM
Nucleofector
TM
  
Cell lines were transfected with plasmid DNA using the Amaxa
TM
Nucleofector
TM
 
(all Nucleofector
TM
 equipment was purchased from Lonza). Prior to electroporation, 
cells were grown in T75 flasks until 80-90% confluent. Cells were released from the 
flask surface (as described in section 2.2.4) and counted. 1x10
6
 cells were 
resuspended in 100µl of Amaxa
TM
Nucleofector
TM
 solution V. Plasmid DNA (5µg) 
was added to the culture, mixed gently by pipetting, and then transferred to an 
Amaxa
TM
Nucleofector
TM
 electroporation curvette. The curvette was then inserted 
into the Amaxa
TM
Nucleofector
TM
 machine and program X-13 (MDA-MB-231) or A-
23 (HEK-293) was selected. After electroporation was complete, the curvette was 
removed from the machine and placed on ice for 5 minutes to help the healing of 
pores on the cell membrane. Finally, cells were removed from the curvette and 
placed directly into fresh growth media and cultured. Growth media was replaced the 
following day and the transfection efficiency was checked 24 and 48 hours post-
transfection.  
 
4.3.2.2 Lipid-based transient transfections  
In this study transient transfections were attempted using a number of lipid-based 
transfection reagents. Each of these has a similar mechanism of action and vary 
slightly in their protocols. The transfections were performed in 6-well plates. 
Protocols for each reagent are described briefly below: 
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Lipofectamine®2000 (Invitrogen): Lipofectamine®2000 is lipid-based transfection 
reagent which has been widely reported as successful in transfecting plasmid DNA, 
including a FOXP3 plasmid into an ovarian cancer cell line (Zhang and Sun 2010). It 
has also been reported to be successful in transfecting MDA-MB-231 cells (Chen, 
Kang et al. 2001; Wu, Chan et al. 2005; Thakur, Sun et al. 2008).  
Transfection complexes were formed by diluting 4µg of freshly isolated plasmid 
DNA, and either 4µl, 8µl or 12µl of Lipofectamine®2000 reagent each in 50ul of 
basal DMEM. Tubes were left to incubate at room temperature for 5 minutes before 
being combined and left to incubate for a further 25 minutes at room temperature 
allowing the liposomes and DNA to form complexes. At the end of incubation, the 
transfection complexes were added drop by drop to each well and the plate was 
gently mixed to disperse complexes. Cells were seeded at a concentration of 
0.5x10
6
/ml into 6-well plates in 2ml of growth media without serum or antibiotics 
and incubated overnight in normal growth conditions. The following day, old media 
was removed and replaced with fresh complete growth media. The transfection 
efficiency was determined 24 and 48 hours post-transfection. 
JetPRIME
TM
 (Polyplus, Illkirch, France): Prior to transfection, cells were serum 
starved for 2 hours. Transfection complexes were formed by diluting 2µg of plasmid 
DNA in 200µl of JetPRIME
TM
 buffer followed by the immediate addition of 4µl, 
6µl, 8µl or 10µl of JetPRIME
TM
 reagent. These complexes were left to incubate at 
room temperature for 10 minutes before being dispensed onto the surface of the 
culture plate. Cells (0.5x10
6
/ml) were then immediately added to the wells and left to 
incubate in the normal growth conditions, in 2ml growth media without antibiotics. 
Transfection complexes were removed after 6 hours and replaced with fresh 
complete growth media. Transfection efficiency was assessed 24 and 48 hours post-
transfection. 
GenJet
TM 
(SignaGen® Laboratories, Peterborough, UK): GenJet
TM 
transfection 
reagent (Ver.II) is an upgraded version of the original GenJet
TM
 reagent, and 
according to the manufacturers protocol, it is able to increase transfection 
efficiencies up to 20 times higher than the previous GenJet
TM
 reagent. MDA-MB-
231 were transfected with plasmid DNA using an advanced protocol supplied by the 
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manufacturers specifically for transfecting MDA-MB-231 cells. This protocol was 
also optimised to increase transfection effeciencies and cell viability.  
GenJet
TM
 reagent and DNA complexes were prepared by diluting 2µg of highly pure 
plasmid DNA and either 4µl, 6µl or 8µl of GenJet
TM
 reagent into 100µl of basal 
DMEM in separate tubes. Each tube was gently vortexed and centrifuged at a low 
speed to bring drops to the bottom of the tube. The diluted GenJet
TM
 reagent was 
then immediately added to the diluted DNA solution and mixed by pipetting 3-4 
times and then left to incubate for 15 minutes at room temperature. During this 
period, 1.2x10
6
 cells were pelleted by centrifugation at 150xg for 10 minutes and the 
supernatant was completely removed. After the transfection complexes had 
incubated for 15 minutes at room temperature, they were used to resuspend the cell 
pellet. The cells were then incubated at 37°C for a further 20 minutes with the 
transfection complexes. Following incubation, the cell suspension was dispensed into 
a 6-well plate with 2ml of complete growth media. The transfection efficiency was 
determined 24 and 48 hours post-transfection. 
TurboFect
TM 
(Fermentas): Transfection of plasmid DNA was attempted using 
TurboFect
TM
 according to the manufacturers protocol. Briefly, transfection 
complexes were prepared by diluting 2µg of DNA in 100µl of basal DMEM. 2µl, 4µl 
or 6µl of TurboFect
TM
 reagent was immediately added to the DNA complexes and 
incubated at room temperature for 15 minutes. Transfection complexes were evenly 
distributed onto the surface of the 6-well plate and 0.25x10
6
/ml cells were dispensed 
on top of complexes in 2ml growth media. Transfection efficiency was determined 
24 hours post-transfection.   
GeneJuice® (EMB Millipore, Billerica, MA, USA): Cells were prepared at a final 
density of 0.5x10
6
 in 3ml of growth media. Transfection complexes were prepared 
by diluting 6µl of GeneJuice® reagent in 100µl of basal DMEM and incubated for 5 
minutes at room temperature. Next, 2µg of DNA was added to the solution, mixed 
gently by pipetting, and incubated for a further 10 minutes at room temperature. 
Transfection complexes were then placed onto the surface of the culture plate and 
cells were dispensed into wells and incubated in normal growth conditions. 
Transfection efficiency was determined after 24 hours.   
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4.3.3 Selection of stably transfected cells using ZeocinTM 
When generating stably transfected cell lines, it is imperative to determine the lowest 
concentration of antibiotic which is required to kill untransfected cells and select 
cells which have integrated plasmid DNA, and can therefore grow in the presence of 
the selection antibiotic. 
When cells are metabolising they frequently produce reducing equivalents as a by-
product. These reducing equivalents pass on their electrons to an electron transfer 
reagent which reduces tetrazolium into a purple coloured aqueous formazan product. 
This can then be detected at 490nm. When cells are no longer viable they fail to 
reduce the tetrazolium product to formazan, therefore, cell metabolism and viability 
is proportional to the intensity of the purple colour (figure 4.1).  
The lowest concentration of Zeocin
TM
 (Invitrogen) required to kill untransfected 
MDA-MB-231 was determined using a CellTiter 96®Non-radioactive cell 
proliferation assay (Promega). This assay uses a tetrazolium substrate (3-4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS) and an electron coupling reagent (phenazine 
methosulphate, inner salt; PMS) to determine cell viability. Approximately 5x10
4
 
MDA-MB-231 were dispensed into 96-well plates and grown overnight in normal 
conditions. The following day, growth media was removed and replaced with fresh 
growth media containing Zeocin
TM
 at concentrations ranging from 0µg/ml to 
700µg/ml, with 100µg/ml increments. Each day cell viability was determined by 
adding 100µl of a MTS/PMS complex (1:20, MTS:PMS) and incubated at 37°C for 2 
hours. The intensity of colour change was determined using microplate reader at 
490nm. Cell viability was determined as a percentage using healthy cells grown in 
the absence of antibiotic, arbitrarily set as 100%. 
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Figure 4-1 - Conversion of MTS tetrazolium into Formazan  
The conversion of MTS tetrazolium into soluble formazan is catalysed by dehydrogenase 
enzymes which are located within metabolically active cells. Therefore, the extent of cells 
which are growing and viable are proportional to the formazan product which can be 
measured at 490nm using a microplate reader. 
 
 
 
 
 
 
 
 
 
 
 
 
 
MTS tetrazolium Formazan
Dehydrogenase
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4.3.4 Transfection of siRNA sequences  
siRNA stands for small interfering RNA. During translation, mature mRNA 
produced within the nucleus is transported into the cytoplasm of the cells where they 
are translated into protein. siRNA sequences which enter the cell via liposomes form 
a complex with ribonucleic proteins called RISC (RNAi silencing complex). Part of 
this complex is a catalytic protein called argonaute which binds to non-coding RNAs 
such as siRNA. siRNA sequences then direct the complex to the complementary 
mRNA sequence and where they exhibit their endonuclease slicer activity (Tolia and 
Joshua-Tor 2007). The cleaved mRNA is then destroyed by the cells as it is 
recognised as aberrant. Thus, siRNA inhibits the protein production by silencing the 
expression of the gene within the cytoplasm of cells.   
siPORT
TM
NeoFX
TM 
(Ambion) is a lipid-based transfection reagent which has high 
specificity for delivering siRNA into cells. Because siRNA is composed of short 
specific bases it is substantially smaller than plasmid DNA, therefore, reagents used 
to deliver siRNA sequences are generally less cytotoxic than those used to deliver 
plasmids. Delivery of siRNA sequences was performed using commercial siRNA 
sequences and the transfection reagents Lipofectamine®2000 and 
siPORT
TM
NeoFX
TM
. Transfections were carried out according to the manufacturers 
protocol. The transfection process using Lipofectamine®2000 is described in section 
4.3.2.2. All knockdown experiments were performed in 12-well plates. Transfection 
using siPORT
TM
NeoFX
TM
 was carried out according to the manufacturers protocol. 
Briefly, 3µl of siPORT
TM
NeoFX
TM 
transfection reagent and 1µM of silencer® select 
FOXP3 siRNA were combined, in separate tubes, with basal growth media to make a 
final volume of 50µl. The tubes were left to incubate at room temperature for 10 
minutes before being combined and left to incubate for a further 10 minutes at room 
temperature. Following incubation, complexes were dispensed onto the surface of a 
culture plate and 1ml of the cells (0.2x10
6
) were dispensed on top of the transfection 
complexes and left to incubate at 37°C in normal growth conditions. This now makes 
a final siRNA concentration of 5nM. The knockdown efficiency was assessed at 
transcript and protein levels after 24 hours.    
All siRNA used in experiments were purchased from Ambion. FOXP3 specific 
sequences and are listed in table 4.2. Control siRNA sequences were also purchased 
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from Ambion (Silencer® select Negative Control No.1 siRNA, catalogue 
no.4390843). 
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siRNA name Assay ID 
FOXP3 siRNA-1 s27191 
FOXP3 siRNA-2 s27192 
FOXP3 siRNA-3 s27190 
Table 4-2 - List of siRNA used in experiments 
All FOXP3 specific siRNA sequences were purchased from Ambion. Specific assay ID’s are 
provided.  
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4.3.5 Functional studies  
A number of functional assays were used to determine the effects on cell behaviour 
following FOXP3 transfection into MDA-MB-231 and FOXP3 knockdown in 
HMEpC. 
  
4.3.5.1 Transwell chemotaxis 
Transwell chemotaxis assays were carried out using specially designed 24-well 
plates (Becton Dickinson) which contain a “lip” on which the transwell chamber can 
rest. Before allowing cells to migrate, the chemotaxis plates were blocked using 
basal media containing 0.1% BSA (Sigma-Aldrich) and 1% L-Glutamine (referred to 
as chemotaxis buffer) and incubated at 37°C for 1 hour. This ensures the chemokine 
remains in suspension and it prevents it from sticking to the surface of the plate. 
Human breast cancer cells require a fibronectin matrix to adhere to, so the underside 
of 8µm-pore chemotaxis filters (Becton Dickinson) were coated with 2.5µg/ml 
fibronectin (Sigma-Aldrich) and incubated at room temperature for 30 minutes. 
Excess fibronectin was removed and the filters were left to air dry for a further 30 
minutes.   
Each well contained an optimised concentration of CXCL12 (Almac, Craigavon, 
UK) which was dispensed into the lower chamber of the well in 800µl of chemotaxis 
buffer. 0.2x10
6
 mammalian cells (previously serum starved for 2 hours) were 
suspended in 500µl of chemotaxis buffer and dispensed into the upper chamber. 
Chemotaxis assays were then incubated at 37°C in normal growth conditions for an 
optimised period of time.  
Following migration, filters were removed and the insert swabbed with a cotton bud 
to remove non-migrated cells. Migrated cells were fixed by placing the filters at -
20°C in ice cold methanol for at least 2 hours. After fixation, the filters were washed 
in tap water and stained in haematoxylin for 1 minute. Filters were then washed by 
submerging in Scott’s tap water to help develop the colour. The cells were then 
dehydrated by passing the filters through ethanol (50%-75%-90%-100%) before 
being left to dry at room temperature for 2 hours. Filters were cut and mounted onto 
cover slides using Di-N-Butyle Phthalate in Xylene (DPX) (Sigma-Aldrich) and 
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counted using a light microscope (counting 6 high powerfields/filter). Cells within 
pores were also counted as migrated. Duplicates of each assay were counted and 
validated by a blind count from another member of the group. 
 
4.3.5.2 Transwell chemo-invasion assay 
Chemo-invasion assays were prepared in the same way as chemotaxis assays (section 
4.3.5.1); however, prior to fibronectin coating, a thin layer of matrigel was added on 
the surface of the membrane inside the filter and left to set at 37°C. Matrigel is 
extremely temperature sensitive. It remains in an aqueous solution when kept at 4°C 
but becomes increasingly viscous as temperature increases. On this basis, matrigel 
(Becton Dickinson) was added to filter inserts at 4°C and incubated at 37°C for 30 
minutes to allow matrigel to set. Chemo-invasion was assessed and counted as 
described in section 4.3.5.1. 
 
4.3.5.3 Proliferation assays 
Proliferation assays are frequently performed in biological studies. There are a 
number of ways to determine cell proliferation. These methods can be grouped as 
either direct or indirect methods of quantification. Direct methods include cell 
counting using a microscope or an electronic particle counter. Indirect methods are 
more frequently used and these often include incorporation of radioactive precursors 
such as thymidine or the use of chromogenic dyes to quantify the cells metabolic 
activity.   
Proliferation was determined using the CellTiter 96®Non-radioactive cell 
proliferation assay (Promega). Because this assay utilises the levels of by-product 
produced during a cell metabolism, it can be used to determine cell viability or the 
proliferation rate of cells. The principle behind this assay and protocol has been 
previously described in section 4.3.3, however, in this scenario, cells which are 
proliferating at a faster rate will produce greater levels of by-product and, therefore, 
the level of proliferation will be directly proportional to the intensity of the formazan 
product and thus the change in colour. 
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4.3.5.4 Cell cycle analysis 
Cell cycle analysis was performed for cell lines using flow cytometry. When cells are 
fixed and permeabilised, they can be stained with a fluorescent dye which 
intercalates with DNA. The fluorescence intensity of the stained cells at specific 
wavelengths will directly correlate with the amount of DNA they contain. During the 
cell cycle, DNA duplicates during the S phase, therefore, the relative amount of cells 
within each phase (G0/G1 phase, S phase, and G2/M phase) can be determined as the 
amount of fluorescence of cells in the G2/M phase will be twice as high as the 
fluorescence from cells which are in G0/G1 phase, thus producing two distinct peaks.    
Cells (5x10
5
) were fixed and permeabilised using an intracellular staining buffer kit 
as previously described in section 2.5.4.2. To prevent the dye from interacting with 
RNA, cells were treated for 30 minutes with 0.1mg/ml RNaseA (Sigma-Aldrich) at 
room temperature in the dark. Cells were washed and resuspended in buffer with 
0.05mg/ml propidium iodide (PI) (Sigma-Aldrich) and incubated at room 
temperature for 2 hours and analysed using FACS canto II on a low flow rate. 
Results were interpreted using Modfit software LT (Verity Software House, Maine, 
USA).  
 
4.3.6 QuantumTM Simply Cellular® Beads  
Quantum
TM
 Simply Cellular
®
 beads (Bangs Laboratories, Indianapolis, USA) are a 
set of microspheres which are used to quantitatively assess the expression of a 
cellular antigen. The beads come in a set of five, where each bead population has its 
own capacity to binding antigen. One set of beads consists of five populations, one 
blank and four which have increasing levels of Fc-specific capture antibody. When 
these beads are stained with the same antibody and analysed within the same 
suspension solution, at the same instrument settings as cell samples, a standard curve 
of antigen binding capacity (ABC) versus bead median fluorescence intensity (MFI) 
can be plotted to draw a standard curve. The MFI of each sample can then be plotted 
on this graph and the ABC of the cells can be interpolated.   
Chapter 4 – in vitro modelling of FOXP3 functions in normal and malignant breast epithelia  
176 
 
4.4 Results  
4.4.1 Construction of a FOXP3-expressing plasmid 
One of the major aspects of this study was to investigate the effects following the re-
introduction of a wild type FOXP3 vector into an invasive breast cancer cell line. As 
demonstrated in chapter 3, FOXP3 within MDA-MB-231 was significantly 
downregulated and predominately restricted to the cytoplasm. These cells are also 
known to be a more aggressive cell line as they have a greater invasive capacity than 
MCF-7. On this basis, it was deemed that MDA-MB-231 would be the most 
appropriate cell line to investigate the effects of FOXP3-overexpression. 
In order to generate FOXP3-overexpressing MDA-MB-231, a plasmid containing 
FOXP3 DNA was firstly constructed. This was done by cloning FOXP3 DNA into a 
pcDNA3.1/Zeo(+) backbone as described below.  
FOXP3 DNA, which was provided by Prof Sakaguchi (Kayoto, Japan), was sent for 
sequencing (Source Bioscience) using T7 Forward and BGH reverse primers to 
determine which restriction sites were present and compatible with sites within the 
multiple cloning region of the pcDNA3.1/Zeo(+) backbone.    
Sequencing results revealed two sites which were compatible with the multiple 
cloning region of pcDNA3.1/Zeo(+). BamH1 was present towards the beginning and 
Xho1 was present at the end of the gene. Importantly, these sites are outside of the 
protein coding domain and therefore should not jeopardise protein production (figure 
4.2 panel A).  
FOXP3 and plasmid DNA were digested with the restriction enzymes BamHI and 
XhoI. The digested products were separated on a 1.2% agarose gel at 90V. After 
confirming the bands produced were the correct size, they were extracted from the 
gel and ligated by incubating overnight at 37°C with a T4 ligase enzyme (promega). 
The following day, the culture containing FOXP3 DNA which was ligated into the 
pcDNA3.1/Zeo(+) backbone was transformed into competent E.coli cells. The 
culture was then spread onto LB agar plates containing ampicillin (100µg/ml), and 
grew overnight at 37°C. The pcDNA3.1/Zeo(+) plasmid contains a gene which 
encodes ampicillin resistance, therefore, colonies which grew had successfully taken 
up the plasmid as they survived in the presence of the selection antibiotic.  
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Individual colonies were picked and grown overnight in LB with ampicillin 
(100µg/ml) in a 37°C heated shaker. The following day, plasmid DNA was extracted 
from the bacterial culture. To check FOXP3 DNA was successfully inserted into the 
pcDNA3.1/Zeo(+) backbone, the newly constructed plasmid was double-digested 
with BamHI and XhoI then run on a 1.2% agarose gel alongside undigested plasmid 
DNA (figure 4.2 panel B). The lane containing the double digested plasmid 
contained three bands. The 1.5kbp band represented the FOXP3 insert, whereas, the 
band at 5kbp was the pcDNA3.1/Zeo(+) backbone. A final band at 6.5kbp 
demonstrated the remnants of undigested plasmid and appeared parallel to the 
undigested plasmid.  
The new FOXP3 plasmid is referred to as pcDNA3.1/Zeo-FOXP3. A map of 
pcDNA3.1/Zeo(+) (referred to as an empty vector) and pcDNA3.1/Zeo-FOXP3 
(referred to as a FOXP3 vector) is provided in figure 4.3. 
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Figure 4-2 - Construction of pcDNA3.1/Zeo-FOXP3 vector  
(A) The FOXP3 DNA was sequenced to determine which restriction sites were compatible 
with the sites within the pcDNA3.1/Zeo(+) plasmid cloning region. Sequencing revealed 
BamH1 and Xho1 sites (highlighted in yellow boxes) within the FOXP3 DNA. Green lines 
represent the limits of the protein coding domain of FOXP3. Sequences were aligned using 
ApE software where the upper row represents FOXP3 DNA provided by Prof Sakaguchi and 
lower row represents wild type FOXP3 (accession number NM_014009.3). Red regions 
represent regions of hang-over from the forward and reverse primer sequences (B) 1µg of 
pcDNA3.1/Zeo-FOXP3 was digested with BamH1 and Xho1 and ran on a 1.2% agarose gel 
alongside undigested plasmid. Bands at 5kbp and 1.5kbp in the digested plasmid lane 
represents FOXP3 DNA (1.5kbp) and pcDNA3.1/Zeo(+) backbone (5kbp). A third band at 
6.5kbp represents some undigested plasmid.  
A
B
6.5kbp
5kbp
1.5kbp
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Figure 4-3 - Schematic representation of FOXP3 insertion into the 
pcDNA3.1/Zeo(+)vector 
FOXP3 was cloned into the pcDNA3.1/Zeo(+) backbone (A) by double digestion using the 
restriction enzymes BamH1 and Xho1. Digested FOXP3 and pcDNA3.1/Zeo(+) DNA was 
ligated overnight at 37°C using T4 ligase enzyme. The new FOXP3 expressing plasmid was 
named pcDNA3.1/Zeo-FOXP3 (B).   
+ FOXP3 gene
1501bp
A B
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4.4.2 Transient transfection of pcDNA3.1/Zeo-FOXP3 into 
HEK cells 
After initially confirming that pcDNA3.1/Zeo-FOXP3 had successfully inserted the 
FOXP3 DNA, the next step was to ensure that this plasmid was able to encode and 
produce FOXP3.  
pcDNA3.1/Zeo-FOXP3 and the empty vector (pcDNA3.1/Zeo[+]), were transiently 
transfected into wild type HEK cells using the Amaxa
TM
Nucleofector
TM
 program A-
23. HEK cells are frequently used in transfection because they readily integrate and 
express exogenous DNA. 24 hours post-transfection, RNA was isolated, reverse 
transcribed and real-time PCR was used to assess FOXP3 upregulation in the 
transfected cells. FOXP3 was upregulated by a mean fold increase of approximately 
96. This demonstrates the construct successfully induces high level FOXP3 
overexpression in cells (Figure 4.4). 
 
4.4.3 Transient transfection of pmax GFP into MDA-MB-
231 using Amaxa
TM
Nucleofector
TM
  
MDA-MB-231 is a cell line known to be notoriously difficult to transfect. To ensure 
that the Amaxa
TM
Nucleofector
TM
 is able to transfect these cells, pmaxGFP (supplied 
with the Amaxa
TM
Nucleofector
TM
) was transiently transfected into MDA-MB-231 
with a program specific for these cells (X-013).  
Results demonstrated that Amaxa
TM
Nucleofector
TM
 can transfect MDA-MB-231 
(figure 4.5). It should also be noted that due to the high voltage there was also a 
relatively high degree of cell death. However, when generating stable overexpressing 
cell lines, a large proportion of cell viability is not the most important aspect because 
stably transfected cells must be selected from single colonies.   
After demonstrating that the pcDNA3.1/Zeo-FOXP3 plasmid is capable of 
overexpressing FOXP3, and the Amaxa
TM
Nucleofector
TM
 is able to transfect MDA-
MB-231, stable transfection of FOXP3 into MDA-MB-231 was begun.   
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Figure 4-4 - Transient transfection of pcDNA3.1/Zeo-FOXP3 into HEK cells 
Wild type HEK cells were transiently transfected with 2µg of pcDNA3.1/Zeo-FOXP3 or the 
empty vector using the Amaxa
TM
Nucleofector
TM
. 24 hours post-transfection, RNA was 
isolated from cells, reverse transcribed and real-time PCR was used to determine FOXP3 
expression. After normalising against endogenous GAPDH the amount of FOXP3 transcripts 
from the HEK cells transfected with the FOXP3 vector was compared with the HEK cells 
transfected with an empty vector, which was arbitrarily set as 1.0. Data shown are means and 
SD of experiments performed in duplicate (n=2). 
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Figure 4-5 - Transient transfection of pmaxGFP into MDA-MB-231 
(A) 2µg of highly purified pmaxGFP was combined with 1x10
6
 MDA-MB-231 suspended in 
100µl of Amaxa
TM
Nucleofector
TM
 transfection solution from kit V. pmaxGFP was 
transfected into the cells using the Amaxa
TM
Nucleofector
TM
 machine (program X-13). 
Successful uptake of DNA was determined by IF microscopy and compared with MDA-MB-
231 transfected with no DNA (B). 
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4.4.4 ZeocinTM killing curve using MDA-MB-231 
pcDNA3.1/Zeo-FOXP3 confers ampicillin resistance to E.coli and allows these cells 
to be grown in the presence of the antibiotic. pcDNA3.1/Zeo-FOXP3 and the empty 
vector also contain a sequence to transcribe resistance to Zeocin
TM
. Untransfected 
cells will not survive in the presence of Zeocin
TM
, which allows the successfully 
transfected cells to be selected by the presence of Zeocin
TM
 in the culture media.  
The vulnerability of cells to certain antibiotics ranges. Some cells are more sensitive 
to antibiotics and do not require high concentrations, whereas, others are less 
sensitive and can still grow despite the presence of an antibiotic. To determine the 
sensitivity of MDA-MB-231 to Zeocin
TM
, ensuring only stably transfected cells are 
able to survive, a killing curve was conducted using varying concentrations of 
Zeocin
TM
 over 7 days to determine the minimum concentration required to kill non-
transfected cells. Wild type MDA-MB-231 were seeded in to 96-well-plates and 
treated with concentrations of Zeocin
TM
 ranging from 0-700µg/ml. The viability of 
the cells was measured each day for 7 days (figure 4.6). 
MDA-MB-231 were sensitive to Zeocin
TM
 as a relatively low concentration of the 
antibiotic was able to kill cells after 7 days. Approximately 40-60% of cells were 
killed after 4-5 days using 150µg/ml Zeocin
TM
 and was therefore determined to be 
the optimum concentration to select stably transfected cells.  
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Figure 4-6 - Zeocin
TM
 killing curve on MDA-MB-231 
5x10
4
 MDA-MB-231 were seeded into individual wells in a 96-well plate and incubated at 
37°C with concentrations of Zeocin
TM
 ranging from 0µg/ml to 700µg/ml. The cell death was 
determined each day for a total of 7 days. Each day PMS and MTS (prepared to a 1:20 ratio) 
solutions were added to each well and incubated at 37°C for 2 hours. Cell death was 
determined by reading absorbance's at 540nm using a 96-well microplate reader at 540nm. 
Viability was recorded as a percentage of the absorbance of untreated cells. Results are 
plotted as mean absorbance from one experiment performed in triplicate. 
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4.4.5 Generation of stably transfected FOXP3 overexpressing 
MDA-MB-231 
Following the successful construction of a FOXP3-expressing plasmid, a number of 
essential parameters were optimised. Firstly, it was demonstrated that the newly 
constructed plasmid is capable of transcribing FOXP3 in transfected cells (figure 
4.4). It was then demonstrated that electroporation using Amaxa
TM
Nucleofector
TM
 is 
a method capable of transfecting MDA-MD-231 (figure 4.5). And finally, the 
required concentration of Zeocin
TM
 to select the transfected cells was determined 
(figure 4.6).    
Random integration of the plasmid can often be an issue which results in cells 
integrating the plasmid DNA into the genome but failing to express the gene of 
interest. In order to minimise this risk, pcDNA3.1/Zeo-FOXP3 was linearised prior 
to transfection using the restriction enzyme ScaI. Only one ScaI sequence is located 
within the pcDNA3.1/Zeo-FOXP3 sequence and it is found within the region which 
confers ampicillin resistance (figure 4.7 panel A). It is a good area to digest the 
plasmid at this point as ampicillin resistance is only required in the growth and 
selection of competent E.coli cells. Following DNA isolation this ampicillin 
resistance is redundant. 
FOXP3 was transfected into MDA-MB-231 using the Amaxa
TM
Nucleofector
TM
 
using the same methods as described in section 4.4.3. Following transfection, cells 
were placed into complete growth media and 24 hours post-transfection, fresh media 
containing 150µg/ml of Zeocin
TM
 was added each day.  
Many transfections were attempted over several months with most failing to result in 
the growth of any colonies. After one transfection, individual colonies became 
apparent. Some of these colonies gradually expanded, albeit at a slow pace. 
Unfortunately, many other colonies failed to expand, became gradually granular and 
eventually died. However, three colonies (colonies 4, 9 and 11) grew adequately, and 
were isolated and dispensed into separate culture flasks to expand further. Real-time 
PCR was used to determine the expression of FOXP3 within each colony, including 
control cells transfected with an empty vector. From the 3 expanded colonies, only 
colony 4 significantly overexpressed FOXP3 in comparison to the cells transfected 
with the empty vector (figure 4.7 panels B and C). Importantly, the level of 
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expression in colony 4 was also significantly greater than the levels of FOXP3 found 
in HMEpC. This suggested that the generated cell line is a good model to 
demonstrate the effects of FOXP3 overexpression in an invasive cancer cell line 
(figure 4.7 panel D).  
Overexpression of FOXP3 was also validated at a protein level. As a transcription 
factor, the nuclear expression of FOXP3 is a perquisite for effective functioning. 
Importantly, transfected MDA-MB-231 overexpressed FOXP3 predominately within 
the nucleus (figure 4.8).     
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Figure 4-7 - Stable FOXP3 overexpressing MDA-MB-231  
(A) Prior to transfection, pcDNA3.1/Zeo-FOXP3 was linearised by digesting with 1 unit of 
ScaI. pcDNA3.1/Zeo-FOXP3 was transfected into MDA-MB-231 and cultured in the 
presence of 150µg/ml Zeocin
TM
 until individual colonies were present and able to be 
selected. Following selection of stable clones, the relative expression of FOXP3 in 
transfected MDA-MB-231 was determined using real-time PCR (B) and compared against 
MDA-MB-231 transfected with empty vector (C) and HMEpC (D) which were arbitrarily 
defined as 1.0. Results are means of SD in experiments performed in duplicate (n=2). 
Statistical analysis was determined using an unpaired t-test. 
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Figure 4-8 - Subcellular distribution of FOXP3 within stably transfected MDA-
MB-231 
(A) Nuclear (Nuc) and cytoplasmic (Cyto) domains of MDA-MB-231 were extracted using a 
NE-PER® fractionation kit. Protein from each domain was separated by SDS-PAGE, 
transferred onto PVDF membrane and immuno-probed using a human anti-FOXP3 antibody 
and developed onto X-ray film. Membrane was stained using copper phthalocyanine to 
ensure equal loading between lanes. (B) Empty vector transfected MDA-MB-231 and 
FOXP3 transfected MDA-MB-231 were seeded into chamber slides and left to grow 
overnight in normal growth conditions. The following day cells were fixed with 4% PFA and 
pemeabilised using Triton X-100. Cells were stained using a human anti-FOXP3 primary 
antibody and a FITC-conjugated secondary antibody. Cells were counter stained with DAPI 
for nuclear visualisation.     
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4.4.6 Effects of stable FOXP3 overexpression in MDA-MB-
231 
Following confirmation that colony 4 stably and significantly overexpressed FOXP3 
at transcript and protein levels in comparison to empty vector transfected MDA-MB-
231 and HMEpC, the effects of this overexpression on gene regulation, and cell 
function were investigated.  
 
4.4.6.1 Primer validation 
TaqMan® real-time PCR primers were validated prior to investigation using a cDNA 
template which was serially diluted 5 times from 1µl to 0.0625µl (figure 4.9). A 
linear drop in Ct through each dilution represents primer specificity. The reaction 
efficiency of each primer was calculated and all were greater than 97% efficient.  
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Figure 4-9 - Reaction efficiency of TaqMan® real-time PCR primers 
cDNA was used to measure reaction efficiency of TaqMan® primers. cDNA was serially 
diluted and ran for 40 cycles. Ct values obtained were plotted against cDNA input in log2 
format and represented as linear regression line plot of Ct value versus cDNA input. 
Reaction efficiency from each primer was calculated incorporating the slope of the linear 
regression into the equation: reaction efficiency = 10
(-1/slope)
-1x100. PBMC cDNA was used 
as a template for CXCR4, SKBr3 cDNA was used for ErbB2, DMSO treated H69 cells was 
used for CDKN1A, MCF-7 cDNA was used for MYC and SKP2.  
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4.4.6.2 Relative expression of genes following stable 
FOXP3 integration in MDA-MB-231  
FOXP3 has been widely reported as a transcriptional regulator of many genes in both 
Tregs and epithelial cells. The genes investigated in this study are all heavily 
implicated in cancer and have been previously reported as FOXP3 target genes (Zuo, 
Liu et al. 2007; Zuo, Wang et al. 2007; Liu, Wang et al. 2009; Wang, Liu et al. 
2009).  
Results demonstrated that ErbB2, SKP2, MYC and CXCR4 were all expressed at 
higher levels in the empty vector transfected MDA-MB-231 in comparison to the 
HMEpC (figure 4.10). This, in accordance with the literature, demonstrates the 
importance of these genes in carcinogenesis.  
Consistent with the literature, stable FOXP3-overexpression in MDA-MB-231 
significantly repressed the expression of ErbB2 (p=0.0264), SKP2 (p=0.0249) and 
MYC (p=0.0416) (figure 4.10 panels A-C). Consistent with its role as an anti-cancer 
molecule, regulating proliferation and cell cycle progression, the expression of 
CDKN1A was significantly lower in MDA-MB-231 compared to HMEpC. FOXP3 
has been demonstrated to directly increase the expression of p21 in MCF-7 (Frattini, 
Pisati et al. 2012) and glioblastoma cells (Liu, Wang et al. 2009). A 7-fold increase 
in CDKN1A transcripts was observed within the FOXP3-overexpressing MDA-MB-
231 (figure 4.10 panel D). This further emphasises the ability of FOXP3 to act as 
either a transcriptional activator or repressor to specific genes.  
Interestingly, out of five independent experiments, two experiments resulted in a 
decreased expression of CXCR4, however, three experiments failed to induce a 
change in expression of the same magnitude. Despite this, the combined change in 
expression was statistically significant (p=0.0496) (figure 4.10 panel E).  
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Figure 4-10 - Changes in oncogene expression following FOXP3 overexpression 
in MDA-MB-231  
After normalising against endogenous GAPDH, the amount of transcripts in MDA-MB-231 
cells transfected with a FOXP3 vector or the empty vector was compared to those from 
HMEpC which were arbitrarily defined as 1.0. Data shown are means and SD of at least 4 
separate experiments performed in duplicate. (A) ErbB2 transcripts, (B) SKP2 transcripts, 
(C) MYC transcripts and (D) CDKN1A transcripts (E) CXCR4 transcripts. HMEpC was 
included as direct comparison of transcript levels in normal mammary cells. An unpaired t-
test was used to analyse MDA-Empty vector vs MDA-FOXP3 Vector columns.  
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4.4.6.3 Effects of FOXP3 overexpression on MDA-
MB-231 proliferation  
Whilst generating FOXP3 overexpressing MDA-MB-231, the process of expanding 
individual colonies was difficult as many colonies grew at slow rates. These colonies 
often became increasingly granular over time in comparison to empty vector 
transfected cells. Many colonies failed to be expanded and eventually died.  
After confirming that colony 4 overexpressed FOXP3, a proliferation assay was used 
to investigate the effects of FOXP3 on the proliferation of MDA-MB-231 (figure 
4.11). Wild type MDA-MB-231 and MDA-MB-231 transfected with an empty vector 
proliferated at a comparably quick rate, whereas, the FOXP3-transfected cells had a 
significantly reduced rate of growth. The incline of the line suggested that these cells 
were still growing, just at a very slow rate. In addition to this, data in section 4.4.6.2 
demonstrated that following FOXP3-transfection, CDKN1A transcripts were 
significantly increased. CDKN1A encodes for p21 which is involved in cell cycle 
arrest at the G1 phase. On the basis of these results, cell cycle analysis was 
performed on MDA-MB-231 using PI to determine what proportion of cells were in 
each stage of the cell cycle (figure 4.12). 
Approximately 58% of both wild type MDA-MB-231 and empty vector transfected 
MDA-MB-231 cells were within G1, whereas, approximately 69% of the FOXP3-
overexpressing MDA-MB-231 was within G1.   
This data, along with findings in the current literature, suggest that FOXP3 is able to 
increase the expression of p21 when overexpressed in breast cancer cells. Moreover, 
this expression may impair cell growth by inducing cell cycle arrest. It could be 
proposed that the failure to expand these cells further could be due to the presence of 
FOXP3 contributing to increased cellular senescence.   
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Figure 4-11 – Effects of FOXP3 overexpression on the proliferation of MDA-
MB-231  
Wild type MDA-MB-231 and MDA-MB-231 transfected with a FOXP3 or empty vector 
were dispensed into 96-well plates and proliferation was determined each day for 6 days 
using a non-radioactive cell proliferation assay kit. Statistical analysis was performed using a 
one way ANOVA. (n=2) 
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Figure 4-12 – Cell cycle analysis of MDA-MB-231 following FOXP3 
overexpression 
Wild type MDA-MB-231 and MDA-MB-231 stably transfected with FOXP3 or an empty 
vector were fixed and permeabilised then treated with 0.1mg/ml RNAse A. Cells were then 
stained with 0.05mg/ml PI. Cell cycle analysis was conducted using ModFit LT software 
(n=2). 
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4.4.7 Optimising transient transfection of MDA-MB-231 
using pmaxGFP 
After failing to expand stably transfected FOXP3 overexpressing MDA-MB-231, 
further experiments investigating FOXP3 overexpression in these cells were 
attempted using transient transfections. 
As demonstrated in section 4.4.3, electroporation using the Amaxa
TM
Nucleofector
TM
 
achieved moderate transient transfection of pmaxGFP into MDA-MB-231. However, 
because of the extreme conditions the cells were exposed to during electroporation, 
the process frequently resulted in low cell viability. Although this is acceptable in 
generating stably transfected cells, cell viability is as crucial as the transfection 
efficiency for functional assays and is therefore not a suitable option for transient 
transfections. Therefore, a range of lipid-based transfection reagents were attempted 
for transient transfections.  
Conditions to transfect MDA-MB-231 using Lipofectamine®2000 were optimised 
using pmaxGFP with ratios of DNA to reagent ranging from 1:1 to 1:3 over 24 hours 
(figure 4.13) and 48 hours (figure 4.14). 
Low transfection efficiencies were witnessed after 24 hours. Even after using a 
higher content of reagent, transfection efficiencies failed to increase. The increase in 
reagent also produced a greater proportion of cell death without causing an 
acceptable level of transfection. As expected, after 48 hours, there was an increase in 
the apparent transfection efficiency, with the greatest efficiency being witnessed 
using a 1:2 ratio of DNA to reagent. Because of the extended exposure to the 
transfection complexes, the cell viability was extremely low.   
These results indicate that Lipofectamine®2000 cannot be used to transiently 
transfect MDA-MB-231 whilst maintaining good cell viability. 
GenJet
TM
 is a reagent specifically marketed to transfect MDA-MB-231 with a pre-
optimised protocol. According to the manufacturers, this protocol is able to generate 
transfection efficiencies of 70% using eGFP. Disappointingly, this reagent also 
induced high cell death with no transfection, even after extended exposure to 
complexes and increased reagent ratios (figure 4.15). 
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Similar optimisation experiments were attempted using JetPRIME
TM
, TurboFect
TM
 
and GeneJuice®. However, results consistently produced high levels of cytoxicity 
and very low transfection efficiencies. Representative images from lipid-based 
transient transfections are included in appendices 3 to 6. 
Unfortunately, because none of the lipid-based transfection reagents were able to 
achieve acceptable transfection efficiencies, and electroporation caused high levels 
of cell death, it was not deemed possible to transiently transfect MDA-MB-231 with 
FOXP3 to a level consistent with functional investigations.  
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Figure 4-13 - Optimisation of pmaxGFP transfection into MDA-MB-231 using 
Lipofectamine®2000 after 24 hours 
MDA-MB-231 were transfected with 4µg of pmaxGFP plasmid using varying ratios of 
Lipofecatmine®2000 reagent ranging from 1:1 to 1:3 (µg of DNA: µl of reagent). 
Transfection efficiency was determined by IF microscopy after 24 hours. Wild type MDA-
MB-231 and MDA-MB-231 treated with 4µl of Lipofectamine®2000 were used as negative 
controls (n=3). Upper panels represent FITC+brightfield merge and lower panels represent 
FITC only.  
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Figure 4-14 - Optimisation of pmaxGFP transfection into MDA-MB-231 using 
Lipofectamine®2000 after 48 hours  
MDA-MB-231 were transfected with 4µg of pmaxGFP plasmid using varying ratios of 
Lipofecatmine®2000 reagent ranging from 1:1 to 1:3 (µg of DNA:µl of reagent). 
Transfection efficiency was determined by IF microscopy after 48 hours. Wild type MDA-
MB-231 and MDA-MB-231 treated with 4µl of Lipofectamine®2000 were used as negative 
controls (n=3). Upper panels represent FITC+brightfield merge and lower panels represent 
FITC only. 
Wild type Reagent only
(1:1) DNA: Reagent (1:2) DNA: Reagent (1:3) DNA: Reagent
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Figure 4-15 - Optimisation of pmaxGFP transfection into MDA-MB-231 using GenJet
TM
 
MDA-MB-231 cells transfected with pmaxGFP using ratios of DNA:GenJet
TM
 reagent from 1:2 to 1:4 were assessed by fluorescent microscopy       after 24 
hours post-transfection (A) and 48 hours post-transfection (B). 
A Wild type Reagent only 1:2 (DNA:Reagent) 1:3 (DNA:Reagent) 1:4 (DNA:Reagent)
B Wild type Reagent only 1:2 (DNA:Reagent) 1:3 (DNA:Reagent) 1:4 (DNA:Reagent)
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4.4.8 Optimisation of FOXP3 knockdown in HMEpC using 
FOXP3 specific siRNA sequences 
Having previously demonstrated that HMEpC do express nuclear FOXP3, another 
aspect of this chapter was to investigate the effects of FOXP3 knockdown in 
HMEpC.  
 
4.4.8.1 Choice of transfection reagent to knockdown 
FOXP3 in HMEpC 
Although the transfection efficiency with pmaxGFP was low in MDA-MB-231 using 
Lipofectamine®2000, it did provide the greatest success. Lipofectamine®2000 can 
also be used to transfect siRNA into cells. Mainly because of the size, transfecting 
siRNA is generally considered easier than transfecting plasmids.  
siPORT
TM
NeoFX
TM
 is another lipid-based transfection reagent which is specifically 
designed for the delivery of siRNA. HMEpC were transfected with GAPDH-Cy
3
 
siRNA using Lipofectamine®2000 and siPORT
TM
NeoFX
TM
. The transfection 
efficiency was determined by flow cytometry 24 hours post-transfection. The Cy
3
 
fluorochrome fluoresces at 570nm and after excitation at approximately 550nm. This 
allows Cy
3
 to be detected on the same channel as PE on flow cytometers. 
After 24 hours, both Lipofectamine®2000 and siPORT
TM
NeoFX
TM
 delivered high 
levels of GAPDH-Cy
3
 siRNA (figure 4.16). However, because the efficiency was 
higher and the reagent was less cytotoxic, siPORT
TM
NeoFX
TM
 was determined to be 
the best reagent to transfect HMEpC. 
 
4.4.8.2 Choice of FOXP3 siRNA 
Three FOXP3 silencer® select siRNAs were available and purchased from Ambion. 
HMEpC were transfected with 5nM of each FOXP3 siRNA or control siRNA. 
Relative transcript expression was determined by real-time PCR (figure 4.17), 
whereas, protein expression was determined by flow cytometry (figure 4.18) 24 
Chapter 4 – in vitro modelling of FOXP3 functions in normal and malignant breast epithelia  
202 
 
hours post-transfection. Each individual FOXP3 siRNA caused greater than 70% 
knockdown of FOXP3 compared to the HMEpC transfected with control siRNA 
which remained constitutive. Importantly, the degree of downregulation was also 
less than that witnessed in wild type MDA-MB-231 which makes the knockdown a 
good model to investigate the effects of FOXP3 downregulation in normal mammary 
cells.   
The fact that all three individual FOXP3 siRNA produced a similar degree of 
knockdown demonstrates the specificity of each primer to FOXP3, and 
downregulation is not as a result of other downstream effects in cells.    
FOXP3 siRNA 2 was selected to be used for subsequent experiments      
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Figure 4-16 - Transfection of GAPDH-Cy
3
 siRNA into HMEpC using 
Lipofectamine®2000 and siPORT
TM
NeoFX
TM
   
HMEpC were transfected with either 5nM of GAPDH-Cy
3
 primers or control siRNA using 
either Lipofectamine®2000 or siPORT
TM
NeoFX
TM
 and incubated in normal growth 
conditions. 24 hours post-transfection, the transfection efficiencies were determined by flow 
cytometry.   
 
 
 
 
 
 
 
 
 
 
 
Wild type
HMEpC
siPORT – GAPDH-Cy3 siRNA Lipofectamine -GAPDH-Cy3 siRNA
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Figure 4-17 - Determination of FOXP3 knockdown in HMEpC using FOXP3 
specific siRNA 
HMEpC were transfected with 5nM of FOXP3 siRNA or control siRNA using 
siPORT
TM
NeoFX
TM
 and cultured in normal growth conditions without serum. After 24 
hours, RNA was isolated and reverse transcribed into cDNA. Real-time PCR was used to 
determine the expression of FOXP3. Panel A-C are representative amplification plots 
demonstrating FOXP3 knockdown using FOXP3 siRNA 1 (A), FOXP3 siRNA 2 (B) and 
FOXP3 siRNA 3 (C). After normalising against endogenous GAPDH, the amount of FOXP3 
transcripts were compared to those from HMEpC transfected with control siRNA (D) and 
MDA-MB-231 (E) which were arbitrarily defined as 1.0.  Data shown are means and SD of 
experiments performed in duplicates (n=2). 
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Figure 4-18 - Determination of FOXP3 in HMEpC following transfection of 
FOXP3 specific siRNA  
HMEpC were transfected with either 5nM of FOXP3 siRNA or control siRNA using 
siPORT
TM
NeoFX
TM
. Cells were left to incubate in normal growth conditions without serum. 
After 24 hours, cells were fixed, permeabilised and stained using a FOXP3-APC antibody or 
a matched isotype control. Images are representative of two experiments performed in 
duplicate. 
  
Ctrl siRNA
Isotype Ctrl Ctrl siRNA
FOXP3 siRNA 1 FOXP3 siRNA 2 FOXP3 siRNA 3
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4.4.9 Effects of FOXP3 knockdown in HMEpC 
After investigating the effects of FOXP3-overexpression in MDA-MB-231, a further 
series of experiments was performed to investigate the transcriptional, proteomic and 
functional consequences of FOXP3 knockdown in HMEpC. 
 
4.4.9.1 Relative expression of genes following FOXP3 
knockdown in HMEpC 
Following confirmation that FOXP3 could be knocked down in HMEpC, the effects 
of this knockdown on ErbB2, SKP2, MYC, CDKN1A and CXCR4 was examined by 
real-time PCR (figure 4.19). 
Levels of ErbB2 and SKP2 were moderately expressed within MDA-MB-231 and 
low in HMEpC. However, following FOXP3 knockdown, these transcripts both 
significantly increased between 4- and 6-fold (figure 4.19 panels A and B).  
Interestingly, FOXP3 knockdown failed to cause a significant increase in MYC or 
CDKN1A transcripts (figure 4.19 panels C and D). However, a clear trend was 
observed within CDKN1A (p=0.0534). A moderate expression of CXCR4 was 
observed in MDA-MB-231, whereas, HMEpC expressed low levels which were 
barely detectable. Following FOXP3 knockdown, the levels of CXCR4 increased in 
three experiments, whereas the other three experiments failed to induce an 
observable change in CXCR4 expression. Nonetheless, taken together, this 
represented a mean fold increase of approximately 2, which was a significant 
increase in CXCR4 expression (p=0.0479) (figure 4.19 panel E). 
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Figure 4-19 - Changes in oncogene expression following FOXP3 knockdown in 
HMEpC 
After normalising against endogenous GAPDH, the amount of transcripts from HMEpC 
transfected with FOXP3 siRNA sequences were compared to those from HMEpC 
transfected with control siRNA cells which were arbitrarily defined as 1.0. Data shown are 
means and SD of experiments performed in duplicates. (A) ErbB2/HER-2 transcripts, (B) 
SKP2 transcripts, (C) MYC transcripts and (D) CDKN1A transcripts (E) CXCR4 transcripts. 
MDA-MB-231 was included as direct comparisons to an invasive cancer cell line. Unpaired 
t-tests were used to analyse HMEpC Ctrl siRNA vs HMEpC-FOXP3 siRNA columns. 
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4.4.9.2 Changes in CXCR4 following FOXP3 
knockdown in HMEpC 
After observing a significant increase in CXCR4 transcripts following FOXP3 
knockdown in HMEpC, it was next determined whether the increase in transcript 
numbers translated to the protein level. Briefly, HMEpC were transfected with 
control siRNA or FOXP3 siRNA sequences. After 24 and 48 hours post-transfection, 
cells were released from the culture flask and were fixed and permeabilised using an 
intracellular staining kit. HMEpC were stained for FOXP3 and CXCR4. Changes in 
CXCR4 and FOXP3 expression were then determined by flow cytometry. 
Representative data from a 48 hour post-transfection is included in figure 4.20. 
Consistent with the literature, flow cytometric dot plots showed that wild type 
HMEpC failed to express membrane CXCR4, whereas, FOXP3 was detectable at 
low levels. These levels of expression remained constant after transfection with 
control siRNA which demonstrates that the control siRNA does not affect the cell 
phenotype.    
The effects of FOXP3 knockdown fluctuated, as some experiments resulted in an 
increase in CXCR4, whereas some experiments failed to induce any changes. These 
results were slightly ambiguous as discussed in section 1.4.10.1.  
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Figure 4-20 - Effects on CXCR4 expression following FOXP3 knockdown in 
HMEpC 
Wild type HMEpC and HMEpC transfected with either FOXP3 siRNA or control siRNA 
sequences were stained for FOXP3 and CXCR4 48 hours post-transfection. HMEpC 
transfected with either FOXP3 siRNA or control siRNA were also each stained with a 
matched APC or FITC isotype control to determine staining specificity. Representative 
images of 48 hour post-transfection from 5 experiments. 
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4.4.10 Cytometric bead assay to determine anti-CXCR4 
antibody binding capacity (ABC) 
To determine the changes in anti-CXCR4 ABC following FOXP3 knockdown, 
Quantum
TM
 Simply Cellular® beads were used to quantitatively analyse the 
membrane expression of CXCR4 on test samples. A standard curve was produced by 
plotting the MFI of an anti-CXCR4 antibody from each bead population versus the 
known ABC of each bead population. Therefore, the total CXCR4 binding capacity 
of each cell sample can be determined by interpolating the CXCR4 MFI from each 
sample, minus the background CXCR4 MFI (isotype controls) from the standard 
curve.  
If monovalent antibody-to-surface receptor is presumed, the antigen binding capacity 
is directly proportional to the number of cell surface receptors.   
Five sets of beads were stained with the same concentration of anti-CXCR4 
antibody, incubated for the same length of time and ran on the same instrument with 
the same settings as test samples. The MFI of each bead population produced a linear 
increase in MFI as each bead has an increased capacity to bind antigen (figure 4.21).  
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Figure 4-21 - Cytometric bead assay to determine ABC of the anti-CXCR4 
antibody 
Each population of bead was dispensed into FACS tubes and stained with anti-CXCR4-
FITC antibody. Bead populations were gated using forward and side scatter dot plots (A). 
Representative histogram of fluorescence intensity from each bead population demonstrates 
an increase in fluorescence as the bead population also increases (B). MFI from each bead 
sample was plotted against the antigen binding capacity from each sample to produce a 
linear standard curve to be used in determining CXCR4 ABC in test samples (C) (n=2).     
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4.4.10.1 Changes in CXCR4 ABC following FOXP3 
knockdown in HMEpC 
The MFI of CXCR4 in fresh HMEpC following transfection of either control siRNA 
or FOXP3 siRNA sequences after 24 and 48 hours was measured by flow cytometry. 
ABC of CXCR4 in each sample was determined and plotted after subtracting the 
ABC of the isotope control (figure 4.22).    
Interestingly, despite CXCR4 barely being detectable by dot plots and histograms, 
the Quantum
TM
 Simply Cellular® beads suggested that HMEpC do contain low 
levels of CXCR4.      
Two independent 24 hour post-transfection FOXP3 knockdown experiments showed 
an increase in CXCR4, whereas, one experiment resulted in a slight decrease (figure 
4.22 panel A). Similar findings were witnessed 48 hours post-transfection. However, 
three experiments resulted in increases in CXCR4 of variable magnitude, whereas, 
CXCR4 decreased in two other experiments (figure 4.22 panel B). Overall findings 
from 24 hour (p=0.33) and 48 hour (p=0.52) post-transfections did not represent a 
significant increase in CXCR4 protein expression.   
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Figure 4-22 - Changes in CXCR4 ABC following FOXP3 knockdown in 
HMEpC 
The CXCR4 antigen ABC was determined in HMEpC transfected with either control siRNA 
or FOXP3 siRNA sequences by measuring MFI of CXCR4 off a standard curve. Data was 
plotted after subtracting the CXCR4 ABC of each isotype (background) from the test 
sample. Panel A represents data 24 hours post-transfection. Panel B represents data 48 
hours post transfection.  
 
 
 
 
 
 
A B
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4.4.11 Optimisation of chemoinvasion towards CXCL12 
using MDA-MB-231 
As a chemokine receptor, the primary function of CXCR4 is to direct cell migration 
towards CXCL12. However, it is also well established that the expression of CXCR4 
and subsequent interaction with CXCL12 induces signals which aid the invasion of 
cells (discussed in section 1.6.2). During metastasis, after excessive tumour growth, 
the initial stage is the ability to invade beyond the basement epithelial-coated 
membrane into the adjacent breast tissue. This is followed by the invasion into 
lymphatic vessels, and finally migration towards new secondary sites.  
Next, the potential migration and invasive functional changes in HMEpC following 
FOXP3 knockdown was investigated.  
MDA-MB-231 is a cell line known to express CXCR4 and respond to CXCL12 
(Muller, Homey et al. 2001). Before determining whether the changes in CXCR4 on 
HMEpC represent a functional change, the concentration of chemokine and 
incubation period was optimised using MDA-MB-231.  
Chemoinvasion assays were set up using CXCL12 concentrations ranging from 0nM 
to 100nM with incubation periods ranging from 24 hours to 96 hours. Despite 
demonstrating that MDA-MB-231 express CXCR4 (figure 4.23 panel A) and 
reports frequently using the cells as positive controls in invasion assays, these cells 
did not invade to the levels reported in previous studies (Muller, Homey et al. 2001). 
However, using 75nM and 100nM of CXCL12, MDA-MB-231 did significantly 
penetrate a matrigel coated membrane after 72 hours and 96 hours incubation (figure 
4.23 panels B-E).     
It was decided that the optimum chemokine and incubation periods for assays were 
between 75nM and 100nM for 72 hours and 96 hours.  
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Figure 4-23 - Optimisation of chemoinvasion towards CXCL12 using MDA-
MB-231 
CXCR4 expression was determined using flow cytometry by staining MDA-MB-231 with a 
CXCR4-FITC antibody and a matched FITC-isotype control (A). Prior to invasion, chemo-
invasion plates were blocked using chemotaxis buffer. 8µM pore filers were firstly coated in 
a thin layer of matrigel inside the filter, followed by 2.5µg/ml of fibronectin. MDA-MB-231 
was then incubated for 24 hours (B), 48 hours (C), 72 hours (D) and 96 hours (E) with 
increasing amounts of CXCL12. Data shown are means and SD of experiments performed in 
duplicates. Statisitcal analysis between columns was done using a paired t-test.  
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4.4.12 Effects of FOXP3 knockdown on invasiveness of 
HMEpC  
After optimising the chemokine concentration and incubation time, the invasive 
potential of HMEpC was investigated following FOXP3 knockdown.  
Using 75nM of CXCL12, neither wild type nor control siRNA transfected HMEpC 
was able to penetrate a matrigel coated filter after 72 hours incubation. HMEpC 
transfected with FOXP3 siRNA also failed to significantly invade after 72 hours. 
Even after an extended incubation of 96 hours, neither wild type, control siRNA 
transfected HMEpC nor FOXP3 siRNA transfected HMEpC significantly invaded 
(figure 4.24). 
Results after 72 hours and 96 hours incubation also showed no significant change in 
invasiveness after increasing the CXCL12 concentration to 100nM (figure 4.25).    
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Figure 4-24 - Chemoinvasion of HMEpC in response to 75nM of CXCL12 
following transfection of FOXP3 siRNA  
Wild type HMEpC and HMEpC transfected with either control siRNA or FOXP3 siRNA 
sequences and incubated in normal growth conditions with 75nM of CXCL12 for 72 hours 
and 96 hours. As a negative control, each cell line was also cultured in the absence of 
chemokine. MDA-MB-231 was used as a positive control. Panels A-D are representative 
images 72 hours post transfection of the following conditions: (A) HMEpC transfected with 
control siRNA with 75nM of CXCl12, (B) HMEpC transfected with FOXP3 siRNA with no 
chemokine (C) HMEpC transfected with FOXP3 siRNA with 75nM of CXCL12 (D) Wild-
type MDA-MB-231 with 75nM of CXCL12. Panel E shows data from 72 hour and 96 hour 
post transfections which are means and SD of experiments performed in duplicates (n=3). 
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Figure 4-25 - Chemoinvasion of HMEpC in response to 100nM of CXCL12 
following transfection of FOXP3 siRNA 
Wild type HMEpC and HMEpC transfected with either control siRNA or FOXP3 siRNA 
and incubated in normal growth conditions with 100nM of CXCL12 for 72 hours and 96 
hours. As a negative control, each cell line was also cultured in the absence of chemokine. 
MDA-MB-231 was used as a positive control. Data shown from 72 hours and 96 hours post 
transfections which are means and SD of experiments performed in duplicates (n=3) 
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4.4.13 Optimisation of chemotaxis assays towards CXCL12 
using MDA-MB-231 
As described, the main role of chemokine receptors, such as CXCR4, is to direct cell 
migration. Therefore, chemotaxis assays were used to determine whether FOXP3 
knockdown is able to increase the migratory ability of HMEpC.  
Initially, the concentration of CXCL12 was optimised. MDA-MD-231 were 
incubated in normal growth conditions, with chemotaxis buffer, for 24 hours with 
doubling concentrations of CXCL12 from 0nM to 50nM (figure 4.26 panels A and 
B). After 24 hours, filters were removed and cells were fixed, stained and mounted 
onto chamber slides.  
MDA-MB-231 is a highly motile cell line and migrated even in the absence of 
CXCL12. In line with the literature, MDA-MB-231 expressing CXCR4 also 
responded strongly to CXCL12. As the chemokine concentration increased, the 
migration of MDA-MB-231 also increased. However, the maximum migration was 
witnessed using 25nM CXCL12. Doubling this concentration to 50nM failed to 
increase the migration of MDA-MB-231 any further, therefore, 25nM CXCL12 was 
considered the optimum concentration.   
Next, the length of incubation was optimised between 6 hours and 36 hours using 
25nM CXCL12 (figure 4.26 panel C).   
Once again, even in absence of CXCL12, MDA-MB-231 migrated strongly after as 
little as 6 hours incubation. A statistically significant increase in migration was 
observed after 16, 24 and 36 hours. Although the cells potently migrated in the 
presence of 25nM CXCL12, as the length of incubation increased, so did the 
background number of cells cultured in the absence of CXCL12. The optimum 
length of incubation was 24 hours.     
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Figure 4-26 - Optimisation of chemotaxis assays towards CXCL12 using MDA-
MB-231 
Prior to migration, chemotaxis plates were blocked using 0.1% BSA in chemotaxis buffer. 
Firstly, 8µM pored filters were coated with 2.5µg/ml of fibronectin and MDA-MB-231 were 
then incubated for 24 hours with increasing concentrations of CXCL12 (A). Chemotaxis 
index represents the fold change in the migration of MDA-MB-231 cultured in the presence 
of CXCL12 over the migration of MDA-MB-231 with no chemokine (background). 
Chemotactic index demonstrates a significant dose dependant increase in migratory response 
to CXCL12 by MDA-MB-231 (B). The length of incubation to allow migration was 
optimised by incubating MDA-MB-231 with 25nM of CXCL12 for 6, 16, 24 and 36 hours 
(C), each time point contained a no chemokine control to measure background. Data shown 
are means and SD of a single experiment performed in duplicate. Statistical analysis 
between columns was performed using a paired t-test. 
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4.4.14 Effects of FOXP3 knockdown on migration of 
HMEpC 
Wild type HMEpC and HMEpC transfected with either control siRNA or FOXP3 
siRNA sequences were incubated in normal growth conditions for 24 hours and 48 
hours with 25nM CXCL12.  
Wild type HMEpC and control siRNA transfected HMEpC failed to migrate towards 
CXCL12 after 24 hours. No significant changes were witnessed in HMEpC 
transfected with FOXP3 siRNA after 24 or 48 hours with 25nM CXCL12 (figure 
4.27).   
Because MDA-MB-231 express CXCR4 (figure 4.24 panel A) and also migrate 
potently towards CXCL12 (figure 4.26), it was deemed that perhaps HMEpC (which 
undoubtedly express less CXCR4 than MDA-MB-231) may require a greater 
concentration of CXCL12. On this basis, another chemotaxis assay was set up using 
double the concentration of CXCL12. Similar to previous results, 24 hours 
incubation with 50nM CXCL12 failed to significantly induce migration, however, 
when HMEpC transfected with FOXP3 siRNA sequences were left to migrate for 48 
hours in response to 50nM CXCL12 there was a significant increase in migration in 
comparison to cells cultured with no chemokine (p=0.048), and also in comparison 
to cells treated with control siRNA and incubated with 50nM CXCL12 (p=0.041) 
(figure 4.28). This demonstrates a chemotactic response which is dependent on the 
presence of CXCL12.   
Interestingly, particularly in assays using 50nM CXCL12, the migration was also 
increased in HMEpC transfected with control siRNA with chemokine in comparison 
to wild type HMEpC. In addition to this, HMEpC transfected with FOXP3 siRNA 
sequences also had an increased migration in the absence of chemokine. This 
suggests the possibility that FOXP3 knockdown not only increases the migration 
towards CXCL12 but also makes cells more motile in general. This has been 
reported within the literature (Zhang and Sun 2010; Frattini, Pisati et al. 2012) 
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Figure 4-27 - Chemotaxis of HMEpC in response to 25nM of CXCL12 
following FOXP3 knockdown in HMEpC  
Wild type HMEpC and HMEpC transfected with either control siRNA or FOXP3 siRNA 
sequences and incubated in normal growth conditions with 25nM of CXCL12 for 24 hours 
and 48 hours. As a negative control, each cell line was also cultured in the absence of 
chemokine. MDA-MB-231 was used as a positive control. Data shown are means and SD 
of experiments performed in duplicates (n=3).  
 
Chapter 4 – in vitro modelling of FOXP3 functions in normal and malignant breast epithelia  
223 
 
 
Figure 4-28 - Chemotaxis of HMEpC in response to 50nM of CXCL12 following 
FOXP3 knockdown in HMEpC 
Wild type HMEpC and HMEpC transfected with either control siRNA or FOXP3 siRNA 
sequences and incubated in normal growth conditions with 50nM of CXCL12 for 24 hours 
and 48 hours. As a negative control, each cell line was also cultured in the absence of 
chemokine. MDA-MB-231 was used as a positive control. Panels A-D are representative 
images 48 hours post transfection (except D which was 24 hours) of the following 
conditions: (A) HMEpC transfected with control siRNA with 50nM of CXCl12, (B) 
HMEpC transfected with FOXP3 siRNA with no chemokine, (C) HMEpC transfected with 
FOXP3 siRNA with 50nM of CXCL12, (D) Wild-type MDA-MB-231 with 25nM of 
CXCL12. Panel E shows data from 24 hours (n=3) and 48 hours (n=5) post-transfection 
which are means and SD of experiments performed in duplicate. Paired t-test was used to 
statistically analyse the HMEpC FOXP3 siRNA 0nM vs 50nM, whereas, unpaired t-test was 
used to compare HMEpC Ctrl siRNA 50nM vs HMEpC FOXP3 siRNA 50nM.  
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4.5 Summary of chapter 4 results 
 Successfully constructed a FOXP3-expressing plasmid 
 
 Successfully generated stably transfected FOXP3 into MDA-MB-213, which 
significantly overexpressed FOXP3 in comparison to MDA-MB-231 
transfected with the empty vector, and HMEpC 
 
 The following was observed after stable FOXP3 transfection into MDA-MB-
231: 
o Significantly reduced ErbB2, SKP2, MYC and CXCR4 transcripts 
o Significantly increased CDKN1A 
o Significantly inhibited proliferation and an increased proportion of 
cells in the G1 phase of cell cycle 
 
 Stably transfected MDA-MB-231 were difficult to continuously expand with 
many colonies eventually dying. Transient transfections were attempted 
using Lipofectamine®2000, GenJet
TM
, Turbofect
TM
, GeneJuice® and 
JetPRIME
TM
 were not able to successfully transfect MDA-MB-231. 
Therefore, the effect of FOXP3 overexpression on migration and invasion 
was not assessed.  
 
 FOXP3 was effectively knocked down at both transcript and protein level 
after 24 hours using three separate FOXP3-specific siRNA 
 
 The following was observed after FOXP3 knockdown in HMEpC: 
o Significantly increased ErbB2, SKP2 and CXCR4 transcripts   
o CXCR4 protein expression was not significantly altered after FOXP3 
knockdown 24 hours and 48 hours post transfection 
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o MDA-MB-231 were capable of penetrating matrigel coated filters in 
response to CXCL12, however, FOXP3 knockdown in HMEpC failed 
to induce an invasive capacity to these cells 
o MDA-MB-231 potently migrated towards CXCL12, whereas, 
HMEpC did not. FOXP3 knockdown in HMEpC significantly 
increased the migratory response of HMEpC in response to 50nM of 
CXCL12 after 48 hours incubation.  
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4.6 Discussion 
FOXP3 is a transcription factor capable of binding and influencing the expression of 
many genes (Zheng, Josefowicz et al. 2007). Much of the literature describing the 
functions of FOXP3 is reported for Tregs where FOXP3 is regarded as the master 
regulator of the development and function of these cells by controlling the high level 
expression of CD25 and CTLA-4 whilst preventing the production of IL-2 (Chen, 
Rowell et al. 2006).  
The ability of FOXP3 to influence gene expression has also been demonstrated 
within epithelial cells where it influences ErbB2 (Zuo, Wang et al. 2007), SKP2 
(Zuo, Liu et al. 2007), p21 (Liu, Wang et al. 2009; Frattini, Pisati et al. 2012), c-
MYC (Wang, Liu et al. 2009; Frattini, Pisati et al. 2012) and LATS2 (Li, Wang et al. 
2011), MMP9 and VEGF (Nakahira, Morita et al. 2013).  
As well as regulating these genes, FOXP3 has also been shown to control 
proliferation, migration and invasion of cancer cells (Liu, Wang et al. 2009; Wang, 
Liu et al. 2009; Zhang and Sun 2010; Li, Wang et al. 2011; Frattini, Pisati et al. 
2012; Nakahira, Morita et al. 2013). This demonstrates that FOXP3 is more than just 
an immune regulator but is also a protein important in preventing carcinogenesis. 
FOXP3 is often dysregulated in breast cancer cases; this contributes to the increased 
expression of oncogenes as previously mentioned (Zuo, Liu et al. 2007; Zuo, Wang 
et al. 2007; Merlo, Casalini et al. 2009). On the other hand, it is now well established 
that CXCR4 plays an important role in breast cancer by influencing a number of 
processes involved with cancer progression (Chang and Karin 2001; Fresno Vara, 
Casado et al. 2004; Luker and Luker 2006; Liang, Brooks et al. 2007).  
Although CXCR4, and another gene implicated in breast cancer, CCR7, have both 
been reported as FOXP3 target genes in thymic T-cells (Zheng, Josefowicz et al. 
2007), to this date no reports have demonstrated links between FOXP3 and CXCR4 
regulation in breast epithelial cells. Therefore, the aim of this chapter was to 
investigate the role of FOXP3 in epithelial cell homeostasis using in vitro techniques 
with a novel insight to its ability to influence CXCR4 expression. 
In attempts to answer this question, two model systems were selected to study the 
effects of FOXP3. After the initial demonstration of the dysregulated expression of 
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FOXP3 within MDA-MB-231 and normal FOXP3 expression in HMEpC, 
experiments were designed to investigate the effects of overexpressing FOXP3 in 
MDA-MB-231, and knocking down wild type FOXP3 in HMEpC.  
FOXP3 DNA was cloned into a pcDNA3.1/Zeo(+) backbone. The DNA contained 
the entire FOXP3 protein coding domain and will therefore encode FOXP3 FL and 
not the Δ3 isoform. The ability of this plasmid to express FOXP3 was tested by 
transiently transfecting the plasmid DNA into wild type HEK cells. FOXP3 was 
highly upregulated after transfection demonstrating that this plasmid is capable of 
expressing FOXP3.      
 
4.6.1 Generation of stable FOXP3 overexpressing MDA-
MB-231 
The stable transfection of MDA-MB-231 with FOXP3 was a challenging aspect of 
the project. Most researchers who have used MDA-MB-231 agree that it is a 
notoriously difficult cell line to transfect. Indeed many reagents are optimised for 
this “difficult-to-transfect” cell line. Nonetheless, MDA-MB-231 transfection has 
been reported in the literature (Chen, Kang et al. 2001; Wu, Chan et al. 2005).  
Despite this difficulty, three colonies were expanded in the presence of Zeocin
TM
. 
However, only one of these, colony 4, stably overexpressed FOXP3. Because 
FOXP3 was overexpressed in comparison to MDA-MB-231 transfected with the 
empty vector and HMEpC, this was a good model to investigate the effects of re-
introducing FOXP3 into an invasive breast cancer cell line.  
As a transcription factor, a nuclear location is imperative to effective functioning. 
Previous results, in chapter 3, suggested that despite low level expression of FOXP3 
within MDA-MB-231, the protein was predominately restricted to the cytoplasm. 
MDA-MB-231 which stably overexpressed FOXP3, expressed the protein 
predominately within the nucleus, which proposes that these cells have retained the 
processes required for normal nuclear translocation of the FOXP3 protein. This 
suggests that nuclear localisation of FOXP3 may depend on other factors which are 
maintained in MDA-MB-231.  
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Indeed, FOXP3 frequently works by cooperating with other transcription factors and 
proteins such as NFAT (Wu, Borde et al. 2006). NFAT is highly expressed in MDA-
MB-231 and is associated with an aggressive phenotype (Yiu and Toker 2006). The 
expression of NFAT is generally located within the cytoplasm and then actively 
transported to the nucleus following dephosphorylation (Danesh, Newton et al. 
1999). Few papers have investigated FOXP3 nuclear transport with many describing 
different mechanisms and often contradicting each other (Lopes, Torgerson et al. 
2006; Hancock and Ozkaynak 2009). This suggests that the exact factors involved 
with FOXP3 transport remain inconclusive. On this basis, it is reasonable to 
hypothesise that FOXP3 may be actively transported to the nucleus in cooperation 
with other transcription factors such as NFAT. Since MDA-MB-231 express low 
levels of FOXP3, it may be that these levels are not sufficient to allow interaction 
with these factors and transfecting high levels of FOXP3 may restore this ability.   
 
4.6.2 Effects of FOXP3 overexpression in MDA-MB-231 
FOXP3 overexpressing MDA-MB-231 showed a reduction in relative expression of 
ErbB2 and SKP2 to levels similar to those observed in HMEpC. These findings are 
consistent with those described in the literature (Zuo, Liu et al. 2007; Zuo, Wang et 
al. 2007). In contrast to this, the expression of CDKN1A was significantly 
upregulated, which is also consistent with reports in the literature (Liu, Wang et al. 
2009).  
Constant expansion of the FOXP3 overexpressing MDA-MB-231 was almost as 
difficult as generating the colonies. Over time these cells seldom grew which was 
demonstrated by a proliferation assay showing a significantly reduced rate of 
proliferation. Interestingly, the overexpression of FOXP3 in cancer cell lines has also 
been demonstrated to significantly inhibit proliferation by several other groups 
(Zhang and Sun 2010; Frattini, Pisati et al. 2012).  
CDKN1A is a gene responsible for encoding the cell cycle inhibitor p21, which is 
responsible for inducing cell cycle arrest at the G1 stage. Along with Ki67, p21 is 
now also considered as one of the most reliable markers of senescence (Kang, Kim 
et al. 2009; Jia, Li et al. 2011; Baker, Weaver et al. 2013). 
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Because there was approximately a 7-fold increase in CDKN1A, it could be that 
FOXP3 transfection resulted in the induction of cellular senescence of MDA-MB-
231. The significant increase in CDKN1A expression in FOXP3 overexpressing 
MDA-MB-231 could be a factor which contributed to the reduced proliferation. Cell 
cycle analysis demonstrated an increased proportion of FOXP3-overexpressing 
MDA-MB-231 in the G1 stage of cell cycle. A report by Zhang and Sun (Zhang and 
Sun 2010) also demonstrated that FOXP3-transfection into a malignant cell line 
caused an increased proportion of cells within the G1 phase. However, because the 
number of cells arrested within the G1 phase was only approximately 11% greater 
than wild type and empty vector transfected MDA-MB-231, the reduced rate of 
proliferation in these cells is unlikely to be solely responsible for the increased 
expression in CDKN1A. It seems more likely that the increase in CDKN1A is merely 
one factor to consider for the reduced proliferation with a reduction in other genes 
responsible for cell growth also contributing to this result. Indeed the expression of 
HER2 (Wolf-Yadlin, Kumar et al. 2006; Johnson, Seachrist et al. 2010), SKP2, 
(Wang, Wu et al. 2009; Inuzuka, Gao et al. 2012; Zhang, Ji et al. 2013) and MYC 
(Alfano, Votta et al. 2010; Liu, Radisky et al. 2012; Zhao, Jian et al. 2013) are all 
well known to increase the proliferation of cancer cells. Therefore, the significant 
reduction in these genes is likely to have a major influence on the proliferation of 
these cells.        
In addition to reductions in the expression of ErbB2, SKP2 and MYC by FOXP3 
overexpressing cells, the expression of CXCR4 was also reduced. Although the 
overall change in the expression in CXCR4 transcripts (p=0.0496) was not as striking 
as the changes observed for ErbB2 (p=0.0264) and SKP2 (p=0.0249), which are both 
reported to be directly repressed by FOXP3 in breast cancer cells, the reduction in 
CXCR4 was still statistically significant. Because the changes observed were small 
and of variable magnitude, the data may suggest that FOXP3 does not directly bind 
CXCR4 like it does to the aforementioned genes, but possibly relies on other 
downstream effectors to influence CXCR4 expression.  
Data from chapter 3 suggested that MDA-MB-231 were defiecent in the natural 
FOXP3Δ3 isoform but despite reduced levels, still expressed the full length variant. 
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Interestingy, because the FOXP3 DNA cloned into the plasmid encoded only the full 
length isoform, the effects observed following overexpression were still a result of 
FOXP3FL and not FOXP3Δ3 varient.      
 
4.6.3 Effects of FOXP3 knockdown in HMEpC 
To further validate the role of FOXP3 in breast epithelial cells, the normal 
expression of FOXP3 by HMEpC was knocked down using commercial siRNA. 
Three FOXP3 specific silencer® select siRNA sequences were validated by 
comparing against HMEpC transfected with control siRNA sequences. In all cases, a 
reduction was observed in FOXP3 expression at both a transcript and protein level 
24 hours post-transfection. Because the half-life of FOXP3 is approximately 21 
minutes (Lee, Gao et al. 2008), this reduction in FOXP3 within a relatively short 
period of time is, therefore, perhaps expected. Following transfection with siRNA 
sequences, FOXP3 transcripts fell below the levels within HMEpC and MDA-MB-
231, and thus provided a good model to investigate the effects of FOXP3 
knockdown. 
The HMEpC with reduced FOXP3 showed a significant increase in ErbB2 and SKP2 
transcripts. However, the level of MYC was not significantly increased. Because the 
potential of FOXP3 to directly repress MYC has only been demonstrated for prostate 
epithelia (Wang, Liu et al. 2009) and glioblastoma cells (Frattini, Pisati et al. 2012) it 
is possible that FOXP3 does not influence MYC in breast epithelia as potently as it 
does in other epithelial cells. In addition to this, FOXP3 knockdown failed to cause a 
significant decrease in CDKN1A transcripts (p=0.0534), however, a clear trend was 
observed. FOXP3 knockdown in HMEpC also resulted in a significant increase in 
CXCR4 transcripts (p=0.0479). Although, in a similar manner to the changes 
witnessed after FOXP3-overexpression in MDA-MB-231, the magnitude of the 
increase observed and reproducibility was not as compelling as the effects witnessed 
in other FOXP3 target genes. This again supports the theory that FOXP3 may not 
directly influence CXCR4 expression.   
Following FOXP3 knockdown, there was no significant change in level of CXCR4 
protein in comparison to HMEpC transfected with control siRNA sequences. 
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Although the changes of CXCR4 at a transcript level were significant, the changes 
were not large which could explain the lack of significant changes observed at a 
protein level.  
It is known that MDA-MB-231 are extremely motile and invasive in response to 
CXCL12 both in vivo and in vitro, whereas their normal HMEpC counterparts are 
incapable of these actions (Muller, Homey et al. 2001). MDA-MB-231 were capable 
of penetrating matrigel coated membranes using in vitro invasion assays, however 
the extent of invasion was not as great as reported in other studies (Muller, Homey et 
al. 2001). Some reports use MDA-MB-231 as positive controls for invasion (Muller, 
Homey et al. 2001). However, in this study, concentrations of up to 75nM of 
chemokine, and incubation periods of 72 hours were required before MDA-MB-231 
significantly invaded.  
On the other hand, migration assays using MDA-MB-231 demonstrated they 
potently responded, and migrated towards 12nM of CXCL12 after 16 hours. In 
accordance with the literature, HMEpC did not migrate or invade in response to 
CXCL12. On the contrary, although results from flow cytometry suggested no 
CXCR4 expression was present on wild type and control siRNA transfected 
HMEpC, the results using the cytometric beads suggested that HMEpC did have 
CXCR4 present on the cell surface. This would suggest that, perhaps, either the 
number of CXCR4 detected is too low to respond to CXCL12, or, the CXCR4 
receptors present on the cell surface are not functionally active.  
FOXP3 knockdown was unable to create an invasive phenotype in HMEpC. 
However, after doubling the period of incubation and the concentration of CXCL12 
from the optimised protocol, it did significantly increase the migratory potential of 
HMEpC. Interestingly, although FOXP3 knockdown increased the migratory 
response in HMEpC when the levels of CXCL12 were doubled, there was also an 
observable increase in the background motility of these cells, as well as an increase 
in the migration of cells transfected with control siRNA. The cytometric bead assay 
suggested that HMEpC transfected with control siRNA also had increased levels of 
CXCR4.  
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Two aspects must be considered when determining the validity of these findings. 
Firstly, control siRNA primer sequences used were unknown. Firstly, these were 
purchased from Ambion who do not allow their control siRNA primer sequences to 
be released. Despite these sequences not affecting FOXP3 expression, we cannot 
rule out the possibility that these primers do bind elsewhere in the genome and the 
increase in CXCR4 may be the result of indirect off-target binding of control siRNA. 
Secondly, it is well reported, and discussed in this report (section 1.6.3.2), that 
CXCR4 can be influenced from factors within cells, such as HER2 (Li, Pan et al. 
2004) and NF-κB (Helbig, Christopherson et al. 2003), but also factors within the 
microenvironment, such as hypoxia and various stress inducing elements (Schioppa, 
Uranchimeg et al. 2003; Ishikawa, Nakashiro et al. 2009). Therefore, it should also 
be considered that treatment with a cytotoxic transfection reagent, such as siPORT, 
may induce cellular stress and increase CXCR4 expression in response to this 
reagent.  
Taken together, this data suggests that although the cells may be responding to the 
CXCR4 ligand, CXCL12, firstly, an increase in CXCR4 may not be due to FOXP3 
knockdown, and secondly, an increase in CXCR4 may not be the sole reason for the 
increase in migration. In fact, previous studies have shown that FOXP3 knockdown 
is associated with increased migration of ovarian epithelial cells, whereas FOXP3-
overexpression can reduce migration of glioblastoma in the absence of chemokines 
(Zhang and Sun 2010; Frattini, Pisati et al. 2012). This suggests that FOXP3 is able 
to regulate the general motility of cells. Indeed, this study and other reports have 
provided strong evidence suggesting that FOXP3 knockdown is able to increase the 
expression of certain oncogenes such as HER2, SKP2 and MYC. Interestingly, all 
these factors have been demonstrated to increase the migration of cells (Wolf-
Yadlin, Kumar et al. 2006; Wang, Wu et al. 2009; Alfano, Votta et al. 2010; 
Johnson, Seachrist et al. 2010; Inuzuka, Gao et al. 2012; Liu, Radisky et al. 2012; 
Zhang, Ji et al. 2013; Zhao, Jian et al. 2013)..  
In addition to this, although they were not investigated in this study, FOXP3 has 
been demonstrated to repress the expression of MMP2 (Zhang and Sun 2010), 
MMP9 (Zhang and Sun 2010; Nakahira, Morita et al. 2013), LATS2 (Li, Wang et al. 
2011) and VEGFA (Nakahira, Morita et al. 2013), as well as NF-κB and mTOR 
signalling (Zhang and Sun 2010) in cancer cells. Interestingly, all of these factors 
Chapter 4 – in vitro modelling of FOXP3 functions in normal and malignant breast epithelia  
233 
 
have been frequently reported to be involved in regulating the migration and 
invasion of cancer cells and the role these factors may also play should not be easily 
dismissed (Rak, Mitsuhashi et al. 1995; Andela, Schwarz et al. 2000; Chang and 
Karin 2001; Zhang, Rodriguez-Aznar et al. 2012; An, Kang et al. 2013; Nakahira, 
Morita et al. 2013).  
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4.7 Conclusion    
FOXP3 is a transcription factor recently implicated in a number of malignancies 
where it is able to influence not only oncogene expression but also cell proliferation, 
migration and invasion of breast, prostate, ovarian cancers and glioblastomas (Zuo, 
Liu et al. 2007; Zuo, Wang et al. 2007; Liu, Wang et al. 2009; Wang, Liu et al. 2009; 
Zhang and Sun 2010; Li, Wang et al. 2011; Frattini, Pisati et al. 2012; Li, Katoh et 
al. 2013). On the other hand, the profound importance of CXCR4 in driving breast 
cancer is well documented within the literature (Muller, Homey et al. 2001; Luker 
and Luker 2006).  
The aim of this chapter was to investigate the effects that FOXP3 has in a breast 
cancer cell line and also a normal mammary epithelial cell line using in vitro models. 
In line with the literature, data in this study suggests that FOXP3 is able to regulate 
the expression of ErbB2, SKP2, c-MYC and CDKN1A. Findings from this study are 
consistent with existing literature and suggest that FOXP3 may play a role in 
limiting the proliferation and migration of normal mammary cells, thereby 
preventing breast cancer progression. However, it should also be noted that these 
effects are most likely not driven by a single molecule and are probably due to an 
accumulation of changes involving FOXP3.   
FOXP3 has already been reported to act on oncogenes which are implicated in cell 
proliferation, migration, and invasion, however, the effects on CXCR4 are 
unreported. Data suggests that FOXP3 may be able to influence the expression of 
CXCR4 at low levels. However, in comparison to the effects witnessed in oncogenes 
already reported as direct FOXP3 target genes, due to the reproducibility and 
magnitude of the changes regarding this aspect of the study, they suggest that 
CXCR4 may not be directly influenced by FOXP3, and more likely to be a 
consequence of other factors affected by alternative signalling pathways involved 
with FOXP3. On the other hand, several potential mechanisms do exist within the 
literature which proposes how FOXP3 may be able to influence the expression of 
CXCR4 through the actions of other molecules. This is discussed further in chapter 
6.      
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After investigating the influence of FOXP3 in vitro, the transcript and protein levels 
of FOXP3 and CXCR4 within breast cancer patients of opposing lymph node 
involvement will be investigated in the next chapter.   
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5 In vivo levels of FOXP3 and CXCR4 expression in 
breast cancer patient samples 
 
5.1 Introduction  
Several studies have investigated the expression of FOXP3 within breast cancer 
patients. Although the majority of studies have reported a dysregulation of FOXP3 
expression in cancer (Chen, Chen et al. 2008; Merlo, Casalini et al. 2009; Wang, Liu 
et al. 2009), there remains a degree of ambiguity. For instance, Hinz et al (Hinz, 
Pagerols-Raluy et al. 2007) reported a lack of FOXP3 in normal pancreatic cells, but 
a marked increase in the malignant counterparts. A similar study by Ebert et al 
(Ebert, Tan et al. 2008) reported that FOXP3 was present within melanoma cells but 
not in normal melanocytes, whilst a recent study by Lal et al (Lal, Chan et al. 2013) 
described an increase in epithelial cell FOXP3 as breast cancer progresses.  
Although the involvement of FOXP3 in epithelial cells and carcinogenesis is a 
relatively new area of cancer research, the involvement of CXCR4 is much more 
defined as it is consistently upregulated in a number of malignancies, including 
breast cancer (Muller, Homey et al. 2001; Luker and Luker 2006; Mukherjee and 
Zhao 2013), melanoma (Kim, Koh et al. 2010; O'Boyle, Swidenbank et al. 2013), 
ovarian cancer (Ray, Lewin et al. 2011; Wang, Cai et al. 2011), and prostate cancer 
(Gladson and Welch 2008).  
Although CXCR4 and FOXP3 have been investigated either individually, or in 
correlation with other proteins, their expression has never been investigated 
simultaneously in the same study.  
 
5.1.1 Tumour microenvironment  
Many diseases which produce chronic inflammation are associated with a high risk 
of cancer. Tumours not only contain cancer cells, but also a wide variety of other cell 
types including stromal cells, fibroblasts, endothelial cells and most importantly, 
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inflammatory cells (Balkwill and Mantovani 2001; Coussens and Werb 2002). 
Experimental, clinical and epidemiological studies have revealed that malignant 
tumours not only exist at sites of chronic inflammation, but inflammation also 
contributes to cancer progression. The first link between cancer and inflammation 
was observed approximately 150 years ago by Rudolf Virchow (Balkwill and 
Mantovani 2001) who reported that many cancers tend to occur at sites which are in 
states of chronic inflammation. Inflammatory breast cancer is one of the most 
aggressive forms of breast cancer and is characterised by very high levels of 
inflammation. Inflammatory cytokines such as TNF-α, IL-1, and chemokines such as 
CCL2 and CXCL8 are key mediators in tissue remodelling and neo-angiogenesis 
(Conti and Rollins 2004; Condeelis and Pollard 2006; Varney, Johansson et al. 2006) 
in cancer.  
There are many components that contribute to a tumours growth, invasion and 
metastasis. These include the extracellular matrix, fibroblasts, endothelial cells, 
inflammatory cells and a network of chemokines and promoters of angiogenesis (Ali 
and Lazennec 2007; Harvey, Mellor et al. 2007; Mellor, Harvey et al. 2007). Reports 
indicate that TAMs are key regulators involved in the link between inflammation and 
cancer (Leek and Harris 2002; Medrek, Ponten et al. 2012; Quatromoni and 
Eruslanov 2012).  
The importance of macrophages in the tumour microenviroment is well documented 
as they are one of the predominate leukocytes in the tumour mass (Balkwill, Charles 
et al. 2005). Macrophages play an indispensible role in innate and adaptive 
immunity. They are activated by a number of stimuli which allows them to 
differentiate into multiple subtypes displaying various phenotypes which are 
dependent on the microenvironment. Two main states of polarised activation for 
macrophages have been described: the classically activated M1 macrophage and the 
alternatively activated M2 macrophage. M1 macrophages are activated following 
stimulation with IFN-γ, a number of cytokines and TNF-α. Once activated, these 
cells then secrete high levels of IL-12 and IL-23, but low levels of IL-10 (Gordon 
and Taylor 2005; Mantovani, Sica et al. 2005; Solinas, Germano et al. 2009)  On the 
other hand, once M2 macrophages are activated by secrete high levels of IL-10 and 
low levels of IL-12 and IL-23 (Mantovani, Sica et al. 2005; Solinas, Germano et al. 
2009).   
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Mainly because of their opposing cytokine profiles, the phenotypes of the polarized 
macrophages are reported to have differing roles within the cancer environment and 
tumour growth. Because the classically activated M1 macrophages express a number 
of pro-inflammatory cytokines, this allows them to act in an anti-tumour manner, 
whereas, the majority of TAMs exhibit M2 phenotypes which express a variety of 
anti-inflammatory molecules. These M2 macrophages are now associated with a 
worse prognosis as they provide an immunosuppressive environment for the tumour 
to grow. Moreover, TAM infiltration has been linked to the interaction with cancer-
stem cells leading to not only tumorigness and metastasis, but also drug resistance 
and increased risk of relapse (Rosen and Jordan 2009).  
Despite the importance of macrophages in the inflammatory environment, research 
has also suggested that they do not work alone and other infiltrating leukocytes 
including neutrophils, mast cells, eosinophils and activated T-cells also release 
chemokines, proteases and angiogenic factors which contribute to malignancy 
(Coussens, Raymond et al. 1999; Coussens, Tinkle et al. 2000; Di Carlo, Forni et al. 
2001). 
 
5.1.1.1 T-cell infiltration  
Infiltration of lymphocytes around the tumour is the main contributor to chronic 
inflammation. These cells may be recruited to the region with the intention of 
combating tumour cells.  
Interestingly, the specific subtype of these T-cells is thought to be important in 
predicting patient survival. Breast cancer patients with high levels of CD4
+
 and/or 
CD8
+
 T-cells within the tumour have a better outcome as they are responsible for the 
production of IFN-γ (Mahmoud, Paish et al. 2011; Liu, Lachapelle et al. 2012; Gu-
Trantien, Loi et al. 2013). On the other hand, alternative reports have also suggested 
that some patients with high levels of CD4
+
 and CD8
+
 T-cell infiltration have a 
worse overall survival (Matkowski, Gisterek et al. 2009). 
The immunoregulatory CD3
+
CD4
+
CD25
hi
 subset, Tregs, are the body’s main 
peripheral defence. Tregs are responsible for suppressing the actions of autoreactive 
T-cells within the peripheral blood. These cells are often reported to be significantly 
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more abundant in the peripheral blood of cancer patients than healthy individuals 
(Liyanage, Moore et al. 2002; Ye, Ma et al. 2013). In particularly, Tregs are most 
commonly found around lymphoid-rich areas around tumours (Mizukami, Kono et 
al. 2008). This is thought to be a mechanism of immune evasion and, as a result, is 
associated with an unfavourable clinical prognosis (Hinz, Pagerols-Raluy et al. 2007; 
Mohos, Sebestyen et al. 2013; Sisirak, Faget et al. 2013). Although the majority of 
reports suggest a strong link between Tregs and a poor patient survival, an 
alternative study opposed this theory and suggested that cancer patients have fewer 
Tregs than healthy individuals (Okita, Saeki et al. 2005).  
The exact mechanism responsible for the infiltration of Tregs into the tumour 
environment is unknown. However, several plausible theories have been described 
and reviewed by Zou (Zou 2006). Tregs are known to express CCR4, whereas, 
tumour cells and TAMs have been shown to secrete the CCR4 ligand, CCL22 
(Curiel, Coukos et al. 2004; Miller, Lundberg et al. 2006). Therefore, the chemokine-
chemokine receptor axis of CCR4/CCL22 could provide a mechanism of Tregs 
homing to tumour environment. Another theory is that the high levels of TGF-β 
present within tumours could contribute to the conversion of CD4
+ 
T-cells into 
induced Tregs (Zou 2006). A similar scenario has been reported by Dumitriu et al 
(Dumitriu, Dunbar et al. 2009) who reported that human lung cancer cell lines can 
prompt dendritic cells to release TGF-β which subsequently transformed CD4+ T-
cells into Tregs. 
 
5.1.2 Breast cancer classification 
At the time of diagnosis, breast cancer is divided into several categories which define 
the stage of the tumour, the grade of the tumour, and whether the tumour cells 
overexpress specific growth factor and hormone receptors.  
The aim of this classification is to describe each individual case in order to select the 
most appropriate treatment. 
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5.1.2.1 Tumour grade 
The tumour grade is often assessed using a light microscope. The pathologist 
examines the appearance of malignant cells in comparison to normal healthy cells. 
Tumours are graded as follows; if the cells are well differentiated and still resemble 
normal cells, they are considered as low grade (grade I). If the cells are moderately 
differentiated, they are considered as intermediate grade (grade II) and if the cells are 
poorly differentiated they are considered to be high grade (grade III). Higher grades 
suggest a worse prognosis because undifferentiated cells divide more rapidly and 
have an increased risk of metastasis, whereas, low grade tumour cells closely 
resemble healthy cells and grow more slowly (Hatteville, Mahe et al. 2002).  
The grade is calculated on three criteria (Hatteville, Mahe et al. 2002); tubule 
formation, nuclear pleomorphism, and the frequency of mitosis. Each of these 
criteria is scored between one and three points and the final score is the sum of the 
individual scores (table 5.1). Each criterion is discussed briefly below:  
Tubule formation: During tumorigenesis the tissue structures, such as the tubules, 
become less orderly as the cancer breaks down mechanisms the cells use to attach to 
each other. Points in this parameter are defined by the percentage of the tumour 
forming normal duct structures. If the tumour has more than 75% tubule formation it 
is scored one point. If tubule formation is between 10-75% of the tumour it is scored 
two points, and if tubule formation is less than 10%, three points are scored.   
Nuclear pleomorphism: A common trait of cancer is dysregulated control over 
various genes. These changes can often result in irregularities in the appearance of 
the nucleus which becomes larger and darker. The pathologist scores this parameter 
by the appearance of the tumour cells nuclei in comparison to that of normal healthy 
cells. A minimal change in the size and shape of the nuclei is scored one point, 
moderate changes are scored two points, whereas, marked variations are scored three 
points. The more pleomorphic the nuclei, the worse the prognosis.   
Mitotic frequency: As previously described in section 1.4.3, one of the hallmarks of 
cancer cells is the ability to divide uncontrollably. The final parameter the 
pathologist scores is the number of dividing cells in a specific number of 
microscopic fields of view (depending on the microscope used). The scoring system 
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described below is based on the Leitz Ortholux microscope at x25 magnification. 0-9 
mitotic counts are scored 1 point. Mitotic counts between 10 and 19 are scored 2 
points, whereas more than 19 mitotic counts are scored 3 points. 
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Grade Points range 
Grade I 3 – 5 points 
Grade II 6 – 7 points 
Grade III 8– 9 points 
 
Table 5-1 - Scoring system used for tumour grading 
Breast tumours are scored by calculating total points regarding tubular formation, nuclear 
pleomorphism and mitotic frequency when assessing tumour. The total points from each 
category are combined and the points range can define the tumour as a specific grade.  
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5.1.2.2 Tumour stage  
When pathologists stage breast cancer, they determine the size of the tumour and 
whether it has spread or not. Determination of the stage of cancer once again helps 
the specialist decide on the best course of treatment for the patient.  
Once the stage has been assessed, clinicians use a formula called the Nottingham 
prognostic index (NPI) to help predict the effectiveness of the treatment. 
 
 
This formula was originally devised in 1982 (Haybittle, Blamey et al. 1982) and 
revised ten years later (Galea, Blamey et al. 1992); however, treatments have 
continued to improve so the true implication of this index is often questioned. After 
calculating the NPI, patients are subcategorised into four groups. This helps to 
predict the prognosis of the patient. The four subcategories are summarised in table 
5.2. 
Breast cancer is most commonly staged using the TNM system which takes into 
account the tumour size (T-tumour), whether the lymph nodes are involved (N-node) 
and finally whether the tumour has spread beyond the lymph nodes to any other 
regions in the body (M-metastases). Table 5.3 summarises a slightly simplified 
version of the TNM system (Singletary and Greene 2003). 
 
 
 
 
 
 
 
 
NPI = (0.2 x Tumour diameter size [cm]) + Lymph node stage + Tumour grade 
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NPI category (based on calculated prognosis) NPI score 
Excellent Equal to or less 
than 2.4 
Good From 2.5 - 3.4 
Moderate 3.5 - 5.4 
Poor Greater than 5.5 
 
Table 5-2 - Table for Nottingham prognostic index ranges  
The NPI is a system utilising a calculation based on the tumour size, grade and lymph node 
status to predict the prognosis of a patient.   
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Tumour status 
(T) 
Description 
Tx Tumour cannot be assessed  
T0 No evidence of primary tumour 
Tis Tumour in situ. This can also refer to Paget’s disease with no tumour 
mass 
T1 Tumour smaller than 2cm in size 
T2 Tumour between 2-5cm in size 
T3 Tumour greater than 5cm in size  
T4 Tumour is affecting chest wall and skin. Inflammatory cancer can also 
be scored T4 
 
Lymph node 
status (N) 
Description 
Nx Lymph node cannot be assessed  
N0 No regional lymph nodes involved  
N1 Between 1-3 regional lymph nodes involved 
N2 Between 4-9 regional lymph nodes 
N3 More than 10 lymph nodes involved 
 
Metastasis (M) Description 
Mx Presence of distant metastasis cannot be assessed   
M0 No distant metastasis detected  
M1 Presence of distant metastasis 
 
Stage Sub-stage Definition by TNM score  
0 - Tis, N0, M0 - - - - 
I - T1, N0, M0 - - - - 
II IIa T0, N1, M0 T1, N1, 
M0 
T2, N0, 
M0 
- - 
IIb T2, N1, M0 T3, N0, 
M0 
- - - 
III IIIa T0, N2, M0 T1, N2, 
M0 
T2, N2, 
M0 
T3, N1, 
M0 
T3, N2, 
M0 
IIIb T4, N0, M0 T4, N1, 
M0 
T4, N2, 
M0 
- - 
IIIc Any T, N3, M0 - - - - 
IV - Any T, any N, 
M1 
- - - - 
Table 5-3 - Classification of the tumour-node-metastasis (TNM) system  
Pathologists diagnose tumours relying on the size of the tumour (T), the number of lymph 
nodes which are involved (N) and whether the tumour has metastasised to distant sites (M). 
Table (A) demonstrates the criteria for the scoring of the tumour size. Table (B) 
demonstrates the criteria for scoring the number of lymph nodes involved. Table (C) 
demonstrates the criteria for scoring the presence of metastases. Table D demonstrates 
possible combinations from the TNM score and the stage of the tumour (Singletary and 
Greene 2003). 
A 
B 
C 
D 
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5.2 Aims and objectives  
 Measure the transcript and protein levels of CXCR4 and FOXP3 from 
epithelial cells within breast cancer samples from lymph node negative, 
lymph node positive patients and sections from normal tissue. 
 
 Investigate the potential correlation between the expression of FOXP3 and 
CXCR4 in breast cancer samples.  
 
 Investigate the potential prognostic implications of FOXP3 and CXCR4 
expression in breast cancer samples. 
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5.3 Specific materials and methods 
5.3.1 Ethical approval  
Ethical approval for the use of paraffin-embedded and frozen human breast tissue 
sections were submitted to the Newcastle and North Tyneside Local Research Ethics 
Committee. Approval was granted for the use of anonymised paraffin-embedded 
sections (REC reference number: 06/Q0906/12) and the use of anonymised frozen 
tissue for RNA isolation in the study (REC reference number: 10/H0906/26). 
 
5.3.2 Selection of patient samples 
Breast cancer samples, isolated at the Queen Elizabeth (QE) Hospital (Gateshead, 
UK) were selected based on the patient’s lymph node involvement and NPI score. 
Ten patients were selected with no nodal involvement (referred to as LN-negative) 
and, and nine patients with high nodal involvement (referred to as LN-positive). All 
samples were derived from patients with IDC of NST. In addition, tissues from two 
separate patients who had undergone breast reduction surgery were used as normal 
breast tissue (referred to as normal #1 and normal #2). To ensure patient anonymity, 
the ten LN-negative breast cancer patients were referred to as cases #1 to #10, 
whereas, the nine LN-positive patients were referred to as cases #11 to #19. The 
details of individual breast cancer patients selected, including the lymph node status 
(and percentage positivity), the NPI, the date of the operation and the post-operative 
follow up status’ are included in table 5.4. 
All frozen tumour samples were stored at -80°C in accordance with the Human 
Tissue Act (HTA). Frozen tumours were used for RNA isolation, whereas, the 
matched paraffin-embedded sections were used for IHC.  
It should also be noted that three LN-negative paraffin tissue samples (cases #1, #5 
and #8) had previously been used by the QE Hospital as control material and were 
not available to be stained using IHC. This information was discovered late in the 
study and alternative tissues were not able to be selected in time. Therefore, only 
seven LN-negative tissues were investigated using IHC.      
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Patient 
number 
Lymph node 
involvement (%) 
NPI Date of 
operation 
Post-op follow up status 
#11 13/16 (81%) N/A 1996 Deceased - 1997 
#12 7/8 (88%) 6.6 (Poor) 1998 Deceased - 2000 
#13 10/12 (83%) 7.2 (Poor) 1999 Alive and well (2013) 
#14 20+ 5.5 (Poor) 1998 Deceased - 1998 
#15 5/5 (100%) 5.3 (Moderate) 2000 Deceased - 2009 
#16 18 6.8 (Poor) 1998 Deceased - 1999 
#17 22/22 (100%) 6.6 (Poor) 1999 Deceased - 2005 
#18 8/13 (61%) 5.5 (Poor) 1998 Deceased - 1998 
#19 13/14 (92%) 5.5 (Poor) 2000 Deceased - 2000 
 
Table 5-4 - Patient histories of selected breast cancer samples 
Details of breast cancer samples from LN-negative patients (A) and LN-positive patients (B)  
 
Patient 
number 
Lymph node 
involvement 
NPI Date of 
operation 
Post-op follow up status 
#1 0/7 3.23 (Good) 2005 Alive and well 
(Discharged 2010) 
#2 0/10 3.36 (Good) 1998 Alive and well 
(Discharged -2007) 
#3 0/8 3.3 (Good) 1998 Alive and well 
(Discharged -2003) 
#4 0/12 3.3 (Good) 1998 Deceased 
Liver mets (2010) 
#5 0/5 3.3 (Good) 2005 Alive and well 
(Discharged - 2010) 
#6 0/4 3.12 (Good) 1997 Alive and well 
(Discharged - 2004) 
#7 0/7 3.28 (Good) 2005 Alive but suffering 
metastasis (2013) 
#8 0/6 3.2 (Good) 2005 Alive and well 
(Discharged - 2010) 
#9 0/8 3.4 (Moderate) 2004 Alive and well 
(Discharged - 2010) 
#10 0/13 3.22 (Good) 2001 Alive and well 
(Discharged - 2006) 
A 
B 
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5.3.3 RNA isolation from frozen patient samples using 
GentleMACS
TM
 dissociator   
The GentleMACS
TM
 dissociator (Milentyi Biotec, Surrey, UK) is an automated 
bench top instrument (figure 5.1 panel A) used to dissociate tissues into single cell 
suspensions using a number of specific pre-optimised applications. This instrument 
was used to dissociate frozen tissue sections for flow cytometric analysis and RNA 
isolation. 
Prior to dissociation, tissues were weighed and partially thawed on ice. Tissues to be 
used for flow cytometry or to be used with RNeasy spin columns (QIAgen) were 
thawed in 2ml of basal DMEM media with 100µg/ml DNase (Sigma-Aldrich), 
whereas, tissues to be used with TRI reagent were homogenised in 2ml of TRI 
reagent. Whilst thawing at room temperature in media, the tissues were cut into 
small sections using fresh sterile scalpels for each section. This prevents the machine 
from becoming blocked due to the size of the sections. The sections and media were 
then dispensed into C-tubes (Miltenyi Biotec) and placed into the GentleMACS
TM
 
dissociator and homogenised using program (H_Tumour RNA). After dissociation, 
the homogenised tissue was strained through a 40µm filter and dispensed into 
appropriate tubes (depending on experiment to be continued with) and washed in 
PBS by centrifugation at 500xg. After centrifugation the supernatant was removed 
and cell pellet was used for future experiments. 
 
5.3.4 RNeasy mini spin columns  
RNeasy (QIAgen) is a silica-based column method of isolating RNA from cells or 
tissue sections. After the initial homogenisation described in section 5.3.3, cells were 
dispensed into 1.5ml Eppindorf tubes and centrifuged to pellet. The cells were lysed 
by the addition of 1ml buffer RLT and vortexed. Next, 500µl of 70% ethanol was 
added and mixed by pipetting. The mixture was dispensed into an RNeasy mini spin 
column 700µl at a time. The column was centrifuged for 15 seconds at 8000xg and 
the flow through was discarded. 700µl of buffer RW1 was added to the spin column 
and centrifuged for 15 seconds at 8000xg. The flow-through was discarded and the 
column was washed twice in buffer RPE at 8000xg, firstly for 15 seconds, followed 
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by a 2 minute spin. Finally, the RNeasy spin column was placed into a fresh, sterile, 
1.5ml collection tube and RNA was eluted from the column by the addition of 50µl 
RNase-free water and centrifuged for 1 minute at 8000xg 
 
5.3.5 IHC staining of breast tissue  
IHC is a technique used in laboratories for localisation of proteins in tissue sections 
using specific primary antibodies directed against the antigen. Once the antibody is 
bound, it is visualised using a coloured reaction which is observable by light 
microscope.  
Direct methods of IHC are when the primary antibody itself carries the signal 
generating molecules that provide the method of visualisation. However, the most 
common methods of IHC are indirect. These methods require additional steps to 
locate the antigen-bound primary antibody and subsequently generate the signal.   
 
5.3.5.1 CD3 and CXCR4 staining 
All CD3 and CXCR4 staining was performed by senior biomedical scientist, Ms 
Denise Woolley, within the Pathology Department within QE Hospital. All staining 
was performed using the autostainer link 48 (DAKO, Cambridge, UK) (figure 5.1 
panel B) with the EnVision
TM
 FLEX
+
 mouse detection kit (DAKO). All equipment 
described in this section was provided by DAKO unless specified. The procedure 
used to stain the slides can be broken down into the following subsections: 
Dewaxing of sections, antigen retrieval, and finally, the automated staining protocol. 
These are described in the following paragraphs.  
Dewaxing: Paraffin-embedded breast tissue on slides were dewaxed by submerging 
in xylene for 5 minutes, followed by rehydrating the tissues by passing through 
decreasing levels of ethanol (100%-90%-75%-50%). Sections were then placed into 
water to remove xylene and ethanol from slides. 
Antigen retrieval: Antigen retrieval was performed using the PT-Link (DAKO) 
(figure 5.1 panel C) with a 1:50 ratio of EnVision
TM
 FLEX Target Retrieval 
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Solution (High pH) with distilled water. The pre-treatment solution was heated to 
65°C in the PT-link, then slides were placed into the solution and incubated for 40 
minutes at 97°C. Slides were cooled back to 65°C in the PT-link and washed in 
EnVision
TM
 FLEX wash buffer for 5 minutes before being loaded into the 
autostainer link 48 for staining.  
Staining protocol: CD3 and CXCR4 staining was carried using the following 
automated protocol. Primary antibodies were diluted in EnVision
TM
 FLEX antibody 
diluent. All steps were performed at room temperature, whereas, all wash steps were 
performed using the EnVision
TM
 FLEX wash buffer (prepared using a 1:20 ratio 
with deionised water). Slides were washed in buffer for 5 minutes before the addition 
of 200µl EnVision
TM
 FLEX Peroxidase-Blocking Reagent for 15 minutes. Slides 
were washed in buffer for 20 minutes before being treated with 200µl of solution 
containing specific dilutions of primary antibody (anti-CXCR4/anti-CD3) + FLEX 
for 50 minutes. CD3 staining is regarded as an “in-house” stain within pathology 
departments and is frequently used so did not require optimising (1:150 dilution). 
However, because CXCR4 staining required optimising, the antibody dilutions 
varied between tests. For this reason, the specific antibody dilution used is described 
within the appropriate figure legends. Slides were washed in buffer and received 
200µl of EnVision
TM
 FLEX
+
 mouse secondary antibody for 15 minutes. The slides 
were washed again, before 200µl of EnVision
TM
 FLEX/HRP was added and left to 
incubate for 20 minutes. The slides were washed twice in buffer for 20 minutes 
before having 200µl of the substrate working solution added and left to incubate for 
10 minutes. The slides were washed for 20 minutes in buffer before being counter-
stained in 200µl EnVision
TM
 FLEX Haematoxylin for 5 minutes. Slides received two 
final 15 minute washes before being passed through increasing amount of alcohol 
(50%-75%-90%-100%) to dehydrate slides before being mounted in DPX. Slides 
were left to air dry for 2-3 hours before being viewed. 
 
5.3.5.2 FOXP3 staining  
FOXP3 staining was attempted using two automated staining protocols (which were 
amended appropriately), and one pre-optimised protocol used by previous members 
of this group. Each is described below:  
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All FOXP3 staining was carried out by Ms Denise Woolley within the Pathology 
Department in the QE Hospital using the same protocol as described in section 
5.3.5.1. Antibody dilutions required optimising, therefore, the specific antibody 
dilution used in each test is described in the figure legend.  
FOXP3 staining was also performed by specialist biomedical scientist, Ms Anna 
Long, within the Pathology Department in the Royal Victoria Infirmary (RVI) 
(Newcastle-Upon-Tyne, UK). All steps were performed using the BenchMark 
ULTRA (Ventana, Tucson, AZ, USA) (figure 5.1 panel D), with all equipment 
described in this section provided by Ventana unless stated.  
A number of protocols were attempted using Ventana machines, including two 
separate detection kits, three antigen retrieval methods and a range of antibody 
dilutions. Each detection kit and antigen retrieval method is described below and the 
conditions used in each test are described within the figure legends.     
Dewaxing: Slides stained within the RVI were dewaxed using EZ prep solution by 
pre-heating slides to 72°C for 4 minutes followed by 3 washes, where EZ prep 
solution was applied for 4 minutes, rinsed off and reapplied.  
Antigen retrieval: Antigen retrieval using the cell conditioning solutions were 
performed using the BenchMark ULTRA. Cell conditioning-1 is a high pH solution 
(set at pH 8.0), whereas, cell conditioning-2 is a low pH solution (set at pH6.0). 
Antigen retrieval was carried out according to the manufacturers protocol. Briefly, 
slides were warmed to 95°C and incubated in the appropriate cell conditioning 
solution for total of 1 hour with fresh solution being added approximately every 15 
minutes.  
Retrieval was also attempted manually with a pressure cooker using Tris/EDTA 
(pH9.0) and citrate (pH6.0) buffers. Briefly, the temperature of the pressure cooker 
was heated to 65°C, followed by the addition of the slides which were incubated for 
1 minute when the cooker reached 100°C. The cooker was then cooled back down to 
65°C before being cooled rapidly in water. Following retrieval, staining was 
commenced.  
Detection kits and staining protocols: The optiview and ultraVIEW detection kits 
were used in the FOXP3 staining in this study. Both kits are compatible for use with 
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the BenchMark ULTRA and are indirect, biotin-free systems for detecting primary 
antibodies.  
The ultraVIEW detection kit, is a 2-step method which uses a cocktail of 
secondary antibodies conjugated to HRP that locates the primary antibody. The 
complex of primary and secondary antibody is then visualised by precipitating the 
enzyme product by the addition of H2O2 and 3,3’Diaminobenzedine 
tetrahydrochloride (DAB) (figure 5.2).  
The optiview detection kit, is a 3-step method. This technique uses a cocktail of 
secondary (linker) antibodies to detect the primary antibody, followed by a tertiary 
antibody which is directly conjugated to HRP. Again, this visualisation is performed 
by the addition of H2O2 and DAB (figure 5.3).         
Manual FOXP3 staining, was carried by myself using a pre-optimised protocol 
developed by previous members of the group. FOXP3 staining was performed using 
the ABC Vectashield mouse staining detection kit (Vector laboratories). This kit 
utilises avidin-biotinylated peroxidase complexes which then develops DAB into a 
brown coloured substrate (figure 5.4). Because the Avidin-biotinylated peroxidase 
complexes are stable at room temperature for several hours, these complexes were 
prepared prior to staining. Complexes were prepared by diluting avidin reagent with 
the biotinyated peroxidase reagent at a ratio of 1:100 (avidin:biotinylated 
peroxidase). All wash steps were done with tris-based-saline (TBS) at pH7.6. All 
steps were performed at room temperature. 
Sections were dewaxed as described in section 5.3.5.1. Antigens were retrieved 
using 1.5L of Tris/EDTA at pH8.0 in the pressure cooker. The pressure cooker was 
brought to 100°C then slides were incubated for 1 minute before the pan was rapidly 
cooled in cold water. Slides were removed and staining was commenced. Briefly, 
sections were washed for 5 minutes before blocking endogenous peroxidase by the 
addition of a blocking serum for 10 minutes which was provided by the company. 
This was then replaced with the primary antibody (at a dilution of 1:50 [diluted in 
TBS]) and incubated for 60 minutes at 4°C. Slides were then washed twice for 5 
minutes before being covered in the biotinylated secondary antibody for 30 minutes. 
5 minute wash steps were performed twice before the addition of the avidin-
biotinylated peroxidase complexes which were then incubated for 30 minutes. 
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Another two wash steps were performed before the DAB substrate solution was 
added for approximately 2 minutes before being washed well in water. Slides were 
then counter stained in haematoxylin for 30 seconds, washed in water, and then 
washed Scott’s tap water to help develop the blue colour. Slides received a final 
wash in water before being dehydrated through increasing ethanol (50%-75%-90%-
100%) and mounted in DPX. 
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Figure 5-1 - Automated equipment used in frozen tissue homogenisation and 
paraffin embedded tissue IHC 
(A) The GentleMACS
TM
 dissociator was used to dissociate frozen breast tissue sections.  (B) 
The autostainer link 48 was used to stain paraffin embedded tissue for FOXP3, CXCR4, and 
CD3 in the QE Hospital. (C) The PT link was used to retrieve antigens before IHC in the QE 
Hospital. (D) The BenchMark ULTRA was used by the RVI Hospital, for antigen retrieval 
and IHC staining for FOXP3. Images were taken from DAKO and Ventana websites. 
 
 
 
 
 
 
A B
DC
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Figure 5-2 - Schematic representation of the ultraVIEW detection kit  
Following dewaxing and antigen retrieval stages, slides were incubated with a primary 
antibody specific for the target antigen (1). The primary antibody is then located by the 
addition of a secondary antibody which is directly conjugated to HRP (2). The complex is 
then visualised by the addition of H2O2 and DAB which produces a brown precipitate which 
is detectable by light microscopy (3).   
 
 
 
 
 
Figure 5-3 - Schematic representation of the optiview detection kit  
Following dewaxing and antigen retrieval stages, slides were incubated with a primary 
antibody specific for the target antigen (1). The primary antibody is then located by the 
addition of a secondary (linker) antibody (2). A tertiary antibody which is directly 
conjugated to HRP (3) is added then the complex is then visualised by the addition of H2O2 
and DAB which produces a brown precipitate which is detectable by light microscopy (4).   
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Figure 5-4 - Schematic representation of the ABC Vectashield detection kit  
(A)  Prior to staining, the avidin-biotinylated peroxidase complexes were prepared by the 
addition of avidin (labelled as A) with biotinylated peroxidase (labelled as B-P).  
(B)  After the antigen retrieval process, the addition of the primary antibody is able to bind 
to the specific antigen (1). A biotinylated secondary antibody which has specificity 
towards the primary antibody is able to locate the antigen (2). Because of the high 
affinity avidin has towards biotin the addition of the avidin-biotnylated peroxidase 
complexes (3) is able to bind directly to the secondary antibody. Finally the addition of 
H2O2 and DAB is able to produce a brown colour which is detectable by microscope (4).  
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5.3.5.3 List of antibodies used for IHC 
Antibodies used for IHC staining are provided in table 5.5. 
 
5.3.6 Quick score algorithm used for IHC staining 
The scoring of patient samples was done blindly by trained pathologist, Dr John 
Brain (RVI, Newcastle, UK). Scoring used Allred quick score which focuses on the 
proportion of cells stained (0 = no nuclear staining, 1 = less than 1% nuclear 
staining, 2 = 1-10% nuclear staining, 3 = 11-33% nuclear staining, 4 = 34-65% 
nuclear staining, 5 = 66-100% nuclear staining) and the intensity of staining (0 = no 
staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining). The score for 
the proportion of cells stained and the score for the intensity of staining were added 
to get the total score, which ranged from 0 to 8 (Mudduwa 2009). 
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Antibody target Clone Species raised in Company 
Human Anti-FOXP3 259D Mouse  BioLegend 
Human Anti-FOXP3 236A/E7 Mouse Abcam 
Human Anti-CXCR4 44716 Mouse  R&D systems 
Human Anti-CD3 F7.2.38 Mouse DAKO 
 
Table 5-5 - List of antibodies used for IHC 
All antibodies used for IHC along with antibody clones, species raised in and the 
manufacturers. 
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5.4 Results 
5.4.1 Separation of T-cells from frozen breast tumours 
As described in section 5.1.1, the tumour microenvironment often contains a large 
number of infiltrating leukocytes. A relatively high percentage of these T-cells are 
known to express FOXP3 and CXCR4. Because this study is focused on measuring 
the levels of FOXP3 and CXCR4 derived from epithelial cells within the tumour 
section, the strategy was developed to exclude infiltrating T-cells by staining with a 
human anti-CD3 antibody and use FACS.  
Because the breast tissues were not fresh and had been frozen for several years, they 
were not in good condition. To test whether the frozen breast cancer cells could be 
successfully stained, sections were homogenised into single-cell suspensions using 
the GentleMACS
TM
 dissociator, then stained with an anti-CD3 antibody and 
analysed by flow cytometry (figure 5.5 panel A). As a positive control, and also to 
locate CD3
+
 cells on the FACS dot plot, half of the homogenised sample was spiked 
with PBMC. Tumour samples spiked with PBMC had high levels of CD3
+
 cells, 
whereas, all of the homogenised breast tumours tested appeared to have less than 6% 
of CD3
+
 cells (figure 5.5 panel B).  
Because T-cell infiltration in breast cancer is common, the results suggesting that 
each breast cancer had very few infiltrating T-cells is most likely not a true reflection 
of the tumour, but a consequence of poor tissue quality. On this basis, it is more 
plausible that a combination of the age, condition, and the process of homogenising 
the tissue left the cells in a state where they could not be adequately stained. 
Therefore, potential T-cells could not be isolated from the sections using FACS.  
To continue the investigation of CXCR4 and FOXP3 transcripts in frozen breast 
tumours, whole tumour sections were analysed and the extent of tumour infiltrating 
T-cells was determined in each tumour section using real-time PCR with CD3 
specific primers and CD3 IHC on the matched paraffin-embedded sections. This is 
demonstrated in section 5.4.4. 
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Figure 5-5 – Determination of infiltrating CD3+ cells in dissociated breast 
tumours by flow cytometry 
Frozen breast tumours were partially thawed on ice and dissociated in serum free media 
supplemented with 100µg/ml DNAse to reveal a single cell suspension. Cells were strained 
through 40µm filters and washed 3 times in FACS buffer. Cells were stained with human 
anti-CD3-PE antibody or an isotype control and analysed by flow cytometry. Red boxes 
indicate regions of CD3
+
 cells. Panel A is a representative image of three experiments. 
Panel B demonstrates the percentage of CD3
+
 cells within each tumour section assessed. 
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5.4.2 Optimisation of RNA isolation from frozen tumour 
sections 
Isolating good quality RNA from tissue sections is considered by many a difficult 
prospect, especially when the tissue is not fresh and cell viability is low. In addition 
to this, since we only had one frozen tumour per patient, RNA isolation could only 
be attempted once. On this basis, RNA extraction from tumours was practised and 
optimised using TRI reagent and RNeasy spin columns to determine the best 
method. 
TRI reagent has been used previously in the study to extract RNA from cell lines 
with success (chapters 3 and 4). However, TRI reagent can also be used to isolate 
RNA from frozen tissue sections. Unlike TRI reagent, which is based around 
phenol:chloroform and phase separation, RNeasy spin columns use silica-based 
columns to isolate and purify RNA.  
RNA isolation was optimised using frozen breast tumours of differing sizes. One 
sample weighed in excess of 100mg (referred to as ‘large tumour’) and the other was 
less than 100mg (referred to as ‘small tumour’). Each tumour was cut into two equal 
sections, with one half being used for each isolation method. This ensures that results 
are not tissue specific and are dependent solely on the extraction process.    
The tissues were homogenised into a single-cell suspension using a GentleMACS
TM
 
dissociator as described in section 5.3.3. Once homogenised, RNA was extracted 
from the tumour in accordance with the manufacturers protocol. Following isolation, 
RNA purity was determined using a nanodrop spectrophotometer, and the integrity 
was determined by running a small sample on an agarose gel. 
As demonstrated by the Nanodrop spectrophotometer, RNA isolation using TRI 
reagent produced high RNA concentrations of approximately 2µg/µl from both the 
large and small tumours (figure 5.6 panel A). The 260/280 and the 230/260 ratios 
were both between 2.00 and 2.15, which demonstrate that the RNA isolated from 
both tumour sizes was of good quality with little contamination by proteins or 
organic solvents such as phenol or ethanol. Despite the high levels of pure RNA 
isolated using TRI reagent, when the integrity was examined by agarose gel 
electrophoresis, the RNA bands were smeared suggesting degradation (figure 5.6 
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panel B). This was commonly observed, implying the condition of the tumours is 
most likely the problem rather than the technique. This was further validated as RNA 
isolated from wild type HEK cells was far less degraded. Despite this, 28S and 18S 
bands were still visible and it was possible to be reverse transcribed and amplified by 
real-time PCR (figure 5.6 panel C). It should also be noted that the Ct values of 
GAPDH were approximately 22 which is quite high for a housekeeping gene which 
are abundantly expressed in the cells. This again suggests poor RNA quality.  
Results from the RNeasy spin columns demonstrated the concentration of RNA 
isolated from both tumours was approximately 5-fold less than that using TRI 
reagent (figure 5.7 panel A). The 260/280 ratios demonstrated that the quality of 
RNA was good, although, the poorer 260/230 ratios demonstrated greater risk of 
contamination. In addition to this, the integrity of RNA on the agarose gel was 
poorer (figure 5.7 panel B). However, real-time PCR results demonstrated that the 
template could still be amplified to a similar level as cDNA templates produced from 
RNA isolated using TRI reagent (figure 5.7 panel C).  
Hence, the TRI reagent was judged superior to spin columns and was deemed the 
optimal method for use in subsequent experiments.  
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Figure 5-6 - Confirmation of RNA integrity following isolation from frozen cells 
using TRI reagent 
RNA was isolated from two separate frozen breast tumours separate using TRI reagent. 
Following isolation, RNA was quantified and the purity was checked using the Nanodrop 
spectrophotometer. Left panel represents RNA isolated from small sized tumour, whereas, 
the right panel represents large sized tumour (A). Integrity of RNA was determined by 
running total RNA isolated from frozen breast tissues on 1.2% agarose gels. Red and yellow 
boxes represent the ribosomal RNA subunits 28S (red box) and 18S (yellow box) (B). RNA 
was reverse transcribed into cDNA and GAPDH was amplified using Taqman® real-time 
PCR primers (C). Data is representative of four independent experiments. 
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Figure 5-7 - Confirmation of RNA integrity following isolation from frozen cells 
using RNeasy spin columns reagent 
RNA was isolated from two separate frozen breast tumours using RNeasy spin columns. 
Following isolation, RNA was quantified and the purity was checked using the Nanodrop 
spectrophotometer. Left panel represents RNA isolated from small sized tumour, whereas, 
the right panel represents large sized tumour (A). Integrity of RNA was determined by 
running total RNA isolated from frozen breast tissues on 1.2% agarose gels. Red and yellow 
boxes represent the ribosomal RNA subunits 28S (red box) and 18S (yellow box) (B). RNA 
was reverse transcribed into cDNA and GAPDH was amplified using Taqman® real-time 
PCR primers (C). Data is representative of two independent experiments 
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5.4.3 Selection of suitable housekeeping genes 
After isolating RNA from all test samples, the most appropriate housekeeping gene 
was determined. Housekeeping genes are endogenously expressed within most 
normal and pathological cells. Uniform expression of these genes between samples 
allows them to be used as a reference to measure the relative expression of a test 
gene.  
The three housekeeping genes tested were: GAPDH, β-Actin, and β-Tubulin. These 
are all commonly used as housekeeping genes in real-time PCR.   
Probably due to the poor RNA integrity from the samples, results demonstrated the 
amplification of all three genes was fairly low with most samples. All genes were 
relatively similar in their expression across the breast cancer samples (GAPDH: 
mean Ct 22.66 ± 3.65 SD, β-Actin: mean Ct 24.11 ± 2.758 SD, β-Tubulin: mean Ct 
25.19 ± 1.36 SD) (figure 5.8). GAPDH was selected as the housekeeping gene to be 
used in subsequent experiments.  
Because cDNA template from cancer case #19 failed to amplify sufficiently with any 
of the housekeeping genes tested, it was excluded from further analysis 
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Figure 5-8 - Determining the most compatible housekeeping gene in frozen 
breast cancer tissues 
RNA was isolated from each breast tumour using TRI reagent and reverse transcribed into 
cDNA. cDNA was then amplified using Taqman® primers for GAPDH, β-Actin and β-
Tubulin. Panel A represents amplification plots produced from each sample. Panel B is the 
mean Ct value produced from each sample for each housekeeping gene tested. Data is the 
mean of a single experiment performed in duplicate.         
 
 
 
 
 
A
Mean Ct Value
Case # GAPDH Actin Tubulin
Normal #1 23.41356754 24.03561497 24.41097641
Normal #2 22.47409821 21.44131851 17.64565754
#1 20.60905266 23.40404892 23.74596214
#2 20.84733295 22.98936749 24.16289997
#3 22.21967793 24.75938988 24.25586605
#4 23.36475563 24.71675587 23.54424286
#5 21.19918346 22.89052391 24.59953022
#6 21.43837833 24.11813927 26.95499992
#7 22.0298872 23.52391052 24.35046005
#8 23.89892769 25.09119034 23.97693729
#9 22.30535507 23.65557671 25.06955814
#10 21.55888844 23.52427769 25.68204594
#11 23.65487862 24.45569992 25.8278904
#12 22.91017723 24.08646584 27.10918808
#13 21.09380627 23.62398529 26.63247776
#14 20.06375122 21.1606245 22.75722408
#15 24.11063004 25.49607468 27.0321455
#16 18.73521996 19.86599922 27.01544094
#17 21.38209057 22.79306507 25.19888878
#18 22.46018791 23.88516235 25.53354263
#19 36.66117287 34.1244812 37.27460766
B
GAPDH β-ACTIN β-TUBULIN
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5.4.4 Determination of T-cell infiltration in breast samples 
Because T-cells could not be excluded from the frozen tissue samples and could 
potentially mask the level of FOXP3 and CXCR4 expressed by epithelial cells, CD3 
infiltration was determined at both transcript and protein levels within each sample.  
The level of CD3 transcripts in breast cancer was compared to the level in two 
normal mammary tissue samples (figure 5.9 panel A). CD3 was only expressed at a 
low level in normal mammary tissues, whereas, the majority of cancer samples 
showed higher levels of CD3 expression. However, despite a clear trend, CD3 was 
not significantly increased in either LN-negative or LN-positive samples in 
comparison to normal tissues (p>0.05; figure 5.9 panel B).    
These findings were further validated at a protein level by performing IHC. Each 
sample also had a NPA stain included which was clean, demonstrating the specificity 
of the anti-CD3 antibody. The results were similar to those observed at transcript 
level, as the two normal mammary tissues had few CD3
+
 cells present (figure 5.10), 
whereas, strong CD3
+
 staining was observed within most LN-negative (figure 5.11 
panel A) and LN-positive (figure 5.11 panel B) breast cancer samples. This 
demonstrates that breast cancer samples do frequently show T-cell infiltration into 
the tumour environment. 
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Figure 5-9 - Determination of CD3 transcripts in normal and breast cancer 
tissues  
CD3 transcripts within each breast sample were determined using real-time PCR. (A) After 
normalising against endogenous GAPDH, the amount of CD3 transcripts were compared to 
those from normal breast tissue. Expression from normal #1 was arbitrarily defined as 1.0. 
Data was plotted in a log10 format which data points representing means and SD of 
experiments performed in duplicates (n=2). (B) The mean relative expression levels from 
each sample were grouped into their lymph node status and compared to normal breast 
tissue. 
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Figure 5-10 - IHC staining of CD3 in normal mammary breast tissue  
Normal mammary breast tissue isolated from reduction surgery was stained by Ms Denise 
Woolley in the QE Hospital. CD3 staining using a pre-optimised protocol with the 
autostainer link 48. Red arrows demonstrate the presence of CD3
+
 positive cells within duct 
epithelial cells. (A) Represents normal mammary tissue #1 (normal #1). (B) Represents 
normal mammary tissue #2 (normal #2). Tonsil was used as a positive control (C), whereas 
each sample tested also had a control NPA as a negative control 
NPA
A
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100µm
100µm
100µm
100µm
100µm 100µm
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Figure 5-11 - IHC staining of CD3 in breast cancer samples 
Representative images of CD3 staining on breast cancer samples were stained for CD3 by 
Ms Denise Woolley using a pre-optimised protocol with the autostainer link 48 in the QE 
Hospital. Panel A represents images from two LN-negative breast cancer patients (upper 
panel shows case #6, lower panel shows case #7). Panel B represents images from two LN-
positive breast cancer patients (upper panel shows case #13, lower panel shows case #12). 
NPA stains were included as individual negative controls. A tonsil positive control is 
included in figure 5.10 as all sections were stained together. 
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5.4.5 Measurement of CXCR4 transcripts in breast samples 
CXCR4 transcripts were determined in each sample using Taqman® primers specific 
for CXCR4. In line with the literature, neither of the normal mammary tissues 
expressed CXCR4 (Muller, Homey et al. 2001). However, CXCR4 was increased in 
all breast cancer samples (figure 5.12 panel A). Although, as determined in the 
previous section, due to the high levels of infiltrating T-cells, the cell specific origin 
of CXCR4 expression could not be determined.  
CXCR4 was significantly increased in the LN-negative samples in comparison to the 
normal breast tissue samples, however, despite a clear increase in CXCR4 in the LN-
positive samples, the expression was not significant when compared to the normal 
tissues, although a clear trend was observed (p=0.076; figure 5.12 panel B).  
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Figure 5-12 - Determination of CXCR4 transcripts in normal and breast cancer 
tissues  
CXCR4 transcripts within each breast sample were determined using real-time PCR. (A) 
After normalising against endogenous GAPDH, the amount of CXCR4 transcripts were 
compared to those from normal breast tissue. Expression from normal #1 was arbitrarily 
defined as 1.0. Data was plotted in a log10 format which data points representing means and 
SD of experiments performed in duplicate (n=2). (B) The mean relative expression levels 
from each sample were grouped into their lymph node status and compared to normal breast 
tissue. Statistical analysis was performed using an unpaired t-test. 
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5.4.6 Optimisation of CXCR4 IHC staining 
Before staining the test tissue, the optimum antibody dilution was determined by 
staining human tonsil. Staining was performed within the QE Hospital using the 
autostainer link 48.   
The optimised dilutions ranged from between 1:100 and 1:500 (figure 5.13). Each 
test also contained a NPA stain as negative controls. Negative controls contained no 
staining which demonstrates the specificity of the primary antibody. The results 
demonstrated that the antibody produced a dilution-dependent response. As the 
dilution increased, the intensity of the stain diminished. Strong staining was 
observed using 1:100 (figure 5.13 panel A). The 1:150 dilution (figure 5.13 panel 
B) still detected the expression of CXCR4, however, the 1:300 (figure 5.13 panel C) 
and 1:500 dilutions (figure 5.13 panel D) did not detect CXCR4 and was similar to 
the NPA controls. 
Because the 1:150 dilution was the lowest dilution to detect CXCR4, this was 
determined as the optimum dilution to stain the breast samples.     
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 – in vivo levels of FOXP3 and CXCR4 expression in breast cancer patient samples  
275 
 
 
Figure 5-13 – Optimisation of CXCR4 IHC staining using human tonsil  
Sections of human tonsil were sourced from the QE Hospital. CXCR4 staining was 
performed by Ms Denise Woolley using the autostainer link 48 with the following dilutions 
1:100 (A), 1:150 (B), 1:300 (C), 1:500 (D). 
A
B
C
D
Stained
NPA
100µm
100µm
100µm
100µm
100µm
100µm
100µm
100µm
Chapter 5 – in vivo levels of FOXP3 and CXCR4 expression in breast cancer patient samples  
276 
 
5.4.7 Measurement of CXCR4 protein expression in breast 
samples  
After determining the optimum dilution to stain the breast tissue, the levels of 
CXCR4 protein were determined within the LN-negative and LN-positive cancer 
cases.  
The normal mammary tissue had no detectable CXCR4 associated with epithelial 
cells of the ducts and lobules (figure 5.14 panels A and B). Low levels of CXCR4 
were detected within the stroma but this might be associated with T-cell infiltration.  
Interestingly, the source of the normal tissue appears to be important. Although the 
normal tissue taken from breast reduction surgeries (used in previous experiments) 
did not show CXCR4 expression, ‘normal’ tissue taken adjacent to a breast tumour 
expressed CXCR4 (figure 5.14 panel C). This suggests that although areas 
peripheral to breast cancers are often described as cancer-free or non-malignant, they 
may still exhibit features different from tissue with no underlying pathology. 
Following this result only tissue from breast reduction surgeries were defined as 
normal.  
CXCR4 was highly expressed in LN-negative (figure 5.15) and LN-positive samples 
(figure 5.16). Staining of epithelial cells and T-cells could be determined from IHC 
by a pathologist based on the size and location of cells. As described by the 
pathologist, CXCR4
 
positive lymphocytes were clearly present. However, the 
epithelial cells within the ductal tumours had also upregulated CXCR4.  
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Figure 5-14 - IHC staining of CXCR4 in normal breast tissue 
Normal mammary breast tissue isolated from reduction surgery ([A] –Normal #1, [B] –
Normal #2) were stained for CXCR4 by Ms Denise Woolley using the autostainer link 48 in 
the QE Hospital. Alternatively, a region of non-malignant tissue from a breast cancer case 
(case #6) was also stained using the same protocol as previously described (C). Tonsil was 
used as a positive control (D), whereas each sample tested also had a NPA as a negative 
control.  
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Figure 5-15 - IHC staining of CXCR4 in LN-negative breast cancer samples  
Breast cancer tissue from patients with no lymph node involvement was stained for CXCR4 
by Ms Denise Woolley with a pre-optimised protocol (1:150 dilution) using the autostainer 
link 48 in the QE Hospital. Tonsil was used as a positive control which is included in figure 
5.14 as samples were ran together. Each sample tested also had a NPA as a negative control. 
Representative images are of cases; Panel A shows case #7, panel B shows case #8 and 
panel C shows case #10. Each sample was stained in duplicates which produced similar 
findings     
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Figure 5-16 - IHC staining of CXCR4 in LN-positive breast cancer samples  
Breast cancer tissue from patients with high lymph node involvement was stained for 
CXCR4 by Ms Denise Woolley with a pre-optimised protocol (1:150 dilution) using the 
autostainer link 48 in the QE Hospital. Tonsil was used as a positive control which is 
included in figure 5.14 as samples were ran together. Each sample tested also had a NPA as 
a negative control. Representative images are of cases; Panel A shows case #11, panel B 
shows case #13 and panel C shows case #15. Each sample was stained in duplicates which 
produced similar findings.     
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5.4.8 Measurement of FOXP3 transcripts in breast samples 
FOXP3 transcripts were determined in each breast sample using Taqman® primers 
specific for FOXP3.  
Relatively low levels of FOXP3 were detected within both normal mammary 
samples. However, variable results were found for both the LN-negative and LN-
positive cancer samples (figure 5.17 panel A). Although there was no statistical 
change in either LN-negative (p=0.92) or LN-positive tissues (p=0.31), four of the 
LN-negative samples (cases #1, #2, #6 and #10) expressed less FOXP3 than the 
normal mammary tissue, whereas, majority of LN-negative tissues (cases #3, #4, #5, 
#7, #8, and #9) expressed FOXP3 at a similar or higher level compared to the normal 
mammary tissues. Six LN-positive patients (cases #13, #14, #15, #16, #17, and #18) 
had lower levels of FOXP3 compared to the normal mammary tissue.  
The varied distribution of FOXP3 in the LN-negative patients is best demonstrated 
by figure 5.17 panel B, which shows that the overall mean distribution of FOXP3 is 
similar to the level in the two normal tissues tested (mean expression of normal 
tissue 0.95±0.194 SD, mean expression of LN-negative tissue 0.99±0.629 SD). On 
the other hand, the distribution of FOXP3 in the LN-positive patients (mean 
expression 0.51±0.55 SD) was decreased compared to the LN-negative breast cancer 
samples, and also the normal breast tissues. 
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Figure 5-17 - Measurement of FOXP3 transcripts in normal and breast cancer 
frozen tissues  
FOXP3 transcripts within each breast sample were determined using real-time PCR. (A) 
After normalising against endogenous GAPDH, the amount of FOXP3 transcripts were 
compared to those from normal breast tissue. Expression from normal #1 was arbitrarily 
defined as 1.0. Data representing means and SD of experiments performed in duplicate 
(n=2). (B) The mean relative expression levels from each sample were grouped into their 
lymph node status and compared to normal breast tissue 
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5.4.9 Optimisation of FOXP3 IHC staining and measurement 
in patient samples 
The expression of FOXP3 in normal breast tissue has been demonstrated by several 
research groups using IHC (Zuo, Wang et al. 2007; Chen, Chen et al. 2008; Merlo, 
Casalini et al. 2009). These groups have consistently shown that the expression of 
this protein in these tissues is low. Indeed, results using Western blot (figure 3.10 
panel A), IF (figure 3.10 panel B) and ELISA (figure 3.11) in this study have 
suggested that the expression of FOXP3 is low within the normal mammary 
epithelial cell line, HMEpC.   
In line with this notion, two FOXP3 antibody clones were tested for their reactivity 
in normal breast tissue. Because the majority of reports demonstrate that FOXP3 is 
most frequently downregulated in malignant tissue in comparison to normal tissue, 
the method best able to stain FOXP3 in normal tissue was considered optimal for 
testing the malignant tissues.  
Initial attempts to stain FOXP3 in normal breast samples were made using the 
236A/E7 (Abcam) and 259D (BioLegend) human anti-FOXP3 antibody clones. The 
236A/E7 antibody was used with the DAKO automated staining equipment within 
the Pathology Department in the QE Hospital, whereas, the 259D antibody was used 
with the Ventana equipment in Pathology Department of the RVI Hospital. 
Because of the low level expression of FOXP3 in normal tissue, all samples tested in 
the QE Hospital underwent antigen retrieval with a high pH solution and received 4 
minutes amplification (referred to as FLEX in the DAKO protocols). Initially, a 
number of antibody dilutions ranging from 1:25, to 1:150 (1:50 increments) were 
used with the autostainer link 48. Unfortunately, despite strong staining within the 
positive tonsil control, methods using this machine were not able to detect FOXP3 
within the breast epithelial cells (representative images of FOXP3 staining with 
each antibody dilution and NPA included in appendix 7).     
A member of this research group has developed a protocol for detection of FOXP3 in 
T-cells using the BenchMark ULTRA machines in the RVI Hospital with the 259D 
antibody. However, because the level of FOXP3 in Tregs is considerably higher than 
the expression in epithelial cells, further optimisation was carried out using a total of 
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four antigen retrieval techniques (Cell Conditioning solution-1 [high pH], Cell 
Conditioning solution-2 [low pH], pressure cooker with Tris/EDA [pH 9] and also 
with citrate buffer [pH 6]), two antigen detection kits (ultraview and optiview), a 
range of antibody dilutions and increased amplification times. Unfortunately, none of 
the techniques was able to detect FOXP3 in normal breast epithelia (representative 
images of all conditions attempted are included in appendices 8 to 10 with 
descriptions of each method labelled in the figure legend).  
It was deemed that the automated protocols were not sensitive enough to detect 
FOXP3 in epithelial cells. Previous members of this research have manually stained 
and detected FOXP3 in normal breast samples using a pre-optimised protocol. Using 
this method, FOXP3 was detectable within the epithelial cells of both normal breast 
tissues tested (figure 5.18 panels A and B). The antibody specificity was validated 
as individual NPA controls for each sample were negative. Staining was also 
validated using tonsil as a positive control, which also showed a clean NPA control 
(figure 5.18 panel C).   
After confirming that this protocol was able to detect FOXP3 within normal 
mammary tissue, the cancer sections were all stained.  
Despite the majority of the literature describing downregulation of FOXP3 in breast 
cancer, results in this study demonstrated strong FOXP3 positive staining in all 
breast cancer samples. Representative images of LN-negative samples are included 
as figure 5.19, whereas representative images of LN-positive samples are included 
as figure 5.20.   
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Figure 5-18 - Manual IHC staining of FOXP3 in normal breast tissue using 
FOXP3 clone 259D  
Normal mammary breast tissue isolated from reduction surgery ([A] –Normal #1, [B] –
Normal #2) were stained for FOXP3 manually using a pre-optimised protocol. (C) Tonsil 
was used as a positive control. Each sample tested also had a NPA control. 
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Figure 5-19 - FOXP3 staining in LN-negative breast cancer samples  
Breast cancer tissue from patients with no lymph node involvement was manually stained 
for FOXP3 with an optimised protocol. Each sample tested also had a NPA control. 
Representative images are of cases; Panel A shows case #6, panel B shows case #10. Each 
sample was stained in duplicates which produced similar findings     
 
 
 
 
 
 
NPA
NPA
A
B
100µm
100µm 100µm
100µm
Chapter 5 – in vivo levels of FOXP3 and CXCR4 expression in breast cancer patient samples  
286 
 
 
Figure 5-20 - FOXP3 staining in LN-positive breast cancer samples  
Breast cancer tissue from patients with no lymph node involvement was manually stained 
for FOXP3 with an optimised protocol. Each sample tested also had a NPA control. 
Representative images are of cases; Panel A shows case #13, panel B shows case #17. Each 
sample was stained in duplicates which produced similar findings     
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5.4.10 Correlation of FOXP3 and CXCR4 protein expression 
in breast samples  
The levels of FOXP3 and CXCR4 expression in the IHC stained breast samples were 
scored blindly and individually by a trained Pathologist using the allred quick score 
method (figure 5.21 panel A).    
As previously described, both normal breast reduction samples expressed FOXP3 
within the epithelial cells. The same tissues also showed no observable CXCR4 
expression in the epithelial cells.  
When the breast cancer samples were scored, results suggested that although CXCR4 
was clearly upregulated in the cancer samples, there was no observable difference in 
the expression between the LN-negative and LN-positive samples (figure 5.21 panel 
B).  
On the other hand, both the LN-negative and LN-positive cases still expressed 
FOXP3 at similar levels to those observed in normal breast tissues. In addition, there 
was no change in the expression between the LN-negative and LN-positive samples 
(figure 5.21 panel C).  
These data sets suggest there is a marked increase in the expression of CXCR4 
within breast cancer cases. However, the relative constant expression of FOXP3 by 
normal and cancerous breast samples suggests that FOXP3 is not frequently 
downregulated in breast cancer, which disagrees with many reports within the 
literature.   
Due to the strong staining of FOXP3 and CXCR4 in all breast cancer samples, this 
finding also suggests there is no link between FOXP3 downregulation and CXCR4 
upregulation in breast cancer in vivo.  
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Figure 5-21 - Quick scores for FOXP3 and CXCR4 expression in breast tissue 
After IHC staining, the expression of FOXP3 and CXCR4 were blind scored by a trained 
pathologist. Panel A demonstrates the expression of FOXP3 and CXCR4 within individual 
LN-negative cases (#2 - #10) and LN-positive cases (#11 - #19). Individual blue point 
represents an equal score of FOXP3 and CXCR4.  Panel B and C represent a comparison 
between the LN-negative and LN-positive expression of CXCR4 (panel B) and FOXP3 
(panel C). 
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5.5 Summary of chapter 5 results 
 T-cells could not be excluded from digested frozen tissues by FACS. 
 
 TRI reagent was used to isolate RNA from frozen tumour sections as it 
provided a greater yield of purer RNA.   
 
 Normal breast tissue showed very low levels of infiltration by T-cells. 
However, the level of T-cells present within both LN-negative and LN-
positive breast cancer samples was clearly increased.  
 
 FOXP3 transcripts within LN-negative cancer samples were comparable to 
levels observed in normal breast tissue. However, there was a marked 
decrease in the level in LN-positive cancer samples.   
 
 FOXP3 protein was difficult to detect within normal tissues using the 
autostainer link 48 and the BenchMark ULTRA automated machines. 
However, FOXP3 was detectable using a manual staining protocol.  
 
 There was no difference in FOXP3 protein expression between normal breast 
tissue, LN-negative and LN-positive cancer samples.  
 
 The source of normal breast tissue is important as non-malignant regions of 
tissue from cancer samples were positive for CXCR4, but normal breast 
tissue from reduction surgery was CXCR4 negative 
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 CXCR4 was increased at transcript and protein levels within both LN-
negative and LN-positive cancer samples in comparison to normal breast 
tissue  
 
 No apparent correlation was observed between FOXP3 and CXCR4 in LN-
negative or LN-positive cancer samples from this study.  
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5.6 Discussion  
Since the discovery that FOXP3 is the first X-chromosome linked TSG, research is 
continuously producing data suggesting it is much more than just a protein involved 
in the function and development of Tregs (Douglass, Ali et al. 2012). 
Few studies have investigated the prognostic implications of FOXP3 expression in 
epithelial cells in vivo. On the other hand, CXCR4 is a relatively well established 
molecule involved with breast cancer metastasis (Muller, Homey et al. 2001; Luker 
and Luker 2006). Therefore, the final aspect of this study had two main aims; firstly, 
to investigate any potential correlation between FOXP3 and CXCR4 expression in 
vivo, and secondly, to investigate the potential prognostic implications of FOXP3 
and CXCR4 expression in breast cancer patients with opposing lymph node 
involvement and survival outcomes.    
 
5.6.1 Correlation of lymph node status in selected patients 
and overall survival 
Patients with no or high lymph node involvement were selected to study aggressive 
and less-aggressive breast cancer. The selection of patients on the basis of their 
lymph node involvement was validated by the patients NPI scores mostly being 
‘good’ (for LN-negative samples) or ‘poor’ (for the LN-positive samples).  
Because there has been a recent increase in more innovative and successful 
therapies, the current prognostic relevance of the NPI has been questioned. However, 
when the follow-up data was examined, the majority of LN-negative patients had 
been discharged and were alive and well after five years, whereas, the majority of the 
LN-positive patients were deceased due to metastasis. This suggests that the NPI was 
a successful basis to select patients for investigating FOXP3 and CXCR4 expression 
in aggressive and less aggressive breast cancers.  
Interestingly, 6 out of the 10 LN-negative samples were dissected post-2000, 
whereas, only 2 out of the 9 LN-positive samples were dissetced post-2000. This 
proposes the arguement that perhaps the more aggressive LN-positive samples were 
more historic, whereas the LN-negative samples were more recent. Because the 
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screening procedures, methods of diagnosis and treatemts for breast cancer are 
always improving, it would have been more ideal to select LN-negative and LN-
positive samples from approximately the same year would eradicate this.  
      
5.6.2 The impact of T-cell infiltrates on real-time PCR results  
One of the most common symptoms associated with breast cancer is the onset of 
chronic inflammation. The cells responsible for this inflammation are a range of 
leukocytes, but most commonly lymphocytes. Both FOXP3 and CXCR4 are 
expressed by a number of these infiltrating leukocytes. However, this study was 
designed to investigate the expression of FOXP3 and CXCR4 specifically in 
epithelial cells.  
Specific selection of epithelial cells from the tumour was attempted by FACS. This 
aimed to prevent the infiltrating leukocytes from obscuring epithelial cell expression 
of FOXP3 and CXCR4. Results consistently suggested that frozen breast tumours 
had very low levels of CD3
+
 T-cell infiltration contradicting many reports within the 
literature (Liyanage, Moore et al. 2002; Liu, Wong et al. 2007; Matkowski, Gisterek 
et al. 2009). The tissues used in this study were extremely old, and in a poor 
condition. This and a combination of the initial freezing process (snap-frozen) led to 
the RNA isolated from the cells being heavily degraded as tumour cells in the frozen 
sections were dead. 
This left no options available to remove potential T-cells from the frozen tissues. 
Therefore, real-time PCR was performed using whole tumour blocks and the extent 
of T-cell infiltration was determined by quantifying CD3 transcripts and performing 
CD3 IHC.  
Real-time PCR and IHC for CD3 suggested that all but three breast cancer samples 
(cases #1, #6 and #13) had high levels of CD3
+
 T-cell infiltration. Since the cell-
specific origin of transcripts cannot be determined, this leaves the significance of the 
real-time PCR data of limited value, as FOXP3 and CXCR4 are well known to be 
expressed by leukocytes, as well as epithelial cells.  
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Both LN-negative and LN-positive breast cancer cases had high levels of infiltrating 
CD3
+
 T-cells in comparison to the normal tissue. Because of the opposing outcomes 
between LN-negative and LN-positive cases, data from this study would suggest that 
there was no correlation between CD3
+
 T-cell infiltration and patient prognosis.  
 
5.6.3 Source of normal tissue for CXCR4 staining 
One the strengths of this chapter was the care taken to find ‘normal’ breast tissue. 
Often, when investigating the changes from normal and cancerous tissue, the 
peritumoural tissue is taken adjacent from the tumour and used as normal control 
breast tissue. Because these regions of tissue show no overt signs of malignancy they 
are considered as good control tissue. However, this study suggests that the 
peritumoural tissue is affected by changes associated with the tumour 
microenvironment. Regions of peritumoural tissue described as non-malignant by a 
Pathologist were stained for CXCR4. This tissue was CXCR4-positive. However, 
tissue from two independent breast reduction surgeries, which were both completely 
free from malignancy, was CXCR4-negative.    
The presence of a tumour mass, which has considerable growth advantages 
compared to normal tissue, changes the levels of nutrients, and oxygen, supplied to 
cells, inducing a hypoxic environment. Interestingly, epithelial cells are known to 
upregulate CXCR4 when exposed to hypoxia. This is driven by HIF-1α (Ishikawa, 
Nakashiro et al. 2009; Liu, Xue et al. 2010; Melchionna, Romani et al. 2010) which 
is discussed in section 1.6.3.1. This suggests that the stresses placed on the normal 
epithelial cells by the presence of the tumour are able to induce CXCR4, potentially 
through induction of hypoxia.   
Although the tissue taken from the reduction surgey was deemed as the best tissue to 
use as “normal”, it could also be questioned to how normal this tissue is as reduction 
surgeries are generally performed due to abnormally large breasts or obesity. 
Interestingly, when the tissue from the reduction surgery was observed, it contained 
a great detail of adipose tissue, suggesting the patients may have been clinically 
overweight. As mentioned in section 1.4.1, risk factors associated with an increased 
risk of breast cancer development include weight and diet. Although these samples 
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were considered as the best source of control tissue available, using tissue from 
breast reuction surgeries should also be approached with caution.  
 
5.6.4 FOXP3 IHC staining in normal tissue  
As discussed, the source of the normal tissue was important, but it should also be 
noted that tissue chosen for optimising FOXP3 staining was also important.  
Because of the different expression levels of FOXP3 in specific cells, staining must 
be optimised for the specific cell type which is targeted. Normal breast reduction 
tissue was used to optimise FOXP3 staining. The expression of FOXP3 is estimated 
to be approximately 100-fold lower than the expression observed in Tregs (Wang, 
Liu et al. 2009). Therefore, if staining was optimised using a positive control, such 
as Tregs, then the conditions might not be sensitive enough to detect the protein in 
cells where the expression is considerably lower. Several studies suggest that FOXP3 
is frequently downregulated amongst breast cancer cases in comparison to their 
normal counterparts (Zuo, Liu et al. 2007; Merlo, Casalini et al. 2009). Therefore, a 
protocol optimised to detect FOXP3 in normal breast cells acts as a benchmark to 
measure potential increases or decreases of FOXP3 in breast cancer samples. 
CD3 and CXCR4 were successfully stained by the QE Hospital using the automated 
staining equipement within the Pathology Department. However, because of the low 
level expression of FOXP3, the automated machinery within the QE Hopsitaland 
RVI Hospital was not able to detect FOXP3 in these tissues. This notion is consistent 
with other studies which have reported similar difficulties with extended antigen 
retrieval steps and antibody incubations being required to stain normal breast tissue 
(Wang, Liu et al. 2009). 
Previous members of this research group have stained FOXP3 in normal breast 
tissue manually. This protocol led to the detection of FOXP3 within epithelial cells 
of normal breast samples.  
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5.6.5 FOXP3 and CXCR4 IHC staining in breast cancer 
patients  
Following FOXP3 and CXCR4 staining in breast cancer samples, each slide was 
blind scored by a pathologist using the allred quick scoring system. When scored, 
only epithelial cells within regions demonstrating clear malignancy were graded.  
Ideally, this element of the study would have been impoved by dual staining of 
FOXP3 and CXCR4 on each patient sample. This would have allowed a more direct 
comparion of FOXP3 and CXCR4 expression in individual epithelial cells. IF 
staining of FOXP3 and CXCR4 with seperate fluorescent probes may have provided 
a clearer, more quantitative, method of determining the expression levels of each 
protein. This also would have made the subcellular distribution of each protein easier 
to distinguish. However, due to the low levels of FOXP3 exxpression, and the 
difficulty in achieving the required staining intensity, it was deemed that staining for 
FOXP3 and CXCR4 on separate slides was the best method to use.  
Although CXCR4 was not detectable in the normal breast reduction tissues, it was 
upregulated on all LN-negative and LN-positive samples. The expression of CXCR4 
is correlated with an increased risk of lymph node metastasis and an overall poor 
prognosis (Salvucci, Bouchard et al. 2006; Parker, Kim et al. 2012; Xu, Shen et al. 
2013). However, this study showed no apparent difference between the CXCR4 
staining in the LN-negative and LN-positive breast cancer patients. This data could 
suggest that CXCR4 is upregulated within the early stages of carcinogenesis, a 
notion in accordance within the literature which have reported that CXCR4 is 
upregulated as early as ADH with the expression of CXCR4 increasing as cancer 
becomes more aggressive (Schmid, Rudas et al. 2004).  Data in this study shows that 
FOXP3 was clearly observable within the LN-negative and LN-positive breast 
cancer cases. In addition to this, there was no observable difference in FOXP3 
expression in the cancerous tissues in comparison to the normal breast tissues which 
suggest that FOXP3 has no prognostic significance in breast cancer.  
Many reports suggest that FOXP3 is downregulated in breast cancer, and that this 
dysregulated expression of FOXP3 is correlated with a poor prognosis (Zuo, Wang 
et al. 2007; Merlo, Casalini et al. 2009). However, several recent reports have 
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opposed these findings by suggesting that FOXP3 expression increases in cancer 
cells as the disease stage progresses (Kim, Koo et al. 2013; Lal, Chan et al. 2013).  
Wang et al (Wang, Liu et al. 2009) reported that FOXP3 downregulation occurred 
with epithelial neoplasia in prostate cancer suggesting FOXP3 inactivation occurs 
within early stages of carcinogenesis. Interestingly, Merlo et al (Merlo, Casalini et al. 
2009) reported that FOXP3 which was absent or restricted to the cytoplasm of breast 
epithelial cells, represented a worse overall survival than patients who had nuclear 
FOXP3. This suggests that despite its presence, the distribution of FOXP3 is equally 
important.  
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5.7 Conclusion 
In conclusion, the aim of this study was to assess the potential correlation between 
the expression of FOXP3 and CXCR4 in breast cancer in vivo.  
Due to the condition of the frozen tumours available epithelial cells were unable to 
be selected using FACS. Normal breast tissue showed little infiltration by CD3
+
 T-
cells, however, the number of these cells is greatly increased in breast cancer.  
Regrettably, since the cell specific origin of FOXP3 and CXCR4 in the frozen 
tumours cannot be determined, the transcript results are of limited value.  
Due to the different sizes of lymphocytes and epithelial cells, IHC staining allows of 
lymphocytes and epithelial cells to be discriminated. The expression of CXCR4 is 
present in increased levels in breast cancer. The expression of CXCR4 was similar 
between LN-negative and LN-positive breast cancer samples. CXCR4 was not 
detected in epithelial cells from normal breast tissue, however, the presence of 
CXCR4 on normal epithelial cells peripheral to areas of cancer suggests that the 
expression of CXCR4, to some extent, may be a non-specific consequence of breast 
cancer.  
IHC protocols to detect FOXP3 expression in normal breast tissue required extensive 
optimisation. This demonstrates that FOXP3 is expressed at low levels in these 
tissues. This technique showed little difference in FOXP3 expression between 
normal and breast cancer tissues. Moreover, these results suggest that CXCR4 
upregulation in breast cancer is not directly correlated with FOXP3 downregulation.  
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6 Discussion  
 
6.1 The role of FOXP3 in breast cancer  
The main aim of this project was to investigate the impact of FOXP3 on breast 
cancer. Until recently, FOXP3 was considered to be a marker of Tregs and restricted 
to the lymphocyte lineage. However, low levels of FOXP3 have now been identified 
within the epithelial cells of some organs (Chen, Chen et al. 2008; Merlo, Casalini et 
al. 2009; Wang, Liu et al. 2009; Zhang and Sun 2010; Frattini, Pisati et al. 2012; Lal, 
Chan et al. 2013). Since the discovery of FOXP3 in these cells is a relatively recent 
area of research, the full function of FOXP3 in epithelial cells has not been fully 
elucidated. 
Normal human epithelial cells contain both natural FOXP3 isoforms within the 
nucleus in approximately equal proportions (Zuo, Wang et al. 2007). However, it is 
frequently downregulated, mutated, completely absent or predominately restricted to 
the cytoplasm in malignant cells (Zuo, Wang et al. 2007; Merlo, Casalini et al. 2009; 
Wang, Liu et al. 2009; Zhang and Sun 2010; Frattini, Pisati et al. 2012). Despite 
recent studies describing an increase in epithelial FOXP3 as cancer progresses (Kim, 
Koo et al. 2013; Lal, Chan et al. 2013), FOXP3 is generally considered to have 
strong anti-cancer properties and acts as a potent TSG by directly repressing the 
expression of many key oncogenes including ErbB2, SKP2, c-Myc, LATS2 whilst 
increasing the expression of p21 (Zuo, Liu et al. 2007; Zuo, Wang et al. 2007; Liu, 
Wang et al. 2009; Wang, Liu et al. 2009; Zhang and Sun 2010; Li, Wang et al. 2011; 
Frattini, Pisati et al. 2012; Li, Katoh et al. 2013; Nakahira, Morita et al. 2013).   
Despite never being identified as direct FOXP3 targets, transfection of a FOXP3 
expression plasmid into ovarian and breast cancer cell lines led to the repression of 
several molecules including MMP2 and uPA (Zhang and Sun 2010) and MMP9 and 
VEGFA (Nakahira, Morita et al. 2013). FOXP3 is also involved in inhibiting the 
activation of NF-κB and mTOR signalling (Zhang and Sun 2010). In a similar 
manner to p21, FOXP3 can also regulate the expression of p18, which is also a 
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molecule involved in cell cycle arrest at the G1 phase (Liu, Wang et al. 2009). 
Therefore, FOXP3 has the capacity to influence a number of important downstream 
pathways involved in carcinogenesis  
Reports have not only demonstrated that FOXP3 is able to regulate the expression of 
oncogenes, in vitro and in vivo studies have suggested it is also able to mediate the 
proliferation (Zuo, Liu et al. 2007; Zuo, Wang et al. 2007; Liu, Wang et al. 2009; 
Wang, Liu et al. 2009; Zhang and Sun 2010; Li, Wang et al. 2011; Frattini, Pisati et 
al. 2012), migration (Zhang and Sun 2010; Frattini, Pisati et al. 2012), invasion 
(Zhang and Sun 2010; Nakahira, Morita et al. 2013) and survival of cancer cells 
(Zuo, Wang et al. 2007; Wang, Liu et al. 2009; Frattini, Pisati et al. 2012; Li, Katoh 
et al. 2013).  
Wang et al (Wang, Liu et al. 2009) used a system to generate mice with a floxed-
FOXP3 gene specific to the prostate epithelial cells. These authors demonstrated that 
a FOXP3 deletion was able to generate the onset of prostate cancer in new born 
mice. This emphasises that FOXP3 is not just a molecule which becomes 
dysregulated as cancer progresses, but it may also be involved in the initial 
carcinogenic transformation of cells. By contrast, a report investigating Foxp3 in 
murine glioblastoma cells demonstrated that Foxp3 was still present in early stages 
of tumour development but diminished through tumorigenesis (Frattini, Pisati et al. 
2012). 
Few mechanisms have been identified which control the expression of FOXP3 in 
epithelial cells. However, a report by Jung et al (Jung, Jin et al. 2010) used chIP to 
demonstrate that p53 directly upregulated FOXP3 in cancer cells. Because p53 is 
mutated in more than 50% of cancers (Hollstein, Rice et al. 1994), this would 
suggest that the frequency of FOXP3 also being dysregulated in these cells is equally 
high.  
Based on data from the current study, the importance of FOXP3 can be discussed 
from two separate angles. Much of the in vitro data agrees that FOXP3 acts as a 
potent TSG, whereas, in vivo data implies the involvement of FOXP3 in breast 
cancer may be limited.  
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Initial experiments focused on the expression of FOXP3 in two breast cancer cell 
lines. Within both these cell lines FOXP3 was significantly downregulated at both 
protein and transcript levels. Interestingly, the non-invasive, MCF-7 contained both 
natural isoforms which were predominately located within the nucleus. This finding 
was similar to HMEpC, although these cells expressed higher levels of FOXP3. On 
the other hand, in the invasive MDA-MB-231, FOXP3 was predominately restricted 
to the cytoplasm and the natural FOXP3Δ3 isoform was not expressed. This isoform 
has been recently reported to be important in preventing migration and invasion of 
cells in vitro (Frattini, Pisati et al. 2012). 
The function of FOXP3 in MDA-MB-231 and HMEpC was investigated by in vitro 
modelling. Stable overexpression of FOXP3 in MDA-MB-231 led to a significant 
reduction in HER2, SKP2, MYC and CXCR4 transcripts. By contrast, the expression 
of p21 was increased. FOXP3-overexpression also inhibited proliferation and 
increased the proportion of cells within the G1 phase of the cell cycle. Conversely, 
when FOXP3 was knocked down in HMEpC, there was almost an exact inverse of 
the profile witnessed when FOXP3 was transfected into MDA-MB-231. FOXP3 
knockdown also increased the migratory capacity of HMEpC. This does not prove 
that FOXP3 limits the potential of breast cancer invasiveness but it does suggest that 
FOXP3 can influence a number factors frequently implicated in cancer progression 
and acts in an ‘anti-tumour’ manner.   
On the other hand, the in vivo data from FOXP3 IHC on breast cancer patient 
samples showed that none of the cancer samples, regardless of LN-involvement or 
survival, had observably downregulated FOXP3 in comparison to normal mammary 
tissue.  
 
6.2 The role of FOXP3 on CXCR4 expression  
Because FOXP3 is a transcription factor, the main role it has in cancer is the ability 
to regulate the expression of specific genes. As reviewed by Douglass et al 
(Douglass, Ali et al. 2012), and data from this study, have suggested that FOXP3 has 
the ability to regulate a number of oncogenes, however, the ability of FOXP3 to 
Chapter 6 - Discussion 
301 
 
influence the expression of CXCR4 is unreported. This makes the investigation of a 
FOXP3-CXCR4 interaction the most novel aspect of this study. 
Unlike FOXP3, CXCR4 is a well established molecule involved in breast cancer (Li, 
Pan et al. 2004; Smith, Luker et al. 2004; Luker and Luker 2006; Liang, Brooks et al. 
2007). CXCR4 is a chemokine receptor which was first identified as a lymphocyte 
homing receptor. It is now also known that CXCR4 is a key mediator in the site-
specific metastasis of breast cancer (Muller, Homey et al. 2001). As well as the 
expression profile of CXCR4 and CXCL12, the signalling pathways involved with 
these molecules demonstrate their importance in breast cancer as they regulate far 
more than just the ability to direct cell migration, including increased survival, 
invasion and proliferation of cancer cells (Murakami, Maki et al. 2002; Allinen, 
Beroukhim et al. 2004; Orimo, Gupta et al. 2005; Luker and Luker 2006).  
Although it would appear that the functions of FOXP3 in lymphocytes and epithelial 
cells are not similar, potential links between FOXP3 and CXCR4 may exist in T-
cells. For instance, naive T-cells have negligible levels of FOXP3, and detectable 
levels of CXCR4. However, following T-cell activation, the levels of FOXP3 
transiently increase (Pekalski, Jenkinson et al. 2013) whilst the expression of 
CXCR4 is reduced (Newton, O'Boyle et al. 2009).  
The European Bioinformatics Institute recently performed a meta-analysis to 
investigate the potential of FOXP3 to regulate CXCR4 expression in MCF-7. Their 
analysis suggested that FOXP3 transfection into MCF-7, results in a significant 
decrease in the expression of CXCR4, thus suggesting FOXP3 is able to regulate 
CXCR4 in breast cancer cells (figure 6.1 panel A) (EMBL-EBI 2013). On the other 
hand, despite FOXP3 being reported to be a TSG in prostate epithelial cells, and 
CXCR4 also reported to be overexpressed in prostate cancer (Singh, Singh et al. 
2004; Chinni, Yamamoto et al. 2008; Wang, Liu et al. 2009), the same company 
reported that FOXP3 transfection into the human prostate cancer cell line (LNCaP) 
would increase CXCR4 expression (figure 6.1 panel B) (EMBL-EBI 2013). This 
suggests that the regulatory function of FOXP3 on CXCR4 expression may not be 
consistent between epithelial cells.   
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Figure 6-1 - Effects of CXCR4 expression following FOXP3 transfection into 
malignant breast and prostate cell lines 
Meta-analysis results produced from EMBL-EBI suggested that following FOXP3 
transfection into MCF-7 would significantly decrease the expression of CXCR4 (A) 
whereas, if FOXP3 was transfected into the prostate cancer cell lines, LNCaP, it increases 
the expression of CXCR4 (B). Screen shot image from webpage (EMBL-EBI 2013). 
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Cancer is a complex genetic disease, and the dysregulation reported in the signalling 
pathways within malignant cells is often difficult to comprehend. Due to the 
complexity of these pathways, and the number of molecules able to regulate them, 
the fact that specific cancers commonly overexpress certain molecules makes it 
unlikely that the factors responsible for the overexpression are consistent between 
the cells. 
The network involved in regulating the expression of CXCR4 is equally complex. 
There are many reports describing a number of factors involved with several 
mechanisms which can regulate the expression CXCR4, suggesting it can be 
influenced downstream of many pathways (Luker and Luker 2006). This wide spread 
ability to increase CXCR4 is most likely one key reason why it is so frequently 
expressed in a number of malignancies. 
 
6.3 Concluding thoughts  
This project was designed primarily to investigate the impact of FOXP3 expression 
in breast cancer progression. I believe that results from this study have provided 
strong evidence to suggest that FOXP3 is able to regulate the expression of several 
important oncogenes and the function of epithelial cells in vitro. FOXP3 canbe 
considered an important factor involved in breast cancer development.  
Another direction the project took was to investigate the potential of FOXP3 to 
regulate CXCR4. The complexity of the signalling pathways and the multitude of 
factors involved in CXCR4 regulation make it very conceivable that there will be 
cross talk between FOXP3 and CXCR4 in breast epithelia at a molecular level. 
Indeed some of the data from this project suggests that FOXP3 is able to influence 
the expression of CXCR4 at low levels in breast cancer cell lines. 
However, from these results, the ability of FOXP3 to directly influence CXCR4 in a 
similar manner to ErbB2 and SKP2 seems unlikely and probably relies on a number 
of other pathways downstream from FOXP3. Therefore, because any changes in 
CXCR4 expression are probably dependent on several other factors, it’s difficult to 
conclude that FOXP3 regulates CXCR4, but is probably more accurate to suggest 
that it has the potential to be influenced at a modest level and FOXP3 represents a 
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small part of a much larger puzzle involving the upregulation of CXCR4 in breast 
cancer.   
A few possible downstream signalling pathways of FOXP3 which could contribute 
to CXCR4 expression are discussed in the next section 
 
6.4 Potential FOXP3 - CXCR4 mechanisms  
The literature describes a number of pathways by which functional FOXP3 can 
modify CXCR4 expression in breast epithelial cells (figure 6.2 panel A).  
Although direct links between FOXP3 and CXCR4 in epithelial cells have never 
been published in the literature, evidence suggests that FOXP3 can regulate CXCR4 
in T-cells. Zheng et al (Zheng, Josefowicz et al. 2007) performed a genome-wide 
analysis of FOXP3 target genes in Tregs. They reported that in naive thymic T-cells, 
CXCR4 was a FOXP3 target gene. This suggests that the CXCR4 promoter may 
contain FOXP3 binding sites allowing FOXP3 to directly regulate the expression of 
CXCR4. However, as mentioned, it remains controversial how translatable the roles 
of FOXP3 and CXCR4 are in lymphocytes and epithelial cells. A number of indirect 
mechanisms also exist which are discussed below:    
The ability of FOXP3 to directly repress HER2 in breast epithelia has been 
demonstrated by Zou et al (Zuo, Wang et al. 2007) using several strong lines of 
evidence where a loss in FOXP3 subsequently resulted in an increased expression of 
HER2. By contrast, the overexpression of HER2 on breast cancer cells has been 
demonstrated to increase the expression of CXCR4 (Li, Pan et al. 2004). It is thought 
that this HER2-mediated increase in CXCR4 occurs via the PI3K/Akt/mTOR 
pathway (Li, Pan et al. 2004).  
A further pathway can be proposed which is mediated through NF-κB signalling. 
FOXP3 has been shown to repress NF-κB in a number of reports (Grant, Oh et al. 
2006; Zhang and Sun 2010; Loizou, Andersen et al. 2011). Loizou et al (Loizou, 
Andersen et al. 2011) published data suggesting that FOXP3 is able to repress the 
expression of NF-κB through the c-Rel domain. This report suggested that the N-
terminal region of FOXP3 was required for c-Rel interaction, whereas, the forkhead 
box domain was not associated with c-Rel interaction. A separate report by Grant et 
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al (Grant, Oh et al. 2006) also demonstrated that FOXP3 was able to inhibit the 
expression of NF-κB, however, the regions of FOXP3 responsible for this repression 
opposed the finding from Loizou et al (Loizou, Andersen et al. 2011). Grant et al 
(Grant, Oh et al. 2006) demonstrated that deletion of the FOXP3 forkhead domain 
abrogated the ability of FOXP3 to suppress NF-κB in HEK cells (the same cell line 
used by Liouzou et al (Loizou, Andersen et al. 2011). Interestingly, the forkhead 
domain was not required for NF-κB repression in primary CD4+ T-cells or Jurkats. 
This suggests that although the ability of FOXP3 to repress NF-κB is consistent, the 
mechanisms responsible for this repression differ between cell types. A report 
investigating the role of FOXP3 in ovarian cancer cells by Zhang and Sun (Zhang 
and Sun 2010) demonstrated that following FOXP3 transfection into SKOV3 cells, 
there was a subsequent decrease in NF-κB. This suggests that FOXP3 is also able to 
inhibit NF-κB in epithelial cells. 
A report by Helbig et al (Helbig, Christopherson et al. 2003) produced 
comprehensive data demonstrating that NF-κB is able to bind directly to the 
promoter of CXCR4 leading to increased expression. The increase in CXCR4 was of 
functional importance as the cells were able to migrate significantly more in 
response to CXCL12, demonstrating the importance of NF-κB in CXCR4-mediated 
breast cancer metastasis (Helbig, Christopherson et al. 2003). Interestingly, research 
groups have also reported that NF-κB is able to regulate the expression of MMP2, 
MMP9 (Ogawa, Chen et al. 2004; Lin, Lu et al. 2010), uPA (Reuning, Wilhelm et al. 
1995; Zhang and Sun 2010; Moreau, Mourah et al. 2011) and a number of cytokines 
in highly metastatic breast cancer cell lines (Karin and Greten 2005; Karin 2009), 
further contributing to the potential downstream effects of FOXP3. 
Although Li et al (Li, Pan et al. 2004) demonstrated the ability of HER2 to increase 
CXCR4, suggesting the PI3K/Akt/mTOR pathway was responsible for this, a study 
by a separate group suggests that an alternative pathway signalling through NF-κB 
may exist. Merkhofer et al (Merkhofer, Cogswell et al. 2010) suggested that HER2 is 
able to activate NF-κB using a completely Akt-independent pathway, utilising a 
canonical pathway involving IKKα. The importance of this signalling pathway in 
breast cancer was emphasised by the ability of this signalling pathway to inhibit 
breast cancer invasion (Merkhofer, Cogswell et al. 2010). The influence of increased 
NF-κB signalling appears to be a key mediator of many breast cancer signalling 
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pathways. Its effects on breast cancer progression can be expanded further by also 
regulating the expression of VEGF (Shibata, Nagaya et al. 2002; Ramanathan, 
Pinhal-Enfield et al. 2007). Interestingly, a recent study by Nakahira et al (Nakahira, 
Morita et al. 2013) reported that upregulation of FOXP3 by LCK in MCF-7 resulted 
in a significant reduction in VEGFA expression. Moreover, the subsequent 
expression of VEGF has also been shown to regulate the expression of CXCR4 
(Kijowski, Baj-Krzyworzeka et al. 2001; Zagzag, Lukyanov et al. 2006) therefore, 
providing another pathway.        
As well as the potential mechanisms of FOXP3-mediated CXCR4 expression 
previously discussed, a number of reports have also suggested possible feedback 
loops which can accentuate CXCR4 expression (figure 6.2 pathways labelled B).   
Upon binding of CXCL12 to CXCR4, a number of processes are activated. 
CXCL12-CXCR4 signalling is able to transactivate HER2 in breast (Cabioglu, 
Summy et al. 2005) and prostate (Chinni, Yamamoto et al. 2008) cancer cells, 
subsequently increasing the ability of cells to migrate and metastasise. CXCR4 
signalling is also able to increase the expression of VEGF (Liang, Brooks et al. 
2007). This CXCR4-mediated VEGF regulation was reported to be dependent on the 
PI3K/Akt pathway (Liang, Brooks et al. 2007).  
Finally, studies on oral cancer have demonstrated that CXCL12 is able to activate 
NF-κB which is able to promote cell invasion through the Carma3/bc110.Malt1 
complex (Rehman and Wang 2009).  
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Figure 6-2 - Potential mechanisms of FOXP3 influencing CXCR4 expression 
Should FOXP3 functioning be lost in epithelial cells, a number of possible pathways could 
increase CXCR4 expression.  
(A1) CXCR4 has been identified as a FOXP3 target gene in developing thymic T-cells, 
therefore, suggesting CXCR4 could be directly regulated by FOXP3. Alternatively, (A2) 
FOXP3 acts as a direct repressor to HER2 in breast epithelial cells, whereas, (A3) increased 
expression of HER2 is able to increase the expression of CXCR4 through the 
PI3K/Akt/mTOR pathway. (A4) FOXP3 has been demonstrated by a number of research 
groups to interact and regulate the activation of NF-κB, which is then (A5) able to upregulate 
CXCR4 by directly binding in the promoter region. (A6) An alternative route via HER2 can 
be proposed as HER2 is able to activate NF-κB expression, independent of the 
PI3K/Akt/mTOR pathway, through the canonical pathway. (A7) NF-κB is able to increase 
the expression of VEGF, which in turn (A8) is able to increase the expression of CXCR4. 
(A9) FOXP3 has recently been identified as a factor which is able to repress the expression 
of VEGF-A.  
A number of feedback loops signalling through CXCR4 could potentially continue the 
increased expression of the chemokine receptor. (B1) Upon binding of the CXCR4 ligand, 
CXCL12, it has been reported in prostate and breast epithelial that HER2 becomes 
transactivated. (B2) CXCR4 signalling has also been demonstrated to increase the activation 
and signalling of NF-κB and also (B3) VEGF. 
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6.5 Therapeutic implications  
Both the emergence of FOXP3, and the established role of CXCR4 in breast cancer 
have been acknowledged by a number of research groups who have investigated the 
potential to possibly treat cancer by targeting FOXP3 restoration and inhibiting 
CXCR4 in vitro and in vivo. A number of these are discussed.  
 
6.5.1 FOXP3 therapies  
Many papers have now demonstrated on several lines of evidence that FOXP3 is a 
potent tumour suppressor regulating a number of oncogenes. Because FOXP3 is 
reported to be dysregulated in many malignant tissues, this suggests the potential for 
FOXP3-based therapies. Many of these therapies have been discussed by Douglass et 
al (Douglass, Ali et al. 2012). 
The majority of breast cancers with FOXP3 mutations have demonstrated that these 
mutations are heterozygous with transcripts of the gene originating from the mutant 
alleles. Similarly, all cases which describe deletions of FOXP3 are also 
heterozygous. This leaves the wild type allele silenced within the tumour cell whilst 
emphasising that a single hit is enough to inactivate FOXP3.  
Some reports have focused on the concept of re-activating wild type FOXP3 to 
normalise the biology of cancer cells which lack the wild type protein. Because one 
of the alleles of the X-linked genes has not undergone selection during 
carcinogenesis, it will remain unaffected; therefore, the prospect of re-activating X-
linked TSGs as a cancer therapy would be appealing. Despite our knowledge of the 
how X-chromosome inactivation is induced, how this inactivation is maintained is 
far less defined. In addition to this, the concept of re-activating the function of an 
inactivated TSG is one of the most challenging aspects in cancer therapy. However, 
even if this became a possibility, it should be emphasised that the re-activation of X-
linked genes must be approached with considerable care due to the potential of side 
effects. Naturally, any potential side effects could be minimised, or avoided, if 
specific genes could be selectively reactivated. 
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As of yet, there are no pharmaceutical companies which have designed drugs to 
reactivate X-linked TSGs; however, a number of studies have well-constructed 
research models which induce the expression of FOXP3 in cancer cells.  
The TSG p53 is able to upregulate the expression of FOXP3 in breast and prostate 
cell lines, whereas, doxorubicin is able to activate p53 which leads to increased 
transcription of FOXP3 (Jung, Jin et al. 2010). Alternatively, administration of 
anisomycin to several human breast cancer cell lines led to increased expression of 
FOXP3. Moreover, this increase in FOXP3 was able to induce apoptosis and reduce 
the growth rate of pre-established tumours in murine models of breast cancer. This 
upregulation was reported to be due to activating c-Jun and AFT2 heterodimers (Liu, 
Wang et al. 2009).     
Recently, gene therapy has become a popular method of restoring normal expression 
of dysfunctional genes. However, these methods have often had technical challenges 
which result in a poor outcome. Alternatively to gene therapy, reasonable success 
has been highlighted using antibody-mediated protein therapy of FOXP3 in 
numerous in vitro and in vivo models (Heinze, Baldwin et al. 2009). When the Fv 
region of a monoclonal antibody tagged with a FOXP3 fusion protein was able to 
induce a dose-dependent cell death of breast, ovarian and colon cancer cells in vitro 
(Heinze, Baldwin et al. 2009). In vivo administration of this antibody in Balb/c mice 
was able to reduce the metastasis of colon tumours to the liver (Heinze, Baldwin et 
al. 2009).  
Not only do these reports provide the early signs of exciting innovative techniques to 
overcome cancer, they also propose that FOXP3-based therapies have real potential 
as a novel therapeutic. However, the requirement to fully understand the molecular 
mechanisms involved in these techniques cannot be underestimated and the need to 
validate whether the re-introduction of FOXP3 can be explored as a safe cancer 
therapy.     
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6.5.2 CXCR4 inhibitors  
Unlike FOXP3, which is still a relatively emerging molecule in cancer research, 
CXCR4 is a well established chemokine receptor in a number of malignancies which 
potentially makes it a good target for cancer.  
Several research groups have now investigated whether inhibition of CXCR4 
expression can potentially prevent tumour growth. Plerixafor, also known as 
AMD3100, is a molecule which is able to block CXCR4. Because CXCR4 acts a co-
receptor for certain HIV virus strains, it was later used as a drug for HIV treatment 
(Davies 2007). 
Because CXCR4 is heavily involved in cancer, it has also recently been hypothesised 
as a potent drug for cancer treatment. This hypothesis has been validated by a 
number of in vitro and in vivo cancer studies. For instance, treatment with AMD3100 
was able to reduce the growth of both the primary and metastatic breast tumours in 
mice (Smith, Luker et al. 2004). However, despite this reported success with 
AMD3100, 70% of the drug is excreted within 24 hours meaning the 
pharmacokinetics of this drugs have made the clinical translation of AMD3100 
difficult. A recent report by O’Boyle et al (O'Boyle, Swidenbank et al. 2013) 
demonstrated that an alternative CXCR4 inhibitor, AMD11070, is not only able to 
reduce the migration of melanoma cells, but the reduced migration was also 
significantly more effective than AMD3100. Because AMD11070 can be taken 
orally and has a more favourable pharmacokinetic profile in comparison to 
AMD3100, if the prospect of using CXCR4 inhibitors to treat breast cancer 
progressed, the use of AMD11070 may be the better choice to use.        
On the other hand, because CXCR4 is expressed by a number of lymphocytes and is 
involved in lymphocyte homing, unless the CXCR4 actions could be targeted 
directly towards epithelial cells, chronic blockage of CXCR4 may result in adverse 
immunological side effects   
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6.6 Limitations and future directions for the study 
A number of factors limited the progress of this research. These are described below 
together with strategies for their mitigation or circumvention. Novel areas for 
investigation suggested by the study are also described. 
 One of the main aims of this project was to investigate the impact of 
restoring FOXP3 into MDA-MB-231. Initially, the project set out to generate 
MDA-MB-231 stably transfected with FOXP3. Although this was achieved, 
it proved technically challenging to transfect these “hard-to-transfect” cells. 
Following successful transfection, an increase in p21 expression was 
observed which led to a reduction in cell proliferation and the suggestion of 
FOXP3-induced senescence. Although this was not formally a “limitation”, 
studies of cell function were not possible.  
One method to address this is by use of a tetracycline-inducible 
FOXP3 system in MDA-MB-231. Tetracycline induction of FOXP3 
expression by HEK cells was used successfully in this study. Other groups 
have reported use of tetracycline-inducible FOXP3 in MCF-7 (Zuo, Liu et al. 
2007; Liu, Wang et al. 2009; Li, Wang et al. 2011). This system would avoid 
the induction of FOXP3-mediated senescence, as FOXP3 expression could 
be regulated when required.  
Alternatively, viral transduction has become a very popular method of 
transfection as it appears to have greater transfection effeciencies and cell 
viability than lipofection or electroporation. This technique uses viruses as 
carriers of the plasmid DNA to infect cells and causes a very reproducible 
and high level of transfection efficiency. Unfortuantely, permission to use 
viral transduction is only granted when the laboratories have the specific 
safety measures in place. During this phase of the project, our laboratory was 
not permitted to perform viral transduction.       
 
 The final aspect of the study aimed to investigate the expression of FOXP3 
and CXCR4 at transcript and protein levels in patient samples. Although a 
range of frozen cancer samples was available for this study, the condition of 
the preserved tissue made it impossible to separate T-cells expressing FOXP3 
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and CXCR4 from breast cancer cells. This meant that transcript findings were 
of limited value as heavy T-cell infiltration was observed in almost all 
tumour samples.     
A further study using fresh tissue would eliminate this problem. 
Combination with either laser microdissection or in situ hybridisation would 
allow specific quantification of cancer cell-associated FOXP3 and CXCR4.  
 
 FOXP3 is expressed at very low levels in normal mammary epithelial cells. 
Protocols to detect this protein by automated IHC all failed as a consequence 
of inadequate sensitivity. A manual protocol developed by previous members 
of this group to detect FOXP3 in normal mammary epithelial cells was more 
successful but the resolution did not allow discriminatation between nuclear 
and cytoplasmic staining. A number of research groups have reported the 
subcellular distribution of FOXP3 to be important in cancer (Hinz, Pagerols-
Raluy et al. 2007; Merlo, Casalini et al. 2009; Wang, Liu et al. 2009). In 
order to generate more useful data the IHC method will require further 
development to enhance its spatial resolution.  
 
 Although results regarding FOXP3-CXCR4 interactions are slightly 
ambiguous in this study, some aspects do suggest that FOXP3 is able to 
influence the expression of CXCR4 at a modest level. Section 6.4 has 
discussed a number of potential mechanisms by which FOXP3 could regulate 
CXCR4 expression indirectly. However, because FOXP3 is a transcription 
factor which is able to directly repress a number of genes, a chIP assay would 
confirm whether FOXP3 is able to directly bind and regulate CXCR4 in a 
similar manner to how ErbB2, SKP2, c-Myc, LATS2, and p21,are regulated.  
 
 As a transcription factor, it is perhaps unsurprising that the majority of 
reports, including this study, have focused specifically on factors which can 
be influenced downstream of FOXP3. However, because FOXP3 is 
commonly reported to be dysregulated which can then lead to an 
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accumulation of other dysregulated factors, it would be of interest to 
investigate the factors which are able to regulate the expression of FOXP3. 
This would represent a very novel direction of research as few studies have 
reported factors able to regulate FOXP3 in epithelial cells. 
Recently, p53 (Jung, Jin et al. 2010) and LCK (Lal, Chan et al. 2013) 
have been identified as factors able to upregulate FOXP3 in cancer cells, 
whereas, the methylation status of CpG motifs and protein phosphorylation of 
FOXP3 are both reported to be important in FOXP3 activation (Lee, 
Fitzpatrick et al. 2001; Lal, Chan et al. 2013).  
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8 Appendices  
 
Appendix 1 – Sequencing of FOXP3 in HMEpC using FOXP3 primer region 1  
Sequencing data from FOXP3FL (upper band on gel) with primer set 1 (A), FOXP3Δ3 
(lower band on gel) from primer set 1 (B).  
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Appendix 2 – Sequencing of FOXP3 in HMEpC using FOXP3 primer set 2 and 
3 
Sequencing data from FOXP3 with primer set 2 (A), FOXP3 from primer set 3 (B). 
A
B
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Appendix 3 – Optimisation of pmaxGFP transfection into MDA-MB-231 using JetPRIME® after 24 hours  
MDA-MB-231 were transfected with 2µg of PmaxGFP plasmid using varying ratios of JetPRIME® reagent from 1:2 to 1:5 (µg of DNA: µl of reagent)      . 
To avoid cytotoxicity, after 48 hours transfection complexes were removed and replaced with growth media without antibiotics. Transfection efficiency     
was determined by IF microscopy after 24 hours  
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Appendix 4 – Optimisation of pmaxGFP transfection into MDA-MB-231 using JetPRIME® after 48 hours  
MDA-MB-231 were transfected with 2µg of PmaxGFP plasmid using varying ratios of JetPRIME® reagent from 1:2 to 1:5                                                   
(µg of DNA: µl of reagent). Transfection efficiency was determined by IF microscopy after 48 hours  
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Appendix 5 – Transfection of pmaxGFP into MDA-MB-231 using GeneJuice® 
after 24 hours 
MDA-MB-231 were transfected with 2ug of pmaxGFP plasmid using GeneJuice® according 
to the manufacturers recommended protocol (2µg of DNA: 6µl of reagent). Transfection 
efficiency was determined by IF microscopy after 24 hours.
FITCBrightfield/FITC merge
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Appendix 6 – Optimisation of pmaxGFP transfection into MDA-MB-231 using 
TurboFect
TM
 after 24 hours  
MDA-MB-231 were transfected with 2µg of PmaxGFP plasmid using varying ratios of 
TurboFect
TM
 reagent from 1:1 to 1:3 (µg of DNA: µl of reagent). Transfection efficiency 
was determined by IF microscopy after 24 hours  
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Appendix 7 – Attempted FOXP3 staining using the autostainer link 48 with 
FOXP3 antibody clone 236A/E7 
Normal breast tissue from breast reduction surgery was stained for FOXP3 by Ms Denise 
Woolley using autostainer link 48 within the QE Hospital. Antigens were retrieved using a 
high pH buffer for 60 minutes and slides were stained for 40 minutes with the primary 
human anti-FOXP3 antibody at dilutions 1:150 (A), 1:100 (B), 1:50 (C), and 1:25 (D).  
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Appendix 8 – Optimisation FOXP3 staining using the BenchMark ULTRA with 
anti-FOXP3 antibody (clone 159D) using the ultraview detection kit 
Normal breast tissue from breast reduction surgery was stained for FOXP3 by Ms Anna 
Long using the BenchMark ULTRA within the RVI Hospital. Antigens were retrieved using 
Cell Conditioning solution-1 (high pH buffer) for 60 minutes. Slides were stained with the 
primary human anti-FOXP3 antibody for 40 minutes at the dilutions 1:100 (A), 1:50 (B), 
1:25 (C), 1:10 (D). All slides received 4 minutes amplification  
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Appendix 9 – Optimisation FOXP3 staining using the BenchMark ULTRA with 
anti-FOXP3 antibody (clone 159D) using the optiview detection kit 
Normal breast tissue from breast reduction surgery was stained for FOXP3 by Ms Anna 
Long using the BenchMark ULTRA within the RVI Hospital. Antigens were retrieved using 
Cell Conditioning solution-1 (high pH buffer) for 60 minutes. Slides were stained for 40 
minutes with a human anti-FOXP3 antibody at the dilutions; 1:100 (A), 1:50 (B), 1:50 + 12 
minutes of amplification (C) and 1:25 +8 minutes amplification (D).  
Alternatively antigens were retrieved using a pressure cooker with citrate buffer (E) or 
Tris/EDTA (F) with primary antibody dilutions at 1:50 for 40 minutes. 
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Appendix 10 – Optimisation FOXP3 staining using BenchMark ULTRA with 
anti-FOXP3 antibody (clone 159D) using the optiview detection kit (2)  
Normal breast tissue from breast reduction surgery was stained for FOXP3 by Ms Anna 
Long using the BenchMark ULTRA within the RVI Hospital. Antigens were retrieved using 
Cell Conditioning solution-1 (high pH buffer) for 30 minutes. Slides were stained for 40 
minutes with anti-FOXP3 antibody at the dilutions 1:50 (A) and 1:25 (B). Alternatively 
antigens were retrieved using Cell Conditioning solution-2 (low pH buffer) and stained with 
anti-FOXP3 primary antibody at the dilutions 1:50 (C) or (D) 1:25 for 40 minutes.    
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Appendix 11:  
A list of the posters, presentations, publications, prizes throughout duration of this 
PhD as listed below: 
Posters: 
 Mammary gland biology – Gordon Conference, Stowe, VT, US (June 2013) 
 
Presentations: 
 Institute of Cellular Medicine (ICM) research seminar series (2011) 
 Women’s cancer detection society (WCDS) annual committee meeting (2011 & 
2012) 
 Applied immunobiology and Transplantation seminar series (2012 & 2013) 
 North-East postgraduate research conference (NEPG) (2011) 
 Boston Brandeis University – Invited guest speaker (June, 2013) 
 
Publications: 
 Douglass S, Ali S, Meeson AP, Browell D, Kirby JA (2012) The role of FOXP3 
in the development and metastatic spread of breast cancer. Cancer Metastasis 
Rev;31(3-4):843-54 
 Asghar K, Brain J, Palmer JM, Douglass S, Naemi F , Kirby  JA, Ali S (2013) 
Immunoregulatory activity of Indoleamine 2, 3-dioxygenase in the pathogenesis 
of Primary Biliary Cirrhosis (Manuscript pending result). 
 Douglass S et al (2013), Dysregulated FOXP3 in breast epithelia promotes an 
aggressive phenotype and increases site-specific metastasis in breast cancer 
(manuscript in preparation) 
 
Prizes:  
 Travel grant awarded by British society of immunology (competitive basis) - 
£1000, 2013 
 Travel grant awarded by Newcastle University graduate school (competitive 
basis) - £800, 2013 
Appendices 
351 
 
Memberships: 
 British association for cancer research (BACR) (2010-Present) 
 British society for immunology (BSI) (2010-Present)  
 
 
